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Summary 
Background 
Herpes zoster (HZ) is a neurocutaneous disease caused by reactivation of the varicella zoster 
virus. The characteristic clinical manifestations of HZ include grouped blistering vesicles 
erupting on a red base of skin, and burning or stabbing pain with a unilateral dermatome 
distribution. The pain of HZ is associated with significant reduction on patients’ health 
related quality of life (HRQoL). Conventional treatments include antiviral therapies and pain 
management. These therapeutic approaches have not been able to provide effective relief of 
these symptoms for all patients. 
 
Hence other therapies such as Chinese medicine (CM) have been used to treat symptoms of 
HZ, either alone or as add-on therapy to conventional approaches. Over the long history of 
Chinese medicine development, valuable information on clinical manifestations, diagnosis, 
and treatment for HZ have been described and explained in-depth in the classical literature, 
which continues to be included in the contemporary guidelines and textbooks for CM 
practice. Currently the classical literature evidence for HZ has not been systematically 
evaluated. 
 
Chinese herbal medicine (CHM) and acupuncture are the two main CM therapies for HZ 
included in contemporary CM textbooks and guidelines. The clinical evidence based on 
several systematic reviews (SRs) of CM indicated that they are beneficial for pain control and 
cutaneous outcomes. However, the quality of current evidence is limited by the databases 
searched, study inclusion criteria, and statistical analyses. To address this gap, SRs based on a 
more comprehensive search of databases and strict inclusion criteria are needed. 
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Objectives 
Guided by the “Whole Evidence” approach, this thesis aims to: 
1. Examine the evidence of Chinese medicine classical literature for HZ. 
2. Evaluate the current clinical trial evidence of CHM and acupuncture for HZ. 
3. Review the current experimental evidence of CHM treatment for HZ. 
4. Design a rigorous trial protocol on a CHM formula for HZ. 
 
Methods 
Classical literature evidence research 
The comprehensive classical literature search was conducted using the Zhong Hua Yi Dian 中
华医典 (ZHYD). Citations identified by search terms were extracted for further analysis. 
Descriptive statistical analyses were performed to identify the frequency of each search term, 
signs and symptoms and treatment. Cluster analyses were performed to discover the potential 
relationships of the HZ symptoms in the data set which were judged to be most likely HZ 
citations. 
 
Modern literature evidence research 
Nine English and Chinese databases were searched for evidence from randomised controlled 
trials (RCTs). Overviews of CHM and acupuncture therapies were conducted to summarise 
and discuss the characteristics of included studies. Two specific interventions were selected 
as the foci for the SRs: a CHM formula Long dan xie gan tang 龙胆泻肝汤 (LDXGT), and 
acupuncture combined with moxibustion. The general methods for the SRs followed the 
3 
 
methods of Cochrane Handbook for Systematic Reviews and Interventions. Data were 
extracted and risk of bias was assessed. All statistical analyses were carried out in RevMan 
5.3. 
 
A literature search for experimental evidence of the most frequently used herbs in the 
included CHM studies was conduct in PubMed. In vivo and in vitro studies which described 
mechanisms relevant to HZ were included for a general review.  
 
Trial protocol design  
According to the classical and modern literature evidence in this research, LDXGT formula 
was the most commonly cited CHM intervention. Clinical evidence showed LDXGT was a 
well-tolerated and effective treatment. However the evidence was limited by the 
methodological limitations. A rigorous trial protocol using LDXGT integrated with antiviral 
therapy was developed to generate new clinical evidence data.  
 
Results 
Classical literature evidence 
Ninety-six (96) classical citations were included. Chan yao 缠腰 and huo dan 火丹 were the 
most common terms in included citations. The symptoms and CHM treatments described in 
classical literature are consistent with contemporary conventional medicine and CM 
textbooks. The most frequently reported formula was LDXGT. A hypothetical symptom 
structure for HZ has been proposed based on cluster analysis, with a key symptoms 
classification of heat disease in CM theory highlighted in further inferential analysis. 
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Clinical trial evidence 
Ninety-four (94) RCTs were included for the overview of CHM for HZ. A variety of CHM 
formulae, single herbs and chemical compounds were evaluated. Findings show that LDXGT 
was the most commonly used formula. Twenty-six (26) studies were included for the SR of 
LDXGT for HZ. Modified LDXGT formula was found to shorten the time to alleviate pain 
and reduce postherpetic neuralgia (PHN) incidence compared with pharmacotherapies. Mild 
adverse events such as gastrointestinal discomfort were reported from one study. 
 
Experimental evidence of the most commonly used herbs in the included CHM clinical trials 
found that many of the constituents isolated from these herbs have shown anti-inflammatory 
actions. Inhibition of inflammatory cytokines and pro-inflammatory enzymes have been 
reported, which may contribute to relieving the acute inflammatory response of HZ. 
 
Twenty- seven (27) RCTs were included for the overview of acupuncture therapies for HZ. 
Acupuncture approaches and acupuncture points selection were consistent with the 
contemporary acupuncture guideline. Nine studies were included for the SR of acupuncture 
plus moxibustion for HZ. Key findings showed promising benefit from acupuncture and 
moxibustion in reducing pain, improving rash healing, and reducing the incidence of PHN, 
with few mild adverse events such as haematoma and bleeding reported. 
 
Trial protocol design  
Guided by the findings from the reviews, a randomised, double-blinded, placebo controlled 
trial protocol using LDXGT integrated with antiviral therapy in the management of HZ was 
developed. The participants are expected to be immunocompetent patients aged ≥50 years 
with acute stage HZ; and CM syndrome of Stagnant heat in the Liver meridian. Both the 
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intervention and control group will receive antiviral therapy. Participants in the intervention 
group will also receive LDXGT granules and those in the control group will receive placebo 
granules. The primary outcome will be evaluation of pain, and secondary outcomes will be 
HRQoL assessment and adverse events. 
 
Conclusion 
This research applied a systematic approach to summarise the whole evidence of CM 
therapies in the management of HZ. Data mining results from the classical literature 
demonstrated that the inflammation symptoms cluster was one of the components of the HZ 
symptoms structure. Modern literature research showed CM therapies of both CHM and 
acupuncture plus moxibustion were well tolerated with promising benefit in hastening pain 
relief, improving cutaneous outcomes, and decreasing the incidence of PHN. The anti-
inflammatory effects of the most commonly used herbs from the experimental studies help to 
elucidate the potential mechanism of actions of these herbs for HZ. To further determine the 
benefit of LDXGT formula as an add-on therapy to antiviral drugs, a rigorous RCT has been 
proposed to be undertaken.  
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Chapter 1. General introduction 
1.1 Background 
Herpes zoster (HZ), or shingles, is a distinctive neurocutaneous disease resulting from 
reactivation of the varicella zoster virus (VZV). The preceding infection of VZV (commonly 
known as chickenpox) occurs during childhood, and the virus remains dormant in the sensory 
ganglia for decades [1]. When the immune system of the virus carrier weakens due to the 
aging process, immune suppression or immunodeficiency, the VZV reactivates, causing HZ 
[2]. Postherpetic neuralgia (PHN) may develop after resolution of the rash, inducing chronic 
pain without any visual lesion [1]. 
 
The global median incidence rate of HZ is 4 - 4.5 per 1,000 person-years, based on data from 
the United States, Canada, South America, Europe, Asia and Australia [3]. The pain that HZ 
causes results in considerable impact on four aspects of health related quality of life: physical 
health, psychological wellbeing, social functioning and activities of daily living [4-6]. 
Accordingly, pain relief is the primary goal of pharmacological management [7]. The 
economic burden of HZ is considerable, and the high cost of caring for elderly patients has 
also raised a particular concern amongst countries [8, 9]. An epidemiological study from 
Spain estimated the cost of hospitalization due to HZ was USD 10 million [10]. The cost of 
vaccination against VZV is relatively high, at approximately USD 197 per dose [11].  
 
The development of lesions is preceded by non-specific clinical symptoms including 
tiredness, headache, low grade fever, and an itchy and tight sensation of the skin [1, 7]. 
Groups of small to medium tight walled vesicles containing clear fluid develop above a red 
macular base, with a unilateral and asymmetric distribution. Itching, tightening, and painful 
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sensation also occur with the cutaneous symptoms [9, 12]. Diagnosis is usually based on 
clinical presentation, although polymerase chain reaction (PCR) may be used to confirm the 
diagnosis [13]. 
 
Pharmaceutical treatments in treatment guidelines aim to relieve the acute pain, limit the 
course and the spread of lesions and prevent PHN and other complications [1, 7]. Whilst 
tolerable, side effects caused by both antiviral (nausea and headache) and pain control 
therapies (vomiting, constipation, drowsiness and dizziness) have been reported [14]. 
Research by Gater et al. [15] found that patients were most satisfied with side effects of 
treatment, but least satisfied by the perceived effectiveness of treatment. The authors 
highlight this as an unmet need for people with HZ. 
 
Chinese medicine (CM) has been used to treat HZ for many years in China, and may provide 
an alternative treatment to conventional management. Various treatment approaches have 
been practiced in the management of HZ, including Chinese herbal medicine (CHM), 
acupuncture, moxibustion and other CM therapies. Over thousands of years, valuable 
information on diagnosis, symptoms, and treatment for HZ have been described and 
explained in depth in the classical literature. This continues to guide the contemporary 
guidelines and textbooks for CM practice. Currently, the classical literature evidence has not 
been evaluated systematically. 
 
According to contemporary CM textbooks [16-18] and the current clinical practice guideline 
[12], CHM and acupuncture therapies are the two main CM treatments recommended for HZ. 
The clinical evidence for these CM treatments has been evaluated by several systematic 
reviews (SRs) [19-28], showing benefits for pain control and improving cutaneous outcomes. 
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However, the evidence is limited by the databases searched, study inclusion criteria, and 
review methods. To address this gap, SRs prepared with a comprehensive search of databases 
and more strict inclusion criteria are needed. This thesis directly addresses this knowledge 
gap. 
 
1.2 Research questions 
The aim of this thesis is to evaluate the classical and modern literature evidence for CM 
treatment of HZ. The research questions of this project are: 
• What is the evidence of classical CM literature for HZ? 
• What is the current clinical trial evidence of CHM and acupuncture for HZ? 
• What is the current experimental evidence for commonly used CM treatments for HZ? 
• Is CHM formula Long dan xie gan tang 龙胆泻肝汤 (LDXGT) effective for people 
with HZ? Will it be safe to use for HZ? 
 
1.3 Scope of thesis 
This thesis addresses the above questions focusing on CHM treatments (for example, oral and 
topical CHMs) and acupuncture-related approaches (for example, manual acupuncture, 
electro-acupunture, moxibustion, acupressure, and ear acupuncture) only. These CM 
therapies are widely used for treating HZ in clinical CM practice and are recommended in 
contemporary CM textbooks and guidelines (see detailed inclusion criteria in Chapter 5) [12, 
16-18]. Other CM therapies are not commonly used outside of China and may not be 
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permitted in some countries (for example, bloodletting, point injection and catgut embedding). 
These therapies are excluded from the research scope of this research. 
 
1.4 Organisation of the thesis 
Chapter One and Two are the introductory chapters of this thesis. Chapter One briefly 
introduces the background of this research. The objectives and research questions are 
proposed.  
Chapter Two reviews the definition, epidemiology, aetiology, pathophysiology, diagnostic 
criteria, clinical manifestations, and current management for HZ in conventional medicine. 
This chapter highlights the unmet need to address the effectiveness of conventional 
medication for treating people with HZ. The latter section of this chapter reviews CM for HZ, 
including definition, aetiology, pathophysiology, syndrome differentiation and CM therapies 
drawn from contemporary CM textbooks and guidelines. A summary of current clinical 
evidence of CM for HZ from systematic reviews is provided. This chapter generally reviews 
the background knowledge of HZ from conventional medicine and CM viewpoints. 
Chapter Three and Four demonstrate the research on classical CM literature for HZ in this 
thesis. These two chapters describe CM knowledge in the classical literature, which 
contributes to the “whole evidence” of CM for HZ. 
Chapter Three details the methods for the data mining and cluster analysis of classical 
literature are provided; the methods of citation identification, data collection, coding and 
sorting of classical CM literature of HZ are presented in the former section of the chapter. 
Statistical analysis methods, including descriptive analysis and cluster analysis is presented in 
the latter section.  
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Chapter Four presents the results of data mining and cluster analysis of classical CM 
literature. The descriptive analysis section systematically evaluates CM interventions used for 
HZ in classical literature. Search terms, publication dynasty, symptoms in the ‘possible’ and 
‘most likely’ to be HZ citations are analysed. The potential relationships of the HZ symptoms 
from most likely to be HZ citations are explored through cluster analysis. Hypothetical 
symptom structures of HZ and huo dan 火丹 skin conditions are proposed based on these 
findings research. 
Chapter Five to Eight present the research in modern literature of CM for HZ in this thesis. 
Two systematic reviews on CHM and acupuncture therapies are demonstrated, and laboratory 
research on the most frequently used herbs for HZ are reviewed. These chapters provide the 
modern literature evidence to the “whole evidence” of CM for HZ. 
Chapter Five introduces the methods used for systematic reviews of modern literature. The 
general methods for the systematic reviews used in this thesis is followed by the methods of 
Cochrane Handbook for Systematic Reviews and Interventions. Details of study inclusion 
criteria, identification of studies and data analysis methods are presented.  
Chapter Six systematically reviews CHM for HZ. The first section provides a general 
overview of CHM treatments in the included randomised controlled trials (RCTs). The 
second section presents the findings of the systematic review for efficacy and safety of 
LDXGT formula. 
Chapter Seven systematically reviews acupuncture therapies for HZ. Following the 
approach used in Chapter six, the first section provides a general overview of acupuncture 
therapies in the included studies. The second section presents the resulting evaluation of 
efficacy and safety of acupuncture plus moxibustion in the management of HZ. Benefits of 
the combination of acupuncture and moxibustion are provided as well as adverse events. 
Chapter Eight provides an overview of the experimental evidence of the most frequently 
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used herbs for HZ identified in modern literature research. In vivo or in vitro studies that 
described mechanisms relevant to HZ were included. 
Based on the findings from the classical and modern literature evidence CM for HZ from this 
thesis, a rigorous RCT has been proposed to inform future research. Chapter Nine details the 
protocol for a randomised, double-blinded, placebo controlled trial using LDXGT integrated 
with antiviral therapy in the management of HZ. 
Chapter Ten summarises and discusses the findings from this research. A discussion of 
limitations of this research has also been discussed in this chapter. 
Appendix 1 to 9 present the tabulations of data presented in the above chapters.  
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Chapter 2. Herpes zoster 
2.1 Conventional medicine 
2.1.1 Definition 
Herpes zoster (HZ), or shingles from the Latin word cingulum, which means belt, is a type of 
neurocutaneous disease caused by reactivation of the varicella zoster virus (VZV) [29]. 
Typical distinctive clinical symptoms include grouped blistering eruption on a red base of 
skin, burning or stabbing pain with a unilateral dermatome distribution [1]. 
 
The preliminary infection of varicella (commonly known as chickenpox) usually occurs 
during childhood, either as infection with the VZV, or through weakened VZV in the varicella 
vaccine [3]. The virus persists dormant in sensory ganglia neurons for up to several decades 
[1]. When the immune system of the virus carrier weakens for reasons such as the aging 
process, immune suppression or immunodeficiency resulting from Acquired 
Immunodeficiency Syndrome (AIDS) [2], the VZV re-activates, causing HZ. 
 
A common chronic sequelae of HZ is postherpetic neuralgia (PHN), which may develop after 
the acute stage of visible lesions has subsided. There is no consensus on the definition of 
PHN, with definitions as chronic pain lasting ranging from one month to three months after 
the resolution of rash [1, 7, 9]. The generally accepted definition is three months. HZ and 
PHN both impact greatly on patients’ daily life. 
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2.1.2 Epidemiology 
2.1.2.1 Prevalence 
A global epidemiology review on HZ indicates that the median incidence is 4 to 4.5 per 1,000 
person-years (PY), which is based on studies conducted in the United States, Canada, South 
America, Europe, Asia and Australia [3]. The statistical data indicated an increasing trend of 
the age-adjusted incidence among the global epidemiology research. As the studies 
demonstrated, the incidence rates of HZ were between 1 and 5 per 1,000 PY under the age of 
18. The trends of the incidence rates increased gradually to a range of 4 to 6 per 1,000 PY by 
the age of 50. After 50 years, the incidence rates increased distinctively, peaking at around 10 
to 16 per 1,000 PY by the age of 90 years [3]. 
 
Epidemiological studies show comparable annual incidence rate across countries. Data from 
the USA reported incidence rate of 4.47 per 1,000 PY in 2011 (95% confidence interval PY: 
4.45, 4.5) with higher prevalence with older adults [30]. Incidence rates in Germany were 
slightly higher (5.3 to 5.5 per 1000 PY) from 2006 to 2009 [31], while data from Sweden 
reported lower incidence of 3.15 per 1,000 PY [32]. In China, the average annual incidence 
rate was 3.43 per 1,000 people aged more than 50 years old in the years 2010 to 2012, based 
on a retrospective cohort study [33]. Findings from MacIntyre et al. in Australia [34], Li et al. 
in China [33] and Hillebrand et al. in Germany [31] support those of Johnson in the US [30], 
showing age and gender differences, with older adults and females having a higher incidence 
rate [30, 31].  
 
In Australia, research from 2007 reports that the HZ annual incidence rate is between 4.7 to 
4.9 per 1,000 patients, which is consistent with that of the USA and Europe [35]. The 
incidence appears to be rising, with recent data showing incidence rate of 5.6 per 1,000 PY 
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from October 2006 to March 2013 [34]. 
 
The incidence of PHN is estimated to be 10 to 20% in all HZ patients and increases with age 
[36]. A study based on German Pharmacoepidemiological Research Databases covering all 
geography regions of Germany indicated that the PHN proportions among HZ cases 
increased from 11.5% in 2005 to 14.9% in 2009 [31]. Eighty per cent of PHN cases occur in 
HZ patients older than 50 years old [3]. 
 
Vaccination against varicella has been shown to reduce the incidence of HZ in children [37]. 
Data from the National Health Insurance Research Database in Taiwan found the incidence 
rate of HZ in children with previous VZV vaccination was 93.3 per 100,000 PY, compared 
with 262.1 per 100,000 PY in those who had not received the vaccination [37]. 
 
2.1.2.2 Impact 
2.1.2.2.1 Herpes zoster related mortality 
Data from individual epidemiology studies and the World Health Organisation (WHO) shows 
HZ associated mortality varied among countries, with a median mortality of 0.039 per 
100,000 [38]. HZ associated mortality significantly increases with age [39, 40]. In younger 
age groups, the mortality rate was higher in males [38]. Conversely, in older groups, mortality 
was greater in females [38]. 
2.1.2.2.2 Impact of herpes zoster on health-related quality of life 
The pain with acute HZ and PHN is always the most significant concern of patients, and can 
remarkably reduce the quality of life of patients. HZ or PHN patients with higher levels of 
pain reported the greatest impact on health-related quality of life (HRQoL) [15]. Impacts can 
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be seen in four aspects of their life: physical health, psychological wellbeing, social 
functioning and activities of daily living (Table 2.1) [4-6].  
 
Table 2.1 Impact of herpes zoster or postherpetic neuralgia on patient quality of life 
Physical Health Psychological 
Wellbeing 
Social Functioning Activities of Daily 
Living 
Insomnia, tiredness, 
anorexia, loss of 
weight, reduced 
mobility and physical 
inactivity 
Depression, anxiety, 
emotional distress, 
difficulty 
concentrating and 
fear 
Withdrawal, 
isolation, reduced 
social interaction, 
increasing 
dependence and 
social role changes 
Cooking and eating 
meals, wearing 
clothes, doing 
housework, traveling 
and shopping 
 
A UK study on the impact of HZ on quality of life found people with HZ had significantly 
lower quality of life than age-matched norms on two quality of life measures (Medical 
Outcomes Study Short-Form 36 (SF 36), and the EuroQol-5 Dimensions (EQ-5D) [15]. The 
main domains where poorer quality of life was seen were “Vitality”, “Social-functioning”, 
“Role-emotional”, “Mental health” and the “Mental Component Summary”. A European 
review on the health burden of HZ indicated that HZ and PHN greatly impacts on patient’s 
mood, mental well-being, family and social relations [41]. In a single-cohort study in Taiwan, 
HZ was found to have significant impact on HRQoL assessed by EQ-5D, with poorer quality 
of life up to 60 days after rash onset [42].  
 
2.1.2.2.3 Economic burden 
The economic burden of HZ is considerable, and the high cost of caring for elderly patients 
has also raised a particular concern [8, 9]. An epidemiological study from Spain estimated the 
cost of hospitalization due to HZ was USD 10 million [10]. The average annual hospital costs 
in the management for HZ was estimated to be GBP 13.0 million in England in the year 2013 
to 2014 [43]. The cost for management of PHN was higher than HZ [41, 44]. Particularly, the 
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direct economic burden of HZ for older patients is higher in terms of visiting the general 
practitioner (GP) or specialist, medication costs and hospitalisations, while the indirect 
burden is higher for younger patients due to absenteeism [41]. An increase in costs for the 
management for HZ and PHN was observed from 1997 to 2014 in Canada, and the primary 
reason might be the increasing use of anticonvulsants (for example, gabapentin) as analgesic 
therapy [45]. Vaccination against VZV is considered relatively high, with cost of USD 197 
per dose [11]. 
 
In Australia, the pain from HZ and PHN also impacts the community significantly and 
prolongedly. Primary care data from the General Practice Resource Network (GPRN) and 
Bettering the Evaluation and Care of Health (BEACH) databases indicate that more than 10% 
of the HZ patients have pain lasting longer than 1 month, 92% of whom require continuous 
use of prescription treatment [46]. An increasing trend of antiviral prescriptions specific for 
HZ was observed, with an increase of 4.2% per year between July 2002 and 2012 [34]. In the 
population aged 50 years or older, the total annual cost to the health care system was 
estimated at approximately AUD 33 million in the management of HZ and PHN [47]. 
 
2.1.3 Aetiology and pathophysiology 
The VZV can cause two distinctive cutaneous diseases, chickenpox, and herpes zoster. The 
connection between these two diseases has been known for many years based on two main 
findings: that VZV is transported up the peripheral nerve and remains dormant in sensory 
ganglion neurons for decades after acute infection of the virus, and sufficient VZV-specific 
cell-mediated immunity (CMI) helps to maintain the dormancy. When the immune system of 
the virus carrier weakens through progressing age, or immune suppression or deficiency, the 
virus reactivates, transports down the peripheral nerve and induces HZ [48].  
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2.1.3.1 Infection of varicella zoster virus   
People who develop HZ are usually infected with VZV in their early age. The virus is highly 
infectious, and is contracted via the respiratory tract. The VZV spreads from the pharyngeal 
lymphoid tissue to the circulating T lymphocytes [48]. Two VZV transmission mechanisms 
have been found in current research: within the superficial epidermis (cell-free), and outside 
the suprabasal epidermis (cell-to-cell contact) [48]. 
 
After an incubation of one to three weeks period, the virus reaches the skin and causes the 
typical cutaneous symptoms of vesicular rash, called varicella (chickenpox). At this point, a 
lifelong immunity against VZV is established, and the majority of people will not have a 
second episode of varicella during their lifetime [49]. Three main components are involved in 
the immune response: innate immunity, humoral immunity and CMI [48]. CMI is considered 
as the essential component for the cell-associated characteristic of VZV, and its T-cell-
mediated immunity response feature [50].  
 
2.1.3.2 Latency 
Two hypotheses have been proposed as to how the virus gets access to the dorsal and cranial 
root ganglia (DRG and CRG, respectively) and maintains latency. First, cell-free VZV which 
originate in the epidermis travel via the axons of sensory neurons to the cell bodies; second, 
the VZV is carried by T-cells to the DRG/CRG and infects the neuronal cell bodies [51-53]. 
Latency is established and maintained by VZV-specified CMI, unless T-cell immunity 
weakens [48]. 
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2.1.3.3 Reactivation 
After the reactivation of VZV, the virus begins replication and transports to infect epithelial 
cells via sensory axons of the sensory neurons, usually without inducing viraemia. The 
infection usually causes inflammation and necrosis of all the cells within the affected 
ganglion, resulting in a dermatome rash, characteristic vesicles and pain symptoms by an 
individual sensory nerve. Thoracic, trigeminal, and cervical sensory nerves are the most 
commonly involved in HZ during clinical observation [48]. 
2.1.3.3.1 Risk factors 
Various risk factors have been shown to have a potential impact on weakening CMI, 
decreasing latency of VZV and causing HZ. Worldwide epidemiology studies indicate that 
older age and female gender are risk factors for developing HZ [30, 31, 34]. Other risk 
factors are as below. 
Cell-mediated immunity dysfunction immunosuppressed individuals  
Reduced CMI, HIV-positive patients, and transplant recipients can have up to ten times the 
risk of getting HZ compared with the general population [48]. 
Diabetes 
People with diabetes mellitus are more likely to get infectious diseases due to the impaired 
cell-mediated immunity [54]. A population-based case control study showed that individuals 
with diabetes had a higher risk of HZ [55]. 
Genetic susceptibility 
Individual studies suggested that the risk of HZ might be related to some genetic factors: 
haplotype of human histocompatibility leukocyte antigen (HLA) [56], polymorphism of the 
interleukin 10 (IL-10) gene [57], and family history of HZ [58].  
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Mechanical trauma 
Mechanical trauma was found to be a risk of inducing HZ in case reports and case series 
studies. Stimulation by trauma of the sensory nerve may activate the VZV latent in the 
ganglion and cause HZ [59].  
Recent psychological stress 
A case-control study indicated that recent stressful events were found significantly more 
commonly in HZ patients [60]. In contrast, a recent study indicated that there was no 
evidence supporting that psychological stress triggers HZ based on the data from 2002 to 
2011 in the USA [61]. Currently, the link between psychological stress and HZ is unclear. 
Ethnicity 
Racial differences in the incidence of HZ were found in epidemiology studies. The survey 
was conducted in a community-dwelling sample of persons > 64 years old in North Carolina, 
USA over three time periods: 1986 to 1987, 1989 to 1990, and 1992 to 1994. Results 
suggested that Caucasians had a significantly higher risk of developing HZ than African 
Americans. [62, 63]. 
 
2.1.3.4 Pathophysiology of herpes zoster in postherpetic neuralgia stage 
After the resolution of cutaneous symptoms in acute stage HZ, the paroxysmal or constant 
pain may persist for more than 3 months. This complication is named as PHN [9]. PHN is a 
heterogeneous disorder that involves both peripheral and central processes [64]. For the 
peripheral processes, an increased expression of messenger ribonucleic acid (mRNA) for 
voltage-gated sodium channels were shown in primary afferent neurons after nerve injury, 
which may contribute to an increased responsiveness of primary nociceptors [64]. The central 
process involves secondary changes in the spinal cord dorsal horn atrophy, affected sensory 
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neuronal cell bodies and axon degeneration, dorsal root ganglion scarring, and epidermal 
innervation loss [64, 65]. Another study showed the unilateral PHN might be associated with 
bilateral sensory neuron damage [66]. 
 
Increasing age [36], high severity of pain and lesion in the acute stage [67], facial and sacral 
locations of HZ [68], female gender, psychological distress [69] and viremia all have a close 
association with the risk of PHN [70]. 
 
2.1.4 Diagnosis 
Herpes zoster characteristic clinical symptoms 
According to current guidelines [7, 14, 71], The diagnosis of HZ is usually confirmed by its 
characteristic clinical symptoms: grouped vesicles rash with asymmetrical dermatomal 
distribution, most commonly located in thoracic dermatome, limited by midline of body, 
prodromal symptoms and HZ-associated segmental pain. Local clinical manifestation may 
include pruritus, paraesthesia, dysesthesia or anaesthesia [71]. The most common anatomic 
location is the thoracic dermatome [7, 71]. The diagnosis based on clinical symptoms of 
classical unilateral HZ that occurred on the thoracic or lumbar dermatomes is strongly 
recommended by the most recent European Academy of Dermatology and Venereology 
(EADV) guideline [71]. 
 
Laboratory diagnostic techniques 
Further evidence of infection of VZV where the symptoms are not obvious can be provided 
by laboratory examination techniques. For suspected infection of newborn infants, pregnant 
women, immune-deficient patients and central nervous system (CNS) involvement, 
laboratory diagnosis must be used to confirm the infection [7, 14, 71]. Currently, the VZV 
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polymerase chain reaction (PCR), specific VZV antigens and antibodies detection, and viral 
culture through cell cultures are recommended by guidelines for the above special 
circumstances [7, 71].  
 
2.1.5 Clinical characteristics 
In the acute stage, the VZV spreads via sensory nerves to the skin and causes prodromal pain 
with papulovesicular rash. Small to moderate size papules with tense wall and clear fluid 
distribute unilaterally in dermatomes as a result of the inflammatory response and necrosis of 
the infected nerve [7, 14]. HZ can occur in any part of the skin, and the thoracic region is the 
most frequently infected area [72]. The time course of HZ is typically divided into 3 phases: 
(1) prodromal phase, (2) vesicular and (3) encrustation phase, and PHN phase.  
 
2.1.5.1 Prodromal phase 
The prodromal phase lasts 3 to 5 days. Clinical symptoms are non-specific, and may include 
tiredness, low grade fever, headache, photophobia, burning pain and unusual sensation such 
as itchy or tight feeling of the skin [7, 9, 12]. 
 
2.1.5.2 Vesicular and encrustation phase 
In the vesicular phase, groups of papules appear which are small to moderate in size. Tight 
wall vesicles with clear fluid develop above a red macular base. The rash will have a 
unilateral and asymmetric distribution, with some itching, tingling and painful abnormal 
sensation of the skin. It usually takes 10 days from the appearance to disappearance of the 
lesion. However, for some immunocompromised patients, the duration of this period may be 
up to several months [9, 12]. 
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2.1.5.3 Postherpetic neuralgia  
PHN is defined as an intractable, chronic, neuropathic pain continuing after the recovery 
from acute infection [9]. No consensus on the time course of PHN has yet been reached 
among various guidelines and reviews, with definitions of chronic pain ranging from one 
month to three months after the resolution of acute rash [1, 7, 9]. The most recognised 
definition is three months.  
 
2.1.5.3 Herpes zoster pain  
Up to 90% of HZ patients report that pain is commonly the predominant symptom through 
either acute or PHN [73].  Due to the inflammatory response and necrosis of the VZV 
infected sensory nerve in the acute phase of HZ, most patients suffer from moderate to the 
severe dermatomal pain of the affected area [74]. Patients ranked the acute HZ pain as more 
severe than labour or post-surgical pain [75]. The symptoms of allodynia, numbness and 
tingling sensation had an adverse effect on quality of life in 70% of people with PHN, with 
these symptoms described as ‘debilitating’ and ‘depressing’ [76]. 
 
2.1.5.4 Other types of herpes zoster 
Reactivation of VZV can occur in any location. When affecting certain nerves, the 
consequences can be more severe and are diagnosed as sub-types of HZ. In this thesis, the 
sub-types of HZ are all excluded for analysis.  
 
2.1.5.4.1 Zoster ocular diseases 
The second most commonly affected area is the ophthalmic division of the trigeminal nerve, 
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which may result in HZ ophthalmicus (HZO) [14]. Hutchinson’s sign, which means the skin 
lesion involves the tip, side or root of the nose, is a strong predictor of the ocular and corneal 
inflammation in HZO [77]. A series of ocular diseases and complications are related to the 
involvement of ocular infection due to the inflammatory and immune response to the VZV: 
episcleritis, scleritis, iridocyclitis, acute retinal necrosis, choroiditis, glaucoma, and keratitis 
[78]. The basic management of HZO is the same as HZ. For viral epithelial keratitis, local 
virostatic agents, acyclovir eye ointment for example, must be prescribed to patients [7]. 
Therapies are emerging which re-establish corneal aesthesia destroyed by the inflammation, 
including substance P and thymosin beta 4 eye drops, and the use of artificial cornea [78].  
 
2.1.5.4.2 Herpes zoster oticus 
Another commonly affected area is the ganglial cells of the VII and VIII cranial nerve, which 
usually results in facial paralysis (Ramsay Hunt Syndrome) [14]. The cranial nerve lesion is 
quite often associated with an acute peripheral facial nerve paresis, leading to a cluster of 
neurological damage disorders: facial muscle paralysis, hypofunction of hearing and balance 
function, disturbances of taste, lacrimal and nasal secretion [79]. First line recommendation 
for HZ oticus is initiating combined antiviral-corticosteroid therapy as early as possible, with 
adequate analgesic therapy [79].  
 
2.1.5.4.3 Zoster encephalitis and meningitis 
In some cases, the virus will travel through liquor and cause severe complications such as 
zoster encephalitis and meningitis [80, 81]. Immunocompromised and CNS involved patients 
have a higher risk of getting encephalitis and meningitis [14]. Acute or subacute delirium are 
the most common clinical symptoms, with other clinical observation of headache, fever, 
ataxia, meningismus, and seizures [82]. High-dose intravenous acyclovir therapy is 
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recommended by guidelines [7, 14]. 
 
2.1.5.4.4 Zoster sine herpete 
In some case reports, HZ may also occur in the absence of skin lesions (zoster sine herpete) 
[83, 84]. Laboratory techniques of PCR or specific VZV antibodies detection can be used to 
confirm diagnosis of the infection [7]. 
 
2.1.6 Current management 
2.1.6.1 Prevention 
From 2006, a vaccine against VZV has been available to reduce the incidence of HZ and 
PHN. In a randomised placebo-controlled trial, zoster vaccine significantly reduced the 
burden of illness of HZ by 61.1%, and reduced the incidence rate of HZ and PHN by 51.3% 
and 66.5% respectively [85].  
 
2.1.6.2 Conventional therapies 
The aim for HZ management is to relieve the acute pain, to limit the spread and time course 
of lesions, and to prevent or relieve PHN and other complications [1, 7]. Current 
pharmaceutical management includes antivirals, corticosteroids, analgesics (nonsteroidal 
anti-inflammatory drugs (NSAIDs), antidepressants, and anticonvulsants) therapies. They are 
all recommended by EADV guideline 2016 [86], German Dermatology Society (DDG) 
guideline 2003 [7], European review 2005 [9], and American guideline 2007 [14]. Table 2.2 
(Therapies recommended in clinical guidelines) highlights the therapies used in both acute 
HZ and PHN as recommended by clinical management guidelines.  
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Table 2.2 Therapies recommended in clinical guidelines 
Guideline 
Therapy 
Antiviral 
Therapies 
CS Analgesics Anti-
convulsants 
Patient 
Education 
Other 
Gross et al. 
2003 [7] 
HZ HZ HZ/PHN HZ NS TENS, 
capsaicin, 
local 
anaesthetic, 
neurosurgery 
Dworkin et 
al. 2007 
[14] 
HZ HZ HZ/PHN HZ HZ Neural, 
blockade, 
TENS  
Werner et 
al. 2016 
[86] 
HZ HZ HZ HZ NS Local 
therapies: 
antiseptics 
and zinc 
oxide 
CS: corticosteroid; HZ: acute stage herpes zoster; PHN: postherpetic neuralgia; TENS: 
transcutaneous electrical nerve stimulation; NS: not specified 
 
For patients presenting with acute HZ, risk factors for PHN need to be assessed. If the patient 
has any of the following risk factors, antiviral therapy should be prescribed for 7 days: 
 Severe acute pain 
 Age >50 years 
 Severe rash 
 Significant prodromal symptoms. 
If no risk factors are present, analgesics should be prescribed (see Figure 2. Stepped care in 
the management of neuralgia of HZ). The American guideline also emphasizes patient 
education as a routine treatment for people with HZ, which can be beneficial to patients’ 
well-being [14]. Review at 3-4 weeks is recommended [9] to assess for ongoing significant 
pain or allodynia. If pain persists, medications such as those suggested in steps 2 and 3 of 
Figure 2.1 may be considered [7, 86]. 
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Figure 2.1 Stepped care in the management of neuralgia of herpes zoster 
 
2.1.6.2.1 Antiviral therapy 
HZ is a self-limiting neurocutaneous disease. It usually heals without any complications 
when it occurs on the trunk or extremities of young individuals without risk factors, even if 
no specific antiviral therapy is prescribed to them [7]. When HZ develops beyond the age of 
50 years, and for people with other risk factors, antivirals are recommended as first-line 
pharmacotherapy [7, 9] (Table 2.3). The use of antiviral treatment has been shown to shorten 
the healing process, limit the duration of viral replication and further damage to the infected 
neuron, and reduce the incidence, duration, and severity of PHN [7, 9]. Topical therapy is not 
usually recommended, as there is limited evidence [14]. 
 
 
Step 1: Non-steroidal analgesics (for example 
paracetamol 1.5- 5g daily). 
Step 2: additional low- potency opioid analgesics 
(for example tramadol 200- 400 mg per day, codeine 
120 mg per day), if necessary, combined 
preparations. 
Step 3: in addition to a ‘peripheral’ analgesic, 
administration of a high-potency central opioid (for 
example buprenorphine 1.5- 1.6 mg per day; oral 
morphine 30-/ 360 mg per day) is indicated. This 
refers to patients who fail to respond the more 
measured treatment approaches. 
Anticonvulsants in 
severe neuralgia. 
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Table 2.3 Indications for antiviral therapy in the management of herpes zoster 
Urgent Indications Non-urgent Indications 
Zoster of any localization in patients beyond the 
age of 50;  
Zoster in the head/neck area of patients at any age; 
Severe zoster on the trunk/ extremities; 
Zoster in immunodeficient patients; 
Zoster in patients with severe atopic dermatitis and 
severe eczemas 
Zoster on the trunk/on the extremities in 
patients younger than 50 years old 
Adapted from Gross et al. [43] 
 
Available clinical practice guidelines and review for the management of acute stage HZ 
recommend antiviral therapy, including acyclovir, valacyclovir (a pro-drug of acyclovir), 
famciclovir, and brivudin [7, 9, 14]. Brivudin is not approved by Food and Drug 
Administration in the USA [7, 14], although the reasons for this are unclear. Commencement 
of therapy is needed as soon as the diagnosis of HZ is made, as the damage to sensory 
neurons is likely to have been occurring for several days before presentation to a General 
Practitioner or emergency department [7, 9]. Clinical trials have initiated antiviral therapy 
within 72 hours of onset of the rash, although Dworkin et al. [14] describe this as an 
“arbitrary inclusion criterion that does not necessarily reflect the cessation of viral 
replication”. In practice, this is unlikely to occur as patients may not present until after this 
time. The effect of antiviral therapy after 72 hours has not been evaluated systematically, 
therefore the effect of later initiation of antiviral therapy is unclear [14]. The dosage of these 
antiviral agents is described in German Dermatology Society guideline 2003 [7], European 
review 2005 [9], American guideline 2007 [14] (see Table 2.4. Antiviral therapy for herpes 
zoster for dosage by guidelines and review). 
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Table 2.4 Antiviral therapy for herpes zoster 
Medication Prescription Type Dosage Duration of Treatment 
Course 
Valacyclovir Oral 1000 mg 1, 2, 3 3 times daily for 7 days 
Acyclovir Oral 800 mg 1, 2, 3 5 times daily for 7 days 
Acyclovir Intravenous 5- 7.5 mg 2 3 times daily for 7 days 
Acyclovir Intravenous 
(immunodeficient 
patients) 
8- 10 mg 2 3 times daily for 7 to 10 
days 
Famciclovir Oral 250 mg (UK) 1, 2, 3  
500 mg (North 
America) 1, 3 
3 times daily for 7 days 
Brivudin Oral 125 mg 1, 2, 3 1 times daily for 7 days 
 1 Dworkin et al. 2007 [14]; 2 Gross et al. 2003 [7]; 3 Volpi et al. 2005 [9] 
 
Valacyclovir and famciclovir have been the most commonly used oral antiviral management 
of uncomplicated acute stage herpes zoster [87]. Both of these drugs have better 
bioavailability than acyclovir with fewer administration times for patients. Benefits with 
valacyclovir are also seen in shortening the time to resolution of pain compared to acyclovir 
[88]. Brivudin has the highest antiviral potency among these antiviral substances, requiring 
only one dose daily. However, this drug is not recommended for children, pregnant or 
lactating women, immunosuppressed patients and patients taking 5-fluoropyrimidines [7]. 
 
2.1.6.2.2 Corticosteroids 
Combining corticosteroids with antiviral therapy is recommended by the DDG [7]. The 
typical dosage for this treatment is prednisone, 60 mg daily for seven days, then reduce the 
dosage for the next two weeks [1]. These drugs should be prescribed with caution due to 
known adverse effects. 
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2.1.6.2.3 Analgesics therapy for neuralgia 
A stepped-care approach has been recommended by the DDG to manage neuralgia of HZ and 
PHN [7]. First line therapy are NSAIDs (Figure 2). Although there has been no systematic 
evaluation of the effects of NSAIDs on acute pain of HZ, it has been hypothesised that using 
analgesics in combination with antiviral therapy may reduce the risk of PHN [14] due to 
severe acute pain being a risk factor for PHN. Opioid analgesics (either peripheral or high 
potency central) may be added or substituted if pain relief is insufficient.  
 
Other analgesics options are anticonvulsants and tricyclic antidepressants (TCAs) when 
moderate to severe pain has not been resolved rapidly by opioid treatment [7]. Although there 
is little evidence for use of TCAs in acute stage HZ, they have been shown to be effective in 
providing moderate to excellent pain relief of PHN, and may be beneficial for acute pain 
[14]. In addition to this, TCAs can benefit through improving patients’ mood and sleep [87]. 
The most widely used TCA for PHN is amitriptyline [14, 87]. A placebo-controlled trial 
suggested that the use of amitriptyline with a dosage of 25 mg once daily for three months 
reduced the incidence of PHN by more than 50% six months after the acute stage [89].  
 
Anticonvulsants can be selected to reduce lancing pain in severe neuralgia cases [7]. 
Gabapentin or pregabalin are the two recommended by guidelines, which inhibit the alpha-2 
delta (α2-δ) subunit to reduce relevant neurotransmitter release [90]. Randomised controlled 
trials showed both gabapentin and pregabalin had demonstrated their efficacy in the pain 
management of PHN [91, 92]. There is no standard dosage recommendation for these 
anticonvulsant medications. From individual clinical trials, gabapentin can be initiated from 
900 mg/day to 1800 mg/day (7 to 10 days) based on the condition of patients [93], while 
pregabalin is usually prescribed at 150 to 600 mg/ day in flexible-dose studies with an 
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acceptable safety profile [87, 94]. Other treatments such as local anaesthetic neural blockade, 
transcutaneous electric nerve stimulation, and neurosurgery can be applied to the patients 
when necessary [7]. 
 
2.1.6.2.4 Safety profile and limitations of pharmaceutical therapies  
Although the management for HZ and PHN has proved to be beneficial, side effects are often 
associated with antiviral and analgesic therapy, and must be considered when determining 
treatment (Table 2.5). Nausea and headache are the two most common side effects of antiviral 
therapy [14]. Patients may suffer from vomiting, constipation, drowsiness and dizziness when 
taking analgesics [14]. With antidepressant use, drowsiness, dry mouth, blurred vision, 
weight gain and urinary retention may occur. More side effects such as gastrointestinal 
distress, oedema, and weight gain would appear when anticonvulsants and corticosteroids are 
used [14]. 
 
Table 2.5 Adverse events of pharmaceutical therapies 
Medication Common Adverse Events 
Antiviral therapy (including valacyclovir, 
acyclovir, famciclovir, and brivudin) 
Nausea, headache 
 
Oxycodone (opioid analgesic) Nausea/vomiting, constipation, sedation, 
dizziness 
Tramadol (opioid-like analgesics) Nausea/vomiting, constipation, sedation, 
dizziness, seizures, postural hypotension 
Prednisone (oral corticosteroid) Gastrointestinal distress, nausea, changes in 
mood, oedema 
Anticonvulsants (gabapentin and pregabalin) Sedation, dizziness, peripheral oedema 
Tricyclic antidepressants (especially 
nortriptyline) 
Sedation, dry mouth, blurred vision, weight 
gain, urinary retention 
 
In addition, Gater et al. [15] evaluated patient satisfaction with antiviral and analgesic 
treatment for HZ using the Treatment Satisfaction Questionnaire for Medication (TSQM, 
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version II [95]). Patient satisfaction was highest on the ‘side effects’ domain and lowest on 
the ‘effectiveness’ domain of the TSQM. The authors highlight this as an unmet need for 
people with HZ. 
 
2.2 Chinese medicine for herpes zoster 
2.2.1 Introduction of Chinese medicine 
Chinese medicine (CM) has been practised for thousands of years in China, with its earliest 
medical treatise Huang Di Nei Jing 黄帝内经 (The Yellow Emperor’s Classic of Internal 
Medicine) dating back to Warring States Period and from the Spring and Autumn period 
(770- 221 BC) [96]. Various treatment methods have been developed by CM practitioners to 
prevent and manage diseases, including acupuncture, Chinese herbal medicine (CHM), and 
other CM therapies (Chinese therapeutic massage, moxibustion, cupping, guasha, qigong, 
and tai chi). The scope of this thesis is limited to CHM and acupuncture therapies. 
 
The unique concepts of qi, yin and yang, and the five elements taken from the ancient 
Chinese naturalistic philosophy are the foundations of the CM theory [97]. The basic 
principles of CM include “concept of holism” (that is, recognising the human body as an 
organic whole and human beings interrelated with nature), and “treatment according to 
syndrome differentiation” (that is, individualised treatment based on grouped, related 
symptoms which facilitate diagnosis) [98]. With its unique theory and approach to diagnosis 
and treatment, CM contributes to the conventional management for diseases as an important 
complementary medicine with its encouraging clinical effect. 
 
In a national survey of Australia in 2005, 68.9% of the 1,067 interviewees used at least one 
kind of complementary and alternative medicine (CAM) in the previous year [99]. These 
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included CM therapies such as acupuncture (9.2%), CHM (7.0%), qigong, martial art and tai 
chi (6.0% in total), Chinese therapeutic massage (5.1%) and CM dietary therapy (2.3%) [99]. 
 
2.2.2 Definition of herpes zoster in Chinese medicine 
CM has been used for treating HZ for a long time, with one of the earliest recognised 
citations of HZ from the Zu Bing Yuan Hou Lun 诸病源候论 (610 AD) [100]. In this classical 
CM literature, HZ was described as “a skin disease encircles the waist” (Original text: 甑带
疮者，绕腰生) [100]. The location of the rash described in this citation is consistent with 
that in conventional medicine and contemporary CM textbooks [7, 16, 17]. 
 
In contemporary CM, HZ is commonly called she chuan chuang 蛇串疮, chan yao 缠腰, or 
huo dan 火丹. In Chinese language, the Chinese characters describe the symptoms as lesions 
grouped in a snake-like belt together on unilateral side of the body, with burning pain [16]. 
Consistent with conventional medicine, the diagnosis principles of HZ in CM textbooks are 
based on its characteristic symptoms [16, 17]. 
 
2.2.3 Aetiology and pathophysiology in Chinese medicine 
According to CM theory, HZ can be caused by both internal and external pathogens [16]. 
Stagnated heat generated by emotional injuries and retention of damp by improper diet are 
the two main internal pathogenic factors that may lodge in the skin and cause HZ. The 
external toxin pathogens can also directly attack the skin and induce cutaneous inflammation 
[16-18]. After the resolution of the acute infection, elderly people with HZ may suffer from 
long-lasting chronic pain (similar to the definition of PHN, consistent with clinical medicine) 
by qi stagnation and Blood stasis generated by the aging process [16-18]. Figure 2.2 
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summarises the possible aetiologies and pathogeneses of HZ according to CM. 
 
 
 
Figure 2.2 Chinese medicine aetiology and pathogenesis of herpes zoster [16] 
 
2.2.4 Syndrome differentiations 
Based on current CM textbooks, there are four main syndromes in acute stage HZ: Stagnant 
heat in the Liver meridian, Spleen deficiency with damp, damp and fire toxin, and qi 
stagnation and Blood stasis. After the resolution of acute lesions, qi stagnation and Blood 
stasis is also the common syndrome that people have for PHN [16-18]. 
 
Stagnant heat in the Liver meridian is a syndrome mainly dominated by heat pathogens. The 
symptoms in the syndrome of damp and fire toxin are similar to Stagnant heat in the Liver 
meridian. Spleen deficiency with damp retention is another syndrome of HZ, which is mainly 
dominated by damp pathogens. Syndrome of qi stagnation and Blood stasis can arise from 
Improper diet 
Attack by external toxin 
pathogens 
Emotional 
injuries 
Stagnation of 
Liver  
Stagnated heat of 
Liver meridian 
Pathogens 
logde in skin 
and cause 
herpes zoster 
Retention of 
damp and heat 
Aging process 
Blood deficiency and 
Liver hyperactivity  
Qi stagnation and Blood stasis 
Post-herpetic 
neuralgia (PHN) 
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residual toxin obstructing meridians, or may result from accumulation of damp. A summary 
of key symptoms for the syndrome differentiations is shown in Table 2.6. 
 
Table 2.6 Syndrome differentiations of herpes zoster 
Syndrome 
Differentiations 
Lesion Accompanying 
Symptoms 
Tongue Pulse 
Stagnant heat in 
the Liver 
meridian 
Red lesion, tense 
blister walls, 
burning heat, 
pricking pain 
Irritability, dry 
throat and bitter 
taste in mouth, 
dry stools with 
yellow urine 
Red tongue 
with thin or 
thick yellow 
coat 
Rapid, 
rolling and 
string-like 
pulse 
Damp and fire 
toxin  
Numerous big 
lesions, red base 
Burning heat and 
severe pain, 
headache, dry and 
bitter taste in 
mouth, yellow 
urine, and dry 
stool  
Red tongue 
with dry and 
yellow coat 
Rapid and 
rolling pulse 
Spleen 
deficiency with 
damp retention 
Light colour lesion, 
loose vesicular 
walls 
Abdominal 
distension with 
poor appetite, 
loose stool 
Pale tongue 
with white or 
greasy tongue 
coat 
Deep or 
rolling pulse 
Qi stagnation 
and Blood stasis 
Long lasting pain 
after disappearance 
of the lesion 
None specified Dark tongue 
with white fur 
String-like 
and thready 
pulse 
 
2.2.5 Chinese medicine treatment 
2.2.5.1 Oral Chinese herbal medicine 
Guided by the basic principle “treatment according to syndrome differentiation”, different 
Chinese herbal formulae are recommended by CM textbooks based on specific syndromes 
[16-18].  There is no clinical practice guideline on CHM for HZ. The CHM formulae 
recommended by CM dermatology textbooks for use in HZ syndromes are outlined in Table 
2.7. As the herbal ingredients of the formulae are not specified in the CM dermatology 
textbooks [16-18], the ingredients have been sources from a CM formulae textbook [101]. 
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Table 2.7 Oral Chinese medicine formulae recommended in Chinese medicine textbooks 
[16-18] 
Syndrome 
Differentiations 
 Formulae Function of the 
Formulae 
Herbal Ingredients [101] 
Stagnant heat in 
the Liver 
meridian 
Long dan xie gan 
tang 龙胆泻肝汤 
Clear heat of 
Liver and 
Bladder, and 
resolve 
dampness 
Long dan cao 龙胆草, huang qin 黄
芩, zhi zi 栀子, ze xie 泽泻, mu 
tong 木通, che qian zi 车前子, dang 
gui 当归, chai hu 柴胡, gan cao 甘
草, sheng di 生地 
Damp and fire 
toxin 
Qing gan xie huo 
jie du tang 清肝泻
火解毒汤 
Clear heat of 
Liver 
Not specified 
Spleen 
deficiency with 
damp retention 
Chu shi wei ling 
tang 除湿胃苓汤 
Clear heat and 
resolve 
dampness 
Cang zhu 苍术, hou po 厚朴, chen 
pi 陈皮, zhu ling 猪苓, ze xie 泽泻, 
fu ling 茯苓, bai zhu 白术, hua shi 
滑石, fang feng 防风, zhi zi 栀子, 
mu tong 木通, rou gui 肉桂, gan 
cao 甘草 
Qi stagnation 
and Blood stasis 
Chai hu shu gan 
san 柴胡疏肝散 
with Tao hong si 
wu tang 桃红四物
汤 
Regulate qi and 
activate blood 
Chai hu shu gan san 柴胡疏肝散: 
chai hu 柴胡, chen pi 陈皮, chuan 
xiong 川芎, xiang fu 香附, shao yao 
芍药, zhi ke枳壳, gan cao 甘草. 
Tao hong si wu tang 桃红四物汤: 
shu di 熟地, dang gui 当归, bai 
shao 白芍, chuan xiong 川芎, tao 
ren 桃仁, hong hua 红花 
 
2.2.5.2 Topical Chinese herbal medicine 
Different CHM formulae and single herbs can be applied to the acute lesions [17]. CHM 
bath, moist compress therapy, and topical application are the common therapies. Herbs used 
for topical application have the actions of clearing heat (eg. ye ju hua 野菊花, da huang 大
黄), activating blood (eg. di yu 地榆, zi cao 紫草, yu jin 郁金), resolving dampness (eg. ku 
shen 苦参), and regulating qi (eg. ru xiang 乳香). The main function of the herbs are 
consistent with the treatment principles for resolving the four main syndromes of HZ. A 
summary of the topical CHM therapies is shown as below: 
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Table 2.8 Topical Chinese medicine herbs/formulae recommended in Chinese medicine 
textbooks [17] 
Topical Chinese Herbal  
Medicine Therapies 
Before Resolution of 
Lesions 
After Formation of Scars 
Chinese herbal  
medicine bath 
Zi cao 紫草, ye ju hua 野菊
花, da huang 大黄, di yu 地
榆, ku shen 苦参 
Yu jin 郁金, ji xue teng 鸡血藤, 
chi shao 赤芍, ru xiang 乳香, 
mo yao 没药, wei ling xian 威
灵仙 
Moisten compress therapy Da huang 大黄, ku fan 枯
矾, ku shen 苦参, zi cao 紫
草, di yu 地榆, wu bei zi 五
倍子 
Not specified 
Topical application San huang xi ji 三黄洗剂, 
qin dai you 青黛油, hong 
tiao zi cao you 红条紫草油. 
Jing su lan ding 金素兰酊 
 
2.2.5.3 Acupuncture therapies and other Chinese medicine therapies  
For acupuncture and other CM therapies such as cupping, pricking to bleed and fire needle 
therapy, a recent acupuncture practice guideline recommends different treatment or 
combinations according to the course of progression of HZ (Table 2.9) [12]. Although 
treatment for HZ varies according to the different stage, the acupuncture point selections have 
similarity: ashi points 阿是穴 (translated as “where is the pain where is the acupuncture point 
for treatment”) are applying the treatment directly to the painful and lesion area; Huatuojiaji 
points 华佗夹脊穴 refer to the acupuncture points distributed parallel to the spinal column. 
The main function of stimulating ashi points 阿是穴 and Huatuojiaji points 华佗夹脊穴 is to 
regulate qi and have a local analgesic effect, which can be beneficial in managing the 
symptoms of HZ. 
 
Some acupuncture therapies including pricking to bleed and fire needling are recommended 
in the Chinese acupuncture practice guideline for HZ. However, these acupuncture practices 
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are seldom used outside of China, and will not be included in this thesis. 
 
Acupuncture treatment described in CM textbooks is more detailed, taking a different 
approach to the acupuncture practice guideline. CM textbooks recommend a group of 
acupuncture points for manual acupuncture selection, without reference to CM syndromes or 
HZ time course [16-18]. As for the main function of the acupuncture points, TE6 Zhigou 支
沟, PC6 Neiguan 内关, GB34 Yanglingquan 阳陵泉 are commonly used for alleviating pain, 
LI4 Hegu 合谷 and LI11 Quchi 曲池 are for clearing heat, while ST36 Zusanli 足三里 and 
SP6 Sanyinjiao 三阴交 are both for strengthening the Spleen and revolving dampness. 
Moxibustion is another acupuncture therapy recommended for HZ, with ashi points阿是穴 
being recommended [17]. 
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Table 2.9 Treatments recommendations by clinical practice guideline of acupuncture for herpes zoster [12] 
Phase Treatments Point Selection Course 
Prodromal phase Manual acupuncture, pricking to 
bleed with plum blossom tapping 
cupping 
Ashi points 阿是穴 (translated as 
“where is the pain where is the 
acupuncture point for treatment”) 
Once a day, 3-5 treatments 
Vesicular phase Pricking to bleed and cupping Vesicles on the trunk: Huatuojiaji 
points 华佗夹脊穴 (refers to the 
acupuncture points distributed parallel 
to the spinal column); vesicles on head 
and facial region: GV14 Dazhui 大椎 
Once a day, 6-10 treatments per 
course 
Fire needling Ashi points 阿是穴 between vesicles Once a day, 10 treatments per course 
Moxibustion Ashi points 阿是穴 on vesicles Once a day, 10 treatments per course 
Surround acupuncture combined 
with electro-acupuncture 
Ashi points 阿是穴 of vesicles Once a day, 10 treatments per course 
Encrustation phase Same as vesicular phase   
Postherpetic 
neuralgia phase 
Fire needling Ashi points 阿是穴 and  Huatuojiaji 
points 华佗夹脊穴 on the affected side 
Once a day, 2 weeks as one course  
Surround acupuncture Ashi points 阿是穴 Once a day, 10 treatments per course, 
2 courses in succession 
Electro-acupuncture Huatuojiaji points 华佗夹脊穴 on the 
affected side 
Once a day, 10 treatments per course, 
2 courses in succession 
Pricking to bleed and cupping Ashi points 阿是穴 and Huatuojiaji 
points 华佗夹脊穴 on the affected side 
Once a day, 10 treatments per course, 
2 courses in succession 
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2.2.6 Current evidence of Chinese medicine treatment for herpes zoster 
Currently, there are no identified systematic reviews (SRs) published in English which 
evaluate CM treatment for HZ. Three SRs evaluating the efficacy and safety of CHM 
therapies in the management for HZ [19-21], and seven SRs evaluating acupuncture therapies 
[22-28] were identified in Chinese databases CBM (China BioMedical Literature), CNKI 
(China National Knowledge Infrastructure), CQVIP (Chongqing VIP) and WanFang data 
(Table 2.10). The comparators reported in these SRs varied, with pharmacotherapies being 
used alone or in combination of CHM or acupuncture.  The evidence of the SRs has shown 
CM therapies might be beneficial in improving HZ symptoms with mild adverse events 
reported (Table 2.10). However, the evidence is limited by some methodogical issues. A 
summary of the current evidence of CM for HZ is shown as below. 
 
2.2.6.1 Chinese herbal medicine systematic reviews 
Of the three SRs evaluating the clinical evidence of CHM, one study evaluated general CHM 
therapies (no specified formulae names provided) [19], one study evaluated formulae which 
included the herb Dan shen 丹参 (alone or combined with other CM or pharmacotherapies) 
[21], and the other one evaluated formulae used to address one treatment principle Huo xue 
hua yu 活血化瘀 (activate Blood and dispel stasis) formulae (Table 2.10) [20] . The CHM 
therapies in these studies showed benefits in shortening time to resolution of skin rash, 
reducing pain and PHN incidence rate compared with pharmacotherapies. Only one SR [20] 
evaluated the safety of Huo xue hua yu 活血化瘀 formulae (Table 2.10). Mild 
gastrointestinal discomfort, diarrhoea, and drowsiness were reported in several studies. The 
formulae were well tolerated by the participants.  
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2.2.6.2 Acupuncture therapies systematic reviews 
Various acupuncture therapies including general acupuncture therapies, electro-acupuncture, 
moxibustion, and fire needling were evaluated systematically in the SRs [22-28] (Table 2.10). 
The evidence from SRs showed that acupuncture therapies shortened the time to resolution of 
pain, reduced the incidence of PHN, and improved cutaneous outcomes compared with 
pharmacotherapies. Only one SR evaluated the safety of fire needling [25]. Fire needling 
showed mild side effects among the included studies, with individual cases of drowsiness and 
fatigue being reported. 
 
2.2.6.3 Limitation of the systematic reviews 
Not all reviews searched the English language databases, and those that did only searched 
two databases (Medline and the Cochrane Library) [20-23, 27, 28]. None of the reviews 
searched the databases Embase, CINAHL (Cumulative Index of Nursing and Allied Health 
Literature), or the specialist database AMED (Allied and Complementary Medicine 
Database). For the Chinese databases, CBM, CNKI, CQVIP, and Wanfang Data were the key 
databases searched. However, only four of the SRs covered all the Chinese databases above 
[23-25]. 
 
One paper clearly stated an inclusion criterion of acyclovir as the comparator [28], all others 
included a broad range of intervention and comparator types. For example, one SR combined 
the results of studies of electro-acupuncture (EA) plus pricking to bleed and cupping with EA 
plus ear pricking to bleed. Pooling of studies with different interventions for statistical 
analysis may cause high heterogeneity and results in weak strength of evidence. The reason 
for pooling studies for statistical analysis was not clear. 
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None of the SRs reported the dosage of the comparators in the included studies, so the 
efficacy of either CHM or acupuncture remains unclear. Among these studies, only two 
studies evaluated the safety of the intervention, which is also a gap to evaluate CM therapies 
systematically. 
 
The evidence from SRs published in Chinese language is insufficient to draw conclusions 
about the efficacy and safety of CM for HZ. To address this gap, SRs prepared with a more 
comprehensive search of both Chinese and English databases and more strict inclusion and 
exclusion criteria are needed.  
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Table 2.10 Systematic reviews of herpes zoster in Chinese language 
Author, 
Year 
Databases No. of 
Trials 
Intervention
; 
Comparator 
Outcome Measures Results 
Cure 
Rate 
Effective  
Rate 
VAS 
Score  
Time to 
Resolution 
of Pain 
Time to 
Resolution 
of Herpes 
Time 
Course 
PHN 
Incidence 
Rate 
Systematic review of Chinese herbal medicine 
Fu, 2014 
[24] 
CNKI, 
Wanfang 
7 CHM; WM X - - - - - - I > C 
Xu, 
2010 
[21] 
Cochrane, 
MEDLINE, 
CBM, CNKI, 
Wanfang 
 
13 Dan shen 丹
参 or dan 
shen 丹参 
+other CHM 
or WM; WM 
X - X X - X - I > C 
Xu, 
2009 
[20] 
Cochrane, 
MEDLINE, 
CBM, CNKI, 
Wanfang 
19 Huo xue hua 
yu 活血化瘀 
formulae; 
WM 
X - - X X X X I > C 
Systematic review of acupuncture therapies 
Yu, 2007 
[26] 
Wanfang, 
CNKI, 
CQVIP 
10  General 
acupuncture; 
WM 
X - - X - - - I > C 
Fu, 2009 
[24] 
Wanfang, 
CNKI, 
CQVIP, 
CBM 
14 Huatuojiaji 
points 华佗
夹脊穴
acupuncture; 
WM or 
general 
acupuncture 
X X X - - - - I > C 
Cao, 
2010 
[22] 
MEDLINE, 
CNKI, 
CQVIP, 
12 General 
acupuncture; 
WM or CHM 
X - - X - - - I > C 
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Wanfang 
Chen, 
2013 
[23] 
MEDLINE, 
Wanfang, 
CNKI, 
CQVIP, 
CBM 
9 Electro-
acupuncture; 
WM 
X - X X X - X I > C 
Zheng, 
2011 
[28] 
MEDLINE, 
SCI, CNKI, 
CQVIP, 
Wanfang 
5 Moxibustion; 
acyclovir 
X - - - - - - I > C 
Zhao, 
2007 
[27] 
Cochrane, 
MEDLINE, 
CBM 
7 General 
acupuncture; 
WM 
- X - - - - - I > C 
Wang, 
2009 
[25] 
PubMed, 
CENTRAL, 
Business 
Source 
Premier, 
HSRPROJ, 
Clinical 
Trials 
Databases, 
CBM, CNKI, 
CQVIP, 
Wanfang 
6 Fire needle; 
WM 
X - - X X - X I > C, 
no 
differen
ce in 
PHN 
inciden
ce rate 
C: comparator; CHM: Chinese herbal medicine; I: intervention; PHN: postherpetic neuralgia; VAS: visual analogue scale; WM: western medicine
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2.3 Chapter summary 
HZ is a distinguishing neurocutaneous disease caused by reactivation of the VZV. Global HZ 
incidence rate is 4 to 4.5 per 1,000 PY and has an age-adjust increasing trend of incidence 
[3]. Both HZ and its most common sequelae PHN have a great impact on patient’s quality of 
life and economic burden to individuals and the healthcare system. 
 
Current management for HZ aims to relieve the acute pain, to limit the spread and time 
course of lesions and to prevent or relieve PHN and other complications. Antiviral therapy, 
corticosteroids, analgesics, anticonvulsants, and antidepressants are recommended by various 
guidelines. For the management of neuralgia either in acute or PHN stage, a stepped-care 
approach is recommended by guideline [7]. Even though adverse events are reported, this 
was the aspect of treatment patients were most satisfied. However, people with HZ were least 
satisfied with the perceived effectiveness of the antiviral and analgesic medication based on  
research using Treatment Satisfaction Questionnaire for Medication [15]. 
 
CM may offer an alternative and complementary treatment method to conventional medicine. 
In CM theory, HZ can be caused by Stagnant heat, retention of dampness, and attack of 
external toxin. Three CM textbooks [16-18] and one acupuncture practice guideline [12] are 
commonly used to guide the practice of CM therapies. Different CHM formulae were 
recommended according to syndrome differentiations of HZ, while acupuncture therapies 
were specified in different stages of lesion progression. 
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The efficacy and safety of CM therapies has been evaluated in various systematic reviews. 
Both CHM and acupuncture therapies showed benefit in shortening time to alleviate pain, 
improving cutaneous outcomes, and reducing PHN incidence rate compared with 
pharmacotherapies. Mild adverse events of CHM and acupuncture therapies were reported. 
The clinical evidence of CM therapies is limited by search strategy, study inclusion criteria, 
and statistical analysis methods. Rigorous systematic reviews are needed for evaluating the 
safety and efficacy of CM therapies more comprehensively. 
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Chapter 3. Methods of data mining and cluster analysis of classical 
literature  
3.1 Introduction 
Over thousands of years, information of aetiology and pathogenesis, symptoms and clinical 
management of Chinese medicine (CM) related to various diseases were described and 
explained in depth in the classical literature. Much of the information continues to guide the 
contemporary guidelines and textbooks for CM practice. 
 
The primary guiding principle for classifying disease and formulating treatments in CM is 
syndrome differentiation (Bian zheng 辨证). To make sense of symptoms and their 
presentation in patients, CM practitioners group or cluster related symptoms together into 
categories to facilitate diagnosis. Although syndrome differentiations of herpes zoster (HZ) 
are described clearly in contemporary CM textbooks, differences in descriptions between 
classical and contemporary literature exist. Some of the classical literature citations such as 
cases reports and practitioners’ experiences often described symptoms only, without aligning 
them with a CM syndrome in texts.  
 
For deeper understanding of the potential symptom/syndromes clusters, cluster analysis may 
be an advanced data mining approach to address this gap. Currently cluster analysis has been 
used to discover the potential relationships of symptoms, related syndromes and treatment 
approaches in the classical literature research. A better understanding of symptom/syndromes 
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clusters through this approach can enhance the current knowledge of diseases. This chapter 
details the general methods of data mining and cluster analysis of the classical literature of 
HZ.  
 
3.2 Aims 
This chapter aims to: 
1. Provide the methods used for citation identification, data collection, coding and 
sorting of classical literature reporting on cases or treatment of HZ. 
2. Describe the methods of descriptive and cluster analysis of data collected from 
classical CM literature. 
 
3.3 Data collection and management 
The data collection and mining work followed the Standard Operating Procedures (SOPs) 
produced by the China-Australia International Research Centre for CM. Similar projects on 
dementia and memory disorders have been published using these SOPs [102, 103]. 
3.3.1 Database 
Zhong Hua Yi Dian (ZHYD) “Encyclopaedia of Traditional Chinese Medicine” (Version 5.0) 
[104] (Figure 3.1) is one of the biggest CM classical literature collections in the world. The 
ZHYD contains more than 1,000 CM books on CD-ROM from ancient times to the period of 
the Republic of China. The latest work included in the ZHYD is the Wai Ke Shi San Fang 
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Kao 外科十三方考 (published in 1947). Previous research comparing collections of the pre-
modern traditional literature on CM has found the ZHYD to be suitable for systematic 
searches, for its size, electronic format and broad spread of genres [103, 105].  
 
 
Figure 3.1 Example of the search screen and data obtainable using the Zhong Hua Yi 
Dian software 
 
3.3.2 Identification of search terms 
To identify the search terms in Chinese language, various sources were consulted including: 
 Contemporary CM clinical textbooks: External Chinese medicine 9
th
 edition 中医外
科学  [16], Chinese medicine integrated with Western medicine of Dermatology and 
Venereology 2
nd
 edition 中西医结合皮肤性病学 [17], External Chinese medicine 1st edition
中医外科学 [18]. 
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 CM dictionaries: Zhong Yi Fang Ji Da Ci Dian 中医方剂大辞典 (ZYFJDCD, Great 
Compendium of Chinese Medical Formulas). It is one of the largest compendiums contains 
96,592 individual formula entries, extracted from 680 CM books. It is also a comprehensive 
classical CM dictionary that contains the ingredients, preparation, treatment principles, and 
the book source of each formula. By checking the information of each formula in the 
category of “herpes zoster”, terms related to HZ might be identified. 
 Guidelines: Clinical Practice Guideline of Acupuncture for Herpes Zoster [12]. 
Consultation with a CM dermatologist was made to identify any additional search terms not 
located through the above searches. Search terms were approved after consultation with 
dermatologists and experts in Guangdong Provincial Hospital of CM.  
 
Besides the common terms such as she chuan chuang蛇串疮, chan yao缠腰, and huo dan
火丹 which were all identified in ZYFJDCD, two “modern” terms pao zhen 疱疹 and she 
dan yu hou tong 蛇丹愈后痛 were also included in the search terms list. As the ZHYD 
contains the CM literature from the era of the Republic of China (1912 to 1949), these terms 
were considered to be relevant. 
 
A total of 30 terms were used to search the ZHYD. The majority of the search terms 
described the lesion appearance, with the characters of “蛇” (snake), “带” (belt), “串” (string 
of beads), “缠” (encircling), and “龙” (dragon), and/or in combination with the location of 
the lesion with character of “腰” (waist). Some of the search terms used the pathogen of fire 
“火” or wind “风”, to describe the skin condition. The full list of the search terms is shown in 
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Appendix 1. 
 
3.3.3 Data collection and extraction 
Data collection work from ZHYD was done by two researchers (Kaiyi Wang, KW, and 
Haiying Liang, HL). Initially, each of the condition search terms was copied to the search 
field in the ZHYD. Each term was searched in the ZHYD software by both headings search 
function (Mu lu sou suo, 目录搜索, where the search term is found in the title/heading) and 
body text search function (Nei rong sou suo, 内容搜索, where the search term is found in the 
body text) to get the most comprehensive results. Relevant passages of text or headings 
which contained the search terms were displayed in the software. The number of hits 
(instances of the term) was also displayed. A Microsoft Excel® file was used to record the 
number of hits for each search term. 
 
The second step was to extract data using the data extraction function in ZHYD. A separate 
Microsoft Excel® file for each search term was created by the software containing the 
preliminary information: keywords (关键词), book title and chapter (关键词所在章节), and 
body text (关键词所在章节对应的正文, that is, the passages of texts which included the 
search term). All Microsoft Excel® files were merged to a final file once the data extraction 
work had been done. Citations were reviewed to identify duplicates, which were excluded 
from further analysis. For each citation, the author and dynasty were obtained from a 
bibliography database of CM classical literature. 
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3.4 Data coding and scoring system 
In order to facilitate analysis, coding was performed in Microsoft Excel®. This was 
undertaken independently by Kaiyi Wang and Haiying Liang. If disagreement occurred, 
resolution was sought by discussion. A third researcher (Tony Zhang) was available for 
consultation if needed, however this was not required. 
 
Initially, a preliminary data sort of all the citations was undertaken to determine whether they 
were documenting a skin condition. A secondary sort was then undertaken to code any 
identified citations for citation type, description of condition and treatment of the condition 
(see Table 3.1). All citations were consequently coded as one of eight different types: 
 code 0: not relevant to any skin condition  citations; 
 code 1: definition of skin condition citations; 
 code 2: aetiology and pathogenesis citations; 
 code 3: pharmacopeia citations; 
 code 4: CHM treatment citations; 
 code 5: acupuncture treatment citations; 
 code 6: moxibustion treatment citations; 
 code 7: other CM therapy treatment citations. 
The original texts which contained both descriptions of the condition and treatment were 
separated into different columns in Microsoft Excel® for further analysis. 
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Table 3.1 Preliminary coding of the citations 
Items Details or Codes 
Citation type 0=Not relevant to any skin condition, 1=Disease 
definition, 2=Aetiology and pathogenesis, 
3=Pharmacopeia citation, 4=CHM treatments, 
5=Acupuncture treatments, 6=Moxibustion treatments, 
7=Other CM therapy treatments 
Description of the condition in 
original citation 
The original text 
Treatment of the condition in 
original citation 
The original text 
 
After the preliminary coding work had been done, all of the relevant citations (excluding the 
citation type=0 not relevant) were further reviewed and coded according to description of 
symptoms (see Table 3.2). Each symptom was coded as “1” if present, or as “0” if absent. 
Symptoms were grouped according to category and allocated a code (eg S1, see Table 3.2) 
 
Table 3.2 Symptom coding 
Symptoms Category Details 
Lesion appearance (S1) 1. Belt 带 
2. Snake 蛇 
3. Encircling 缠/绕 
4. String of beads 串珠  
5. Patchy 斑片  
Lesion type (S2) 1. Blister 疱/泡  
2. Papules 疹  
3. Erythema/red spot 红斑 
Pain (S3) 1. Pain 痛 
2. Burning pain 灼痛 
Lesion color (S4) 1. Red 红 
2. Yellow 黄 
3. White 白 
Itch (S5) Itch 痒 
Heat (S6) Heat 热 
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Treatment details/ingredients including the Chinese herbal medicine formulae and herbs, 
acupuncture therapies and other CM treatments were also coded. The details included 
treatment methods (formula, single herb, acupuncture, and other therapy), formula name (for 
example, Long dan xie gan tang 龙胆泻肝汤), herbal ingredients (for example, cang zhu 苍
术, chen pi 陈皮, etc.), acupuncture points, preparation type (decoction, granules, etc.), and 
administration (oral or topical). 
 
Citations which included multiple descriptions of HZ (for example, different syndrome 
differentiations), were separated into multiple descriptions for statistical analysis and data 
mining. If the citations included multiple treatments, the citations were divided so that each 
description or treatment was counted separately for statistical analysis. 
 
Some citations did not specify the herb ingredients. In these cases, I searched the book 
containing the citation to identify other instances of the same formula which did list the 
ingredients. If identified, these ingredients were used for analysis. If the ingredients were not 
identified from another entry from the same book, the citations were excluded from statistical 
analysis of ingredients.  
 
3.5 Inclusion criteria 
The typical presentation of HZ has not changed over time. Accordingly, the characteristic 
symptoms described in contemporary clinical HZ guideline were used as inclusion criteria for 
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classical literature. These included grouped blistering eruptions on a red base of skin, burning 
or stabbing pain with a unilateral dermatome distribution [7]. 
 
The HZ ocular disease might contain special diagnosis criteria (for example, symptoms were 
limited around the eyes, accompanied by  headache) and CM treatment techniques may be 
different from those used for typical HZ. Citations which were judged to be HZ ocular 
disease were excluded from this research. After consultation and discussion with 
dermatologists and experts in Guangdong Provincial Hospital of CM, citations were 
categorised as follows: 
 
1. Not relevant to HZ (code 0): based on the description of the citation, the disease is 
definitely not HZ.  
2. No information or not enough information to permit judgment (code 1): if the citation 
described only one of symptoms S1, S2 and S3, and/or S4, and/or S5, and/or S6 (see Table 
3.2). 
3. “Possibly HZ” (code 2): if the citation described the symptoms containing any two of 
from S1, S2 and S3; and/or S4, and/or S5, and/or S6 (see Table 3.3 see note below). 
4. “Most likely to be HZ” (code 3): if the citation described the symptoms containing all 
symptoms S1, S2 and S3; and/or S4, and/or S5, and/or S6. 
The following table illustrates the disease judgment and codes for the citations: 
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Table 3.3 Disease judgment 
Symptoms “Most Likely 
to Be Herpes 
Zoster” 
Citations 
(code 3) 
“Possibly 
Herpes 
Zoster” 
Citations 
(code 2) 
No 
Information 
or Not 
Enough 
Information 
to Identify 
(code 1) 
Citations Not 
Relevant to 
Herpes Zoster 
(code 0) 
Lesion appearance 
(for example, belt, 
snake) 
All three 
characteristic 
symptoms 
Any two of the 
three 
characteristic 
symptoms 
Only one of 
the three 
characteristic 
symptoms 
A condition 
judged not to 
be herpes 
zoster Lesion type (for 
example, blister, 
papules) 
Pain 
Lesion colour (for 
example, red, yellow) 
+/- +/- +/- 
Itch +/- +/- +/- 
Heat +/- +/- +/- 
+/-: may or may not contain the symptom 
 
Citations judged as “0” (not HZ) were reviewed to determine what other conditions they may 
be, and this was documented. Only “Possibly HZ” (code 2) and “Most likely to be HZ” (code 
3) citations were eligible for further analysis. 
 
3.6 Descriptive analysis 
After the data extraction and coding work had been completed, data were transferred to 
Statistical Package for the Social Science (SPSS; version 21.0) software for further data 
analysis. Statistical analysis was conducted for the two categories of “possibly HZ” and 
“most likely to be HZ” separately: 
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1. Frequency analysis of search term: the total frequency of all search terms, and 
frequency of each search terms by dynasty (cross tabulation). 
2. Symptom frequency: frequency analysis of all symptoms in included citations. 
3. Treatment frequency: frequency analysis of CHM formulae and the standardised 
herbal ingredients. The herbal ingredients were standardised through a cross-referenced 
nomenclature list of commonly used CHMs published by the Chinese Medicine Board of 
Australia (CMBA, last updated September 2015) [106]. The reason for standardisation was 
due to the multiple names of the same herbs might be used in different citations. For example, 
da huang 大黄, sheng jun 生军 and jiang jun 将军 were the three common names of Rheum 
rhabarbarum L. used in the classical literature. The official name of this herb approved by 
CMBA is da huang 大黄, so herbal ingredients from the same plant with other names were 
standardised to da huang 大黄. 
 
3.7 Cluster analysis 
3.7.1 Data set 
In order to discover the potential relationships of the HZ symptoms, cluster analysis was 
conduct for the data set of symptoms. The cluster analysis was conducted for citations judged 
to be “most likely to be HZ” citations only, as the symptoms described in these citations were 
the most relevant to HZ. 
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3.7.2 Similarity measurement 
According to the basic theory of cluster analysis [107], the similarity (proximity), is used to 
identify how related the individuals are to each other in a data set. The data set included 
binary data (code 1= the symptom was present; code 0= the symptom was absent that is not 
described). Two individual symptoms i and j, have a similarity coefficient Sij of unity if both 
have identical values for variables [107]. For example, Sheat and belt means the similarity 
coefficient of unity of individual symptoms “heat” and “belt” in the included citations. The 
value differs in the scale of the interval between 0 and 1 generally, which show the likelihood 
of both individual symptoms being present. For example, Sheat and belt = 0.7 (70%), means that 
there is a 70% chance of both “heat” and “belt” both presented in all citations. Table 3.4 
describes the relationship between individual symptoms i and j.  
 
Table 3.4 Counts of binary outcomes for two individual symptoms  
 Individual Symptom i 
Outcome 1 0 Total 
Individual 
symptom j 
1 a b a + b 
0 c d c + d 
Total a + c b + d p = a + b + c + d  
a: co-present of i and j; b: i presents without j; c: j presents without i; d: co-absence of i and 
j; p: all the relationships above. 
 
A number of approaches for the Sij are recommended [107]. An important consideration 
which determines the analytical approaches to use is to deal with the 0 - 0 matches, where 
neither symptom is present (d in Table 3.4).  
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In some data sets, the co-absence of two factors may be important for statistical analysis, for 
example, gender or blood type. For this data set, identification of the co-absence of both 
individual symptoms isn’t clinically useful, so the d count was not required. As a result, two 
similarity measures were selected; the Jaccard coefficient and Sneath and Sokal 
Measurement. The Jaccard coefficient (Sij = a/ (a+b+c)) excludes joint absences, with equal 
weight being given to matches and non-matches. The Sneath and Sokal Measurement (Sij = a/ 
[a+2(b+c)]) uses double weight given to non-matches. A third measurement, Gower and 
Legendre Measurement (Sij = a/ [a+0.5(b+c)]), was also considered; however, as this test is 
not possible in the available software [108] it was not able to be performed. In cluster 
analysis, the application of all available and applicable measurements is recommended [107]. 
 
3.7.3 Agglomerative hierarchical clustering methods 
The process of grouping the individual items to the whole classification varies, according to 
different agglomerative hierarchical clustering methods [107]. The agglomerative method 
means the clustering process follows a “bottom up” approach, with each item (individual 
symptom of HZ in this case) starting in its own cluster, and grouping of clusters being 
merged as one moving up the hierarchy. In other words, cluster analysis began with n clusters 
each containing a single individual symptom, to a classification with all the individual 
symptoms. The specified agglomerative methods may provide a series of successive fusions 
of the individual symptoms into groups. The agglomerative hierarchical clustering methods 
of single linkage (or ‘nearest neighbour’ in SPSS), complete linkage (or ‘furthest neighbour’ 
in SPSS), average linkage (between group linkage and within groups linkage in SPSS) were 
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selected to conduct the analyses of these binary data sets. While weighted average linkage is 
also recommended, it is not available in SPSS software and was not conducted. 
 
After the parameter of the similarity measurement and agglomerative method had been set, 
the results of the cluster analysis were displayed as dendrograms. A dendrogram is also 
known as tree diagram. The horizontal axis of the dendrogram represents the distance or 
dissimilarity between clusters, where a lower value indicates greater similarity, while the 
vertical axis represents the objects and clusters. Details of the selected agglomerative 
hierarchical clustering methods are shown in  
 
Table 3.5 Standard agglomerative hierarchical clustering methods for binary data set  
Method Definition of Distance 
Between Clusters 
Features 
Single linkage Minimum distance between 
pair of individuals, one in 
one cluster, one in the other 
Tends to produce unbalanced and 
straggly clusters, especially in large data 
sets. Does not take account of cluster 
structure 
Complete linkage Maximum distance between 
pair of individuals, one in 
one cluster, one in the other 
Tends to compact clusters with equal 
diameters (maximum distance between 
objects). Does not take account of 
cluster structure 
Average linkage 
(Between-group) 
Joins the two clusters for 
which the average distance 
between members of those 
two clusters is the smallest 
Tends to join cluster with small 
variances. Intermediate between single 
and complete linkage. Takes account of 
cluster structure. Relatively robust. 
Average linkage 
(Within-groups)  
Joins the two clusters for 
which the average distance 
between members of the 
resulting cluster will be 
smallest  
Adapted from Brian S. 2010 [107] 
 
The main difference among these agglomerative methods is the definition of the distance 
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between clusters, with single linkage applying the minimum distance, the complete linkage 
applying the maximum distance, while between-group and within-group applying the 
intermediate average distance. These are the main agglomerative methods used for 
hierarchical cluster analysis. A process recommended by Brian S. et al. [107] is to apply all 
the available agglomerative methods to hierarchical cluster analysis. Analysis of symptoms 
clusters were conducted based on each dendrogram generated, as per similarity measurement 
and hierarchical clustering methods. Sub-cluster analyses were conducted where 
dendrograms showed more small classifications of individual symptoms. A comparison of the 
dendrograms was conducted between the applied agglomerative methods, and clusters of 
symptoms were identified according to the characteristics of the dendrograms. 
 
3.8 Chapter summary 
This chapter generally describes the methods of data mining and cluster analysis of classical 
literature in this research. The comprehensive classical literature search was conducted in 
ZHYD. A total of 30 search terms were identified in CM textbooks, dictionaries, and 
guidelines, which were confirmed after consultation with dermatologists and experts. Data 
were exported and merged to a Microsoft Excel® file. After duplicates removal, citations 
were reviewed and coded. Relevant citations were further reviewed and coded according to 
description of symptoms. Based on the symptoms, the citations were categorised as four 
groups: most likely HZ citations, possibly HZ citations, citations contain no information or 
not enough information to permit a judgement, and not relevant to HZ citations. Treatment 
details of the most likely HZ and possibly HZ citations were also extracted and coded.  
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Data were transferred to SPSS software for further data mining after extraction and coding 
work had been completed. Descriptive analysis was conducted for the two categories of 
“possibly HZ” and “most likely to be HZ” separately. Frequency analysis of search terms, 
symptoms and treatments were conducted and analysed. The cluster analysis was conducted 
for “most likely to be HZ” citations only, to discover the potential relationships of the HZ 
symptoms. Two similarity measurements and four agglomerative methods were selected 
according to the data characteristics and functions available in SPSS software. Cluster results 
were displayed as dendrograms. Meaningful clusters of the HZ symptoms were identified 
after comparison among the dendrograms. 
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Chapter 4. Data mining and cluster analyses of classical literature  
4.1 Introduction 
Contemporary literature suggests the earliest citation of herpes zoster (HZ) is from the Zhu 
Bing Yuan Hou Lun 诸病源候论 dating back to 610 AD [100, 109, 110]. In this citation, the 
term zeng dai chuang 甑带疮 was used to describe HZ as a skin condition that encircles the 
waist (Original text: 甑带疮者，绕腰生). Another typical citation from Za Bing Yuan Liu Xi 
Zhu 杂病源流犀烛 (1773) named HZ as chan yao huo dan 缠腰火丹 and huo dai chuang 火
带疮. This citation described HZ as “a skin disease distributes in the lumbar and thoracic 
region of the human body, with countless vesicles like a belt” (Original text: 缠腰火丹者，
即火带疮，缠于带脉，故腰间生疮，累累如珠，如束带者然), which was similar to the 
symptoms described in conventional medicine and contemporary Chinese medicine (CM) [7, 
9, 14, 16-18].  
 
Over a long history, a complete CM system of terminology, symptoms, syndrome 
differentiations and therapies for HZ, has been developed from clinical practice and literature. 
The valuable information contained in the classical literature continues to influence and 
instruct contemporary CM practice. Currently, this information has not been systematically 
evaluated and analysed. 
 
This chapter describes a systematic evaluation (data mining) of citations collected from 
Zhong Hua Yi Dian (ZHYD) 中华医典, one of the largest collections of CM classical 
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literature. Frequently used disease terms, symptoms and treatments in classical literature were 
statistically analysed and compared with modern evidence. Further, cluster analyses of the 
data were also conducted to discover the potential relationships between symptoms and 
implications for clinical practice. The methods used have been described in Chapter 3. 
 
4.2 Aims 
This chapter aims to: 
1. Evaluate the CM interventions used for HZ in classical literature. 
2. Examine the most frequently used herbs, formulae, and therapies through descriptive 
statistical analysis; and to compare management for HZ between modern and that recorded in 
the classical literature. 
3. Discover the potential relationships of the HZ symptoms extracted from the classical 
literature through inferential statistics/cluster analysis.  
 
4.3 Results  
A total of 208 hits (instances of the term) were identified through title/heading search and 
1,455 hits through body text search in ZHYD (Version 5.0) using the search terms separately. 
Many hits were identified by two or more search terms. Terms huo dan火丹 and chan yao 缠
腰 produced the greatest number of hits: 145 title/heading hits with 1,047 body text hits, and 
16 title/heading hits with 106 body text hits, respectively (see Appendix 2). It is not 
surprising that term huo dan 火丹 returned the greatest number of hits in the search of 
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ZHYD. The term huo dan火丹 was used to described a wide range of diseases in ancient 
times including HZ, erysipelas, mumps, etc. Many terms such as chan yao huo long 缠腰火
龙, she dan yu hou tong蛇丹愈后痛, pao zhen 疱疹, and she xing dan 蛇形丹/蛇型丹 which 
were included in the search failed to hit any title/heading or body text (see Appendix 2). 
These terms may have been used in texts which were not included in the ZHYD.  
 
In total 1,107 citations (including the information of body texts related to the search terms, 
books, chapters) were collected from the database search (see Figure 4.1). Eight hundred and 
seventy-five citations were reviewed after duplicates were removed. During preliminary 
screening, citations were excluded for the following reasons: not classical citations (published 
after 1949, 56 citations), ocular disease (5 citations). Eight hundred and fourteen citations 
were then assessed to determine whether they referred to skin conditions. Preliminary 
information were coded.  
 
Of these 814 citations, 136 citations were judged to be not relevant to any skin conditions and 
excluded. Two hundred and ninety-six citations were considered to be describing skin 
conditions not related to HZ (code 0), and 286 citations had no information or insufficient 
information to judge the likelihood of being HZ (code 1). Ninety-six citations which were 
considered to be possibly (code 2) or most likely (code 3) citations of HZ were included for 
further information extraction and data analysis. Results were presented in two categories: 
citations judged as “possible” HZ citations (62 citations, see full texts in Appendix 3) and 
those judged most likely to be HZ citations (34 citations, see full texts in Appendix 4) based 
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on symptoms descriptions. The following flow chart shows the data sorting and management 
process (Figure 4.1).  
 
Figure 4.1 Flow chart of the selection process of the classical literature citations 
 
4.3.1 Search terms and dynasty 
Eighteen search terms identified citations that were possibly or most likely to be HZ. Forty-
nine citations were identified by more than one search term. The search terms chan yao 缠腰 
and huo dan 火丹 provided the greater number of possibly and most likely to be HZ citations: 
54 and 44 citations respectively (Table 4.1). The most commonly used term in contemporary 
CM textbooks she chuan chuang 蛇串疮 was cited only 10 times (5.2% of total citations) in 
the included citations. The dataset suggests a change in terminology over time (Table 4.2). 
Zhong Hua Yi Dian (Encyclopaedia of Traditional Chinese Medicine) 
that contains over 1,000 books  
Search 
Collect  
Collect citations that contain the term(s) that possibly referred to herpes 
zoster (n =1,107) 
Sort  
Remove duplicates, evaluate citations based on the symptoms described 
and clinician’s overall judgment (n=814) 
Analyse Statistical analysis of most likely to be herpes zoster citations (n=34) 
and possible herpes zoster citations (n=62)  
Frequency analysis: Publication dynasty, 
symptoms, treatment details  
Cluster analysis: symptoms hierarchical 
clustering 
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Table 4.1 Number of citations identified by each search term 
Pinyin, Chinese Characters Number of Citations 
Obtained By the Search 
Term 
Percentage of Total 
Citations  
Chan yao缠腰 54 56.3% 
Huo dan火丹 44 45.8% 
Chan yao huo dan缠腰火丹 32 33.3% 
She chan dan蛇缠丹 13 13.5% 
She chuan chuang蛇串疮 10 10.4% 
Huo dai chuang火带疮 9 9.4% 
Chan yao dan缠腰丹 7 7.3% 
She chan chuang蛇缠疮 7 7.3% 
She dan蛇丹 5 5.2% 
Bai she chan yao白蛇缠腰 2 2.1% 
Chan yao chuang缠腰疮 2 2.1% 
Huo dan chuang火丹疮 2 2.1% 
She ke chuang蛇窠疮 2 2.1% 
Chan yao long缠腰龙 1 1.0% 
Huo yao dai火腰带 1 1.0% 
Huo yao dai du火腰带毒 1 1.0% 
Zeng dai chuang甑带疮 1 1.0% 
Zhi zhu chuang蜘蛛疮 1 1.0% 
Note: the total percentage exceeds 100 as many citations were identified by multiple search 
terms 
4.3.1.1 “Possible” herpes zoster citations 
A total of 17 search terms identified citations that were judged as “possibly” HZ. For search 
terms which yielded citations, the distribution of terms over time is shown in Table. 4.2.  
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Table 4.2 “Possible” herpes zoster citations per search term by dynasty  
 Dynasty 
Search Term Before 
Tang 
(before 
618 AD) 
Tang 
(618- 
907 
AD) 
Yuan 
(1272 - 
1368) 
Ming 
(1368-
1644) 
Qing 
(1636- 
1912) 
Minguo 
(1912- 
1949) 
Japan Total 
Chan yao 缠腰 0 1 0 2 18 3 0 24 
Huo dan 火丹 0 0 0 3 14 0 0 17 
She chan dan 蛇
缠丹 
0 0 0 4 8 1 0 13 
Chan yao huo 
dan 缠腰火丹 
0 0 0 2 5 0 0 7 
She chan 
chuang 蛇缠疮 
0 0 1 3 2 0 0 6 
Chan yao dan 
缠腰丹 
0 0 0 0 5 0 0 5 
Huo dai chuang 
火带疮 
0 0 0 4 0 0 1 5 
She dan 蛇丹 0 0 0 2 3 0 0 5 
She chuan 
chuang 蛇串疮 
0 0 0 0 2 0 0 2 
She ke chuang 
蛇窠疮 
0 0 0 0 2 0 0 2 
Bai she chan 
yao 白蛇缠腰 
0 0 0 0 1 0 0 1 
Chan yao long 
缠腰龙 
0 0 0 0 1 0 0 1 
Huo dan chuang 
火丹疮 
0 0 0 0 1 0 0 1 
Huo yao dai 火
腰带 
0 0 0 0 1 0 0 1 
Huo yao dai du 
火腰带毒 
0 0 0 0 1 0 0 1 
Zeng dai chuang 
甑带疮 
1 0 0 0 0 0 0 1 
Zhi zhu chuang 
蜘蛛疮 
0 0 0 0 1 0 0 1 
Note: many citations were identified by more than one search term, therefore the total 
number of citations by dynasty is greater than the total number of citations. 
 
The most frequently used terms were chan yao 缠腰 (24 citations), huo dan 火丹 (17 
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citations), she chan dan 蛇缠丹 (13 citations), chan yao huo dan 缠腰火丹 (seven citations), 
she chan chuang 蛇缠疮 (six citations), chan yao dan 缠腰丹 (five citations), huo dai 
chuang 火带疮 (five citations), and she dan 蛇丹 (five citations). The other terms were 
identified in only one or two citations. The majority of citations were from the Ming and 
Qing dynasties. The earliest citation was from Zhu Bing Yuan Hou Lun 诸病源候论 (610 
AD) identified by the term zeng dai chuang 甑带疮 (Original text: 甑带疮者，绕腰生), 
which is also recognised by several contemporary CM literature [100, 109, 110]. In this 
citation, HZ was described as “a skin disease encircles the waist”. Although the location of 
the rash described in this citation was consistent with that in conventional medicine and 
contemporary CM textbooks [7, 17, 18], there was insufficient HZ characteristic symptoms to 
judge it to be the citation referred to HZ. The most recent citation was from the Ben Cao Jian 
Yao Fang 本草简要方 (1938) identified by term she chan dan 蛇缠丹 (Original text: 杂甘草
擂醋搽蛇缠丹毒). 
 
Another example of a “possible” HZ citation was from Ben Cao Dan Fang 本草单方 (1633), 
which described the skin condition as “huo dai chuang 火带疮, is encircling the waist” 
(Original text: 火带疮，绕腰生者). Although the body text provided key characters “belt” 
(dai in pin yin or 带), and “encircling”, the lack of other characteristic HZ symptoms meant it 
was not able to be judged as most likely to be HZ. 
 
4.3.1.2 “Most likely” to be herpes zoster citations 
For the citations that were judged “most likely” to be HZ, the distribution of the search terms 
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is shown in Table 4.3. The most frequently used terms were chan yao 缠腰 (30 citations), huo 
dan 火丹 (27 citations), chan yao huo dan 缠腰火丹 (25 citations), she chuan chuang 蛇串
疮 (eight citations), huo dai chuang 火带疮 (four citations), with other terms identifying only 
one or two citations. The “most likely” to be HZ citations were from Ming (five citations) 
and Qing dynasties (29 citations) only. 
 
Fewer search terms identified citations that were judged “most likely” HZ. Terms chan yao 
long 缠腰龙, huo yao dai du 火腰带毒, chan yao dan 缠腰丹, she dan 蛇丹, she ke chuang 
蛇窠疮, zeng dai chuang 甑带疮, and zhi zhu chuang 蜘蛛疮 were not found in “most 
likely” HZ citations. The number of search terms identifying “most likely” HZ citations was 
lower than that for “possible” HZ citations. This may be due to the criteria for judgment of 
citations, where “possible” HZ citations may have included skin conditions other than HZ. 
 
Table 4.3 “Most likely” to be herpes zoster citations per search term by dynasty 
Search Term Dynasty 
Ming  
(1368-1644) 
Qing  
(1636- 1912) 
Total 
Chan yao 缠腰 5 25 30 
Huo dan 火丹 5 22 27 
Chan yao huo dan 缠腰火丹 5 20 25 
She chuan chuang 蛇串疮 0 8 8 
Huo dai chuang 火带疮 1 3 4 
Chan yao chuang 缠腰疮 0 2 2 
Chan yao dan 缠腰丹 1 1 2 
Bai she chan yao 白蛇缠腰 0 1 1 
Huo dan chuang 火丹疮 0 1 1 
She chan chuang 蛇缠疮 0 1 1 
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The standard contemporary term for HZ she chuan chuang蛇串疮 was identified since Qing 
dynasty in these citations. The earliest citation of she chuan chuang 蛇串疮 was in Wai Ke 
Da Cheng 外科大成 (1665), and the most recent citation in Wai Ke Bei Yao 外科备要 
(1904).  
 
The earliest citation judged “most likely” to be HZ from this search was from Zheng Zhi 
Zhun Sheng - Yang Yi证治准绳·疡医 (1602), that was identified by four search terms chan 
yao 缠腰, chan yao huo dan 缠腰火丹, huo dai chuang 火带疮, and huo dan 火丹. This 
citation presents some information of symptoms and a severe condition causing death. A 
reasonable English translation for this earliest citation is: 
Question: What is the skin condition that encircles the waist, with a string of 
beads?  
Answer: This is called huo dai chuang 火带疮, with another name chan yao huo 
dan 缠腰火丹. If the people with this disease are not treated in time, the toxin 
invades into the body via umbilicus, causing distension and death. (Original 
Chinese text: 或问：绕腰生疮，累累如珠何如？曰：是名火带疮，亦名缠腰
火丹。此证若不早治，缠腰已遍，则毒由脐入，膨胀不食而死。) 
 
The symptoms described in this citation, such as “string of beads”, “waist”, are consistent 
with the contemporary definition of HZ which includes grouped vesicles rash and 
dermatomal distribution [7]. The citation also describes a severe condition causing death, for 
people not receiving prompt treatment and the “toxin invades into the body via umbilicus”. 
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HZ complications zoster encephalitis and meningitis are severe, potentially fatal results of 
HZ infection [80, 81]. As no further details were provided, whether this citation refers to HZ 
complications is unclear. 
 
The most recent citation was from Wai Ke Nei Yao 外科备要 (1904), that was identified by 
four search terms: chan yao 缠腰, huo dan 火丹, chan yao huo dan 缠腰火丹, and she chuan 
chuang 蛇串疮. This citation described the symptoms and syndrome differentiation of HZ. A 
reasonable English translation for this most recent citation is: 
“Chan yao huo dan缠腰火丹 is also called she chuan chuang蛇串疮. Chan yao 
huo dan 缠腰火丹 can be defined as two main types: dry and damp, and can be 
differentiated by the lesion colour: red and yellow. Both have string of beads. If 
this disease occurs in the lumbar and thoracic area, it is caused by Liver Fire.” 
(Original Chinese text: 缠腰火丹 俗名蛇串疮，有干湿不同，红黄之异，皆如
累累珠形。若单生腰肋，系肝火妄动。)  
 
In this citation, the description of the lesions was found to be more similar to contemporary 
clinical medicine, with text fragments of “red”, “string of beads”, and “lumbar and thoracic 
area”. The term currently used for HZ she chuan chuang 蛇串疮, was also found in this 
citation.  
 
Another typical description found in citations “most likely” to be HZ was from Wai Ke Zheng 
Zhi Quan Shu 外科证治全书 (1617). This citation contained a comprehensive explanation of 
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the aetiology and pathogenesis, characteristics of the condition and extensive treatment 
options. The dry type chan yao huo dan 缠腰火丹 was characterized by red, patchy lesions, 
itchy and heat sensation, and was associated with the syndrome of heat and wind in the Liver 
and Gall Bladder. Dry type should be treated with the herbal formula Long dan xie gan tang 
龙胆泻肝汤. Damp type was characterized by yellow lesions, or with white fluid filled 
vesicles unequal in size, and was due to damp-heat in the Liver and Spleen. Damp type could 
be treated with Wei ling tang胃苓汤, in combination with herbs shan zhi zi 山栀子, fang feng 
防风, and shi gao 石膏. Pricking the lesion to break the skin was also recommended for 
damp type HZ. The description of the skin condition in this citation was very similar to the 
contemporary clinical medicine. More recent citations included greater detail about the 
symptoms than earlier citations. 
 
4.3.2 Symptoms 
Twenty-five “most likely” HZ citations, and 26 “possible” HZ citations contained 
descriptions of symptoms. Citations which contained multiple descriptions of symptoms were 
separated for analysis. This resulted in 28 “most likely” to be HZ descriptions and 29 
“possible” HZ descriptions being used for the data analysis (below) and data mining in 
section 4.5. 
 
4.3.2.1 Symptoms in “possible” herpes zoster citations 
Twenty-three “possible” HZ citations specified the location(s) of the rash (one description 
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specified two locations). Rash was most commonly located in the lumbar area (18 citations). 
Other locations were described as skin (generally, in two citations), and one each in Dai 
meridian (referring to the area around the waist from anterior to posterior in contemporary 
acupuncture theory [111]), neck, abdomen, limbs and all around the body. Five citations did 
not specify the location of the skin condition. 
 
The most frequently described symptoms were “encircling” 缠/绕, and “red” 红, found in 16 
and 15 descriptions, respectively. Other frequently described symptoms included “snake” 蛇 
(10 descriptions), “pain” 痛 (four descriptions), “belt” 带 (three descriptions) and “blister” 疱
/泡 (three descriptions). Symptoms “string of beads” 串珠 “white” 白, and “itchy” 痒 was 
identified in only one “possible” HZ citation (Table 4.4). 
 
Table 4.4 Frequency of symptoms/descriptions in “possible” herpes zoster citations 
Symptoms Count  
Encircling 缠/绕 16 
Red 红 15 
Snake 蛇 10 
Pain 痛 4 
Belt 带 3 
Blister 疱/泡 3 
String of beads 串珠 1 
White 白 1 
Itchy 痒 1 
 
4.3.2.2 Symptoms in “most likely” herpes zoster citations 
Of the 28 “most likely” to be HZ descriptions, 26 descriptions specified the location(s) of the 
skin rash (one description specified two locations). Similar to the descriptions of “most 
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likely” to be HZ, the rash was most commonly located in the lumbar area (26 descriptions). 
One citation specified the location was Shen shu 肾俞, which referred to an acupuncture 
point on the lumbar area (BL23), 1.5 cm lateral to the lower border of the second lumbar 
spinous process. This finding is consistent with contemporary descriptions of HZ, where 
dermatomes innervated by the thoracic nerves are among the most common presentations [7]. 
 
Table 4.5 Frequency of symptoms/descriptions in citations “most likely” to be herpes 
zoster  
Symptoms Count 
Encircling 缠/绕  21 
Red 红  16 
String of beads 串珠 13 
Snake 蛇  11 
Yellow 黄 9 
Blister 疱/泡 8 
Belt 带 7 
Pain 痛 6 
Heat 热 4 
Patchy 斑片 2 
Itchy 痒 2 
Burning pain 灼痛 1 
Papules 疹 1 
Erythema/red spot 红斑 1 
White 白  1 
 
Twenty-one citations described the rash as “encircling” 缠/绕, and 16 descriptions described 
skin redness (红). Other frequently described symptoms included “string of beads” 串珠 (13 
descriptions), “snake” 蛇 (11 descriptions), and “yellow”黄 (nine descriptions). The 
symptoms/descriptions “patchy” 斑片, “papules” 疹, “erythema/red spot” 红斑, “burning 
pain” 灼痛, “yellow” 黄, and “heat” 热 were only identified in citations judged “most likely” 
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to be HZ. While some of these descriptions can be common to other skin conditions, several 
terms are unique to contemporary descriptions of HZ, including “burning pain” and “belt” 
(Table 4.5). 
 
4.3.2.3 Summary of symptoms  
Compared with the “possible” HZ citations, more characteristic symptoms of HZ were 
identified in the “most likely” to be HZ citations’; likely due to their classification. For the 
“possible” HZ citations, fewer descriptions of rash locations were seen specified. For 
example, the symptom “string of beads” 串珠 was identified in 13 citations in the “most 
likely” to be HZ citations, but found in only one “possible” HZ citation. Other HZ 
characteristic symptoms “blister” 疱/泡 (eight in “most likely” versus three in “possible” HZ 
citations) and “belt” 带 (seven in “most likely” versus three in “possible” HZ citations) were 
seen more frequently in “most likely” to be HZ citations. Additionally, some symptoms were 
only described in the citations judged to be “most likely” to be HZ, there were: “yellow” 黄, 
“heat” 热, “patchy” 斑片, “burning pain” 灼痛, “papules” 疹, and “erythema/red spot” 红斑. 
The combination of these terms of symptoms may be the better predictor to identify the HZ 
citations in classical CM literature. 
 
4.3.3 Treatments 
Citations that contained multiple treatments were separated for analysis, that is, 70 citations 
were separated into 103 treatments. Five acupuncture therapy and two praying therapy entries 
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were also identified the data pool. Details of the treatments were outlined and analysed.  
4.3.3.1 Treatments in “possible” herpes zoster citations 
In total, 44 of the 62 “possible” HZ citations described treatments. Details of the treatments 
are presented below. 
 
4.3.3.1.1 Chinese herbal formulae  
Forty-two of the 62 citations judged as possibly HZ described the Chinese herbal formulae. 
Fifty three name and unnamed formulae were described. Two citations were pharmacopeia 
type entries, which described herbs bai shan ni 白鳝泥 and jian chun luo 剪春罗. Thirty-
seven citations described 41 unnamed formulae, and 12 citations described eight named 
formulae. The most frequently cited formula was Long dan xie gan tang 龙胆泻肝汤, 
included in five “possible” HZ citations (Table 4.6). Other formulae were cited once in 
individual citation. 
 
The majority of formulae were prescribed for topical use (37, 69.8%). Nine (9, 18.9%) 
formulae were for oral use, one was recommended for both oral and topical use, and five did 
not specify the route of administration. Named formulae were more commonly used orally 
(eight of 12 citations). For unnamed formulae, topical application was more common (36 of 
41 citations) 
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Table 4.6 Common formulae in “possible” herpes zoster citations  
Formula Name Herb Ingredients Number of 
Citations 
Long dan xie gan 
tang 龙胆泻肝汤 
(oral) 
Long dan cao 龙胆草, zhi zi 栀子, huang qin 黄芩, 
sheng di 生地, che qian zi 车前子, ze xie 泽泻, mu 
tong 木通, gan cao 甘草, dang gui 当归, lian qiao 连
翘, huang lian 黄连, da huang 大黄 (All formulae 
were identified from the same book in different 
sections, and no variant was found) 
5 
Chai hu qing gan 
tang 柴胡清肝汤 
(oral) 
Chai hu 柴胡, sheng di 生地, chi shao 赤芍, niu bang 
zi 牛蒡子, dang gui 当归, lian qiao 连翘, chuan 
xiong 川芎, huang qin 黄芩, zhi zi 栀子, hua fen 花
粉, fang feng 防风, gan cao 甘草 
1 
Chu shi wei ling 
tang 除湿胃苓汤 
(oral) 
Fang feng 防风, cang zhu 苍术, Fu ling 茯苓, chen 
pi 陈皮, hou pu 厚朴, shan zhi 山栀, mu tong 木通, 
ze xie 泽泻, hua shi 滑石, gan cao 甘草, bo he 薄荷, 
bai zhu 白术, zhu ling 猪苓 
1 
Bai ye san 柏叶散 
(topical) 
Shi bai mo 石柏末, qing fen 轻粉, xiong huang 雄
黄, qing dai 青黛, hua shi 滑石, han shui shi 寒水石, 
yin zhu 银朱, chen sha 辰砂, qian fen 铅粉, ce bai ye 
侧柏叶, si gua ye 丝瓜叶 
1 
Jie she you 解蛇油 
(NS) 
Wu gong 蜈蚣 1 
Jie zhu dan解蛛丹 
(NS) 
Zhu ma gen 苎麻根, bing pian 冰片, qing fen 轻粉, 
ji dan ke 鸡蛋壳, deng cao hui灯草灰, bai ming fan 
白明矾 
1 
She dan yan fang蛇
丹验方(oral) 
Zhi zhu 蜘蛛 1 
Ru yi jin huang san 
如意金黄散 
(topical) 
Ru yi jin huang san 如意金黄散 (ingredients NS), 
xin ji shui 新汲水, dian zhi 靛汁 
1 
NS: not specified 
 
4.3.3.1.2 Herbal ingredients  
The ten most frequently used herbal ingredients in “possible” HZ citations are shown in Table 
4.7. The most frequently used herb was xiong huang 雄黄. Most citations described topical 
application of this herb (14 out of the 16 citations), while only two of citations described this 
78 
 
herb for oral use. Xiong huang 雄黄 (realgar, arsenic disulphide), is a herb widely used in 
CM practice for resolving dampness and detoxifying. However, concerns have been raised of 
hepatic and renal toxicity with xiong huang 雄黄 [112]. This herb should be prescribed with 
caution, at a maximum dosage of 0.1 g per day [113]. 
 
Although there was a degree of uncertainty whether these citation refer to HZ, the majority of 
the most frequently used herbs were consistent with the herbs used in contemporary CM 
textbooks (Table 4.7) [16-18]. Their inclusion in the list of most frequently used herbs 
suggests that they may be used to treat skin conditions which have similar pathophysiology to 
HZ. Two herbs lian qiao 连翘 and huang lian 黄连 were on the most frequently reported list 
for “possible” HZ citations in classical literature, while not in the recommended list of 
contemporary CM textbooks. Lian qiao 连翘 and huang lian 黄连 are often used for clearing 
heat and detoxifying in CM practice, fitting with the treatment principle for the syndrome of 
heat in Liver meridian.  
 
Table 4.7 Most frequently reported herbs in “possible” herpes zoster citations  
Herb Name Scientific Name  No. of Citations (n) 
Xiong huang 雄黄 Arsenic disulphide 16 
Gan cao 甘草 Glycyrrhiza spp 8 
Lian qiao连翘 Forsythia suspensa (Thunb.) Vahl 8 
Long dan cao 龙胆草 Gentiana scabra Bge. 7 
Zhi zi 栀子 Gardenia jasminoides Ellis 7 
Che qian zi 车前子 Plantago asiatica L. 5 
Dang gui 当归 Angelica sinensis (Oliv.) Diels 5 
Huang lian 黄连 Coptis spp 5 
Mu tong 木通 Akebia quinata 5 
Ze xie 泽泻 Alisma orientalis (Sam.) Juzep. 5 
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4.3.3.1.3 Acupuncture and other therapies  
Three citations described moxibustion therapy in the management of HZ. One citation 
described the location of application at the beginning and end of the lesion length (皮损两
头), while the other two described the location to be “seven cun” (七寸处). In ancient times 
there was a saying that to kill a snake, the “seven cun” spot must be hit. The “seven cun” 
point is likely to be where the heart of a snake is located. This explains its application in HZ, 
which is described as being like a snake. Two citations described other techniques of prayer 
祝由 as a form of therapy in the “possible” HZ citations. 
 
4.3.3.2 Treatment in “most likely” herpes zoster citations 
In all, 26 of the 34 “most likely” HZ citations described the treatments. Details of the 
treatments are presented as follows. 
 
4.3.3.2.1 Chinese herbal formulae  
Twenty-one citations described Chinese herbal formulae that included 39 formulae. Several 
citations described multiple formulae. Ten citations included unnamed formulae, and 20 
citations included 16 named formulae. Four formulae were described in two or more citations 
(Table 4.8). The most frequently reported formula was Long dan xie gan tang 龙胆泻肝汤, 
described in five citations. As formulae from different books provided different sets of herbal 
ingredients, variants were seen among the formulae with the same names.  
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Table 4.8 Common formulae in “most likely” herpes zoster citations  
Formula Name Herb Ingredients Number of 
Citations  
Long dan xie gan 
tang 龙胆泻肝汤 
(oral) 
Variant 1: Long dan cao 龙胆草, zhi zi 栀子, huang qin 黄芩, chai hu 柴胡, sheng di 生地, che qian zi 
车前子, ze xie 泽泻, mu tong 木通, gan cao 甘草, dang gui 当归 
5 
Variant 2: Long dan cao 龙胆草, zhi zi 栀子, huang qin 黄芩, sheng di 生地, che qian zi 车前子, ze xie 
泽泻, mu tong 木通, gan cao 甘草, dang gui 当归, lian qiao 连翘, huang lian 黄连, da huang 大黄 
Variant 3: Long dan cao 龙胆草, lian qiao 连翘, sheng di 生地, ze xie 泽泻, che qian zi 车前子, mu 
tong 木通, huang qin 黄芩, huang lian 黄连, dang gui 当归, zhi zi 栀子, gan cao 甘草, sheng jun 大黄 
(da huang大黄) 
Variant 4: Long dan cao 龙胆草, lian qiao 连翘, sheng di 生地, ze xie 泽泻, che qian zi 车前子, mu 
tong 木通, huang qin 黄芩, huang lian 黄连, dang gui 当归, zhi zi 栀子, gan cao 甘草, sheng jun 大
黄 (da huang大黄) 
Variant 5: Long dan cao 龙胆草, dang gui 当归, huang qin 黄芩, ze xie 泽泻, mu tong 木通, che qian 
zi车前子, sheng di 生地, gan cao 甘草 
Chai hu qing gan 
tang 柴胡清肝汤 
(oral) 
Variant 1: Chai hu 柴胡, sheng di 生地, chi shao 赤芍, niu bang zi 牛蒡子, dang gui 当归, lian qiao 连
翘, chuan xiong 川芎, huang qin 黄芩, zhi zi 栀子, hua fen 花粉, fang feng 防风, gan cao 甘草 
4 
Variant 2: Chai hu 柴胡, sheng di 生地, dang gui 当归, chi shao 赤芍, chuan xiong 川芎, lian qiao 连
翘, niu bang zi 牛蒡子, huang qin 黄芩, zhi zi 栀子, tian hua fen 天花粉, gan cao 甘草, fang feng 防风 
Variant 3: Chai hu 柴胡, huang qin 黄芩, zhi zi 栀子, chuan xiong 川芎, jie geng 桔梗, gan cao 甘草, 
lian qiao 连翘 
Bai ye san 柏叶
散 (topical) 
Variant 1: Ce bai ye 侧柏叶, huang bo 黄柏, xiong huang 雄黄, qing fen 轻粉, qiu yin fen 蚯蚓粪, da 
huang 大黄, chi xiao dou 赤小豆, bai ye zhi 柏叶汁 
3 
Variant 2: Bai ye 柏叶, di long fen 地龙粪, da huang 大黄, huang bai 黄柏, chi xiao dou 赤小豆, xiong 
huang 雄黄, qing fen 轻粉 
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Formula Name Herb Ingredients Number of 
Citations  
Variant 3: Ce bai ye侧柏叶, di long fen 地龙粪, huang bo 黄柏, da huang大黄, xiong huang雄黄, chi 
xiao dou赤小豆, qing fen轻粉 
Chu shi wei ling 
tang 除湿胃苓汤 
(oral) 
Variant 1: Fang feng 防风, cang zhu 苍术, fu ling 茯苓, chen pi 陈皮, hou pu 厚朴, shan zhi 山栀, mu 
tong 木通, ze xie 泽泻, hua shi 滑石, gan cao 甘草, bo he 薄荷, bai zhu 白术, zhu ling 猪苓 
2 
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The numbers of formulae used orally and topically were similar (19 and 17, respectively). 
The route of administration was not specified in three formulae. Unnamed formulae were 
more likely to be for topical use (nine citations, compared with one citation for oral use), and 
named formulae were more likely to be used orally (18 citations, compared with eight for 
topical use and three not specified). 
 
As the contemporary CM textbook also recommends this formula for treating acute HZ [16-
18], Long dan xie gan tang 龙胆泻肝汤 remains one of the most important formulae in the 
management of HZ from ancient times to the present day. However, the number of Long dan 
xie gan tang 龙胆泻肝汤 identified in this research is considerably small. Future research on 
other sources of classical literature (for example, Zhong Hua Ben Cao Quan Shu 中华本草全
书) is needed to confirm or refute this finding. 
 
Chu shi wei ling tang 除湿胃苓汤 was another formula common to both classical literature 
and contemporary texts, which is recommended in contemporary CM textbooks for treating 
HZ of the Spleen deficiency with damp retention syndrome.  
 
In the classical citations, the commonly used formulae where the chief herb was chai hu 柴胡 
were Chai hu qing gan tang 柴胡清肝汤 with variants. This formula is also recommended in 
contemporary CM textbooks [16-18]. Based on the actions of herbs listed in classical 
formulae and contemporary formula, formulae where the chief herb was chai hu 柴胡 used in 
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ancient times were mainly for clearing heat in the Liver and regulating qi, while the modern 
formulae are mainly functioning to regulate qi only. This is not surprising, as contemporary 
CM textbooks tend to standardise syndrome differentiation and recommendation of formulae. 
For people with HZ of qi stagnation and Blood stasis syndrome, Chai hu shu gan san柴胡疏
肝散 is the formula used to resolve this syndrome.  
 
One topical formula cited in classical citations, Bai ye san 柏叶散, is not recommended in 
contemporary CM textbooks [16-18]. This may be due to one of the ingredients in this 
formula, qing fen 轻粉 (calomel), which may result in severe dermatitis, liver, and kidney 
failure [113]. Laboratory research suggests that the single daily dose of qing fen 轻粉 for 
topical application in adults should be less than 1.5 g. The hepatic and renal function of 
patients should be monitored when applying any product containing qing fen 轻粉 [38].  
 
4.3.3.2.2 Herbal ingredients  
In citations judged as “most likely” to be HZ, a total of 110 herbal ingredients were 
described. Some ingredients were excipients such as sesame oil 麻油/香油, vinegar 醋, and 
salt 盐, which were used in preparations to bind the herbs. As these ingredients have no 
intended therapeutic action, they were excluded from further analysis. A selection of the most 
frequently used herbs are described in Table 4.9. Gan cao 甘草 was the most frequently 
reported herb, found in 18 citations. Gan cao 甘草 is frequently used to harmonise 
ingredients in a formula according to CM formulation theory. While this may in part explain 
its inclusion in the list of most frequently used herbs, gan cao 甘草 has other therapeutic 
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effects relevant to dermatological conditions. Gan cao 甘草 is known to have steroid like 
effects [114], which may shorten the time to resolution of the rash and alleviate pain in acute 
HZ. 
 
Table 4.9 Most frequently reported herbs in “most likely” herpes zoster citations  
Herb Name Scientific Name No. of Citations 
Gan cao 甘草 Glycyrrhiza spp 18 
Zhi zi 栀子 Gardenia jasminoides Ellis 14 
Huang qin 黄芩 Scutellaria baicalensis Georgi 12 
Lian qiao 连翘 Forsythia suspensa (Thunb.) Vahl 10 
Dang gui 当归 Angelica sinensis (Oliv.) Diels 9 
Xiong huang 雄黄 Arsenic disulphide 9 
Long dan cao 龙胆草 Gentiana scabra Bge. 8 
Da huang 大黄 Rheum spp 8 
Fang feng 防风 Saposhnikovia divaricata (Turcz.) Schischk. 7 
Sheng di 生地 Rehmannia glutinosa Libosch.   7 
Ze xie 泽泻 Alisma orientalis (Sam.) Juzep. 7 
 
Another important note for the most frequently used herb list is mu tong 木通, which was 
described in six citations and included in the ingredient list of all citations that described 
Long dang xie gan tang 龙胆泻肝汤 (LDXGT). Mu tong 木通 has been sourced from a 
variety of species. Akebia quinata and A. trifoliata (Thunb.) Decne. are considered the 
official species for mu tong 木通, while Clematis armandii Franch. and C. montana Buch. 
Ham. are the official species for chuan mu tong 川木通. However, aristolochia species of mu 
tong 木通, which contain the toxin aristolochic acid, are considered to lead to the severe 
complication renal failure [115-117]. None of the classical citations specified which species 
of mu tong 木通 was used, nor did they described the adverse event in texts. In the 
Guidelines for Diagnosis and Treatment of Common Diseases of Dermatology in Traditional 
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Chinese Medicine 中医皮肤科常见病诊疗指南 [118], mu tong 木通 is not in the herbal 
ingredients recommendation list for HZ. This has been substituted with tong cao 通草, which 
has a similar function of resolving dampness without toxicity.  
 
4.3.3.2.3 Acupuncture and other therapies  
Five citations judged as “most likely” to be HZ described acupuncture therapies to manage 
symptoms. Four citations described the use of acupuncture techniques, three of which used a 
technique of pricking the lesion with a needle. One citation used a technique of pricking the 
lesions at the “head” or start of the lesion length (“snakeheads” 蛇头). No other citations 
describing acupuncture or other therapies were judged as “most likely” HZ. 
 
4.4 Cluster analysis 
In order to discover the potential relationships of the HZ symptoms described in the 34 “most 
likely” HZ citations (including 28 symptom descriptions), the symptoms described in section 
4.2.2.2 were subjected to cluster analysis. The symptoms included lesion appearance (that is, 
belt, snake, encircling, string of beads, and patchy), lesion type (that is, blister, papules, and 
erythema/red spot), pain (that is, pain and burning pain), lesion colour (that is, yellow, red, 
and white), itch and heat . Results of the cluster analyses using different methods and 
similarity measurements are illustrated in dendrograms below. 
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4.4.1 Single linkage (nearest neighbour) method 
The details of single linkage method have been described in Chapter 3. Single linkage 
method is one of the standard agglomerative hierarchical clustering methods for the binary 
data set. It defines the distance (similarity) between clusters as the minimum distance 
between the pair of individuals. Within this method, two approaches were used as parameters: 
Jaccard coefficient (JC) and Sneath and Sokal measurement (SM).  
 
To interpret the data from the dendrogram, a basic rule is that items that are close together 
(have more similarity) will be linked near to the base of the X axis. The scale of X axis shows 
the distance between individuals/clusters, as calculated by SPSS software. The smaller the 
distance between individual symptoms/clusters, the closer relationship. All of dendrograms 
were reviewed and clusters split on the basis structure and appearance. A dotted line was 
manually added to each dendrogram to denote where clusters were split.  
 
From the single linkage method dendrogram (Figure 4.2), with JC as the parameter of 
similarity, symptoms of {patchy, itchy, papules, erythema/red spot, pain, heat, string of beads, 
yellow, snake, blister, encircling, red} form a big cluster, while three individual symptoms 
{belt}, {burning pain}, and {white} were not belonging to or forming any cluster (sitting to 
the right of the dotted line). 
 
Within the big cluster, several sub-clusters were also identified: {patchy, itchy}, {papules, 
erythema/red spot}, {pain, heat}, {string of beads, yellow}, and {encircling, red}. 
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Figure 4.2 Single linkage dendrogram: Jaccard coefficient 
 
From the dendrogram using single linkage method (Figure 4.3), with SM as the parameter of 
similarity, a big cluster of {patchy, itchy, papules, erythema/red spot, heat, white, burning 
pain, pain, yellow, blister, belt, string of beads} was identified, with three individuals 
{snake}, {white}, {encircling} which didn’t join any cluster. Two sub-clusters {patchy, 
itchy}, {papules, erythema/red spot} were seen with quite small distance from each other, 
suggesting they are closely related.   
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Figure 4.3 Single linkage dendrogram: Sneath and Sokal measurement 
4.4.2 Complete linkage (furthest neighbour) method 
In contrast to single linkage, complete linkage defines the distance (similarity) between 
clusters as the maximum distance between the pair of individual, and tends to produce 
compact clusters with equal diameters. Two approaches of JC and SM were also used to 
conduct the analysis as below. 
 
Four clusters of {patchy, itchy, papules, erythema/red spot}, {pain, heat, burning pain}, 
{encircling, red, belt}, {string of beads, yellow, snake, blister} were shown in the 
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dendrogram using the complete linkage of JC (Figure 4.4), with an individual symptom 
{white} did not belong to any cluster. Some sub-clusters were also identified as {patchy, 
itchy}, {papules, erythema/red spot}, {pain, heat}, {encircling, red}, and {string of beads, 
yellow, snake}. 
 
 
Figure 4.4 Complete linkage dendrogram: Jaccard coefficient 
 
Two main clusters were identified in the dendrogram where the similarity coefficient was 
SM: {patchy, itchy, papules, erythema/red spot, pain, heat, burning pain, white, string of 
beads, yellow, snake, blister}, and {encircling, red, belt} (Figure 4.5). Four sub-clusters: 
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{patchy, itchy, papules, erythema/red spot}, {pain, heat}, {string of beads, yellow, snake}, and 
{encircling, red} were also seen. 
 
 
Figure 4.5 Complete linkage dendrogram: Sneath and Sokal Measurement 
 
4.4.3 Average linkage (between groups) method 
For average linkage methods, two agglomerative hierarchical clustering methods were used 
to conduct cluster analysis: between groups and within group methods, where the distance is 
defined as the average distance between individual symptoms. The between groups method 
considers the average distance between members of those two clusters is the smallest and 
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joins them together, while the within-group method considers the average distance between 
members of the resulting cluster will be smallest and joins them together. They both tend to 
join the cluster with small variances, and the definition of distance are intermediate between 
single and complete linkage. The cluster analysis were all conducted with the two parameters 
described previously. Dendrograms of average linkage (between groups) are shown as below. 
Moreover, dendrograms of average linkage (within group) are shown in the following section 
4.4.4. 
 
While applying average linkage (between group) method with the JC to the data set (Figure 
4.6), two main clusters appeared as {patchy, itchy, papules, erythema/red spot, pain, heat}, 
and {encircling, red, string of beads, yellow, snake, blister}, with three symptoms {belt}, 
{burning pain},{white}presented separately. 
 
Some sub-clusters were also identified: {patchy, itchy}, {papules, erythema/red spot}, {pain, 
heat}, {encircling, red}, and {string of beads, yellow, snake}. 
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Figure 4.6 Average linkage (between groups) dendrogram: Jaccard coefficient 
 
One big cluster containing {patchy, itchy, papules, erythema/red spot, burning pain, pain, 
heat, white, string of beads, yellow, snake, blister, belt} was shown in the dendrogram using 
SM, while a small cluster containing two symptoms of {encircling, red} was seen (Figure 
4.7). Four sub-clusters of {patchy, itchy, papules, erythema/red spot}, {burning pain, white}, 
{pain, heat}, and {string of beads, yellow, snake} were identified from the big cluster. 
 
93 
 
 
Figure 4.7 Average linkage (between groups) dendrogram: Sneath and Sokal 
measurement 
 
4.4.4 Average linkage (within groups) method 
In the cluster analysis using the method of average linkage (within groups) with JC, two 
clusters were shown in the dendrogram (Figure 4.8). One was {patchy, itchy, heat, pain, 
papule, erythema/red spot, blister, burning pain, white}, and the other was {string of beads, 
yellow, snake, encircling, red, belt}. Several sub-clusters could be found in the dendrogram: 
{patchy, itchy}, {papules, erythema/red spot}, {string of beads, yellow}, and {encircling, 
red}. 
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Figure 4.8 Average linkage (within groups) dendrogram: Jaccard coefficient 
 
When using average linking (within groups) with SM, no obvious cluster could be seen in the 
dendrogram. Two sub-clusters of {patchy, itchy}, and {papules, erythema/red spot} were 
apparent (Figure 4.9).  
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Figure 4.9 Average linkage (within groups) dendrogram: Sneath and Sokal 
measurement 
 
4.4.5 Summary and discussions 
The following table summarises the clusters and sub-clusters from the analysis above using 
different agglomerative hierarchical clustering methods with different similarity 
measurements. 
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Table 4.10 Summary of clusters in “most likely” herpes zoster citations  
Hierarchical 
Clustering 
Methods 
Jaccard Coefficient Sneath and Sokal Measurement 
Clusters Sub-clusters Clusters Sub-clusters 
Single linkage 
(nearest neighbour) 
method 
{Patchy, itchy, papules, 
erythema/red spot, pain, heat, 
string of beads, yellow, 
snake, blister, encircling, red} 
{Belt} 
{Burning pain} 
{White} 
{Patchy, itchy} 
{Papules, erythema/red 
spot } 
{Pain, heat} 
{String of beads, yellow} 
{Encircling, red} 
 
{Patchy, itchy, papules, 
erythema/red spot, heat, 
white, burning pain, pain, 
yellow, blister, belt, string of 
beads} 
{Snake} 
{Red} 
{Encircling} 
{Patchy, itchy} 
{Papules, erythema/red 
spot} 
 
Complete linkage 
(Furthest 
neighbour) method 
{Patchy, itchy, papules, 
erythema/red spot} 
{Pain, heat, burning pain} 
{Encircling, red, belt} 
{White} 
{String of beads, yellow, 
snake, blister} 
{Patchy, itchy} 
{Papules, erythema/red spot} 
{Pain, heat} 
{Encircling, red} 
{String of beads, yellow, 
snake } 
{Patchy, itchy, papules, 
erythema/red spot, pain, heat, 
burning pain, white, string of 
beads, yellow, snake, blister} 
{Encircling, red, belt} 
 
{Patchy, itchy, papules, 
erythema/red spot} 
{Pain, heat} 
{Encircling, red} 
{String of beads, yellow, 
snake} 
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Hierarchical 
Clustering 
Methods 
Jaccard Coefficient Sneath and Sokal Measurement 
Clusters Sub-clusters Clusters Sub-clusters 
Average linkage 
(between groups) 
method 
{Patchy, itchy, papules, 
erythema/red spot, pain, 
heat} 
{Encircling, red, string of 
beads, yellow, snake, blister} 
{Belt} 
{Burning pain} 
{White} 
{Patchy, itchy} 
{Papules, erythema/red spot} 
{Pain, heat} 
{Encircling, red} 
{String of beads, yellow, 
snake} 
{Patchy, itchy, papules, 
erythema/red spot, pain, heat, 
burning pain, white, string of 
beads, yellow, snake, blister, 
belt} 
{Encircling, red} 
{Patchy, itchy, papules} 
{Burning pain, white} 
{Pain, heat} 
{String of beads, yellow, 
snake} 
Average linkage 
(within groups) 
method 
{Patchy, itchy, heat, pain, 
papules, erythema/red spot, 
blister, burning pain, white} 
{String of beads, yellow, 
snake, encircling, red, belt} 
{Patchy, itchy} 
{Papules, erythema/red spot} 
{String of beads, yellow, 
snake} 
{Encircling, red} 
No cluster identified {Patchy, itchy} 
{Papules, erythema/red 
spot} 
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4.4.5.1 General characteristics of the clustering results 
This research has followed the process of selecting the applicable measurement by the 
characteristic of the variable (binary variables in this research) and consideration of co-
absence (co-absence not relevant in this research). Several approaches for cluster analysis 
were employed. The next step is to compare the dendrograms and consider which has 
provided the most valuable and meaningful results [107]. 
 
Among the clustering results, many of the dendrograms did not show obvious classification 
of the symptoms. Big clusters plus several individual symptoms were seen in the 
dendrograms of single linkage method with JC and SM as similarity measurements, complete 
linkage method with SM, and average linkage (between group) method with SM. This is not 
surprising, for the reason that different similarity measurements and clustering methods may 
come up with various structures of clustering results [107].  
 
The analysis of the average linkage (between group) method with JC and average linkage 
(within groups) method with JC contained two significant clusters in the classifying process. 
While differences of the symptoms contained in the clusters existed between these clustering 
methods, there were some symptoms in common as {patchy, itchy, papules, erythema/red 
spot, pain, heat} (Group 1 symptoms), and {encircling, red, string of beads, yellow, snake} 
(Group 2 symptoms). It is curious that almost all symptoms are related to the skin rash, while 
Group 2 symptoms appear to be unique characteristic of HZ. Further analysis of Group 1 and 
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2 symptoms will be discussed in the following section.  
 
One cluster analysis using complete linkage method with JC, produced better classifications 
than all other dendrograms. Characteristic clusters were shown as:  
 {Patchy, itchy, papules, erythema/red spot} (general symptoms of skin rash),  
 {Pain, heat, burning pain} (characteristic symptoms of heat and fire disease in CM),  
 {Encircling, red, belt} (characteristic symptoms of HZ), and  
 {String of beads, yellow, snake, blister} (characteristic symptoms of HZ).  
 
When comparing these clusters and Group 1 & 2 symptoms, Group 1 symptoms seemed to be 
representative of “general symptoms of skin rash” cluster plus “characteristic symptoms of 
heat and fire disease in CM” cluster (only “burning pain” was not included in Group 1), while 
Group 2 symptoms seemed to be the combination of the two clusters (“belt” and “blister” was 
not in Group 2).  
 
Although a better classification was provided by complete linkage method with JC, one 
symptom {white} was separated from any cluster. When reviewing the other dendrograms, 
one interesting connection of {white}and {burning pain} was seen in the single linkage 
method with SM, complete linkage method with SM, and average linkage (between groups) 
method with JC. All of these dendrograms suggest the close relationship between these two 
symptoms in the descriptions of the “most likely” to be HZ citations. As a result, {white} was 
classified with {burning pain} in the following partition of all the symptoms. 
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A possible partition of all of the symptoms could be considered based on the Group 1 & 2 
symptoms, and the clusters from the complete linkage method with JC as follows: 
 
{Patchy, itchy, papules, erythema/red spot}: This cluster contained symptoms related to 
skin rash generally. In conventional medicine, these symptoms may appear in the prodromal 
or vesicular and encrustation phase of HZ [9]. While these symptoms could also be observed 
in some other skin conditions such as erysipelas, epifolliculitis, and eczema, a proposed 
classification for this cluster is “symptoms related to skin rash”.  
 
{Pain, heat, burning pain, white}: These four symptoms were also the symptoms related to 
skin rash. “Pain (or burning pain)” and “heat” are the two typical symptoms in the heat and 
fire disease in CM, while “white” is related to damp-heat in the Liver and Spleen. In the 
original text from Wai Ke Zheng Zhi Quan shu 外科证治全书, “white” referred to herpes 
with white colour (fluid in the vesicles) related to burning pain (see details of this citation in 
section 4.4.1.2); this citation shows the connection between these symptoms. In 
contemporary CM textbooks, these symptoms could be found in the heat-related syndromes 
of Stagnant heat in the Liver meridian, and damp and fire toxin (see details in Chapter 2, 
section 2.2.5.1).  
 
An argument is that the syndrome of “qi stagnation and Blood stasis” may also have the 
symptom of “pain”. However, based on the classical citations identified from ZHYD, none of 
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the citation described this syndrome in their original texts. In contemporary CM textbook 
[16-18], this syndrome is more likely to occur after the resolution of acute rash in elderly 
people. None of the citations clearly described those conditions. Based on the grouped 
symptoms, a proposed classification for the cluster of symptoms is “characteristic symptoms 
of heat disease in CM”. When combining the above two clusters together, characteristic 
inflammation symptoms of erythema, pain, and heat were identified.  
 
{Encircling, red, belt} and {String of beads, yellow, snake, blister}: These two clusters 
describe the main characteristic symptoms of HZ. When combining these symptoms together, 
a possible interpretation could be “herpes presents with yellow fluid on a red base, forming a 
belt on the skin, like a snake encircling”, which is consistent with the description from the 
conventional medicine and contemporary CM descriptions of HZ. As a result, these two 
clusters could be merged to form an overarching cluster named “characteristic symptoms of 
HZ”. 
 
This research also identified sub-clusters in all of the eight dendrograms. The sub-clusters 
were all consistent with the clusters described above. The most frequently identified sub-
clusters were: 
 {patchy, itchy} (six sub-clusters),  
 {pain, heat} (five sub-clusters),  
 {string of beads, yellow, snake} (five sub-clusters),  
 {encircling, red} (five sub-clusters), and  
102 
 
 {papules, erythema/red spot} (four sub-clusters).  
This finding strengthens the reliability of the classifications of all of the symptoms above. 
The details of the partition of the symptoms from this cluster analysis is shown in Figure 
4.10, with sub-clusters indicated with {}. 
 
 
Figure 4.10 Classification of symptoms from cluster analysis: herpes zoster 
 
Based on the findings of the cluster analysis, the symptoms of HZ may be divided into three 
groups to induce a hypothetical overall symptom structure of HZ:  
HZ = {Symptoms related to heat disease} and, 
{Symptoms related to skin rash} and, 
{Characteristic symptoms related to HZ}. 
 
103 
 
4.4.5.2 Testing the theoretical symptom structure: the case of erysipelas 
4.4.5.2.1 A discussion of erysipelas 
Huo dan 火丹, with its direct translation as “fire pellets” from the Chinese characters, refer to 
a series of “red rash” skin conditions. The Chinese character “fire” 火, suggests these 
diseases may be caused by the pathogens fire and heat. In this research, many citations were 
judged not likely to be HZ. Assessment of which conditions they might be were made, and 
diseases identified by the search term huo dan 火丹 included erysipelas, acne, mumps, 
carbuncle, and epifolliculitis.  
 
In the complete dataset of citations, 166 of the 334 (49.7%) “Not relevant to HZ” (code 0) 
citations were judged likely to be erysipelas based on the descriptions of the symptoms. It is 
interesting that all of these citations were identified by the search term huo dan 火丹. In all 
citations identified by the term huo dan 火丹 (221 in total) that were judged not relevant to 
HZ, the majority of citations (165, 74.7%) were considered likely to be erysipelas. 
 
Erysipelas is caused by the infection of Group A streptococcus bacteria, involving dermis and 
upper subcutaneous tissue [119]. The clinical manifestation of erysipelas is similar to 
cellulitis, causing local signs of inflammation, such as heat, erythema, pain, and 
lymphangitis. The area most commonly affected by erysipelas is the face and lower limbs, 
but it can occur all around the human body, including ears, trunk, fingers, and toes [120]. 
Erysipelas is usually called dan du 丹毒 or huo dan 火丹 in CM. It is usually caused by 
pathogenic factors of heat toxin, combining with wind, Liver fire, or damp [16].  
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A typical citation of erysipelas was from You You Xin Shu 幼幼新书 (1150), in which the 
author described 19 different types of huo dan 火丹, based on the place of occurrence and 
symptoms. In this citation, some symptoms of “burning pain”, “erythema”, and “patchy” 
were described, which were also in the cluster of “Symptoms related to skin condition” 
summarised above. It appears that classical literature citations for HZ and erysipelas had 
some symptoms in common. 
 
Twenty-seven citations identified by the search term huo dan 火丹 were judged “most likely” 
HZ citations in this research (section 4.3.1.2). Twenty-five (92.6%) of these citations were 
identified by the whole term chan yao huo dan 缠腰火丹. It could be inferred that huo dan 
火丹 might be a whole classification of skin conditions in classical literature. “Most likely” 
HZ citations were mostly frequently identified by a specific term chan yao huo dan 缠腰火
丹, within the huo dan 火丹 series skin conditions. The majority of huo dan 火丹 were used 
to describe erysipelas, based on the citations identified in this search. 
 
4.4.5.2.2 Cluster analysis of huo dan 火丹 citations judged likely to be erysipelas 
 
In order to verify whether the hypothetical symptom structure applies to other skin 
conditions, another cluster analysis was conducted. A total of 159 descriptions containing 
symptoms were selected from the huo dan 火丹 citations judged likely erysipelas. All of the 
symptoms were extracted and transferred to SPSS (21.0) for cluster analysis, following the 
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same cluster approach for “most likely” HZ citations.  
 
The following table (Table 4.11) summarises the clusters and sub-clusters from the analysis 
of symptoms from huo dan 火丹 citations using different agglomerative hierarchical 
clustering methods with the different similarity measurements (JC and SM). All resultant 
dendrograms can be founding Appendix 5.  
 
Based on the clustering results, all agglomerative hierarchical clustering methods with JC 
seemed more likely to group the symptoms of {red, swelling, heat, pain, burning pain}, 
{yellow, white, itchy}, and {papules, erythema/red spot, patchy, encircling} in clusters. The 
SM method did not provide meaningful cluster results, with little similarity between 
symptoms. In the dataset of descriptions judged likely erysipelas, a possible partition of all of 
the symptoms as follows: 
 
{Red, swelling, heat, pain, burning pain}: Similar to one of the clusters from “most likely” 
HZ citations {Pain, heat, burning pain, white}, this cluster contained symptoms all related to 
heat disease in CM. “Characteristic symptoms of heat disease in CM” may be a proposed 
classification name for this cluster. The symptoms red, swelling, heat, and burning pain are 
the four typical manifestations of local signs of inflammation according to conventional 
medicine. 
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Table 4.11 Summary of clusters in likely erysipelas citations  
 
 
 
 
Hierarchical 
Clustering 
Methods 
Jaccard Coefficient Sneath and Sokal Measurement 
Clusters Sub-clusters Clusters Sub-clusters 
Single linkage 
(nearest neighbour) 
method 
{Red, swelling, heat, pain, 
burning pain} 
{yellow, white, itchy} 
{papules, erythema/red spot, 
patchy, encircling} 
{Red, swelling} 
{pain, heat, burning pain} 
{yellow, white} 
{Patchy, papules, encircling, 
white, burning pain, itchy, 
erythema/red spot, yellow} 
{pain} {heat} 
{swelling}{red} 
 
{Patchy, papules, encircling, 
white, burning pain} 
Complete linkage 
(Furthest 
neighbour) method 
{Red, swelling} 
{heat, pain, burning pain} 
{yellow, white, itchy, 
papules} 
{erythema/red spot} 
{patchy}  
{encircling} 
 
{pain, burning pain} 
{yellow, white} 
{Patchy, papules, encircling, 
burning pain, erythema/red 
spot, white, itchy, yellow} 
{pain, heat} 
{swelling} 
{red} 
{Patchy, papules, encircling, 
burning pain} 
{white, itchy} 
Average linkage 
(between groups) 
method 
{Red, swelling, heat, pain, 
burning pain} 
{yellow, white, itchy, 
papules} 
{erythema/red spot} 
{patchy}  
{encircling} 
 
{Red, swelling} 
{pain, heat, burning pain} 
{yellow, white, itchy} 
{Patchy, papules, encircling, 
burning pain, erythema/red 
spot} 
{white, itchy} 
{yellow} {pain} 
{heat} {swelling}{red} 
No cluster identified 
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Hierarchical 
Clustering 
Methods 
Jaccard Coefficient Sneath and Sokal Measurement 
Clusters Sub-clusters Clusters Sub-clusters 
Average linkage 
(within groups) 
method 
 
{Red, swelling, heat, pain, 
burning pain, erythema/red 
spot, patchy}  
{yellow, white, itchy, 
papules, encircling} 
{Red, swelling} 
{heat, pain, burning pain} 
{yellow, white} 
No cluster identified {Patchy, papules, encircling} 
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{Yellow, white, itchy}: This cluster contains the symptoms related to skin rash generally. 
Two signs are related to rash colour (“yellow” and “white”), with a symptom “itchy” 
describing a sensation of the patient. A proposed classification for this cluster would be 
“symptoms related to skin rash”. 
 
{Papules, erythema/red spot, patchy, encircling}: Symptoms contained in this cluster refer 
to the appearance of skin rash more generally. The proposed classification for this cluster 
would also be “symptoms related to skin rash”. 
 
When comparing all of the symptoms identified in the likely erysipelas citations with the 
“most likely” HZ citations, characteristic symptoms related to HZ “belt”, “snake”, “string of 
beads”, and “blister” were not identified in the erysipelas citations. In addition, one symptom 
“swelling” identified in erysipelas citations was not found in HZ citations. Characteristic HZ 
symptoms were found in descriptions of erysipelas in classical literature. This is likely due to 
the clinical manifestation of erysipelas as local signs of inflammation associated with heat 
disease in CM. “Swelling” is one of the prominent symptoms of inflammation, which is more 
likely to be described in erysipelas. That may explain why this symptom was not found in 
“most likely” HZ citations. 
 
The details of the partition of the symptoms from this cluster analysis are shown in Figure 
4.11. 
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Figure 4.11 Classification of the symptoms from the cluster analysis: erysipelas 
 
4.4.5.2.3 A discussion of the key symptoms and the symptom structure in the huo dan 火
丹 skin conditions 
One cluster, “characteristic symptoms of heat disease in CM”, was identified in both HZ and 
erysipelas cluster analyses. Also referring to the term huo dan 火丹 (fire pellets), contains the 
Chinese character “huo”, which means “fire/heat” in Chinese. It can be inferred that the 
characteristic symptoms of heat disease may be the classification that all the huo dan 火丹 
skin conditions have in common. When looking into the symptoms {red, swelling, heat, pain, 
burning pain}, these are the typical signs of inflammation. Findings suggest that there is 
overlap in the symptoms of heat disease in CM and symptoms cluster identified in huo dan 
火丹 skin conditions. The characteristic symptoms of heat disease in CM may be the key 
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symptom classification in huo dan 火丹 skin conditions. In conventional medicine, clinical 
manifestation of local signs of inflammation are the key symptoms among these conditions. 
 
Based on the cluster analysis of the “most likely” to be HZ citations, and the wrysipelas 
citations, a hypothetical modified formula that summarised the structure of the symptoms 
could be shown as follows:  
 
HZ = {Symptoms of inflammation} and  
{Symptoms related to skin rash} and  
{Characteristic symptoms of HZ} 
 
Erysipelas = {Symptoms of inflammation} and  
{Symptoms related to skin rash} 
 
Considering not all of the skin conditions have characteristic symptoms like HZ (for example, 
erysipelas), the characteristic symptoms of a certain skin condition may be or may not be 
contained in the symptoms structure for a given disease. 
 
From these findings a formula was deduced for the other huo dan 火丹 skin conditions 
(Figure 4.12): 
A certain huo dan 火丹 series skin condition =  
{symptoms of inflammation} and {Symptoms related to skin rash} or {characteristic 
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symptoms of the certain huo dan 火丹 skin condition} 
 
 
Figure 4.12 Hypothetical symptom structure in the huo dan 火丹 skin conditions 
 
This research proposes a hypothetical symptom structure formula of huo dan 火丹 skin 
conditions based on the results of cluster analyses. Unlike conventional medicine in which a 
disease name usually refers to a specific disease, many terms used in CM can be used for 
multiple diseases. One possible reason for this might be the classification of some diseases in 
CM was based on a certain pathogens such as fire, damp, wind, etc. (for example, shi chuang 
湿疮, zhong feng 中风). A group of diseases were identified with one term and had some 
symptoms in common because they may be caused by the same pathogens. Some may have 
been identified by multiple terms. Using this hypothetical symptoms structure formula, a 
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better understanding of each disease categorised within the term could be achieved. A 
standardised hypothetical symptoms structure formula could be deduced in the following 
way:  
Disease A = {key symptoms coursed by pathogen X} and  
{Symptoms related to the grouped diseases} or {characteristic symptoms of the disease A} 
 
4.5 Limitations 
This research conducted comprehensive data mining using the ZHYD to identify the classical 
literature citations of HZ. The results were limited by the number of book collections 
contained in the database and the number of citations identified. Another collection of 
traditional texts on Chinese materia medica which contained more than 6,000 books has been 
developed but is not yet available electronically. This resource may provide future 
information on Chinese herbal medicine (CHM) treatment of HZ. 
 
Results of cluster analysis were limited by the sample size of the included HZ symptoms, and 
available statistical tests for cluster analysis. Analysis using other methods may produce 
different results. In addition, the pre-defined citation inclusion criteria, is likely to have 
influenced the clustering results. For example, the judgment for “most likely” HZ citation 
was based on the symptoms combining lesion appearance, lesion type, and pain. Some 
citations that were judged to be “possible” HZ might in fact refer to “most likely” HZ, an 
aspect that could not be controlled. 
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This research proposes a modified hypothetical symptom structure formula to summarise huo 
dan 火丹 skin conditions and deduces a standard symptom structure formula for the diseases 
caused by a certain pathogen. Further research of its applicability in other diseases would 
provide further support for its accuracy and value.  
 
4.6 Chapter summary 
This chapter has systematically reviewed the classical evidence collected from ZHYD, one of 
the largest collections of CM classical literature in the world.  
 
From this review, the earliest citation judged “most likely” to be HZ was from Zheng Zhi 
Zhun Sheng - Yang Yi证治准绳·疡医 (1602). Citations were identified by one or multiple 
search terms. The most commonly used terms were chan yao 缠腰 and huo dan 火丹 in 
citations judged “most likely” or possibly to be HZ. From the “most likely” to be HZ 
citations, the symptoms described in classical literature are consistent with convention 
medicine.  
 
CHM treatments for HZ in the classical literature were also consistent with contemporary 
CM textbooks. The most frequently reported formula was Long dan xie gan tang 龙胆泻肝
汤. Some notable differences were herbs with associated toxicity being present in classical 
literature, which are not included in contemporary texts. Some herbs frequently used in 
ancient times are not recommended by current guidelines or textbooks, likely due to their 
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safety profile. 
 
Hypothetical symptom structure of HZ has been proposed through cluster analysis of the 
symptoms from “most likely” HZ citations. Another cluster analysis of citations likely to be 
erysipelas was also conducted to verify the symptom structure, and discover the key 
symptoms in the huo dan 火丹  skin conditions. Findings show that the characteristic 
symptoms of heat disease in CM theory may be the key symptoms classification in huo dan 
火丹 skin conditions. However, these results are limited by the sample size for cluster 
analysis. 
 
Implication for clinical practice and research 
This research highlights the long history of use of two formulae recommended in 
contemporary CM textbooks: Long dan xie gan tang 龙胆泻肝汤 and Chu shi wei ling tang 
除湿胃苓汤. Other named formulae such as Chai hu qing gan tang 柴胡清肝汤 and Ru yi jin 
huang san 如意金黄散 (topical) were also reported to use in the management of HZ in 
ancient times. These formulae may be beneficial for management of HZ and further clinical 
evidence should be sought.  
 
The hypothetical symptom structure of HZ provides a comprehensive understanding of HZ 
symptoms through inferential statistical techniques. Moreover, application of such a 
hypothetical model for symptoms structure formula may provide a new method for 
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discovering diseases caused by a certain pathogen based on CM theory. Future cluster 
analyses research will be of value in verifying and refining relevant symptom structure(s). 
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Chapter 5. General methods of systematic reviews 
5.1 Introduction 
Systematic reviews (SRs) and meta-analyses are recognised as the highest level of evidence 
according to the levels of evidence guidelines provided by the Australian National Health and 
Medical Research Council (NHMRC) [121]. The Cochrane Collaboration is recognised 
internationally as a leader in SR methodology, through gathering and summarizing the 
highest quality clinical evidence in Cochrane systematic reviews. The Cochrane 
Collaboration has been in transforming the way that healthcare decisions and policy are made 
since its establishment in 1993.  
 
Systematic reviews summarise and evaluate empirical evidence critically to answer specific 
research questions. Systematic methods are applied to identify and evaluate eligible studies 
meeting pre-determined criteria. Through evaluating existing evidence and estimating the 
potential bias, more authentic conclusions and findings can be provided to healthcare policy 
makers and practitioners [122]. Systematic reviews also assess the methodological quality of 
the current clinical research evidence and highlight methodological shortcomings in the 
studies, suggesting directions for future research. 
 
The clinical evidence from SRs published in Chinese language is insufficient to draw 
conclusions about the efficacy and safety of Chinese medicine (CM) for herpes zoster (HZ) 
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(see Chapter 2). To address this gap, SRs prepared with a more comprehensive search of both 
Chinese and English databases and more strict inclusion and exclusion criteria are needed. 
 
This thesis provided a general overview of Chinese herbal medicine (CHM) and acupuncture 
treatment of HZ from randomised controlled trials, as well as more targeted systematic 
reviews of specific interventions. The methods for these reviews are described below.  
 
5.2 Aims 
This chapter aims to: 
1. Present the general methods of overviews of modern literature reporting on CHM and 
acupuncture therapies for HZ in this research. 
2. Present the general methods of SRs of modern literature reporting on Long Dan Xie 
Gan Tang (LDXGT) 龙胆泻肝汤, and acupuncture plus moxibustion in the management for 
HZ in this research. 
 
5.3 Overview of randomised controlled trials of Chinese medicine treatments  
The general methods of the overviews in this thesis followed the evidence based medicine 
research approach - Standard Operating Procedures (SOPs) provided by the China-Australia 
International Research Centre for Chinese Medicine (CAIRCCM).  
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5.3.1 Study inclusion criteria 
5.3.1.1 Study design 
Randomised controlled trials (RCTs) using Chinese herbal medicine (CHM) or acupuncture 
and related therapies to treat people with acute stage HZ were included in these SRs. Non-
randomised controlled clinical trials (CCTs), and non-controlled studies  identified from the 
comprehensive database searches were excluded. 
 
5.3.1.2 Population 
The definition of acute HZ is less than 28 days from onset of rash [9]. The SRs in this 
research included studies which included participants based on this criteria. All 
immunocompetent participants diagnosed with acute stage HZ were included in the SRs, with 
no limitation of gender or ethnicity. Diagnosis based on clinical presentation or laboratory 
confirmation (polymerase chain reaction/other laboratory confirmation) were accepted. 
Considering the medication or dosage might be different for people less than 18 years old, 
only adults (age ≥18 years) were included.  
 
People with Ramsay Hunt syndrome, zoster encephalitis, zoster ocular diseases, zoster sine 
herpete, visceral HZ, disseminated HZ, and immunocompromised patients (eg Human 
Immunodeficiency Virus, cancer, diabetes, pregnant, breastfeeding) were excluded. 
Participants with post-herpetic neuralgia (PHN) stage were also excluded from this overview.  
 
119 
 
5.3.1.3 Interventions 
Eligible interventions were CHMs (oral or topical CHMs), and acupuncture-related 
interventions (manual acupuncture/acupressure, electro-acupuncture, moxibustion, ear 
acupuncture/acupressure), used alone or in combination with the same category of CM 
therapies (for example, studies using acupressure plus electro-acupuncture as the intervention 
were included, while studies using CHM plus acupuncture therapies were excluded), or with 
conventional medicine. 
 
Interventions involving complementary and alternative medicines not used in CM, or HZ 
vaccine were excluded. CM interventions other than CHM and acupuncture therapies were 
excluded, because some of the therapies are not commonly used outside of China and several 
interventions may not be permitted in some countries (for example, point injection and catgut 
embedding).  
 
5.3.1.4 Comparators  
Studies which used clinical practice guideline recommended management (antiviral therapy, 
pain management therapies) [7, 14], no treatment/waitlist, and placebo/sham treatment as 
control interventions were included. Studies which used CM therapies or treatments other 
than those recommended in clinical practice guidelines in the control group were excluded.   
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5.3.1.5 Outcome measures 
The primary outcome was evaluation of pain measured on visual analogue scale (VAS) or 
other scales such as the MacGill pain questionnaire [123]). Secondary outcomes included 
PHN incidence, cutaneous outcomes, health-related quality of life (HRQoL), therapeutic 
effective rate (TER) and adverse events. 
 
Pain severity 
Zoster related pain is one of the characteristic symptoms of HZ. One of the most frequently 
used methods of assessing pain severity is the VAS pain scale, a 10 cm/100 mm line where 0 
equates with no pain and 100 mm/10 cm is the maximum imaginable pain. Patients are 
instructed to mark along the line to indicate their level of pain. The MacGill pain 
questionnaire is another widely used method to assess the pain severity in clinical studies. It 
consists primarily of three categories of word descriptions for pain: sensory, affective and 
evaluative. The questionnaire also includes a 1-5 intensity scale to determine the experience 
of pain [123].  
 
Incidence of postherpetic neuralgia  
Various definitions of PHN have been used for clinical studies, varying from one to six 
months’ pain persisting after resolution of the HZ rash [124]. Studies which used a defined 
incidence of PHN were included from data analysis, others which used an undefined 
incidence of PHN were excluded. 
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Cutaneous outcomes 
The cutaneous outcomes included time to resolution of herpes, time to formation of crusts, 
and time to resolution of crusts. Timing for measurement may have been made from the onset 
of the skin rash, randomization process, or beginning of treatment; all possibilities were 
included. Time was reported in either hours or days.  
 
Health-related quality of life 
HZ can remarkably reduce the quality of life of patients. Two disease specific questionnaires 
and two general wellbeing questionnaires were included. Disease specific questionnaires 
were the Zoster Brief Pain Inventory (ZBPI) [125] and the Zoster Impact Questionnaire 
(ZIQ) [125]. General wellbeing questionnaires included the Medical Outcomes Study 36-item 
Short Form Health Survey (SF36) [126], and the EuroQol-5 Dimensions (EQ-5D) [127].  
1. The ZBPI is developed from the Brief Pain Inventory. In this questionnaire, an 11-
point Likert scale (0-10) is used to rate the pain in four hierarchies (worst, least, average, and 
now) [125]. Seven functional categories are also assessed, including general activity, mood, 
walking ability, work, relations with others, sleep, and enjoyment of life. 
2. The ZIQ measures the HZ patients' ability or desire to perform activities of daily 
living, which are not measured in the ZBPI (for example, eat, travel, shop, concentrate, do 
leisure activities, and be sexually active) [128]. The responses of ZIQ range from 0 (HZ does 
not interfere) to 10 (HZ completely interferes).  
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3. The SF36 and EQ-5D questionnaires measure the general health status. The SF36 
evaluates quality of life in eight domains, including vitality, physical functioning, bodily pain, 
general health perceptions, physical role functioning, emotional role functioning, social role 
functioning, and mental health [129]. The EQ-5D focuses on mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression of patients [130]. 
 
Therapeutic effective rate 
Chinese research guideline recommends TER as the main outcome measurement for treating 
HZ, where the minimum threshold for effectiveness is 30% resolution of lesion and 
significant decrease of pain [131]. Studies which used undefined TER were excluded.  
 
Adverse events 
Adverse event is the outcome measurement evaluating the safety profile of the interventions. 
Information included the nature and severity of the disease, the number of cases and action 
taken. Any reported unfavourable or unintended symptoms were included for analysis.  
 
5.3.2 Identification of studies 
The search terms for interventions and study designs are based on the search strategies 
developed by The China-Australia International Research Centre for Chinese Medicine [122], 
based at RMIT University. 
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5.3.2.1 Identification of search terms 
As the comprehensive search was conducted in both English and Chinese language databases, 
search terms of both languages were identified using different methods. For English language 
database search, medical subject headings (MeSH) terms, clinical guidelines [7, 9], SRs [132-
134], textbook [13], and general reviews [1] were consulted to identify relevant search terms. 
Search terms in Chinese language used for modern literature research were consistent with 
the classical literature research. The detail of identification process has been described in 
section 3.3.2 Identification of search terms. A number of CM textbooks [16-18], dictionary 
[135] and guideline [12] were consulted to identify the search terms. All of the Chinese terms 
were reviewed and approved by dermatologists and experts in Guangdong Provincial 
Hospital of CM. 
 
Terms for interventions were grouped according to the broad categories of CHM and 
acupuncture. Search terms for different study designs were grouped into three categories: 
reviews, controlled clinical trials (RCT and CCT) and non-controlled studies (see Appendix 
6). In this thesis, only RCTs were included for overviews and systematic reviews. 
 
5.3.2.2 Databases 
An initial comprehensive literature search was undertaken from database inceptions to 
February 2014, with an update search in February 2015. The search included four Chinese 
databases: CBM (China BioMedical Literature), CNKI (China National Knowledge 
Infrastructure), CQVIP (Chongqing VIP) and WanFang database; and five English databases: 
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PubMed, Embase, CINAHL (Cumulative Index of Nursing and Allied Health Literature), 
CENTRAL (Cochrane Central Register of Controlled Trials) and AMED (Allied and 
Complementary Medicine Database). 
 
5.3.2.3 Search strategies and sample search strategy 
The search strategy was based on combining three blocks of search terms: condition (HZ, 
zona, shingles, varicellovirus and variants), intervention (CHM, acupuncture and related 
therapies and variants) and study design (randomised controlled trial, controlled clinical trial 
and variants) (see Appendix 6). Considering the complexity of the Chinese language and the 
use of generic terms to describe the interventions, a more comprehensive list of search terms 
was used to ensure that all relevant citations were captured. References identified through 
database searches were downloaded from each database, and imported to EndNote reference 
management software for removal of duplicates.  
 
5.3.3 Data collection and analysis 
5.3.3.1 Selection of studies 
Two researchers (Kaiyi Wang collected citations from Chinese databases, and Suzi Mansu 
from English databases) worked to screen and assess titles and abstracts identified from the 
searches according to the inclusion criteria. Studies were screened against the inclusion 
criteria outlined above. All full texts of potentially relevant studies were obtained for further 
assessment. When there were disagreements about the inclusion criteria, the two researchers 
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would resolve disagreement through discussion. A third researcher (Meaghan Coyle) was 
consulted when no agreement could be reached.  
 
5.3.3.2 Data extraction 
For eligible studies, data were extracted into a pre-defined Microsoft Excel® spread sheet 
provided by the research centre. The data extracted for each trial included: 
 Characteristics: Author, publication year, setting, study design, blinding, number of 
arms, treatment and follow-up duration, syndrome differentiation, disease stage, severity, 
duration of condition, and participants (number, age and gender). 
 Intervention and comparator: CM syndrome and principle of treatment, intervention 
and comparator details (type, frequency and duration, route of administration, treatment 
details). 
 Outcomes: Results as reported by group for pain outcomes, cutaneous outcomes, 
HRQoL, TER, PHN incidence rate and adverse events.  
Where there was missing or incomplete data, the trial author was contacted to obtain 
additional data or to seek clarification via email. If the missing or incomplete data was still 
not available, the data was excluded from analysis. 
 
5.3.3.3 Data analysis 
5.3.3.3.1 Overview of Chinese herbal medicine randomised controlled trials 
A summary of the characteristics of included studies was prepared, including the number of 
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participants, age, gender, duration of HZ, CM syndrome differentiation, and comparators 
used. Details of CHM interventions, such as formula names, formula function, and herb 
ingredients, were also summarised and discussed. 
 
5.3.3.3.2 Overview of acupuncture and related therapies randomised controlled trials 
The same approach was applied for acupuncture and related therapies RCTs as was used for 
CHM RCTs. Acupuncture points and treatment approaches were summarised and discussed. 
 
5.4 Systematic review of clinical evidence  
In addition to the general overview, more targeted systematic reviews were conducted to 
evaluate the evidence for specific CM interventions. Two specific interventions were selected 
as the focus for the systematic reviews: the CHM formula LDXGT (Chapter 6), and 
acupuncture combined with moxibustion (Chapter 7). These interventions are both 
recommended by contemporary CM textbooks and guideline [12, 16-18]. No systematic 
reviews focussing on these intervention have been identified through English and Chinese 
database searches. The general methods for the systematic reviews in this thesis followed the 
methods of Cochrane Handbook for Systematic Reviews and Interventions [122].  
 
5.4.1 Inclusion criteria 
As the systematic reviews focussed on specific interventions, the inclusion criteria used in the 
overview of RCTs (section 5.3) were modified. This involved two key changes: 
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1. For the population, all age groups were included for the systematic reviews of Long dan 
xie gan tang 龙胆泻肝汤, compared with only adults being included in the general overview 
of CHM RCTs.  
2. Only studies which used Long dan xie gan tang 龙胆泻肝汤 or acupuncture plus 
moxibustion alone were included. Studies using integrative medicine (CM plus 
pharmacotherapies as the intervention) were excluded from the systematic review. 
 
The reason for the adjustment was that this research intended to provide more specific 
evidence of an individual treatment, rather than a general review of CM treatments for HZ. 
So, a broader age group and narrower intervention criteria were applied for systematic 
evaluation. All other inclusion criteria were consistent with those stated in section 5.3. 
 
5.4.2 Identification of studies and data collection 
As both the overview of CM therapies and systematic review of clinical evidence were 
produced from the same data set, the approach for identification of studies and data collection 
for the systematic review was the same as the overview of RCTs, which has been stated in 
section 5.3.2 and 5.3.3. 
 
5.4.3 Data analysis for systematic reviews 
5.4.3.1 Methodological quality assessment 
Two researchers (Kaiyi Wang, Iris Zhou) assessed separately the risk of bias of each selected 
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study. Risk of bias was assessed as per the instructions of “The Cochrane Collaboration’s tool 
for assessing risk of bias” in Cochrane Handbook for Systematic Reviews of Interventions 
(V5.1.0) [122]. Forms of bias included selection bias (random sequence generation, 
allocation concealment), performance bias (blinding of participants and personnel), detection 
bias (blinding of outcome assessment), attrition bias (incomplete outcome data), reporting 
bias (selective reporting) and other bias (baseline imbalances, risk from funding source, or 
claims of fraud). The trials were judged as “High risk of bias”, “Low risk of bias” or 
“Unclear” for each domain described above. If disagreement occurred, resolution was sought 
by discussion. A third researcher (Tony Zhang) was consulted if needed. 
 
5.4.3.2 Statistical analysis 
Statistical analysis 
All statistical analyses were carried out in RevMan 5.3 [136]. Where the results of the trials 
present statistical and clinical homogeneity, meta-analysis was performed to estimate the 
efficacy of the intervention. For dichotomous data, risk ratios (RR) was used to describe the 
results. For continuous data, the calculated mean differences (MDs) were reported. All 
statistical methods were presented with 95% confidence intervals (CIs). A random effects 
model was used for all meta-analyses. 
 
Results of the included studies were synthesized in a meta-analysis where the interventions 
were judged to be similar. Subgroup analysis was performed where applicable based on 
129 
 
detected clinical heterogeneity, and different interventions (eg. Modified LDXGT formula, 
and modified LDXGT formula plus other topical CHM). 
 
Investigation of heterogeneity 
The clinical heterogeneity was assessed by factors of participants (that is, age and gender), 
and trial design factors (that is, allocation concealment, blinding, treatment duration, and 
assessment methods of therapeutic effective rate). Statistical heterogeneity among the 
included studies for analysis was detected by examining the I2 statistical result. The I2 
statistic is used to describe the proportion of total variation which is due to heterogeneity of 
the studies [137]. If the results of meta-analysis present chi-squared (Chi2) test with P<0.1 
and I2>50%, this was assessed as substantial heterogeneity (as per the Cochrane Handbook 
[122]). Where 10 or more studies were included in a meta-analysis, potential publication bias 
was planned to be explored by visual inspection of funnel plot for asymmetry. However, this 
was not possible due to the number of studies included for the meta-analyses in this research. 
 
5.5 Chapter summary 
This chapter introduces the general methods of overviews and systematic reviews of CHM 
treatments and acupuncture therapies in this research. A comprehensive literature search was 
undertaken in four Chinese and five English databases. In the overviews of CM treatments 
for HZ, RCTs using CHMs or acupuncture and related therapies to treat people with acute 
stage HZ were included. Studies which used clinical practice guideline recommended 
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management no treatment/waitlist, and placebo/sham treatment as comparators were 
included. The primary outcome was evaluation of pain. Secondary outcomes included PHN 
incidence, cutaneous outcomes, HRQoL, TER and adverse events. Data were extracted into a 
pre-defined form, including characteristics, intervention and comparator details, and outcome 
measurements of the studies. Summaries and discussions of the above information were 
prepared. 
 
Two specific interventions: the CHM formula LDXGT and acupuncture combined with 
moxibustion were selected as the focus for the SRs. The general methods followed the 
methods of Cochrane Handbook for Systematic Reviews and Interventions in this thesis. 
Methodological quality of the included studies was assessed using the Cochrane 
Collaboration’s Risk of Bias tool. The statistical analyses were carried out in RevMan 5.3.  
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Chapter 6. Chinese herbal medicine for herpes zoster 
6.1 Introduction  
Currently, no overall review of Chinese herbal medicine (CHM) for herpes zoster (HZ) has 
been identified. Several systematic reviews (SRs) have focused on single herbs [138], CM 
formulae (dan shen 丹参 formulae) [21], and CM treatment principles (Huo xue hua yu 活血
化瘀 formulae) [20]. Current clinical evidence from these SRs shows benefits for CHM in 
improving cutaneous outcomes and pain management compared to pharmaceutical therapies, 
with few side effects reported. However, the reviews were limited by diversity in intervention 
and comparator types. Long dan xie gan tang 龙胆泻肝汤 (LDXGT) is one of the formulae 
recommended in Chinese medicine (CM) textbooks to treat acute stage HZ. LDXGT has been 
widely used for many years, however, there remains a paucity of clinical evidence to support 
its use as a treatment of HZ. 
 
6.2 Aims 
 
In order to summarise the current evidence for CHM treatment of HZ, this chapter will 
provide an overview of randomised controlled trials (RCTs) of CHM treatments for HZ (the 
‘general review’), and will evaluate the efficacy and safety of LDXGT formula systematically 
in people with HZ (SR). 
 
To achieve these aims, I will summarise the characteristics of, and CHM treatments in RCTs 
for HZ. I will conduct a systematic evaluation of the efficacy and safety of one formula 
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(LDXGT) for HZ.  
 
6.3 Methods 
The methods for the general review of CHM treatments for HZ, and the SR of LDXGT were 
described in Chapter 5. 
 
6.4 General review of Chinese herbal medicine for herpes zoster 
A total of 31,943 citations were identified through the comprehensive databases search from 
inception to February 2014, with an update search run in February 2015. After titles and 
abstracts screening, 5,617 articles were retrieved for full-text eligibility assessment. Ninety-
five RCTs were included for this general review (Figure 6.1). Details of formulae and herb 
ingredients used as the intervention in these studies were all extracted and analysed. Among 
the included studies, one study included two intervention arms evaluating two topical CHM 
formulae alone and the details of the two intervention arms were extracted separately. The 
remaining 94 studies used a two-arm parallel design. Seventy-nine RCTs integrated CHM 
formulae with pharmacotherapies as the intervention, while 15 RCTs used CHM formulae 
alone. 
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Figure 6.1 Flow chart of study selection process: Chinese herbal medicine  
CHM, Chinese herbal medicine; CM, Chinese medicine; n: number; RCT: randomised controlled trial. 
Records identified through Chinese 
language database searching 
(n = 31,943) 
Records identified through English 
language database searching 
(n = 4,677) 
Records identified through other 
sources 
(n = 1) 
Records after duplicates removed 
(n = 16,602) 
Records screened (n = 16,602) 
Full-text articles assessed for eligibility  
(n = 5,693) 
Records excluded (n = 10,909) 
Randomized controlled trials 
(n = 95) 
Full text articles excluded, with 
reasons (n = 5,598) 
Not acute HZ (n = 1,604) 
Not CM (n = 248) 
Not a clinical study (n = 31) 
Combined CM study (n = 616) 
Duplicates (n=14) 
Not meeting the inclusion criteria 
(n = 2,903) 
Review (n = 38) 
Not CHM study (n = 76) 
Not RCTs (n= 60) 
Not topical/oral used therapies 
(n=8) 
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6.4.1 Characteristics of the included studies 
A total of 7,864 adult participants were included in the RCTs [139-233], with median of mean 
age of 54.4 years in the data reported (see details in Table 6.1). For the studies that reported 
gender data, the number of male participants was greater than the number of female. The 
duration of HZ at the time of study inclusion, and the duration of treatment varied. 
 
CM syndrome differentiations were used in the included studies in two ways: as an inclusion 
criterion for participants (11 studies) [144, 156, 161, 166, 175, 179, 185, 186, 190, 231, 233], 
and to guide the selection of CHM treatment (14 studies) [139, 144, 156, 161, 166, 175, 179, 
185, 186, 190, 216, 218, 231, 233]. The syndromes used for inclusion criterion were also 
used for guiding CHM treatment in the same studies. The most frequently used syndromes 
were the pattern/syndrome of qi stagnation and Blood stasis (six studies), Stagnant heat in the 
Liver meridian (five studies), Liver-Gall Bladder dampness-heat (three studies), and 
pattern/syndrome of qi stagnation and Blood stasis (three studies). Other syndromes were 
reported in single studies individually (Table 6.1). 
 
All of the studies adopted at least one type of guideline-recommended pharmacotherapy: 
antiviral therapies (91 studies, including acyclovir, famciclovir, valacyclovir, ganciclovir, and 
ribavirin), and/or analgesics (32 studies, including nonsteroidal anti-inflammatory drugs, 
gabapentin, steroids, and nerve block therapies). In the studies that reported the dosages of 
antiviral therapies, only eighteen (18) studies used doses which matched those recommended 
in clinical practice guidelines. Other studies used dosages lower than that recommended in 
guidelines.  
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Table 6.1 Chararistic of the included studies  
Items Details 
General Characteristic 
Paticipants 7,864 
Age range (years) 18 to 90 
Median of mean age (years) 54.4 
Gender 4,129 males and 3,735 females 
Duration of herpes zoster (mean) 1.2 days to 27 days 
Duration of treatment (range) 5 days up to 6 weeks 
Duration of treatment (median) 10 days 
Syndrome differentiation 
Syndromes used as an inclusion criterion for 
participants (n) 
11 
Syndromes used to guide the selection of CHM 
treatment (n) 
14 
Qi stagnation and Blood stasis (n) 6 
Stagnant heat in the Liver meridian (n) 5 
Liver-Gall Bladder dampness-heat (n) 3 
Qi stagnation and Blood stasis (n) 3 
Spleen dampness encumbrance (n) 1 
Dampness encumbrance in Spleen meridian (n) 1 
Spleen deficiency with dampness-heat (n) 1 
Dampness-heat (n) 1 
Dampness-heat-fire accumulation (n) 1 
Pattern/syndrome of depressed Liver qi transforming 
into fire (n) 
1 
Blood stasis, Liver fire (n) 1 
Liver-Gall Bladder fire (n) 1 
Spleen dampness (n) 1 
Dampness encumbrance (n) 1 
Heat encumbrance (n) 1 
n: number of studies 
 
6.4.2 Characteristics of the Chinese herbal medicine treatments in the included studies 
Eighty-three formulae, two single herbs and two chemical compounds were identified. 
Seventy formulae were named formulae (that is, were known classical formulae), and 13 
were self-designed formula without names. Of the 70 named formulae, modified Long dan 
xie gan tang龙胆泻肝汤 formula was the most frequently used, being evaluated in 25 RCTs. 
Chu shi wei ling tang (CSWLT) 除湿胃苓汤 was the second most frequently evaluated 
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formula (four studies in total). LDXGT and CSWLT are recommended by contemporary CM 
textbooks to treat syndromes of “Stagnant heat in the Liver meridian” and “qi stagnation and 
Blood stasis” respectively (see Chapter 2). Another two formulae described in Chapter 2, Tao 
hong si wu tang 桃红四物汤 and Chai hu shu gan san 柴胡疏肝散, were recommended to be 
used together. However none of the studies used them as a combination, and they were used 
separately. Besides the CM textbooks recommended formulae, a variety of formulae were 
evaluated in the studies, many of which were used only once or twice. It is not surprising that 
a large number of trials evaluated formulae other than those recommended in CM textbooks. 
It is common that different formulae are selected based on practitioners’ experience and 
preference to treat a specific patient’s syndrome. Regardless, the selection of different CHM 
approaches were guided by the core CM principle of “treatment according to syndrome 
differentiation”.  
 
Guided by the CM textbook Formulas 方剂学 [101], the function of the various formulae 
evaluated in these RCTs was determined. Formulae that have the function of clearing heat, 
and/or detoxifying were most commonly tested (50 formulae in total). Formulae with the 
function of activating Blood, and/or dispelling stasis were the second most frequently 
evaluated (24 in total). Other formulae included the functions of resolving dampness (six 
formulae), regulating qi (six formulae), tonifying qi (two formulae), cooling Blood and 
detoxifying (one formula), and moistening dryness and resolving itch (one formula). The 
main function of the formulae is consistent with the treatment principles for resolving the 
four main syndromes of HZ in CM. Table 6.2 summarises the details of CHM interventions in 
multiple included studies. The list of ingredients can be found in Appendix 7 at the end of this 
chapter. 
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Table 6.2 Summary of Chinese herbal medicines used in multiple included studies  
Formula Name (Pinyin or translation, Chinese) Number of Studies 
Long dan xie gan tang 龙胆泻肝汤 ▲ 25 
Self-designed formulae (unnamed formulae) 自拟
方  
13 
Chu shi wei ling tang 除湿胃苓汤 ▲ 4 
Modified xiao chai hu tang 加味小柴胡汤/小柴胡
汤化裁 
3 
Xin huang pian (tablet) 新癀片 2 
Wu wei xiao du yin 五味消毒饮 2 
Tao hong si wu tang 桃红四物汤 ▲ 2 
Chai hu shu gan san 柴胡疏肝散 ▲ 2 
▲,CM textbooks recommended formulae 
6.4.3 Characteristics of the herb ingredients  
One hundred and fifty-eight different herbs were reported in the above formulae. Herbs were 
standardised through a cross-referenced nomenclature list of commonly used CHMs 
published by the Chinese Medicine Board of Australia (CMBA, last updated September 
2015) [106]. This was due to multiple names of the herbs being used among these studies 
which refer to the same herbs (for example, zhi zi 栀子 and shan zhi zi 山栀子 are the two 
common used names of Gardenia jasminoides Ellis, while the standardised name of this herb 
is zhi zi栀子). The details of the 11 most frequently used herbs are illustrated in Table 6.3. 
 
Six of the herbs have the clinical function of clearing heat based on CM theory (gan cao 甘
草, huang qin 黄芩, long dan cao 龙胆草, zhi zi 栀子, sheng di 生地, and ban lan gen 板蓝
根) [234] , while four herbs can be used to resolve dampness (huang qin 黄芩, long dan cao
龙胆草, ze xie 泽泻, and che qian zi 车前子). Other herbs have the functions of activating 
Blood (two herbs: dang gui 当归 and yan hu suo 延胡索), detoxifying (two herbs: gan cao 
甘草 and ban lan gen 板蓝根), tonifying Blood (one herb: dang gui 当归), cooling Blood 
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(one herb: sheng di 生地), regulating qi (one herb: chai hu 柴胡), and tonifying qi (one herb: 
gan cao 甘草). Similar to the formulae evaluated in these studies, the main function of the 
herbal ingredients are consistent with the treatment principles for resolving the four main 
syndromes of HZ in CM theory.  
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Table 6.3 Most frequently used herbs in included randomised controlled trials  
Herb Name 
(Pinyin, Chinese) 
Scientific Name  Pharmaceutical 
Name 
Common 
English Name  
Frequency Function of the 
Herbs 
Gan cao 甘草 1. Glycyrrhiza uralensis Fisch. 
2. Glycyrrhiza inflata Bat. 
3. Glycyrrhiza glabra L. 
Glycyrrhizae Radix 
et Rhizoma 
Liquorice Root 49 Tonify qi, clear 
heat and detoxify 
Huang qin 黄芩 1. Scutellaria baicalensis Georgi  Scutellariae Radix Baical 
Skullcap Root 
43 Clear heat and 
resolve dampness 
Long dan cao 龙
胆草 
1. Gentiana manshurica Kitage. 
2. Gentiana scabra Bge. 
3. Gentiana triflora Pall. 
4. Gentiana rigescens Franch. 
Gentianae Radix et 
Rhizoma 
Chinese 
Gentian 
39 Clear heat and 
resolve dampness 
Chai hu 柴胡 1. Bupleurum chinense DC. 
2. Bupleurum scorzonerifolium 
Willd. 
Bupleuri Radix Chinese 
Thorowax 
Root 
39 Regulate qi 
Zhi zi 栀子 1. Gardenia jasminoides Ellis Gardeniae Fructus Cape Jasmine 
Fruit 
38 Clear heat 
Dang gui 当归 1. Angelica sinensis (Oliv.) Diels Angelicae Sinensis 
Radix 
Chinese 
Angelica 
36 Tonify and 
activate Blood 
Sheng di 生地 1. Rehmannia glutinosa Libosch. Rehmanniae Radix Rehmannia 
Root 
35 Clear heat and 
cool Blood 
Ban lan gen 板蓝
根 
1. Isatis indigotica Fort. Isatidis Radix Isatis Root 31 Clear heat and 
detoxify 
Ze xie 泽泻 1. Alisma orientalis (Sam.) Juzep.  Alismatis Rhizoma Oriental 
Waterplantain 
Rhizome 
31 Resolve 
dampness 
Yan hu suo 延胡
索 
1. Corydalis yanhusuo W.T. Wang  Corydalis Rhizoma Yanhusuo  25 Activate Blood 
and analgesia 
Che qian zi 车前
子 
1. Plantago asiatica L.  
2. Plantago depressa Willd. 
Plantaginis Semen Plantain Seed 25 Resolve 
dampness 
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6.4.4 Discussion 
Findings from this general review showed that many study participants were older people, 
and more male participants were included in the studies. Global epidemiology reports showed 
that HZ is more common in older people and in women [30, 31, 34]. The reason for the 
gender-related difference is unclear. 
 
CM syndrome differentiation was widely used in these trials, either as an inclusion criterion 
for participants or as guidance for CHM treatment. Current CM textbooks included four main 
syndromes: Stagnant heat in the Liver meridian, Spleen deficiency with damp retention, 
damp and fire toxin, and qi stagnation and Blood stasis. In the included studies, heat in the 
Liver meridian, and qi stagnation and Blood stasis were the two most frequently described 
syndromes. This might provide an explanation of why the formulae which have the function 
of “clearing heat, and/or detoxifying”, and “activating Blood, and/or dispelling stasis” were 
most commonly evaluated in these studies. Although there were various syndromes described 
in these studies, the key CM concepts being described in RCTs included heat, damp, fire, 
Liver, Spleen, qi stagnation and Blood stasis, which echoes the syndromes seen in CM 
textbooks and clinical guidelines. 
 
All of the studies used guideline recommended pharmacotherapies as comparators. However, 
less than one-fifth of the studies used the guideline recommended dosage. None of the studies 
provided a rationale for dosing. The use of a sub-threshold dose of anti-virals as comparators 
may exaggerate the efficacy of CHM treatments in the clinical research. The evidence of 
CHM in the management of HZ from the modern literature is limited by the dosage that these 
studies used, among other factors.  
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Based on the current evidence of CHM formulae from this general review, formulae LDXGT 
and CSWJT recommended in contemporary CM textbooks were both used in two or more 
studies. While Tao hong si wu tang 桃红四物汤 and Chai hu shu gan san 柴胡疏肝散 are 
recommended by textbooks to be used together, none of the included RCTs evaluated this 
combination. Tao hong si wu tang 桃红四物汤 was one of three formulae used in two studies 
[161, 218], where formula selection was based on syndrome differentiation. The individual 
use of Tao hong si wu tang 桃红四物汤 may be due to two reasons. The first reason relates to 
the use of syndrome differentiation, where included studies appear to use one formula for one 
syndrome. The second reason relates to clinical practice. Based on clinician’s experience and 
knowledge of the patient’s symptoms and syndrome, one formula is selected and modified to 
add herbs which address the syndrome and symptoms. In the case of Tao hong si wu tang 桃
红四物汤, the modifications may include key herbs from Chai hu shu gan san 柴胡疏肝散. 
In this situation, the formula is called modified Tao hong si wu tang 桃红四物汤, and is not 
referred to as Tao hong si wu tang 桃红四物汤 plus Chai hu shu gan san 柴胡疏肝散. From 
this angle, clinical practice differs from the CM textbooks.  
 
LDXGT was the most commonly used formula among the CHM treatment, and nine of the 
most frequently used herbal ingredients are listed ingredients of LDXGT, which highlights 
the importance of this formula in the management of HZ. When considering the function of 
formulae and herbal ingredients in these studies, most were used to treat the four main 
syndromes mentioned in the CM textbooks. 
 
The modern literature evidence showed consistency with the classical literature evidence in 
this research. LDXGT was the most frequently reported formula in both classical and modern 
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literature. The majority of the most frequently used herbs in modern literature were also the 
most commonly reported herbal ingredients in “most likely” HZ citations (see Chapter 4, 
section 4.4.3.2.2 Herbal ingredients). Evidence showed that the information about treatments 
in classical literature continues to guide the contemporary CM research. 
 
6.5 Systematic review of LDXGT for herpes zoster 
6.5.1 Rationale for selecting LDXGT for systematic review 
According to the three current standard CM textbooks used in China: External Chinese 
medicine 9th edition [16], Chinese medicine integrated with Western medicine of Dermatology 
and Venereology 2nd edition [17], and External Chinese medicine 1st edition [18], HZ is 
categorized as four main syndrome differentiations. One of these syndromes, Stagnant heat in 
the Liver meridian, is more commonly seen during the acute stage [16]. LDXGT formula is 
recommended in CM textbooks to treat this syndrome [16-18], with practitioners advised to 
modify the formula based on the patient’s individual symptoms. The core herbal ingredients 
of modified LDXGT generally used in practice include long dan cao 龙胆草 (Gentiana 
species), zhi zi 栀子 (Gardenia jasminoides Ellis.), huang qin 黄芩 (Scutellaria baicalensis 
Georgi), mu tong 木通 (Akebia quinata Thunb. Decne), ze xie 泽泻 (Alisma orientalis Sam. 
Juzep.), che qian zi 车前子 (Plantago species), chai hu 柴胡 (Bupleurum species), gan cao 
甘草 (Glycyrrhiza species), dang gui 当归 (Angelica sinensis Oliv. Diels), and sheng di 生地 
(Rehmannia glutinosa Libosch)[118]. 
 
According to the findings from the general review of CHM in the management of HZ, 
LDXGT was the most frequently used formula in the included studies, accounting for around 
20% of all the CHM interventions. This highlights the importance of LDXGT in the CHM 
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management of HZ. Although LDXGT formula has been recommended by CM textbooks and 
widely used for HZ for many years, the clinical evidence has not been synthesized yet to 
provide a quantification of the likely treatment effect of this formula. Search of the literature 
did not identify any English or Chinese SRs evaluating LDXGT formula in the management 
for HZ. To address this gap, this research conducted a SR to evaluate the efficacy and safety 
of randomised controlled trials of LDXGT formula compared with pharmacotherapy. This SR 
has been published online in Phytotherapy Research [235]. 
 
6.5.2 Results 
6.5.2.1 Descriptions of studies 
A total of 31,906 citations were identified (see Figure 6.2). After screening titles and 
abstracts, 117 full-text articles were retrieved for eligibility assessment. Twenty-six RCTs of 
LDXGT enrolling 2,955 participants were included in the review.  
 
All studies were conducted in both inpatient and outpatient departments of hospitals in China. 
The age of participants ranged from 11 to 81 years, and the median of the mean age in studies 
that reported age was 36.1 years. For studies that reported participant gender, 1,623 were 
male and 1,244 were female (see Table 6.4). One study reported two drop outs in both the 
intervention and control groups due to loss of contact [147]. All of the studies referred to 
clinical symptoms for diagnosis, and none of them reported used laboratory detection to 
confirm the diagnosis 
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Figure 6.2 Flow chart of study selection process for systematic review of Long dan xie 
gan tang in the management of herpes zoster  
CM, Chinese medicine; HZ, herpes zoster; LDXGT, Long dan xie gang tang; n, number; 
PHN, postherpetic neuralgia; RCT, randomised controlled trial. 
 
The outcome measures reported in the included RCTs varied. Outcomes included time to 
resolution of pain [147, 236-239], PHN incidence [147, 238, 240], time to resolution of 
lesions [147, 236-238], time to formation of crust [147, 236-239], and cure and therapeutic 
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effective rates [140, 147, 155, 236-258]. No studies reported VAS pain score or health-related 
quality of life (HRQoL). The studies reporting on the therapeutic effective rate (TER) used 
different methods to evaluate effectiveness. Measurement of effectiveness was based on 
lesion count (≥30% reduction in lesion count and significant reduction of pain considered as 
effective) [140, 155, 237, 239, 241-244, 246-248, 250, 253-255, 257, 258], symptom severity 
(resolution in pain and lesion count considered as effective) [240, 245, 249, 252, 256], or 
change in pain severity (30% or greater change from baseline considered as effective) [147, 
236, 251]. 
 
6.5.2.2 Details of intervention 
All studies administered modified LDXGT formula decoction orally to participants, with 
treatment duration varying from seven days to one month (Table 6.4). Twelve studies used 
modified LDXGT formula alone [147, 155, 241-245, 249, 250, 252, 254, 255], one study 
combined LDXGT with other CHM formula for oral use [140], and the remaining 13 studies 
combined LDXGT with topical CHM formula [236-240, 246-248, 251, 253, 256-258]. All 
studies used antiviral therapies as their comparators, with acyclovir and valacyclovir the most 
common pharmaceuticals used. Other pharmaceuticals included analgesic therapies [155, 
238, 240, 248, 249, 253, 256] and vitamins B1 and B12 [140, 155, 237, 239, 240, 248, 249, 
252, 257, 258]. 
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Table 6.4 Characteristics and intervention details of the included trials of LDXGT  
First 
Author, 
Publication 
Year 
Treatment 
Duration, 
Follow-up 
Duration 
Duration of 
Condition 
No. of 
Participants 
Randomised
/Assessed, 
Dropouts 
Age (mean 
(±SD) or 
range) 
Dose Comparators 
Modified LDXGT formula (oral) 
 
Ding, 2011 
[241] 
7 days, NS Total: 2-7 days I: 26/26, 0  
C: 24/24, 0 
I: 16-63 
C: NS 
One package, one 
dosage per day. 
Acyclovir 0.2 g, 5 times per 
day, po; acyclovir cream 
bid ext. 
Gu, 2008 
[242] 
10 days, 2 
courses, NS 
I：2-19 days 
C: 2-29 days 
I: 66/66, 0  
C: 62/62, 0 
I: 17-70 
C: 18-62 
One package, one 
dosage per day. 
Acyclovir 0.4 g, qid, po. 
Li, 2012 
[243] 
7 days, NS Total: 1-4 days I: 109/109, 0 
C: 105/105, 0 
Total: 28-73 One package, three 
dosages per day. 
Acyclovir (5 mg/kg). iv; 
methylrosanilinium 
chloride solution or 
calamine lotion, ext. 
Li, 2010 
[244] 
10 days, 2 
courses, NS 
I：2-19 days 
C: 2-29 days 
I: 60/60, 0 
C: 60/60, 0 
I: 17-70 
C: 18-68 
One package, one 
dosage per day. 
Acyclovir 0.4 g, qid, po. 
Lin, 2014 
[245] 
7 days, NS NS I: 50/50, 0 
C: 50/50, 0 
I: 20-70 
C: 22-68 
One to three packages, 
three to six dosages per 
day. 
Acyclovir 0.2-0.8 g, 5 times 
per day, po. 
Liu, 2001 
[249] 
7-10 days, NS Total: <1 week I: 81/81, 0 
C: 40/40, 0 
I: m=41 
C: m=45 
One package, two 
dosages per day. 
Moroxydine hydrochloride 
0.2g; vit B1 20 mg; 
cimetidine 0.2 g; 
indomethacin 25 mg, tid, 
po. 
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First 
Author, 
Publication 
Year 
Treatment 
Duration, 
Follow-up 
Duration 
Duration of 
Condition 
No. of 
Participants 
Randomised
/Assessed, 
Dropouts 
Age (mean 
(±SD) or 
range) 
Dose Comparators 
Shi, 2013 
[250] 
10 days, NS I: m=13.4 (2-
21) days 
C: m=15.3 (2-
27) days 
I: 29/29, 0 
C: 29/29, 0 
I: 18-69 
C: 21-70 
One package, one 
dosage per day. 
Acyclovir 0.4 g, qid, po. 
Shi, 2001 
[155] 
7 days, NS I: 2-10 days 
C: 2-9 days 
I: 60/60, 0 
C: 40/40, 0 
I: m= 34.7 
C: m= 36.1 
One package, two 
dosages per day. 
Acyclovir 0.2 g, five times 
per day; vit B1 20 mg; 
indomethacin 25 mg tid, 
po; polyinosinic-
polycytidylic acid injection 
2 mg qd, im. 
Wang, 2008 
[252] 
NS, NS I: m=8.3 (3-15) 
days 
C: m=9.6 (2-22) 
days 
I: 51/51, 0 
C: 51/51, 0 
I: 20-52 
C: 18-50 
One package, two 
dosages per day. 
Vit B1 20 mg; vit C 0.3 g; 
indomethacin 25 mg, tid, 
po; ribavirin 0.5 g; 
penicillin 4.8 million IU qd, 
iv. 
Xu, 2014 
[254] 
7 days, NS NS I: 109/109, 0 
C: 109/109, 0 
Total: 
30.2±3.1 
One package, three 
dosages per day. 
Acyclovir iv; 
methylrosanilinium 
chloride solution or 
Calamine lotion ext. 
Yang, 2014 
[255]  
NS, NS I: m=15.2 (3-
24) days 
C: m=15.5 (4-
25) days 
I: 20/20, 0 
C: 20/20, 0 
I: 18-69 
C: 19-67 
One package, one 
dosage per day. 
Acyclovir 0.5 g, tid, po 
(antibiotics when 
infection). 
Zhou, 2004 
[147] 
10 days, 
3/7/11/15/28 
days 
I: 2.3±0.7 days 
C: 2.4±0.6 days 
I: 76/74, 2 
C: 76/74, 2 
I: 41.2±16.5 
C: 38.5±17.2 
One package, two or 
three dosages per day. 
Acyclovir 0.2 g, 5 times per 
day, po. 
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First 
Author, 
Publication 
Year 
Treatment 
Duration, 
Follow-up 
Duration 
Duration of 
Condition 
No. of 
Participants 
Randomised
/Assessed, 
Dropouts 
Age (mean 
(±SD) or 
range) 
Dose Comparators 
 
Modified LDXGT formula & other CHM formula (oral) 
 
Jiang, 2010 
[140] 
7 days, NS 1-7 days I: 110/110, 0 
C: 110/110, 0 
I: 22-70 
C: 19-70 
One package (Gentiana 
formula plus Chuan 
xiong cha tiao san), 
three dosages per day. 
Valacyclovir 0.25 g, tid, po; 
thymosin 30 mg, qd, iv; vit 
B12 0.25 mg im, qd. 
Modified LDXGT formula & other CHM formula (topical) 
 
Fu, 2014 
[236] 
10 days, 1 
month 
Total: 1-7 days I: 30, 0 
C: 30, 0 
Total: 18-70 Decoction: One 
package, two dosages 
per day; 
San huang zhi yang 
lotion (ku shen, da 
huang, huang qin, and 
huang bai), bid, ext, 
Calamine lotion ext. 
Valacyclovir 0.3 g, bid, po. 
Li, 2011 
[240] 
1-2 weeks, 
NS 
NS I: 70, 0 
C: 50, 0 
Total: 18-65 Decoction: One 
package, two dosages 
per day;  
CM herbs (cang shu, 
huang bai, qing dai, and 
xiong huang), 2-3 times 
per day, ext. 
Polyinosinic-polycytidylic 
acid injection 2 mg; vit B12 
100 mg, im, every 2 days; 
vit B1 10 mg; aspirin 0.3 g 
tid, po. 
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First 
Author, 
Publication 
Year 
Treatment 
Duration, 
Follow-up 
Duration 
Duration of 
Condition 
No. of 
Participants 
Randomised
/Assessed, 
Dropouts 
Age (mean 
(±SD) or 
range) 
Dose Comparators 
Li, 2013 
[237]  
14 days, NS NS I: 114, 0 
C: 106, 0 
I: 54.3±10.46 
C: 
55.31±10.43 
Decoction: One 
package, two dosages 
per day;  
Kang fu xin ye 
(ingredients, NS), bid, 
ext. 
Acyclovir 0.2 g qid; vit B12 
50 μg tid, po; mupirocin 
cream qid, ext. 
Liu, 2012 
(a) [246] 
1 month, 1 
year follow 
for 
Intervention 
group 
Total: 1-7 days I: 64, 0 
C: 64, 0 
I: m=57 (51-
63) 
C: m=58 (43-
64) 
One package, one 
dosage per day;  
Er wei ba du san (xiong 
huang and bai fan), bid, 
ext. 
Acyclovir 0.75 g qd, iv; 
acyclovir cream bid, ext. 
Liu, 2014 
[245] 
14 days, NS NS I: 60, 0 
C: 60, 0 
I: 52.81±4.25 
C: 
51.38±4.89 
Decoction: One 
package, three dosages 
per day;  
Bing chan cream 
(ingredients NS), tid, 
ext. 
Acyclovir 0.5 g; cefoxitin 
4.0g, qd, iv. 
Liu, 2012 
(b) [248] 
7 days, NS NS I: 15, 0 
C: 15, 0 
I: m=48 (16-
60) 
C: m=50 (16-
60) 
Decoction: One 
package, two dosages 
per day;  
Qing liang gao 
(ingredients NS), bid, 
ext. 
Acyclovir 0.4 g tid; vit. B1 
10 mg tid; vit B12 500μg 
tid, po (fenbid po, when 
necessary). 
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First 
Author, 
Publication 
Year 
Treatment 
Duration, 
Follow-up 
Duration 
Duration of 
Condition 
No. of 
Participants 
Randomised
/Assessed, 
Dropouts 
Age (mean 
(±SD) or 
range) 
Dose Comparators 
Shi, 2002 
[238] 
7 days, NS I: m=5.4(2-10) 
days 
C: m=6.3 (3-11) 
days 
I: 61, 0 
C: 61, 0 
I: m=56.2 
(11-81) 
C: m=55.3 
(12-79) 
Decoction: One 
package, three dosages 
per day;  
Liu shen wan 
(ingredients NS), 1-2 
times per day, ext.  
Acyclovir 10 mg/kg qd, iv; 
indomethacin 25 mg, tid, po 
(methylrosanilinium 
chloride solution or 
calamine lotion when 
necessary). 
Wang, 1999 
[251] 
NS, NS NS I: 96, 0 
C: 60, 0 
I: m=46 (25-
66) 
C: m=43 (23-
62) 
Decoction: One 
package, three dosages 
per day;  
Qing dai san (qing dai, 
hua shi, and sheng shi 
gao), tid, ext. 
Moroxydine hydrochloride 
tablets 0.2 g, tid, po; 
penicillin 8 million IU qd, 
iv. 
Wang, 2007 
[253] 
14 days, NS I: 1-13 days 
C: 1-15 days 
I: 64, 0 
C: 42, 0 
I: 14-65 
C: 17-72 
Decoction: One 
package, two dosages 
per day;  
San huang cream (da 
huang, huang bai, huang 
qin, and bing pian), qd, 
ext. 
Acyclovir 0.2 g, tid, po; 
polyinosinic-polycytidylic 
acid injection 4 ml, every 2 
days, im; ribavirin 400 mg, 
qd, iv (indomethacin, 
VOLTAREN® when 
necessary). 
Ye, 2000 
[256] 
21 days, NS I: 2-6 days 
C: 1-7 days 
I: 33, 0 
C: 33, 0 
I: m=52.3 
(30-65) 
C: m=50.1 
(32-60) 
Decoction: One 
package, three dosages 
per day;  
Jin huang san 
(ingredients NS), bid, 
ext. 
Acyclovir 250 mg, tid, iv, 
cimetidine 0.4 g qd, iv; 
indomethacin 25 mg, tid;  
prednisone 10 mg tid, po; 
acyclovir cream bid, ext 
(antibiotics when 
necessary). 
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First 
Author, 
Publication 
Year 
Treatment 
Duration, 
Follow-up 
Duration 
Duration of 
Condition 
No. of 
Participants 
Randomised
/Assessed, 
Dropouts 
Age (mean 
(±SD) or 
range) 
Dose Comparators 
Zheng, 
2009 [257] 
NS, NS I: 1-30 days 
C: 3-30 days 
I: 32, 0 
C: 32, 0 
I: 15-75 
C: 15-65 
Decoction: One 
package, two dosages 
per day;   
CM herbs (xiong huang, 
bing pian, yun nan bai 
yao, and lv cha): 3-5 
times per day, ext. 
Acyclovir 0.1-0.2 g tid, po; 
vit B12 250-500 μg; vit 
B1 100mg qd, im; acyclovir 
cream 3-5 times per day, 
ext. 
Zhou, 2011 
[239] 
14 days, NS I: 5 days - 2 
months 
C: 7 days - 2 
months 
I: 40, 0 
C: 40, 0 
I: 45.2±18.5 
C: 47.7±16.3 
Decoction: One 
package, three dosages 
per day;  
Qing huang san (qing 
dai, huang bai, chuan 
xiong, huang lian, and 
yan hu suo) bid, ext. 
Acyclovir 0.4 g tid; vit B1 
10 mg tid, po; acyclovir 
cream tid, ext. 
Zhu, 2004 
[258]  
10 days, NS Total: m=4.1 (2-
8) days 
I: 30, 0 
C: 30, 0 
Total: 18-72 Decoction: One 
package, two dosages 
per day;   
Calamine lotion: ext. 
Acyclovir 0.2 g 5 times a 
day, vit B12 qd, po. 
 
bid, twice a day; C, control group; ext, external use; I, intervention group; im, intramuscular injection; iv, intravenous injection; m, mean; NS, 
not specified; po, oral use; qd, once a day; qid, four times a day; SD, standard deviation; tid, three times a day; vit, vitamin.
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6.5.2.3 Methodological quality 
Methodological quality of included studies was low to moderate (see Figure 6.3) Two studies 
were assessed as low risk of bias for sequence generation as a random number generator was 
used [236, 255]. Three studies were assessed as high risk as they randomized participants 
according to visit order [239, 242, 252]. None of the studies mentioned the method of 
allocation concealment, and all were assessed as unclear risk. For blinding of participants, 
personnel and outcome assessors, no details were provided and the potential risk for all 
studies was assessed as unclear. One study reported loss of contact with two participants in 
both the intervention and control groups. As the number of withdrawals and reasons were 
equal across groups, the study was assessed as low risk for incomplete outcome data [147]. In 
all other studies, data were available for all participants, and were assessed as low risk of 
bias. None of the studies provided the details of the trial protocol or trial registration, and 
were all assessed as unclear risk for selective outcome reporting. One study was assessed as 
unclear risk for other bias as the intervention group size was double that of the control group 
with no reason provided [249]. All other studies were assessed as low risk of bias for other 
bias as no baseline imbalances, risk from funding source, or claims of fraud were identified. 
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Figure 6.3 Summary of risk of bias assessment of included studies 
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6.5.3 Effects of the intervention 
6.5.3.1 Modified LDXGT alone 
Twelve studies compared the clinical effect of modified LDXGT formula alone with 
pharmacotherapy [155, 239, 241-245, 249, 250, 252, 254, 255]. 
 
6.5.3.1.1 Time to resolution of pain 
One study reported that resolution of pain was achieved 2.6 days earlier in those who 
received modified LDXGT formula compared to pharmacotherapy, with significant statistical 
difference shown (MD -2.60 days; 95% CI -3.61 to -1.59) (see Figure 6.4) [147]. 
 
 
Figure 6.4 Modified LDXGT vs pharmacotherapy: time to resolution of pain 
 
6.5.3.1.2 Cutaneous outcomes 
One study reported that time to resolution of lesions was achieved 0.5 days earlier in the 
participants who received modified LDXGT, compared to pharmacotherapy (MD -0.50 days; 
95% CI -0.94 to -0.06) (see Figure 6.5) [147].  
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Figure 6.5 Modified LDXGT vs pharmacotherapy: time to resolution of lesions 
 
The study also showed benefits of modified LDXGT alone in shortening the time to 
formation of crusts by 1.2 days compared to pharmacotherapy (MD -1.20 days; 95% CI -2.31 
to -0.09) (see Figure 6.6) [147].  
 
 
Figure 6.6 Modified LDXGT vs pharmacotherapy: time to formation of crusts 
 
6.5.3.1.3 Postherpetic neuralgia incidence rate 
One study reported the PHN incidence rate [147]. In this study, PHN was defined as pain 
continuing after resolution of crusts. No significant difference between modified LDXGT and 
pharmacotherapy groups was seen regarding incidence of PHN (RR 0.29; 95% CI 0.06 to 
1.33) (see Figure 6.7). 
 
 
Figure 6.7 Modified LDXGT vs pharmacotherapy: incidence rate of postherpetic 
neuralgia 
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6.5.3.1.4 Therapeutic effective rate 
Eight studies reported on TER referring to the Chinese research guideline, which defines 
measurement of effectiveness based on lesion count (≥30% reduction in lesion count and 
significant reduction of pain considered as effective) [131]. Statistical heterogeneity was 
detected for the outcome TER (I2=67%), so data were not pooled for analysis (see Figure 6.8) 
[155, 241-244, 250, 254, 255]. The majority of studies showed no benefit of LDXGT alone in 
improving symptoms.  
 
 
Figure 6.8 Modified LDXGT vs pharmacotherapy: therapeutic effective rate (based on 
guideline) 
 
One study reported on TER referring to the Therapeutic Index (TI). Therapeutic Index was 
calculated as follows: 
[(Symptoms Scores before treatment)-(Symptoms Scores post treatment)] 
*100% 
(Symptoms Scores before treatment) 
 
where TI >30% was considered as effective [147]. No significant difference was seen in TI 
between intervention and pharmacotherapy (RR 1.03; 95% CI 0.98 to 1.08) (see Figure 6.9).  
 
157 
 
 
Figure 6.9 Modified LDXGT vs pharmacotherapy: therapeutic effective rate (based on 
therapeutic Index) 
 
Three studies reported on TER using investigator-developed criteria, where all defined 
effectiveness as “resolution of part of redness, pain and lesions, with crusts remained and 
PHN occurred”. Since the assessment of resolution of above symptoms was not clear, the 
decision was made not to pool the result together to conduct meta-analysis and results are 
presented individually (see Figure 6.10). Results from all individual studies showed benefits 
of using modified LDXGT alone, with improved TER based on investigator-developed 
criteria compared with pharmacotherapy [245, 249, 252]. 
 
 
Figure 6.10 Modified LDXGT vs pharmacotherapy: therapeutic effective rate (based on 
investigator-developed criteria) 
 
6.5.3.1.5 Cure rate 
Twelve studies reported on the cure rate using the same definition: resolution of all clinical 
symptoms [155, 239, 241-245, 249, 250, 252, 254, 255]. Results of meta-analyses showed 
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that modified LDXGT alone could significantly improve the chance of resolving both 
cutaneous and pain symptoms compared with pharmacotherapy (RR 1.62, 95% CI 1.47 to 
1.79; I2=0%) (see Figure 6.11).  
 
 
Figure 6.11 Modified LDXGT vs pharmacotherapy: cure rate 
 
6.5.3.2 Modified LDXGT plus other oral Chinese herbal medicine formula 
One study combined modified LDXGT with other oral CHM formula [140]. TER and cure 
rate were the two outcome measures reported. Results showed that modified LDXGT plus 
Chuan xiong cha tiao san 川芎茶调散 formula improved the effective rate more than 
pharmacotherapy based on reduction in lesion count (RR 1.29; 95% CI 1.13 to 1.48) (see 
Figure 6.12).  
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Figure 6.12 Modified LDXGT plus oral Chinese herbal medicine vs pharmacotherapy: 
therapeutic effective rate 
 
Benefits were also seen in improving the cure rate defined as resolution of all clinical 
symptoms (RR 1.53; 95% CI 1.07 to 2.19), although variation in results was indicated by 
wide confidence intervals (see Figure 6.13). 
 
 
Figure 6.13 Modified LDXGT plus oral Chinese herbal medicine vs pharmacotherapy: 
cure rate 
 
6.5.3.3 Modified LDXGT plus other topical CHM formula 
Thirteen studies combined LDXGT with topical CHM formula as intervention, which was 
compared with pharmacotherapy [236-240, 246-248, 251, 253, 256-258]. 
 
6.5.3.3.1 Time to resolution of pain 
Four studies reported on time to resolution of pain [236-239]. Meta-analysis was not possible 
due to considerable heterogeneity which couldn’t be explained through planned sensitivity 
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analysis (I2=94%). Results from all individual studies showed resolution of pain occurred 
earlier in those who received modified LDXGT plus other topical CHM formula (see Figure 
6.14). 
 
 
Figure 6.14 Modified LDXGT plus topical Chinese herbal medicine vs 
pharmacotherapy: time to resolution of pain 
 
6.5.3.3.2 Cutaneous outcomes 
Three studies reported on time to resolution of lesions [236-238]. Studies could not be pooled 
for meta-analysis due to considerable heterogeneity which couldn’t be explained through 
planned sensitivity analysis (I2=52%). Resolution of lesions occurred earlier in two studies 
which combined LDXGT with other topical CHM formula (see Figure 6.15). 
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Figure 6.15 Modified LDXGT plus topical Chinese herbal medicine vs 
pharmacotherapy: time to resolution of lesions 
 
Four studies reported on time to formation of crusts [236-239]. Crusts formation was 
achieved 1.13 days earlier with LDXGT plus other topical CHM formula than with 
pharmacotherapy (95% CI -1.44 to -0.83; I2=13%) (see Figure 6.16). 
 
 
Figure 6.16 Modified LDXGT plus topical Chinese herbal medicine vs 
pharmacotherapy: time to formation of crusts 
 
6.5.3.3.3 Postherpetic neuralgia incidence rate 
Two studies reported on PHN incidence, but did not describe the criteria for assessment [238, 
240]. The results demonstrated a significant reduction in the incidence of PHN in those who 
received modified LDXGT formula plus other topical CHM formula compared to those who 
received pharmacotherapy (RR 0.14; 95% CI 0.03 to 0.74; I2=32%) (see Figure 6.17) 
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Figure 6.17 Modified LDXGT plus topical Chinese herbal medicine vs 
pharmacotherapy: incidence rate of postherpetic neuralgia 
 
6.5.3.3.4 Therapeutic effective rate 
Eight studies which reported on the TER based on reduction in lesion count were pooled for 
meta-analysis [237, 239, 246-248, 253, 257, 258]. The chance of achieving a 30% or greater 
reduction in lesion count with LDXGT plus other topical CHM formula was 1.12 that of 
pharmacotherapy (95% CI 1.06 to 1.17; I2=13%) (see Figure 6.18). 
 
 
Figure 6.18 Modified LDXGT plus topical Chinese herbal medicine vs pharmacotherapy: 
therapeutic effective rate (based on guideline) 
 
One study reported on TER using the TI calculation method, and defined TI >30% as 
effective) [236]. No significant difference was seen between intervention and 
pharmacotherapy in effective rate based on reduction of symptoms scores (see Figure 6.19).  
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Figure 6.19 Modified LDXGT plus topical Chinese herbal medicine vs 
pharmacotherapy: therapeutic effective rate (based on therapeutic index) 
 
Three other studies reported on TER using investigator-developed criteria [240, 251, 256]. 
The decision was made not to pool the results together to performed meta-analysis, since no 
clear assessment criteria was provided. Results from all of the individual studies show TER 
was better in those who received LDXGT plus topical CM formula than pharmacotherapy 
(see Figure 6.20). 
 
 
Figure 6.20 Modified LDXGT plus topical Chinese herbal medicine vs 
pharmacotherapy: therapeutic effective rate (based on investigator-developed criteria) 
 
6.5.3.3.5 Cure rate 
Twelve studies reported on the cure rate [147, 236, 237, 240, 246-248, 251, 253, 256-258]. 
Cure rate was defined as resolution of all clinical symptoms among these studies. At the end 
of treatment, the chance of resolving both cutaneous and pain symptoms with LDXGT plus 
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other topical CHM formula was 1.33 times that of pharmacotherapy (95% CI 1.22 to 1.45; 
I
2
=25%) (see Figure 6.21).  
 
Figure 6.21 Modified LDXGT plus topical Chinese herbal medicine vs 
pharmacotherapy: cure rate 
 
6.5.4 Adverse events 
Three cases of gastrointestinal (GI) adverse events were reported in the intervention group in 
one study [147]. In the pharmacotherapy groups, two cases of vertigo and fatigue and 10 
cases of GI adverse events were reported in four studies [140, 147, 250, 255]. 
 
6.5.5 Discussion  
6.5.5.1 Discussion of systematic review of LDXGT in the management of herpes zoster 
Findings from this review showed that when used alone, modified LDXGT shortened the 
time to relieve pain effectively. The combination of modified LDXGT with topical formulae 
may reduce time to resolution of pain, although statistical heterogeneity was detected. 
LDXGT alone or in combination with other topical CHM formula reduced the incidence of 
PHN and improved cutaneous outcomes. None of the studies reported on HRQoL, therefore 
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the impact of LDXGT for this outcome remains unclear. LDXGT was found to improve the 
cure rate and TER when used alone, or in combination with either oral or topical CHMs. 
These results should be interpreted with caution, as considerable statistical heterogeneity was 
detected and the outcome has not been validated. 
 
Modified LDXGT was well tolerated by patients, with fewer side effects reported than 
pharmacotherapy, although few studies reported on this outcome. GI complaints are common 
adverse events with CHM [259, 260]. Adverse events were reported in studies using 
acyclovir or valacyclovir as the comparator. Vertigo, fatigue and GI discomfort are all known 
side effects of these antiviral therapies. Modified LDXGT may be considered a safe therapy 
for HZ based on the trials in this review.  
 
No SRs of LDXGT were identified through the database search. The benefits seen with 
modified LDXGT plus other topical formulae in this review were similar to those seen with 
dan shen 丹参 and huo xue hua yu 活血化瘀 formulae in terms of incidence of PHN and 
TER [20, 21]. In CM theory, formulae such as those based on dan shen 丹参 and huo xue hua 
yu 活血化瘀 formulae are clinically recommended for pain after resolution of the lesions [16, 
261]. Therefore, this review of LDXGT is clinically important in evaluating CHM for 
addressing the acute symptoms of HZ. 
 
The pathogenesis of acute pain and cutaneous symptoms in HZ is the inflammatory response 
and necrosis of the varicella zoster virus infected sensory nerve [14]. The key herb in 
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LDXGT, long dan cao 龙胆草  (Gentiana scabra Bunge.), has been evaluated in 
experimental studies, with evidence supporting anti-inflammatory actions. Secoiridoid 
glycosides from long dan cao龙胆草 (Gentiana scabra Bunge.) have been shown to inhibit 
activity of interleukin-6 (IL-6), nitric oxide (NO), and tumour necrosis factor alpha (TNFα) in 
lipopolysaccharide (LPS) induced RAW264 cells [262], and interleukin-2 (IL-2) in bone-
marrow derived dentriditic cells (BMDCs) [263], suggesting inflammatory mediation. The 
anti-inflammatory actions of the constituents may contribute to relieving the acute 
inflammatory response in patients with HZ, which may contribute to the clinical effect of 
hastening alleviation of pain and improving cutaneous outcomes of LDXGT formula. 
 
This review also found that the incidence of PHN in people who received LDXGT combined 
with topical CHM was less than those who received pharmacotherapy. The constant chronic 
pain in PHN arises from inflammatory damage to peripheral nerves and the central nervous 
system caused by the virus or immune response, and secondary changes in the nociceptive 
pathway [9, 264]. The anti-inflammatory actions of the herbs in LDXGT may contribute to 
the lower PHN incidence rate seen in this review. 
 
Antiviral therapy is recommended as first-line therapy for HZ in clinical practice guidelines 
[7, 9, 14]. The dose recommended for valacyclovir is one gram three times daily for seven 
days, and for acyclovir is 0.8 gram five times daily for seven days (5 to 7.5 mg/kg, three 
times daily for intravenous therapy) [7]. None of the included studies used the dosage as 
recommended, nor did they provide a rationale for dosing. No Chinese guidelines for 
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conventional medical management of HZ could be identified to explain the doses used in 
included studies. Therefore, it is unclear whether the benefit with LDXGT seen in this review 
would be different when compared with accepted dosing regimens. 
 
Several studies used comparators other than those recommended in guidelines [140, 155, 239, 
240, 249, 251, 252, 257, 258]. This included other antivirals and vitamins. In China, the 
prescribing practice for HZ often combines antiviral and analgesic therapy with vitamins B1 
and B12 to repair infected nerves and regulate the function of synaptic transmission [265, 
266]. It is unclear whether the addition of vitamin B1 or B12 alters the efficacy of antiviral 
and analgesic therapies, and results should be interpreted in light of this. 
 
6.5.5.2 A further discussion of therapeutic effective rate used in LDXGT studies 
Therapeutic effective rate (TER) is an important outcome measurement in CM research, and 
was utilised in the studies included in the SR of LDXGT. Twenty-five out of the 26 included 
studies reported this outcome. However, the assessment criteria for TER differed among 
these studies. The TER reported in included studies fell into one of three categories 
(described below). 
 
6.5.5.2.1 Resolution of lesion count 
Nine studies [140, 155, 237, 239, 243, 246, 248, 253, 254] referred to the criteria described in 
The Standard of Diagnosis and Assessment of Treatment Effects of Dermatological 
Conditions in Chinese Medicine 中医病症诊断疗效标准 [131]. This guideline is widely 
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used in clinical practice and research. The HZ section of this guideline recommends TER as 
the main outcome measurement for treating HZ, where the minimum threshold for 
effectiveness is 30% resolution of lesion.  
 
One study [247] used the criteria from Clinical Dermatology 临床皮肤病学 [267]. In this 
textbook, the resolution of lesion count is also the criterion for assessment. However, the 
minimum threshold for effectiveness in this textbook (70%) is much higher than the guideline 
recommends. For the purpose of meta-analysis, it was considered appropriate to pool this 
data with those using the guideline above, since ≥70% resolution of lesion is certainly 
within the range of ≥30%. 
 
6.5.5.2.2 Resolution of herpes zoster-related symptoms  
Six studies [240, 245, 249, 251, 252, 256] used investigator-developed criteria to assess the 
participant’s symptoms as cured, improved or not improved. The methods for assessment 
were not clear. The description provided in included studies referred to “resolution of part of 
redness, pain and lesions, with crusts remained and PHN occurred” as the criteria for 
improvement. No explicit value of the resolution of any symptoms was provided. The 
description that “PHN occurred” is unusual, as this would not be considered as an 
improvement. This may be an error in the reporting of assessment criteria in these studies. 
The results of these studies were considered not appropriate to pool for meta-analysis. As 
such, data were presented individually. 
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6.5.5.2.3 Therapeutic Index 
Three studies used the TI to assess symptoms. In studies which reported this outcome, 
researchers stated that this method was adapted from the guideline, where the minimum 
threshold for effectiveness is 30% of TI. The difference between TI and the guideline is that 
TI includes a scoring system for calculation, which covers lesion count, pain and PHN 
incidence rate. Compared with the guideline, the scoring system used to calculate the 
treatment effect is an improvement on the subjective TER, eg. patient pain sensation 
evaluated in the studies of HZ. However, the detail of the scoring system was not provided by 
these studies, which further limits interpretation. Table 6.5 summarizes the different assessing 
criteria of TER. 
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Table 6.5 Different criteria of calculating therapeutic effective rate  
Items Assessing Criteria Clinical Outcomes 
Cure Significant 
Improvement 
Improvement No  
Improvement 
The Standard of 
Diagnosis and 
Assessment of 
Treatment Effects of 
Dermatological 
Conditions in Chinese 
Medicine (《中医病
症诊断疗效标准》) 
Resolution of lesion 
count and pain 
Resolution of lesion 
and pain 
NA Resolution of lesion 
count≥30%, and 
significant decrease 
of pain 
Resolution of lesion 
count <30%, and pain 
still exists 
Clinical Dermatology 
(《临床皮肤病学》) 
Resolution of lesion 
count 
Resolution of lesion 
≥95% 
NA Resolution of lesion 
count≥70% 
No change or worse 
Resolution of herpes 
zoster-related 
symptoms (self-made 
criteria)  
Resolution of herpes 
zoster-related 
symptoms 
Resolution of part of 
redness, pain and 
lesions, with crusts 
remained and PHN 
occurred 
NA Part of the redness, 
pain, and lesion 
disappear, with 
crusts, and PHN 
No improvement 
TI TI: [(symptoms 
scores before 
treatment)-
(symptoms scores 
post 
treatment)]/(sympto
ms scores before 
treatment) *100% 
TI=100% TI>60% 60%>TI>30% TI<30% 
NA, not applicable; PHN, post-herpetic neuralgia; TI, therapeutic index 
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6.5.6 Limitations of the LDXGT systematic review 
The findings of this review are limited by the methodological quality of the included studies. 
Few studies reported details relating to the risk of bias domains sequence generation, 
allocation concealment, blinding of participants, personnel and outcome assessors, and this is 
likely to contribute to bias and heterogeneity. The validity of the evidence for LDXGT was 
limited by the variability in both intervention and comparator groups. The outcomes reported 
in the included studies have not been validated, and none of the studies reported on HRQoL. 
The findings should be interpreted in light of these limitations.  
 
6.5.7 Chapter summary 
6.5.7.1 Implication for future research  
The overview of the CHM treatments for HZ showed that a variety of formulae, single herbs 
and chemical compounds isolated from the herbs had been evaluated by various RCTs. 
However, the evidence of CHM treatments for HZ is limited by the sub-threshold dosage of 
antiviral therapies as guidelines recommended. Exaggeration of the efficacy of CHM 
treatments may occur when conducting the clinical trials.  
 
Meta-analysis in this research showed modified LDXGT formula shortened the time to 
resolution of pain, reduced the incidence of PHN, and improved cutaneous outcomes 
compared with pharmacotherapies. However, the small number and poor quality of the 
included studies is insufficient to draw a valid evaluation of the efficacy of LDXGT formula. 
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Rigorous RCTs on LDXGT formula are needed to provide stronger evidence regarding the 
efficacy and safety of the formula. 
 
For future clinical research, several key points in the design of RCTs can be taken into 
consideration based on the findings from this SR: 
 Proper randomisation, allocation concealment, and blinding methods. 
 Interventions: use guideline recommended pharmacotherapies and appropriate dosage. 
 Participants: Refer to CM diagnostic criteria for syndrome differentiation as inclusion 
criteria for the participants. The age range of the participants should be another consideration 
(eg. Antiviral therapies are recommended to the people with HZ older than 50 years). 
 Outcome measurements: As HZ has a significant impact on patients’ quality of life, 
HRQoL questionnaires should be included for outcome measurements. 
 
6.5.7.2 Implication for clinical practice  
According to the general review of CHM and the classical literature research (see Chapter 4), 
LDXGT was the most frequently reported or cited formulae in both classical and modern 
literature included in this research. The contemporary CM textbook also recommends 
LDXGT to treat HZ patients with Stagnant heat in the Liver meridian syndrome. The 
symptoms contained in this syndrome are similar to the description of HZ in conventional 
medicine, which may be an explanation that LDXGT is one of the most common CHM 
treatments in managing HZ in clinical practice. Although the valid conclusion of the efficacy 
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of LDXGT formula had not been established, the formula was well tolerated by the 
participants with few mild adverse events reported. As satisfaction with efficacy of 
conventional medication is still unmet of for people with HZ [15], LDXGT may be a 
potential formula as an alternative therapy in the management of HZ. 
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Chapter 7. Acupuncture therapies for herpes zoster 
7.1 Introduction 
Acupuncture has been shown to be an effective treatment for some types of pain, and various 
skin conditions [268], and may provide benefit during the acute stage of herpes zoster (HZ) 
[269]. Published systematic reviews (SRs) [22-28] focusing on a diverse range of 
acupuncture techniques (for example, manual acupuncture, moxibustion) and other CM 
therapies (for example, cupping) for HZ have been identified through database searches. The 
evidence from SRs showed that acupuncture therapies shortened the time to resolution of 
pain, reduced the incidence of post-herpetic neuralgia (PHN), and improved cutaneous 
outcomes compared with pharmacotherapies (refer to Chapter 2). However, the reviews were 
limited by the databases searched, diversity in intervention and comparator types. The 
evidence from these SRs is insufficient to draw conclusions about the efficacy and safety of 
acupuncture therapies for HZ. 
 
Acupuncture and moxibustion are recommended in CM clinical practice guidelines for 
treating the acute symptoms of HZ [12], and are frequently used in combination in clinical 
practice. However the efficacy and safety of the combination of acupuncture with 
moxibustion for HZ remains unknown. 
 
To address these gap, this chapter will provide an overview of randomised controlled trials 
(RCTs) of acupuncture treatments for HZ (the ‘general review’), and will evaluate 
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systematically the efficacy and safety of acupuncture plus moxibustion compared with 
pharmacotherapy in the management of HZ (the ‘systematic review’). 
 
7.2 Aims 
This chapter aimed to:  
1. To summarise the characteristics and acupuncture treatments in RCTs for HZ. 
2. To conduct a systematic evaluation of the efficacy and safety of acupuncture plus 
moxibustion for HZ.  
 
7.3 Methods 
The methods for the general review of acupuncture therapies for HZ, and the SRs of 
acupuncture plus moxibustion has been described in Chapter 5. 
 
7.4 Overview of acupuncture therapies for herpes zoster 
A total of 37,717 citations were identified through the comprehensive database searches from 
inception to February 2014, with an update search run in February 2015. After titles and 
abstracts screening, 5,913 articles were retrieved for full text eligibility assessment. Twenty-
seven (27) RCTs were included for this general review (Figure 7.1) [270-296]. All studies 
were conducted in China. 
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Details of acupuncture therapies evaluated in these studies were extracted and analysed. 
Among the included studies, two studies included more than one treatment arm [275, 283]. 
Details of the intervention arms were extracted separately. One arm in each study included 
the intervention fire needling, which is not common practice outside of China. This arm of 
each study was excluded from analysis. The other treatment arms evaluated manual 
acupuncture and moxibustion, and were included in this review. The remaining 25 studies 
used a two-arm parallel design, using acupuncture therapies alone or in combination with 
pharmaceutical therapies as intervention, compared with pharmaceutical therapies. 
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Figure 7.1 Study selection flow chart.  
HZ, herpes zoster; n, number; RCT, randomised controlled trial. 
 
7.4.1 Characteristics of the included studies 
A total of 2,286 participants were included in the RCTs, whose age ranged from 18 to 85 
years. The median of mean age was 51 years in the studies that reported mean age. For the 
studies which reported gender data, the number of male participants was slightly more than 
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the number of female (1,006 males and 957 females respectively). The duration of HZ at the 
time of study inclusion varied, ranging from one day to 20 days. The duration of treatment 
also varied, from a minimum of five up to 28 days. The median treatment duration was 10 
days. Eleven studies reported follow-up assessment, ranging from 14 days to three months 
(see Table 7.1) [270, 274, 275, 279, 280, 283, 286, 287, 290, 292, 295].  
 
One study used syndrome differentiation to guide diagnosis and treatment [282]. The CM 
syndromes described in the study were consistent with the guideline: Spleen deficiency with 
dampness encumbrance, and pattern/syndrome of qi stagnation and Blood stasis. Differences 
existed in the treatment approaches used in acupuncture therapy RCTs in this Chapter 
compared to Chinese herbal medicine (CHM) RCTs in Chapter 6. The Chinese acupuncture 
guideline [12] describes the selection of points and treatment approach according to HZ 
stage. For example, in the prodromal phase, ashi 阿是穴 points are selected. While no 
guideline is available for CHM, the treatment approaches are selected based on syndrome 
differentiations. Therefore, it was not surprising that only one study reported syndrome 
differentiation. 
 
All studies used at least one type of guideline recommended pharmacotherapy as the 
comparator: antiviral therapies (26 studies, including acyclovir, famciclovir, valacyclovir, and 
moroxydine), and/or analgesics (eight studies, including NSAIDS, carbamazepine, 
gabapentin, steroids, and nerve block therapies). Eight studies used vitamin B as an adjunct to 
pharmacotherapy, which is commonly used in China to aid nerve repair [297, 298]. However, 
vitamin B is not a guideline recommended treatment for HZ. The evidence for vitamin B 
remains unclear as to whether it could improve the efficacy of antiviral or analgesic therapies.  
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Two studies used other therapies in addition to pharmacotherapies: patient education [284], 
and semiconductor laser (on irradiation nerve root and pain points) [273]. In the studies 
which reported the dosages of antiviral therapies, only five studies used doses which matched 
those recommended in clinical practice guidelines. Other studies used dosages lower than that 
recommended in guidelines. 
 
7.4.2 Characteristics of the acupuncture interventions  
The interventions in the included RCTs contained various acupuncture therapies: manual 
acupuncture, surrounding acupuncture, electro-acupuncture, plum blossom needling, and 
moxibustion. Different acupuncture approaches were adopted individually or in combination 
with other acupuncture techniques. Eight studies integrated acupuncture therapies with 
pharmacotherapies. Details of the different acupuncture therapies are illustrated below. 
 
Manual acupuncture   
 
Manual acupuncture is one of the most commonly used techniques of stimulating 
acupuncture points, where the skin is penetrated by thin metal needles manually [299]. 
Thirteen studies involved manual acupuncture as the intervention [277-282, 287, 288, 291-
294, 296], five of which were integrated with pharmacotherapies as the intervention [272, 
278-281]. Only one study used manual acupuncture alone [281] while others were all 
combined with other acupuncture techniques.  
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Table 7.1 Characteristics and intervention details of the included randomised controlled trials 
First 
Author, 
Publication 
Year 
Treatment 
Duration, 
Follow-up 
Duration 
Duration of 
Condition 
(mean (±SD) or 
range) (days) 
No. of 
Participants 
Randomised
/Assessed, 
Dropouts 
Age (mean 
or range) 
Gender 
(male/ 
female) 
Acupuncture Points Comparators (antiviral 
and pain management 
only) 
Acupuncture (including manual, electro, surrounding) alone 
 
Li, 2011 
[283] 
10 days, 60 
days 
I: 6.03, C: 5.26 I: 100/94, 6 
C: 100/95, 5 
I: 43.83 
C: 46.42 
I: 45/49 
C: 34/61 
SA: Ashi points 阿是穴; EA: 
Huatuojiaji points 华佗夹脊
穴, TE6 Zhigou 支沟, SI3 
Houxi 后溪 
Valacyclovir 0.3 g, bid, 
po; vitamin B1, po, tid 
Zhou, 2013 
[289] 
10 days, NS I: 3.09, C: 3.49 I: 30/30, 0 
C: 30/30, 0 
I: 51.29 
C: 54.59 
I: 14/16 
C: 13/17 
MA: Huatuojiaji points 华佗
夹脊穴, TE6 Zhigou 支沟, SI3 
Houxi 后溪; SA: rash area 
Valacyclovir 0.3 g, bid, 
po 
 
Zhang, 
2014 [292] 
10 days, NS I:5.17, C: 5.03 I: 30/30, 0 
C: 30/30, 0 
I: 51.64 
C: 47.79 
I: 15/10 
C: 15/10 
EA: Huatuojiaji points 华佗夹
脊穴, Ashi points 阿是穴  
Acyclovir 0.3 g, tid, po; 
carbamazepine 0.1 g, qd, 
po 
Acupuncture (including manual, electro, surrounding) in combination with pharmacotherapy 
 
Luo, 2008 
[272] 
7 days, NS I: 1-5, C: 1-4 I: 40/40, 0 
C: 36/36, 0 
I: 58 
C: 60 
I: NS 
C: NS 
MA: PC6 Neiguan 内关, ST36 
Zusanli 足三里, TE6 Zhigou 
支沟, GB34 Yanglingquan 阳
陵泉, Huatuojiaji points 华佗
夹脊穴, Ashi points 阿是穴; 
SA: rash area; 
Acyclovir 0.2 g, five 
times per day, po; 
vitamin B12, im, qd 
Chen, 2010 
[281] 
10 days, NS Total: 7.4 I: 46/46, 0 
C: 46/46, 0 
NS 
 
I: NS 
C: NS 
MA: Huatuojiaji points 华佗
夹脊穴, Ashi points 阿是穴; 
LR3 Taichong 太冲, LR2 
Xingjian 行间, GB34 
Famciclovir 0.25 g, tid, 
po; vitamin B1, po, tid 
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Yanglingquan 阳陵泉, SP6 
Sanyinjiao 三阴交, SP10 
Xuehai 血海, SP9 Yinlingquan 
阴陵泉, EX-HN3 Yintang 印
堂, GB14 Yangbai 阳白, EX-
HN5 Taiyang 太阳, GB7 
Qubin 曲鬓, GB8 Shuaigu 率
谷, TE17 Yifeng 翳风, GB20 
Fengchi 风池, LI15 Jianyu 肩
髃, TE14 Jianliao 肩髎, SI9 
Jianzhen 肩贞, SI10 Naoshu
臑俞, SP21 Dabao 大包, LR14 
Qimen 期门, LR13 Zhangmen 
章门, EX-HN15 Jingbaolao 颈
百劳, GB27 Wushu 五枢 
Lin, 2012 
[287]  
NS, NS I: 4.6, C: 4.3 I: 40/40, 0 
C: 38/38, 0 
I: 54.8 
C: 56.2 
I: 20/20 
C: 20/18 
MA: TE6 Zhigou 支沟, LR3 
Taichong 太冲, ST36 Zusanli 
足三里, GB34 Yanglingquan 
阳陵泉, GB41 Zulingqi 足临
泣, LI4 Hegu 合谷, TE5 
Waiguan 外关, EX-HN5 
Taiyang 太阳, BL40 Weizhong 
委中; SA: rash area 
Acyclovir 0.2 g, five 
times per day, po 
Zheng, 
2010 [280] 
10 days, 3 
months 
Total: 1-20 I: 40/40, 0 
C: 40/40, 0 
NS I: NS 
C: NS 
MA: Huatuojiaji points 华佗
夹脊穴; SA: rash area; 
Nerve block, qd 
Zhang, 
2012 [285] 
NS, NS Total: <7 I: 50/50, 0 
C: 50/50, 0 
I: 52.3 
C: 52.6 
I: NS 
C: NS 
EA: GB20 Fengchi 风池, EX-
HN5 Taiyang 太阳, BL2 
Cuanzhu 攒竹, ST7 Xiaguan 
Famciclovir 0.25 g, tid, 
po; Acyclovir ointment, 
five times per day, ext; 
vitamin B1, po, tid 
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下关, LI4 Hegu 合谷, TE5 
Waiguan 外关, TE6 Zhigou 支
沟, GB34 Yanglingquan 阳陵
泉 , LR3 Taichong 太冲, ST36 
Zusanli 足三里, SP6 
Sanyinjiao 三阴交, Ashi points 
阿是穴, Huatuojiaji points 华
佗夹脊穴, Bladder meridian 
Plum blossom needling in combination with pharmacotherapy 
 
Deng, 2008 
[273] 
7 days, NS NS I: 25/25, 0 
C: 25/25, 0 
I: 50 
C: 48 
I: 12/13 
C: 13/12 
Rash area Famciclovir 0.25 g, bid, 
po 
Moxibustion alone 
 
Jiang, 2010 
[276] 
20 days, NS Total: <7 I: 50/50, 0 
C: 48/48, 0 
I: 30-75 
C: 27-70 
I: 29/21 
C: 26/22 
Huatuojiaji points 华佗夹脊穴 Acyclovir 0.25 g, tid, po; 
acyclovir ointment, bid, 
ext. 
Wang, 2010 
[277] 
5 days, NS I: 3-10, C: 2-12 I: 30/30, 0 
C: 30/30, 0 
I: 23-82 
C: 27-76 
I: 14/16 
C: 17/13 
Snakehead (the first rash 
appears), 蛇眼 (Snakehead,the 
rashes surrounding the 
snakehead), 蛇尾 (the farthest 
rash from snakehead) 
Acyclovir 0.2 g, tid, po; 
diclofenac sodium 
enteric coated sustained 
release capsules 0.1 g, 
qd, po; vitamin B1, po, 
tid 
Wen, 2014 
[295] 
10 days, 30 
days 
I: 1-7, C: 2-7 I: 46/46, 0 
C: 37/37, 0 
I: 19-75 
C: 23-68 
I: 21/25 
C: 22/15 
Zhi Zhu point (spider point) 蜘
蛛穴, BL15 Xinshu 心腧 
Valacylovir 0.3 g, bid, 
po; ibuprofen 0.2 g, bid, 
po; vitamin B1, po, tid; 
vitamin B12, po, tid 
Moxibustion in combination with pharmacotherapy 
 
Yue, 2009 
[274] 
NS, 14 days NS I: 39/39, 0 
C: 37/37, 0 
I: 44.92 
C: 42.96 
I: 19/20 
C: 18/19 
Rash area, TE6 Zhigou 支沟, 
GB34 Yanglingquan 阳陵泉, 
Famciclovir 0.25 g, tid, 
po 
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GB40 Qiuxue 丘墟 
Lei, 2013 
[290] 
7days, 14 days I: 1-3, C: NS I: 40/40, 0 
C: 40/40, 0 
I: 53.25 
C: 52.69 
I: 21/19 
C: 20/20 
Rash area Famciclovir 0.25 g, tid, 
po 
Acupuncture plus plum blossom needling alone 
 
Zhao, 2010 
[279] 
10 days, 4 
weeks 
Total: <7 days I: 53/53, 0 
C: 52/52, 0 
I: 50.5 
C: 49.6 
I: 26/27 
C: 24/28 
MA: GB20 Fengchi 风池, BL2 
Cuanzhu 攒竹, GB14 Yangbai 
阳白, EX-HN5 Taiyang 太阳, 
ST2 Sibai 四白, ST6 Jiache 颊
车, LI4 Hegu 合谷; SA: rash 
area; EA:Huatuojiaji points 华
佗夹脊穴; PB: rash area 
Acyclovir 0.4 g, five 
times per day, po 
Acupuncture plus moxibustion alone 
 
Lu, 2004 
[270] 
10 days, 3 
months 
I: 3-10, C: 4-9 I: 28/28, 0 
C: 28/28, 0 
I: 55~73 
C: 56~68 
I: 17/11 
C: 16/12 
SA: rash area; Moxi: rash area Carbamazepine 0.1 g, qd, 
po; Moroxydine 0.6 g, 
qd, po 
Liu, 2010 
[275] 
10 days, 90 
days 
I: 4.96, C: 5.03 I: 30/30, 0 
C: 30/30, 0 
I: 47.91 
C: 47.79 
I: 16/14 
C: 13/17 
EA: Ashi points 阿是穴 points, 
Huatuojiaji points 华佗夹脊
穴; Moxi: Ashi points 阿是穴 
points 
Valacyclovir 0.3 g, bid, 
po; carbamazepine 0.1 g, 
tid, po; vitamin B1, po, 
tid 
Bao, 2011 
[282] 
10 days, NS I: 2~10, C: 2~8 I: 32/32, 0 
C: 32/32, 0 
I: 51 
C: 53 
I: 19/13 
C: 17/15 
MA: LI11 Quchi 曲池 , TE5 
Waiguan 外关, SP6 Sanyinjiao 
三阴交, SP10 Xuehai 血海, 
ST36 Zusanli 足三里, LR14 
Qimen 期门, LR3 Taichong 太
冲, GB34 Yanglingquan 阳陵
泉; SA: rash area; Moxi: rash 
area 
Acyclovir 0.8 g, tid, po 
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Li, 2011 
[283] 
10 days, 60 
days 
I: 5.56, C: 5.26 I: 100/94, 6 
C: 100/95, 5 
I: 47.54 
C: 46.42 
I: 50/50 
C: 50/50 
SA: Ashi points 阿是穴; EA: 
Huatuojiaji points 华佗夹脊
穴, TE6 Zhigou 支沟, SI3 
Houxi 后溪; Moxi: Ashi points 
阿是穴  
Valacyclovir 0.3 g, bid, 
po; vitamin B1, po, tid 
Wang, 2011 
[284] 
10 days, NS Total: <7 I: 64/58, 6 
C: 56/56, 0 
I: 63.5 
C: 62.3 
I: 26/32 
C: 26/30 
EA: Huatuojiaji points 华佗夹
脊穴, Ashi points 阿是穴; 
Moxi: rash area; 
Valacyclovir 0.3 g, bid, 
po; prednisone 10 mg, 
tid, po; acyclovir cream, 
6 times per day, ext. 
Chen, 2012 
[288] 
10 days, NS I: 3~6, C: 2~5 I: 31/31, 0 
C: 31/31, 0 
I: 38~72 
NS 
I: NS 
C: NS 
rash area Acyclovir 0.25 g, bid, iv; 
acyclovir ointment, ext. 
Lin 2012 
[287] 
10 days, 30 
days 
I: 4.37, C: 4.54 I: 32/32, 0 
C: 30/30, 0 
I: 53.26 
C: 52.42 
I: 17/15 
C: 16/14 
MA: LI4 Hegu 合谷, LR3 
Taichong 太冲, EX-HN5 
Taiyang 太阳, TE6 Zhigou 支
沟, GB34 Yanglingquan 阳陵
泉; SA: rash area; Moxi: rash 
area; 
Acyclovir 0.8 g, 5 times 
per day po;  acyclovir 
cream, 5 times per day, 
ext. 
Li, 2014 
[293] 
10 days, NS Total: 1-7 I: 32/32, 0 
C: 30/30, 0 
I: 34.1 
C: 35.2 
I: 19/13 
C: 16/14 
MA: Huatuojiaji points 华佗
夹脊穴, Ashi points 阿是穴; 
EA: Huatuojiaji points 华佗夹
脊穴 (the ones above and 
below); Moxi: Ashi points 阿
是穴; 
Valacyclovir 0.3 g, bid, 
po; vitamin B1, po, tid; 
vitamin B12, po, tid 
Yang, 2014 
[294] 
14 days, NS I: 5.13, C: 4.77 I: 29/29, 0 
C: 30/30, 0 
I: 38.79 
C: 41.97 
I: 11/18 
C: 13/17 
rash area Acyclovir 0.4 g, tid, po; 
gabapentin 0.3 g, tid, po; 
acyclovir ointment, ext. 
Acupuncture plus plum blossom needling plus moxibustion alone 
 
Zhang, 
2014 [292] 
10 days, 3 
months 
I: 6.36, C: 5.64 I: 25/25, 0 
C: 25/25, 0 
I: 63.72 
C: 60.2 
I: NS 
C: NS 
MA: LI11 Quchi 曲池, LI4 
Hegu 合谷, ST36 Zusanli 足三
Valacyclovir 0.3 g, bid, 
po; vitamin B1, po, tid 
185 
 
里, SP6 Sanyinjiao 三阴交, 
LR3 Taichong 太冲; PB: rash 
area; Moxi: rash area 
 
Sun, 2015 
[296] 
10 days, NS I: 1-15, C: 1-13 I: 50/50, 0 
C: 50/50, 0 
I: 38 
C: 38 
I: 30/20 
C: 30/20 
MA: rash area, LI11 Quchi 曲
池, LI4 Hegu 合谷, ST36 
Zusanli 足三里, SP6 
Sanyinjiao 三阴交, LR3 
Taichong 太冲 
Valacyclovir 0.3 g, bid, 
po; vitamin B1, po, tid 
 
Plum blossom needling plus moxibustion alone 
 
Yang, 2012 
[286] 
7 days, 30 days I: 5.1, C: 5.2 I: 63/60, 3 
C: 60/60, 0 
I: 47.1 
C: 46.3 
I: 35/25 
C: 36/24 
Rash area, Huatuojiaji points 
华佗夹脊穴, LI11 Quchi 曲池, 
TE5 Waiguan 外关, ST36 
Zusanli 足三里, LR3 Taichong 
太冲 
Valacyclovir 0.3 g, bid, 
po;  acyclovir cream, 5-6 
times per day, ext; 
vitamin B1, po, tid 
bid., twice a day; C, control group; ext., external used; EA, electro-acupuncture; I, intervention group; m, mean; MA, manual acupuncture; 
Moxi, moxibustion; NS, not specified; PB, plum blossom needling; po, oral used; qd., once a day; SA, surrounding acupuncture; SD, standard 
deviation; tid., three times a day 
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A total of 43 acupuncture points were selected across these studies and the point selection 
varied. The most frequently used acupuncture points were LR3 Taichong 太冲 (in seven 
studies), ashi points 阿是穴 (or rash area, in six studies), GB34 Yanglingquan 阳陵泉 (six 
studies), ST36 Zusanli 足三里 (six studies), Huatuojiaji points华佗夹脊穴 (points parallel 
0.5 cun to the spine) (five studies), LI4 Hegu 合谷 (five studies), SP6 Sanyinjiao 三阴交 
(five studies), LI11 Quchi 曲池 (four studies), TE6 Zhigou 支沟 (four studies), and EX-HN5 
Taiyang 太阳 (four studies). Details of these top ten frequently used points are shown in 
Table 7.2 
 
Table 7.2 Ten most frequently used acupuncture points in the included studies  
Acupuncture 
Points 
Pinyin/Chinese 
Character 
Frequency Point Function [111] 
LR3 Taichong 太冲 7 
Subdues Liver yang, expels interior 
wind, promotes the smooth flow of 
Liver qi, calms the mind. 
Ashi (or rash 
area) 
Ashi points 阿是穴  6 
“Where is the pain, where is the point 
for treatment” 
GB34 
Yanglingquan 阳陵
泉 
6 
Promotes the smooth flow of Liver qi, 
resolves damp-heat, removes 
obstructions from the channel, and 
rebellious qi. 
ST36 Zusanli 足三里 6 
Benefits Stomach and Spleen, tonifies 
qi and Blood, dispels cold, strengthens 
body, regulates nutritive and defensive 
qi, raises yang, expels wind and damp, 
and resolves oedema. 
Huatuojiaji 
points 
Huatuojiaji points 
华佗夹脊穴  
5 Regulate the qi between zang and fu. 
LI4 Hegu 合谷 5 
Dispels exterior wind, releases the 
exterior, stimulates the dispersing 
function of the Lungs, stops pain, 
removes obstructions from the 
channel, tonifies qi and consolidates 
the exterior, clears heat. 
SP6 Sanyinjiao 三阴交 5 
Strengthens Spleen, resolves damp, 
promotes function of Liver and 
smooth flow of Liver qi, nourishes 
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Blood and yin, moves and cools Blood 
and eliminates stasis, stops pain, 
calms mind. 
LI11 Quchi 曲池 4 
Expels exterior wind, clears heat, 
cools Blood, resolves dampness, 
regulates nutritive qi and Blood, and 
benefits the sinews and joints. 
TE6 Zhigou 支沟 4 
Regulates qi, removes obstructions 
from the channel, removes 
obstructions from the Large Intestine, 
clears heat, and expels wind. 
EX-HN5 Taiyang 太阳 4 
Dispels wind, clears heat, and 
alleviates pain. 
 
Three main point functions were evident: regulating qi (LR3 Taichong 太冲, GB34 
Yanglingquan 阳陵泉, Huatuojiaji points 华佗夹脊穴, SP6 Sanyinjiao 三阴交, and TE6 
Zhigou 支沟), clearing heat (LI4 Hegu 合谷, LI11 Quchi 曲池, TE6 Zhigou 支沟, and EX-
HN5 Taiyang 太阳), and resolving damp (GB34 Yanglingquan 阳陵泉, ST36 Zusanli 足三
里, SP6 Sanyinjiao 三阴交, and LI11 Quchi 曲池). Currently there is no acupuncture point 
recommendation for manual acupuncture in the Chinese guideline [12]. Findings indicated 
that point selection for manual acupuncture was consistent with the guidance of the three 
main syndromes (Stagnant heat in the Liver meridian, Spleen deficiency with damp retention, 
and qi stagnation and Blood stasis) described in Chinese guideline [12]. All of the most 
frequently used points have an analgesic effect in clinical practice, and this finding highlights 
that principles of treatment with acupuncture are similar to pharmacotherapy.  
 
Surrounding acupuncture 
Surrounding acupuncture (SA) is a kind of acupuncture therapy which intends to strengthen 
the efficacy of manual acupuncture [300]. When practicing SA, needles are inserted obliquely 
at a 15° angle to surround the lesion site [12]. Nine studies used SA in combination with 
other acupuncture therapies as intervention [270, 272, 278-280, 282, 283, 287, 291]. All 
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studies applied SA around the rash area as the guideline recommends [12]. The rash area is 
recognised as a kind of ashi point in the guideline, involving the painful spots and vesicular 
areas [12].  
 
Electro-acupuncture 
Electro-acupuncture (EA) is a developed acupuncture therapy. Electric stimulation is applied 
to acupuncture points to promote the efficacy of manual acupuncture [111]. Seven studies 
used EA in their intervention [275, 279, 283-285, 289, 293]. Two studies used EA alone [285, 
289], while others combined it with other acupuncture approaches. Huatuojiaji points 华佗夹
脊穴, that are recommended for treating HZ in contemporary guideline [12], were selected in 
all of the studies; three studies combined with this approach with ashi points [275, 284, 289, 
292], and one study selected multiple points [285]. The finding also showed that the point 
selection in the included studies was consistent with recommendations in contemporary 
acupuncture guidelines [12].  
 
Plum blossom needling 
Six studies used plum blossom needling as the intervention [271, 273, 279, 286, 292, 296]. 
All of the studies tapped the pyonex needle on the rash area as the guideline recommended, 
and one study tapped on multiple acupuncture points (Huatuojiaji points 华佗夹脊穴, LI11 
Quchi 曲池, TE6 Zhigou 支沟, ST36 Zusanli 足三里, and LR3 Taichong 太冲) [286]. 
Contemporary acupuncture guideline recommends plum blossom needling should be 
practiced on ashi points with Huatuojiaji points 华佗夹脊穴 (when the rash occurs on the 
trunk) or GV14 Dazhui 大椎 (rash on facial and head region) [12]. However, only one study 
[271] followed the acupuncture guideline [12]. In this study, the multiple points selected for 
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tapping also followed the three main syndrome differentiations (see manual acupuncture 
above). The main purpose for plum blossom needling is to clear Stagnant Blood and relieve 
the pain [111], which may be a mechanism of this therapy to treat the syndrome of qi 
stagnation and Blood stasis of HZ. 
 
Moxibustion 
To improve the immunity of patients and prolong the analgesic effect [111], seventeen studies 
adopted moxibustion therapies as the intervention [270, 274-277, 282-284, 286-288, 290, 
292-296]. Most of the studies followed the guideline and applied the moxibustion on the ashi 
points 阿是穴 (or rash area), while two studies selected Huatuojiaji points 华佗夹脊穴 [276] 
and zhizhu point 蜘蛛穴 [295] respectively. Zhizhu point 蜘蛛穴 is a special acupuncture 
point selection method for moxa cone moxibustion [301]. By measuring the patient’s head 
circumference using a thread, the centre of the thread is placed at the front of the patient’s 
neck and ends placed on the patient’s back, with both ends level. Moxa cones are placed at 
the level of the thread ends. One study described the rash area as ‘snake head 蛇头’ (where 
the first rash appears), ‘snake eye 蛇眼’ (the rashes surrounding the snake head), and ‘snake 
tail 蛇尾’ (the farthest rash from snake head). Similar description can also be found in the 
classical literature, in which pricking lesion were applied (see Chapter 4, 4.4.3.2.3 
Acupuncture and other therapies).  
 
7.4.3 Discussion 
Participants in included RCTs were older people, which is similar to the general review of 
CHM therapies in Chapter 6. More male participants were included in these studies than 
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females. Global epidemiology reports showed higher incidence rate of HZ in women [30, 31, 
34]; the reason for the gender difference is not clear.  
 
A variety of different acupuncture approaches have been evaluated by RCTs included for this 
review. The acupuncture approaches and the selection of acupuncture points in the majority 
of the studies were consistent with the contemporary guideline [12]. The acupuncture points 
selection varied among studies which used manual acupuncture as intervention. Although 
there are no acupuncture points recommended for manual acupuncture in contemporary 
guideline, the function of the most commonly used acupuncture points echoes the three main 
syndromes described in the acupuncture guideline [12]. From this review, many studies 
combined different acupuncture approaches as intervention, as it may strengthen the clinical 
efficacy. More research has to be conducted to confirm the efficacy of combination of 
different acupuncture approaches compared with the individual approach. 
 
Among the studies included for this general review, only five studies used the guideline 
recommended dosage of pharmacotherapies as comparators, a finding also seen in the general 
review of CHM therapies in Chapter 6. The evidence of acupuncture therapies in the 
management of HZ from the modern literature is limited by the dosage that these studies 
used, among other factors. The use of a sub-threshold dose of pharmacotherapies as 
comparators may exaggerate the efficacy of acupuncture treatments in the clinical research. 
More rigorously designed clinical research is needed to address this gap. 
 
7.5 Systematic review of acupuncture plus moxibustion for HZ 
As the combination of acupuncture plus moxibustion was commonly evaluated in the general 
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review described previously, this combination of interventions was selected for further 
evaluation of efficacy and safety. This SR has been accepted for publication in Dermatologic 
Therapy [302]. 
7.5.1 Descriptions of the studies 
Database searches identified more than 37,000 citations (Figure 7.1). More than 11,000 were 
excluded based on screening of titles and abstracts, and the full text of almost 6,000 studies 
were reviewed. Nine RCTs (945 participants) met the inclusion criteria (Table 7.3) [270, 275, 
282-284, 288, 293, 294, 303]. All studies were conducted in China, and compared the 
combination of acupuncture plus moxibustion with pharmacotherapy. Two studies included 
more than one treatment arm, and those additional treatment arms were excluded from this 
review [275, 283]. 
 
The sample size of included studies ranged from 56 [270] to 400 participants [283], and the 
median sample size was 62. Participants were recruited from hospital outpatient departments 
[275, 284, 293, 294, 303], inpatient departments [288], or both inpatient and outpatient 
departments [275, 283, 294]. The duration of HZ ranged from one [275, 283, 293, 294] to 10 
days [270, 282]. Treatment was provided for two weeks in one study [294], and for 10 days in 
remaining studies. Four studies reported follow-up assessment, which was made at 30 days 
[303], 60 days [283], or 90 days/three months [270, 275]. Two studies lost participants to 
follow up (n=32) [283, 284] (Table 7.3). 
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Table 7.3 Characteristics and intervention details of the included trials of acupuncture and moxibustion 
 
First 
Author, 
Publication 
Year 
Treatment 
Duration, 
Follow-up 
Duration 
Duration of 
Condition 
(mean (±SD) or 
range) (days) 
No. of 
Participants 
Randomised
/Assessed, 
Dropouts 
Age (mean 
or range) 
Gender 
(male/ 
female) 
Acupuncture Points Comparators (antiviral 
and pain management 
only) 
Lu, 2004 
[270] 
10 days, 3 
months 
I: 3-10, C: 4-9 I: 28/28, 0 
C: 28/28, 0 
I: 55~73 
C: 56~68 
I: 17/11 
C: 16/12 
SA: rash area; Moxi: rash area Carbamazepine 0.1 g, qd, 
po; Moroxydine 0.6 g, 
qd, po 
Liu, 2010 
[275] 
10 days, 90 
days 
I: 4.96, C: 5.03 I: 30/30, 0 
C: 30/30, 0 
I: 47.91 
C: 47.79 
I: 16/14 
C: 13/17 
EA: Ashi points 阿是穴 points, 
Huatuojiaji points 华佗夹脊
穴; Moxi: Ashi points 阿是穴 
points 
Valacyclovir 0.3 g, bid, 
po; carbamazepine 0.1 g, 
tid, po; vitamin B1, po, 
tid 
Bao, 2011 
[282] 
10 days, NS I: 2~10, C: 2~8 I: 32/32, 0 
C: 32/32, 0 
I: 51 
C: 53 
I: 19/13 
C: 17/15 
MA: LI11 Quchi 曲池 , TE5 
Waiguan 外关, SP6 Sanyinjiao 
三阴交, SP10 Xuehai 血海, 
ST36 Zusanli 足三里, LR14 
Qimen 期门, LR3 Taichong 太
冲, GB34 Yanglingquan 阳陵
泉; SA: rash area; Moxi: rash 
area 
Acyclovir 0.8 g, tid, po 
Li, 2011 
[283] 
10 days, 60 
days 
I: 5.56, C: 5.26 I: 100/94, 6 
C: 100/95, 5 
I: 47.54 
C: 46.42 
I: 50/50 
C: 50/50 
SA: Ashi points 阿是穴; EA: 
Huatuojiaji points 华佗夹脊
穴, TE6 Zhigou 支沟, SI3 
Houxi 后溪; Moxi: Ashi points 
阿是穴  
Valacyclovir 0.3 g, bid, 
po; vitamin B1, po, tid 
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First 
Author, 
Publication 
Year 
Treatment 
Duration, 
Follow-up 
Duration 
Duration of 
Condition 
(mean (±SD) or 
range) (days) 
No. of 
Participants 
Randomised
/Assessed, 
Dropouts 
Age (mean 
or range) 
Gender 
(male/ 
female) 
Acupuncture Points Comparators (antiviral 
and pain management 
only) 
Wang, 2011 
[284] 
10 days, NS Total: <7 I: 64/58, 6 
C: 56/56, 0 
I: 63.5 
C: 62.3 
I: 26/32 
C: 26/30 
EA: Huatuojiaji points 华佗夹
脊穴, Ashi points 阿是穴; 
Moxi: rash area; 
Valacyclovir 0.3 g, bid, 
po; prednisone 10 mg, 
tid, po; acyclovir cream, 
6 times per day, ext. 
Chen, 2012 
[288] 
10 days, NS I: 3~6, C: 2~5 I: 31/31, 0 
C: 31/31, 0 
I: 38~72 
NS 
I: NS 
C: NS 
rash area Acyclovir 0.25 g, bid, iv; 
acyclovir ointment, ext. 
Lin 2012 
[287] 
10 days, 30 
days 
I: 4.37, C: 4.54 I: 32/32, 0 
C: 30/30, 0 
I: 53.26 
C: 52.42 
I: 17/15 
C: 16/14 
MA: LI4 Hegu 合谷, LR3 
Taichong 太冲, EX-HN5 
Taiyang 太阳, TE6 Zhigou 支
沟, GB34 Yanglingquan 阳陵
泉; SA: rash area; Moxi: rash 
area; 
Acyclovir 0.8 g, 5 times 
per day po;  acyclovir 
cream, 5 times per day, 
ext. 
Li, 2014 
[293] 
10 days, NS Total: 1-7 I: 32/32, 0 
C: 30/30, 0 
I: 34.1 
C: 35.2 
I: 19/13 
C: 16/14 
MA: Huatuojiaji points 华佗
夹脊穴, Ashi points 阿是穴; 
EA: Huatuojiaji points 华佗夹
脊穴 (the ones above and 
below); Moxi: Ashi points 阿
是穴; 
Valacyclovir 0.3 g, bid, 
po; vitamin B1, po, tid; 
vitamin B12, po, tid 
Yang, 2014 
[294] 
14 days, NS I: 5.13, C: 4.77 I: 29/29, 0 
C: 30/30, 0 
I: 38.79 
C: 41.97 
I: 11/18 
C: 13/17 
rash area Acyclovir 0.4 g, tid, po; 
gabapentin 0.3 g, tid, po; 
acyclovir ointment, ext. 
bid., twice a day; C, control group; ext., external used; EA, electro-acupuncture; I, intervention group; MA, manual acupuncture; Moxi, 
moxibustion; NS, not specified; po, oral used; qd., once a day; SA, surrounding acupuncture; SD, standard deviation; tid., three times a day 
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7.5.2 Details of the intervention 
All studies evaluated the combination of acupuncture plus moxibustion against 
pharmacotherapy. Studies used various acupuncture approaches, including manual 
acupuncture [282, 288, 293, 294, 303], inserting needles surrounding the lesion sites (SA) 
[270, 282, 283, 303], and electro-acupuncture [270, 282, 283, 303] (see Table 7.3). As all 
approaches are typical of acupuncture clinical practice, it was considered suitable to pool 
results for analysis. The most commonly used acupuncture approach was to treat the rash area 
(five studies) [270, 284, 288, 294, 303] or to use ashi points 阿是穴 (local tender points, or 
points surrounding the rash area; four studies) [275, 283, 284, 293] or Huatuojiaji points 华
佗夹脊穴 (points parallel to the spine; four studies) [275, 283, 284, 293]. Other commonly 
reported acupuncture points were GB34 Yanglingquan 阳陵泉 [282, 303] and LR3 Taichong 
太冲 (two studies each) [282, 303]. 
 
Treatments used in the comparator groups included guideline recommended treatments, alone 
or in combination with other treatments (see Table 7.3). Two studies compared acupuncture 
plus moxibustion to antiviral therapy alone (acyclovir) [288, 303], three studies used antiviral 
therapy such as acyclovir [282] and valacylovir [283, 293] in combination with vitamins (B1, 
B12 or derivatives) [282, 293] or vitamins and saline compresses [283]. One study used the 
antiviral drug moroxydine in combination with the anticonvulsant carbamazepine [270], and 
three studies used antiviral drugs acyclovir [294] or valacyclovir [275, 284] with pain 
medications gabapentin [294], prednisone [284], or carbamazepine [275] and other treatments 
[275, 284, 294]. Vitamins B1 and B12 are commonly used in China to aid nerve repair. Of the 
nine studies, only one [303] used antiviral therapy at doses recommended in clinical practice 
guidelines [14]. 
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7.5.3 Outcome measurements 
All studies reported on at least one of the pre-specified outcome measures. Of the two 
primary outcomes, one study reported on pain intensity using visual analogue scale (VAS) 
score [283], and two studies reported on time to resolution of pain [284, 303]. Therapeutic 
effective rate (TER) was the most frequently reported secondary outcome (six studies) [275, 
282, 284, 288, 294, 303]. The TER is a global assessment of symptoms, where a 30% or 
greater improvement in skin lesions and significant pain reduction constitutes a clinical 
effect. Five studies reported time to crust formation [275, 283, 284, 293, 303], four studies 
reported time to cessation of new lesion formation [275, 283, 293, 303] and incidence of 
PHN at either one [283, 303] or three months [270, 275] after resolution of the rash, three 
reported time to resolution of the rash [283, 284, 293], and two studies reported adverse 
events [275, 283]. 
 
7.5.4 Methodological quality 
Three studies used a random number generator [275, 284, 303] and one used computer based 
central randomisation [283]; all were assessed as low risk of bias for sequence generation. 
The remaining studies did not provide sufficient information about randomisation processes, 
and were judged to be at unclear risk of bias. One study which used central allocation was 
judged as low risk of bias for allocation concealment [283], while all others were judged as 
unclear risk due to insufficient detail. Due to the nature of the intervention and comparator, it 
was not possible to blind participants and personnel to group allocation, and all studies were 
judged to be at high risk of bias. One study reported blinding outcome assessors to group 
allocation [283], and was considered to be at low risk of bias for this domain. One study 
reported participant loss but did not describe the reasons [283]. As the number of dropouts 
was similar in both groups, this study was judged as low risk of bias. Another study reported 
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loss to follow up [284] (n=6), but the number in each group was not specified. This study was 
judged as unclear risk of bias. Other studies reported data for all participants randomised and 
were judged as low risk. One trial was registered [283], but the details provided were 
insufficient, and the study was considered as unclear risk of bias for selective outcome 
reporting. No trial protocol or registration was available for all other studies, which were at 
unclear risk of bias (see Figure 7.2).  
 
 
Figure 7.2 Summary of risk of bias assessment of included studies 
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7.5.5 Effects of the intervention 
7.5.5.1 Pain related outcomes 
Pain intensity 
One study reported on VAS pain scores at the end of treatment and at 60 days [283]. Pain 
score at end of treatment was 8.25 mm lower in those who received acupuncture plus 
moxibustion compared to valacyclovir plus vitamin B1 and saline compress, with significant 
statistical difference shown (MD -8.25 mm; 95% CI -12.36 to -4.14) (Figure 7.2). Whilst 
statistically significant, this result is less than a 1 cm difference between groups. This is 
unlikely to be clinically meaningful, particularly when considering the wide variation in 
results and the trial being unblinded. This effect was not sustained at follow up (MD -1.62 
mm; 95% CI -3.39 to 0.15).  
 
 
Figure 7.3 Visual analogue scale pain scores 
 
Time to resolution of pain 
Two studies reported time to resolution of pain [284, 303]. One study did not specify the time 
from which measurement was made [284], and data were excluded from this outcome. The 
other study reported the time from start of treatment to resolution of pain [303]. Pain 
resolution was achieved 6.59 days earlier in the participants who received acupuncture plus 
moxibustion compared to oral and topical acyclovir (MD -6.59 days; 95% CI -8.07 to -5.11). 
It should be noted that topical acyclovir is not effective for HZ and is not recommended in 
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clinical practice guidelines [14]. 
 
7.5.5.2 Cutaneous outcomes 
Time to resolution of rash 
Three studies reported on time to resolution of rash [283, 284, 293]. Two studies didn’t 
specify the time point from which measurement was made, and were not analysed [284, 293]. 
One study reported the time from rash onset to resolution [283]. Resolution of the rash 
occurred 3.4 days earlier in the acupuncture plus moxibustion group than in the comparator 
group (valacyclovir plus vitamin B1 and saline compress; MD -3.4 days; 95% CI -3.71 to -
3.09).  
 
Time to crust formation 
Five studies reported on time to crust formation [275, 283, 284, 293, 303]. Three studies 
didn’t specify the time point from which measurements were made, and were excluded from 
the analysis [275, 284, 293]. Crust formation measured from rash onset occurred 1.42 days 
earlier in those who received acupuncture plus moxibustion compared with those who 
received valacyclovir plus vitamin B1 and saline compress (MD -1.42 days; 95% CI -1.52 to 
-1.32) [283]. When measured from the start of treatment, benefit was also seen with 
acupuncture plus moxibustion compared with oral and topical acyclovir [303], with crust 
formation occurring 1.64 days earlier (MD -1.64 days; 95% CI -2.87 to -0.41).  
 
Time to cessation of new lesion formation 
Four studies reported the time to cessation of new lesion formation [275, 283, 293, 303], with 
two excluded from analysis due to lack of detail about the time from which measurements 
were made [275, 293]. Acupuncture plus moxibustion resulted in a lesser time to cessation of 
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new lesion formation compared with valacyclovir, vitamin B1 and saline compress when 
measured from rash onset (MD -0.29 days; 95% CI -0.35 to -0.23) [283]. When measured 
from start of treatment, acupuncture plus moxibustion reduced the time to cessation of new 
lesions compared with oral and topical acyclovir (MD -1.26 days; 95% CI -2.16 to -0.36) 
[303]. 
 
7.5.5.3 Incidence of postherpetic neuralgia 
Four studies reported on the incidence of PHN [270, 275, 283, 303]. Sub-group analysis was 
performed according to PHN definition (one/three months after resolution of the rash). Meta-
analysis showed a significant reduction in the incidence of PHN (one month after rash 
resolution) in those who received acupuncture plus moxibustion compared to 
pharmacotherapy (two studies; RR 0.29; 95% CI 0.16 to 0.53; I2=0%) [283, 303]. In studies 
which measured PHN three months after rash resolution, no statistical difference was seen 
(two studies; RR 0.16; 95% CI 0.02 to 1.35; I2=0%) [270, 275]. 
 
7.5.5.4 Therapeutic effective rate 
Of the six studies which reported TER, one study reported data in a different way to that 
described in the guideline [294]. This study was excluded from analysis. The chance of 
achieving a 30% or greater improvement in lesions and significant pain reduction with 
acupuncture plus moxibustion was 2.67 that of pharmacotherapy (RR 2.67; 95% CI 2.03 to 
3.52; I2=43%).  
 
7.5.6 Adverse events 
Two cases of haematoma and five cases of bleeding were reported in the intervention group 
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of one study [283]. The adverse events were mild and the symptoms were relieved by local 
pressing or massage. One study reported that there was no adverse event observed in either 
intervention or control group [275], while the other studies did not mention adverse events 
[270, 275, 282, 284, 288, 293, 294, 303]. 
 
7.5.7 Discussion 
The findings from this systematic review suggest potential benefit from acupuncture and 
moxibustion in reducing pain intensity, improving rash healing, and reducing the incidence of 
PHN, although few studies reported these outcomes. Meta-analysis of five studies showed 
improvement in lesions and significant reduction in pain based on the therapeutic effective 
rate. TER has not been validated, and should be interpreted with caution.  
 
Acupuncture and moxibustion were well tolerated by patients, with few mild side effects 
reported. Bleeding and haematoma are the most common adverse events with acupuncture 
[304-306], resulting from needles puncturing the capillary vessels [111]. Due care minimises 
the risk of this occurring. Although no adverse events were reported related to moxibustion in 
the included studies, appropriate distance between burning moxibustion cigar and 
acupuncture points should be maintained to avoid empyrosis [111]. 
 
The findings in relation to incidence of PHN require further investigation. There is no 
consensus on the definition of PHN, but pain persisting three months after the resolution of 
the rash is generally accepted as the clinical definition and is used for research purposes [124]. 
When assessed at one month, acupuncture plus moxibustion reduced the incidence of PHN 
more than pharmacotherapy. No such benefit was seen when assessed at three months. This 
result may be due to the definition used. Pain from acute stage HZ has been reported to take 
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up to 61 days to resolve [307]. In this review, fifty cases of pain were reported one month 
after rash resolution, while six cases (all in the comparator group) were reported three months 
after resolution of the rash. This follows the trend for zoster related pain to resolve over time, 
and is not likely to be an indicator of the efficacy of acupuncture plus moxibustion.  
 
The pathogenesis of acute pain in HZ is the inflammatory response and necrosis of the 
varicella zoster virus infected sensory nerve [14]. Acupuncture and moxibustion are both 
important analgesic therapies in the acute stage of HZ [12]. The analgesic effect of 
acupuncture has been well-researched. Acupuncture promoted cortical endocrine 
involvement through evoking endogenous opiates, such as β-endorphin, encephalin, 
dynorphin, and endomorphin [308]. Other research suggests acupuncture could produce anti-
inflammatory effects via the autonomic nerve system in animal models [309]. The 
mechanism of the anti-nociception effect of electro-acupuncture is still unclear. Recent 
animal studies showed that electro-acupuncture may alleviate inflammation by suppressing 
certain pain-related molecular, protein and mRNA pathways [310-312]. 
 
Antiviral therapy (with or without analgesic therapy) is recommended as first line therapy for 
immunocompetent patients over 50 years of age [7, 9, 14]. The recommended dose of 
antiviral drug valacyclovir is one gram three times daily for seven days, and for oral acyclovir 
is 0.8 g five times a day for seven days [7]. Only one study included in this review used the 
guideline recommended dosage [303], while the dosage of the other studies included in this 
review was considerably less than those recommended in guidelines. One study used the 
anticonvulsant carbamazepine as analgesic therapy for managing acute zoster pain (0.1 g per 
day) [270], which was also lower than the guideline recommended dosage (0.4 to 1.2 g per 
day) [7]. None of the included studies described referring to clinical practice guidelines, and 
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no Chinese guidelines for conventional medical management of HZ could be identified to 
verify the dosage of antiviral and anticonvulsant therapies. Finally, several studies [284, 288, 
294, 303] used topical application of antiviral therapy, which is contrary to clinical practice 
guidelines. Therefore, the clinical relevance of the findings of this review are uncertain. 
 
Several studies included in this review used vitamin B medications or derivatives, which are 
not recommended in clinical practice guidelines. In China, the prescribing practice for acute 
stage of HZ often combines vitamin B1 and B12 for repairing infected nerves and regulating 
the function of synaptic transmission [297, 298]. It is unclear whether the addition of vitamin 
B1 or B12 alters the efficacy of valacyclovir, and results should be interpreted in light of this. 
 
7.5.8 Limitation 
Many of the studies included in this review had methodological flaws which limits 
interpretation of the results. There was a lack of detail about the randomisation process, 
blinding and outcome assessment. These factors are likely to influence the reliability of the 
results. With the exception of the VAS, few outcomes in HZ research have been standardised 
or validated. With a complex intervention like acupuncture, the selection of objective 
outcomes becomes even more important to minimise bias in the results.  
 
7.6 Chapter summary 
7.6.1 Implication for future research  
From the overview of acupuncture therapies, a variety of different acupuncture techniques 
were evaluated by the included studies. Only a small number of studies used clinical 
guideline recommended dosages. The use of a sub-threshold dosage was also seen in the 
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overview of CHM in Chapter 6, which may exaggerate the efficacy of acupuncture therapies 
in clinical research. Among other factors, the modern literature evidence of acupuncture 
therapies for HZ is limited by the dosage the studies used. 
 
Systematic review of acupuncture plus moxibustion showed the intervention reduced pain 
intensity, improved rash healing, and reduced the incidence of PHN compared to 
pharmacotherapies. Overall there is insufficient evidence from high quality studies reporting 
on objective outcomes. The lack of detail relating to some outcomes such as time to 
resolution of pain or rash limited evaluation of the evidence. Further research comparing 
acupuncture plus moxibustion to guideline recommended doses of pharmacotherapy, which 
report definitions used for outcomes and which use the accepted definition for PHN are 
needed. 
 
For future clinical research using acupuncture therapies as interventions, the feasibility may 
be another concern in Australia. Current acupuncture guideline recommends the acupuncture 
therapies should be practiced on patients once daily, with an average treatment duration for 
ten days (see Table 2.9) [12]. When the target participants are older people, it may be 
inconvenient or difficult for them to have a daily visit to the clinic. Alternative solutions may 
include conducting the trial in in-patient department or home visiting practice, but these may 
cause difficulty in recruiting patients or significant cost.  
 
7.6.2 Implication for clinical practice  
According to the general review of acupuncture therapies in the management for HZ, most of 
the therapies and acupuncture points selection were consistent with the contemporary 
acupuncture guideline. Although differences were seen in point selection of manual 
204 
 
acupuncture, the main function of points followed the treatment principle for the main 
syndromes of HZ. Many of the studies combined multiple acupuncture therapies as the 
intervention to strengthen the efficacy. For clinical practice, the combination of different 
acupuncture therapies or integrate with pharmaceutical treatments may be considered in the 
management of HZ. 
 
Although the clinical interpretation of the results from meta-analysis was limited by the 
methodological flaws, the combination of acupuncture and moxibustion were well tolerated 
by patients, with few mild side effects reported. As the treatment efficacy of the 
pharmacotherapies is not meeting the expectations of people with HZ [15], acupuncture and 
moxibustion may offer an alternative treatment option in the management of HZ. The 
acupuncture treatments may be appropriate for people with HZ for which antivirals are not 
indicated. 
 
As per discussion in 7.6.1, it is sometimes difficult for senior people to have daily visit to the 
clinic seeking for guideline recommended acupuncture treatments. For clinical practice, 
acupuncture treatments could be integrated with other CM therapies such as Chinese herbal 
medicine to promise the clinical effects.  
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Chapter 8. Experimental evidence of the most frequently used herbs for 
herpes zoster 
8.1 Introduction  
As stated in Chapter 6, a range of Chinese herbal medicine (CHM) formulae and individual 
herbs were used for the management of herpes zoster (HZ). A CHM formula Long dan xie 
gan tang (LDXGT) 龙胆泻肝汤, which contained the majority of the most frequently used 
herbs, showed clinical benefits in hastening alleviation of pain, in improving cutaneous 
outcomes, and in reducing the incidence rate of postherpetic neuralgia (PHN). The clinical 
efficacy of the formulae and herbs is mediated by their constituents. Experimental studies on 
LDXGT formula showed a promotion of macrophage phagocytosis and lymphocyte 
transformation in mice [313]. The physiological effects of the herbal ingredients have been 
evaluated in various laboratory studies, and their key biological actions are sumamrised 
below. 
 
8.2 Aims 
This chapter will examine and provide a general review on the experimental evidence of the 
most frequently reported herbs in clinical studies in further detail to identify possible 
mechanisms of action related to HZ.  
 
8.3 Methods 
As this chapter was aiming to conduct a general review of the experimental evidence, 
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literature search process was different from the systematic reviews which adopted more 
comprehensive methods in the previous chapters. A literature search was conducted in 
PubMed from inception to July 2016, with language being limited to English. Key words 
included pinyin of the herbs (for example, longdancao, longdan, and long dan cao), scientific 
names (for example, Gentiana scabra Bunge., Gentiana manshurica Kitag., and Gentiana 
triflora Pall.), and key chemical compounds isolated from the herbs described in the 
pharmacopeia of Chinese herbs (for example, secoiridoids, entiopicroside, sweroside and 
swertiamarin) [314]. A whole list of the key words of the herbs are shown in Appendix 8. In 
vivo or in vitro studies which described mechanisms relevant to HZ were included. 
Experimental evidence of each herb was summarised and synthesised into a general review.  
 
8.4 Experimental evidence 
8.4.1 Experimental evidence for Gentiana species (long dan cao 龙胆草)  
In addition to being used for HZ, Gentiana scabra Bunge. has been widely used in Chinese 
medicine (CM) practice to treat inflammation, chronic hepatitis, rheumatism, cholecystitis 
and fungal infection. The anti-inflammatory actions of Gentiana scabra Bunge. compounds 
have been well researched. Much of the research has come from studies of Gentiana scabra 
Bunge. and Gentiana triflora Pall. The key findings of the main chemical compounds are as 
described below. 
 
8.4.1.1 Iridoids and secoiridoids 
Secoiridoid glycosides are the major constituents of Gentiana scabra Bunge. species and 
Gentiana triflora Pall. species [262, 315, 316]. More than 20 kinds of secoiridoids had been 
isolated and purified in laboratory research, including gentiopicroside, sweroside and 
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swertiamarin. The inhibitory actions of these compounds against several inflammatory 
cytokines and pro-inflammatory enzymes have been shown in vitro (see below). While long 
dan cao 龙胆草 is traditionally sourced from Gentiana scabra Bunge. and Gentiana triflora 
Pall., compounds found in these two herbs have also been isolated from Gentiana lutea ssp. 
Symphyandra species. In chicken embryonic fibroblast gentiopicroside, secoiridoids, 
sweroside and swertiamarin have demonstrated wound healing activity [317]. 
 
Tumour necrosis factor α  
Tumour necrosis factor alpha (TNFα) has been identified as a key mediator in many immune-
mediated inflammatory diseases [318]. Previous studies have shown secoiridoids isolated 
from Gentiana scabra Bunge. and Gentiana triflora Pall. species demonstrated weak 
inhibition of TNFα in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells [262, 316]. 
Stronger inhibition of TNFα was seen with deglucosylscabraside in LPS-stimulated bone 
marrow-derived dendritic cells (BMDCs) [319].  
  
Interleukins  
Interleukins (ILs) are a group of cytokines that are expressed by various leucocytes such as T 
helper cells and natural killer cells. Interleukins promote inflammatory responses and are 
implicated in a wide range of inflammatory diseases [320]. Secoiridoid glycosides isolated 
from Gentiana scabra Bunge. species inhibited IL-6 production by LPS-stimulated RAW 
264.7 cells [262]. IL-6 inhibition was also seen in LPS-stimulated BMDCs, in addition to 
inhibition of IL-12 [319]. The suppression of interleukins may be one mechanism through 
which Gentiana scabra Bunge. produces anti-inflammatory effects. 
 
Nitric oxide  
208 
 
Nitric oxide (NO) plays a key role in the response to inflammatory stimuli in macrophages, 
which involves the pro-inflammatory enzyme inducible nitric oxide synthase (iNOS) [321]. 
Secoiridoid glycosides from Gentiana scabra Bunge. showed suppression effects on 
production of NO, induced by LPS in RAW 264 cells [262]. Gentiolactone, a secoiridoid 
dilactone from Gentiana triflora Pall., was found to inhibit the expression of iNOS in LPS-
induced RAW 264 cells [316]. 
 
Cyclooxgenase-2  
Cyclooxgenase-2 (Cox-2), a pro-inflammatory enzyme, converts free fatty acids to 
prostanoids leading to inflammation. Gentiolactone isolated from Gentiana triflora Pall. has 
demonstrated an inhibitory effect on LPS-stimulated RAW 264 cells at the messenger 
ribonucleic acid (mRNA) level, indicating another mechanism pathway of the anti-
inflammatory action of the secoiridoid [316].  
 
8.4.1.2 Triterpenes 
Few studies were identified which examined the biological actions of triterpenes in 
inflammation or immunomodulation. Triterpenes isolated from the rhizomes and roots of 
Gentiana scabra Bunge. demonstrated inhibitory activity against indoleamine 2, 3-
dioxygenase (IDO) [322]. Inhibition of IDO increases the rate at which tryptophan is 
converted to kynurenine [323], which in turn suppresses T-cell activation and induces T-cell 
death. Preliminary evidence from this study suggest a potential role for triterpenes in 
modulating the immune response. 
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8.4.2 Experimental evidence for Gardenia jasminoides Ellis. (zhi zi 栀子)  
Gardenia jasminoides Ellis. (zhi zi 栀子) has been widely used in treating inflammatory 
diseases in CM. Two main constituents, genipin and geniposide isolated from Gardenia 
jasminoides Ellis. have been researched for their anti-inflammatory effects and mechanism of 
action on the nociceptive pathway.  
 
8.4.2.1 Genipin 
Genipin has been shown to have anti-inflammatory effects through its inhibitory action on 
inflammatory cytokines and pro-inflammatory enzymes [324, 325]. Genipin was found to 
suppress iNOS expression and consequently reduce NO release in LPS-stimulated RAW 
264.7 cells [325]. In the same study, genipin was found to relieve the croton oil-induced ear 
oedema in mice when applied topically. Suppression of COX-2 may be one pathway for 
reducing inflammation. Genipin exhibited significant anti-inflammatory effect on 
carrageenan-induced rat paw oedema in a latter study by Koo et al. [324]. In the carrageen-
induced air pouch model, genipin demonstrated a similar reduction in volume of exudate and 
nitrite levels as dexamethasone. The inhibitory effect on NO production and COX-2 
expression may have contributed to its anti-inflammatory effect.  
 
8.4.2.2 Geniposide and other constituents 
Geniposide is another iridiod isolated from Gardenia jasminoides Ellis. and its anti-
inflammatory actions have been explored in some experimental studies [326, 327]. 
Geniposide has been shown to inhibit expression of NO, prostaglandin E2 (PGE2), TNFα and 
IL-6 in LPS-stimulated RAW 264.7 murine macrophage cells and peritoneal macrophages 
[327]. Geniposide also suppressed iNOS and COX-2 expression by downregulating mRNA 
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transcription levels. The inhibition of NO and PGE2 may explain the biological actions of 
geniposide in reducing inflammation.  
 
In addition to genipin and geniposide, 6α-hydroxy-geniposide, 6β-hydroxygeniposide, 
ixoroside and shanzhiside showed significant inhibition of IL-2 secretion by human 
peripheral blood T-cells, which were co-stimulated by phorbol myristate acetate and anti-
CD28 monoclonal antibodies [326]. 
 
8.4.3 Experimental evidence for Scutellaria baicalensis Georgi. (huang qin 黄芩)  
Scutellaria baicalensis Georgi. (huang qin 黄芩) contains various compounds including 
flavonoids, flavone glycosides and chalcones, which have potential anti-inflammatory and 
immunomodulatory actions [328, 329]. Baicalin, a flavonoid, has been found to inhibit 
inflammatory cytokines IL-6 production and IL-6 receptor mRNA expression in HEK 293 T-
cells [329]. Baicalein, another constituent of Scutellaria baicalensis Georgi. demonstrated 
inhibition of NO and nuclear factor-κB (NF-κB) production in LPS-activated mouse 
microglial cells [328]. Two flavonoids, baicalein and wogonin, exhibited suppression of NO 
production and iNOS expression in LPS-stimulated RAW 264.7 macrophage cells. 
Scutellaria baicalensis Georgi. may improve symptoms of HZ through suppressing 
inflammatory cytokines and pro-inflammatory enzymes. 
 
8.4.4 Experimental evidence for Bupleurum species (chai hu 柴胡)  
The herb chai hu 柴胡 used in CHM is mainly sourced from two species Bupleurum chinense 
DC., and Bupleurum scorzonerifolium Willd [314]. Two key groups of chemical compounds 
have been isolated from Bupleurum species: triterpene saponines and volatile oils [314]. D-
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limonene, a volatile oil, and its main circulating metabolites limonene-1-2-diol and perillic 
acid have been examined for their immunomodulatory effects in many studies. These 
constituents demonstrated inhibitory action against the production of interferon-gamma (IFN-
γ), interleukins, and TNFα by CD3+CD4+ T-cells, and the production of IFN-γ, IL-2 and 
TNFα by CD3+CD8+ T-cells [330]. 
 
D-limonene also demonstrated similar dose-dependent inhibition of the expression of pro-
inflammatory cytokines and enzymes in the research by Yoon et al, which may contribute to 
reducing the inflammation of sensory nerve caused by HZ [331]. In this study, d-limonene 
showed inhibition of the expression of interleukins and TNFα, decreased the production of 
NO and PGE2, and decreased expression of iNOS and COX-2 in LPS stimulated RAW 264.7 
murine macrophage cells. 
 
The metabolite perillic acid showed suppressing action of IL-2 and IL-10 production in 
human mitogen-activated T-cells and peripheral blood mononuclear cells (PBMC) [332]. In 
the same study, perillic acid also decreased levels of phosphorylated mitogen activated 
protein kinases (MAPK), which are believed to be involved in the responses to pro-
inflammatory cytokines [333]. Limonene and perillic acid also showed an 
immunomodulatory effect in BALB/c mice by increasing white blood cell count, bone 
marrow cell count, plaque forming cells in the spleen and circulating antibody count [334]. 
 
8.4.5 Experimental evidence for Rehmannia glutinosa Libosch (di huang 地黄)  
Rehmannia glutinosa Libosch (di huang 地黄) is one of the most commonly used herbs in 
CM practice to treat haematological conditions, insomnia and diabetes, in addition to HZ. 
Iridoids and iridoid glycosides, sugars, organic acids and amino acids are the four main 
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groups of constituents isolated from this herb [314]. One study demonstrated the 
immunomodulatory action of Rehmannia glutinosa Libosch that may contribute to improving 
the inflammation symptoms of HZ [335]. Rehmannia glutinosa polysaccharides (RGP), a 
sugar contained in the herb, showed a significant promoting effect of B and T lymphocyte 
proliferation in mice spleens. Being stimulated with RGP, the production of IL-2 and IFN-γ 
by T lymphocyte was upregulated significantly [335]. The water extract of Rehmannia 
glutinosa Libosch in the research by Baek et al. [336], demonstrated the suppression of the 
expression of pro-inflammatory genes including TNFα, MCP-1, IP-10, COX-2, and iNOS.  
 
8.4.6 Experimental evidence for Angelica sinensis (Oliv.) Diels (dang gui 当归)  
Angelica sinensis (Oliv.) Diels (dang gui 当归) is widely used in CM for cardiovascular 
diseases, inflammation, headache, infection and fatigue. Volatile oils are the main 
constituents contained in A. sinensis, in addition to amino acids, sugars and sterols [2]. Anti-
inflammatory and immunomodulatory actions of the chemical constituents have been shown 
in some laboratory research. Hydrosoluble fractions of A. sinensis including polysaccharide, 
oligosaccharide, sucrose, and A. sinensis total amino acids, dose-dependently increased cell 
proliferation of mouse peritoneal macrophages [337]. In the same study, these four fractions 
increased phagocytic and lysosomal activity compared to LPS, especially at higher 
concentrations. The production of peroxide (H2O2) was also seen, suggesting enhanced 
inflammatory response. In addition, these four fractions also increased the production of NO 
significantly in a time-dependent manner, and promoted the activity of iNOS. 
 
Selenizing Chinese angelica polysaccharides (sCAPs) isolated from the water extraction of A. 
sinensis, showed immune-enhancing activity in the study by Qin et al. [338]. sCAPs were 
shown to promote lymphocyte proliferation and increase serum antibody titer significantly in 
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chicken vaccinated with Newcastle Disease vaccine. Polysaccharides from A. sinensis also 
showed promotion effect of cell proliferation in total spleen cell population, macrophage 
depleted cell population, peritoneal macrophages and macrophage/B cell depleted cell 
population from BALB/c mice [339]. An acidic A. sinensis polysaccharide showed dose-
dependent promotion of lysosomal enzyme activity in murine peritoneal macrophages in 
vitro, and increased lysosomal activity and in vivo [340]. The production of NO was also 
increased in the same study, associated with the promoted expression of iNOS. 
 
Other constituents of A. sinensis have shown potential benefit through anti-inflammatory 
actions, which may alleviate the acute symptoms of HZ. N-butylidenephthalide, a constituent 
derived from A. sinensis, significantly decreased the production of IL-6 and TNFα in LPS-
stimulated murine dendritic 2.4 cells via NF-κB-dependent pathways [341]. The anti-
inflammatory effects of ligustilide of A. sinensis, has been evaluated by Su et al. on LPS-
induced RAW 264.7 macrophages cells [342]. Ligustilide has demonstrated strong inhibitory 
action against NO, PGE2, and TNFα in vitro. The expression of iNOS was inhibited by 
ligustilide at protein and mRNA levels. Furthermore, pre-treatment of cells with ligustilide 
prior to LPS stimulation significantly inhibited NF-κB p65 expression and reduced the 
nuclear level of c-Jun (indicative of transcription of activator protein 1, AP1). Ligustilide 
appears to exert its effects through inhibiting nuclear factor kappaB (NF-κB) and AP-1 
pathways. 
 
8.4.7 Experimental evidence for Alisma orientalis (Sam.) Juzep. (ze xie 泽泻)  
Alisma orientalis (Sam.) Juzep. (ze xie 泽泻) is a commonly used herb in CHM practice. In 
addition to being used for HZ, A. orientalis is often used as a diuretic to treat diabetes, 
hyperglycemia, hyperlipidemia, neuroprotection, and nephritis. The immunomodulatory and 
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anti-inflammatory effects of the chemical constituents from A. orientalis has been examined 
in several studies. Alismol and alisol B monoacetate, showed dose-dependent inhibition of 
NO production in IFN-γ plus LPS stimulated RAW 264.7 murine macrophage-like cells 
[343]. The inhibition may be due to the suppression of iNOS expression at mRNA levels. 
Some guaiane-type sesquiterpene, and protostane- and seco-protostane-types triterpenes were 
also found to have significant suppression of LPS-induced NO production [344]. In the same 
study, alismol and alisol F showed inhibition of iNOS induction.  
 
Alisol B-23 monoacetate, which is a constituent of Alisma Plantago-aquatica (another 
species of ze xie 泽泻), showed immunomodulatory effect in inducing cell apoptosis and 
significantly reducing the mitochondrial cell membrane potential in A7r5 rat aortic smooth 
muscle cells and human acute lymphoblastic leukaemia cell line [345].  
 
8.4.8 Experimental evidence for Isatis indigotica Fort. (ban lan gen 板蓝根) 
Isatis indigotica Fort. (ban lan gen 板蓝根) is one of the most widely used herbs in CHM 
practice to treat influenza, bacterial infection, hepatitis, and fever. Alkaloids, nucleosides, 
amino acids, organic acids, flavonoids, volatile oils and polysaccharides are the main 
constituents of this herb. The antiviral action of the constituent isoquinoline derivatives from 
I. indigotica. has been explored, showing inhibitory effects against herpes simplex virus type 
1 (HSV-1) in Vero cells by MTT assay [346]. 
 
The anti-inflammatory action in suppressing inflammatory cytokines and enzymes of the 
constituents of I. indigotica has been demonstrated in various studies. Indole alkaloids [347] 
and methanolic extracts [348] of I. indigotica inhibited NO production in LPS-stimulated 
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RAW 264.7 murine macrophage cells, and reduced expression of iNOS [348]. Chemical 
constituents from I. indigotica also showed suppression of PGE2 and pro-inflammatory 
cytokines PGE2, TNFα and IL-6 in LPS-stimulated RAW 264.7 cells [348, 349]. Methanolic 
extracts of I. indigotica also reduced inflammation in 12-O-Tetradecanolyphorbol 13-acetate 
(TPA) induced ear edema in mice [348], which may suggest its potential therapeutic efficacy 
in the management of skin conditions.  
 
8.4.9 Experimental evidence for Corydalis yanhusuo W.T. Wang (yan hu suo 延胡索) 
Corydalis yanhusuo W.T. Wang (yan hu suo 延胡索) is a widely used herb in CM for treating 
pain. Alkaloids are the main constituents isolated from C. yanhusuo [314], and their anti-
inflammatory and analgesic mechanisms have been explored in some studies. Extract of C. 
yanhusuo demonstrated anti-nociceptive effect on acute and neuropathic pain in mice [350], 
which may be partially mediated through dopamine D2 receptor antagonism. 
Dehydrocorybulbine (DHCB), an alkaloid from C. yanhusuo, showed effective analgesic 
effect in managing thermally induced acute pain, inflammatory pain and injury-induced 
neuropathic pain in mice [351]. The anti-nociceptive effect was contributed to DHCB’s 
interaction with D2 receptors. Another alkaloid, DI-tetrahydropalmatine, showed dose-
dependent analgesic action in acetic acid-induced writhing in mice [352].   
 
Inhibitory action on the in vivo and in vitro production of interleukins were seen with 
dehydrocorydaline [353], and tetrahydropalmatine [354]. This suggests the anti-inflammatory 
mechanisms of C. yanhusuo may contribute to managing the acute symptoms of HZ. Another 
constituent, Berberine, found in many herbal products including C. yanhusuo [355], showed 
promotion of IL-12 production in both macrophages and dendritic cells. These experimental 
evidence suggest the potential therapeutic mechanism of C. yanhusuo. 
216 
 
 
8.4.10 Experimental evidence for Plantago species (che qian zi 车前子) 
Plantago asiatica L., and Plantago depressa Willd. are the two species that CM herb che 
qian zi 车前子 is sourced from. Iridoid, phenylpropane glycosides, organic acids and other 
constituents (for example, β-sitosterol) have been isolated from Plantago species [314]. 
Antiviral and immunomodulatory actions of these constituents have been evaluated in some 
experimental studies, which may be relevant to HZ. Hot water extract of Plantago asiatica L. 
species was shown to have weak antiviral activity against the herpes simplex type 2 (HSV-2) 
virus [356]. In the same study, Plantago asiatica L. also demonstrated immunodulatory 
activity in promoting lymphocyte proliferation at low concentrations, but inhibited this effect 
at high concentration (≥50 μg/mL). In contrast, the secretion of IFN-γ increased at higher 
concentration. Seed extract of Plantago asiatica L. species was shown to induce the 
maturation of murine dendritic cells (DCs), which can directly stimulate naïve T lymphocytes 
and initiate primary immune responses [357].  
 
Plantagoside, a chemical constituent identified from the seed extract of Plantago asiatica L., 
was identified as having dose-dependent inhibitory actions on jack bean α-mannosidase 
activity [358]. Plantagoside was shown to decrease the antigen forming ability against sheep 
red blood cells in spleen cells from mice. Plantagoside also demonstrated suppression of T-
cell proliferation caused by concanavalin A in this study. 
 
8.4.11 Experimental evidence for Glycyrrhiza species (gan cao 甘草) 
Glycyrrhiza (gan cao 甘草) is one of the most frequently used herbs in CHM formulae. 
Glycyrrhiza is traditionally source from three species including Glycyrrhiza uralensis Fisch., 
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Glycyrrhiza inflata Bat., and Glycyrrhiza glabra L. Triterpenes, flavonoids and coumarin 
derivatives are the three main groups of chemical constituents isolated from Glycyrrhiza 
species [314]. Glycyrrhiza and its compounds have been widely used in both conventional 
and CM to treat skin conditions. Antiviral and analgesic properties of Glycyrrhiza and its 
compounds have been evaluated by various experimental studies that have highlighted 
mechanisms through which it may improve the symptoms of HZ.  
 
Glycyrrhizin (GL), a key constituent of Glycyrrhiza, showed rapid pain alleviation in people 
with HZ [359]. In this study, GL appeared to decrease human leukocyte antigen-antigen D 
related (HLA-DR+) expression in CD8+ T-cells from peripheral blood of HZ patients. As 
cytolytic CD8+ T-cells contribute to controlling varicella zoster virus (VZV) replication in 
sensory ganglia during the acute state of HZ [360], evidence from this study suggest antiviral 
activity of GL. 
 
The antiviral action on VZV of GL has also been evaluated in vitro [361]. GL demonstrated 
suppression action on VZV replication in pre-treated and post-treat VZV infected human 
embryonic fibroblast cells [361]. The authors postulated the mechanism may due to GL 
suppressing the penetration, uncoating or release of virus particles. GL was also shown to 
have antiviral actions in Vero cell cultured VZV from vesicular aspirates from children 
diagnosed with varicella [362]. In BALB/c mice, GL induced apoptotic cell death in mature 
splenic and thymic lymphocytes in vitro, suggesting it has an anti-inflammatory effect [363].  
 
Glycyrrhetinic acid (GA) isolated from Glycyrrhiza exhibited analgesic effects in an inflamed 
rat model [364]. The compound dose-dependently suppressed the capsaicin-induced flinching 
behaviour. In this study, GA also effectively inhibited pain-related behaviours in the late 
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phase of the formalin test. Tachykinin receptor inhibition induced by GA may be the 
mechanism of its analgesic effects.  
 
8.5 Chapter summary 
Much of the experimental evidence for the most frequently used herbs has shown anti-
inflammatory actions. Inhibition of inflammatory cytokines and pro-inflammatory enzymes 
have been demonstrated, with some studies showing actions at the mRNA level. The main 
mechanism of action appears to be through inhibition of NO [262, 325, 340, 344, 348], ILs 
[262, 319, 341, 348, 349], and tumour necrosis factor production [327, 330, 348, 349], and 
COX-2 [316, 324] and iNOS expression [316, 327]. This may contribute to relieving the 
acute inflammatory response in patients with HZ, which in turn may reduce sensory nerve 
necrosis.  
 
Some constituents of the herbs have demonstrated antiviral actions, in which Glycyrrhizin 
isolated from Glycyrrhiza spp showed direct evidence of inhibition of VZV replication [360, 
361]. The antiviral activity of other constituents from the most commonly used herbs remains 
unknown. The analgesic action of some constituents has also been demonstrated in the 
experimental evidence of C. yanhusuo [350-352] and Glycyrrhiza spp [364]. The evidence 
suggests their possible mechanisms of alleviating acute neuropathic pain of HZ. 
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In conclusion, anti-inflammation, antiviral, and analgesic actions shown in the experimental 
evidence of these herbs may be the key mechanisms for symptom improvements seen in 
clinical studies.  The mechanisms appeared to be consistent with the conventional medication 
of antiviral and analgesic therapies recommended by contemporary guidelines. More research 
is needed to confirm their mode of actions, including direct anti-inflammatory action on 
sensory ganglion, and immunomodulatory and antiviral action against the replication of VZV. 
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Chapter 9. Long dan xie gan tang plus antiviral therapy for herpes zoster: 
a trial protocol 
9.1 Introduction 
In this research, the classical literature evidence showed that Long dan xie gan tang 龙胆泻
肝汤 (LDXGT) was the most commonly cited formula to treat herpes zoster (HZ) in ancient 
times (Chapter 4). From the modern literature evidence research, LDXGT was the most 
frequently evaluated formula in clinical studies (Chapter 6), while nine of the ten most 
frequently used herbs were the listed ingredients of LDXGT in the overview of Chinese 
herbal medicine (CHM) for HZ (Chapter 6). The experimental evidence showed that the 
herbs of LDXGT demonstrated anti-inflammatory, antiviral, and analgesic actions, which 
may contribute to relieving the acute inflammatory response and pain in patients with HZ 
(Chapter 8). The systematic review showed LDXGT was a well-tolerated and effective 
treatment for HZ. However, the evidence was limited by the methodological flaws (Chapter 
6). A rigorous trial protocol is needed to confirm the clinical efficacy of LDXGT. 
 
Systematic review of acupuncture combined with moxibustion in the management of HZ 
demonstrated promising benefits in pain alleviation and cutaneous improvement. Considering 
that conducting a trial of acupuncture therapies requires daily visit for participants according 
to acupuncture guideline recommends, this might not be feasibile for older people. 
Accordingly, the formula LDXGT was selected considering factors such as efficacy, safety 
and convenience of use. 
 
This chapter will detail the protocol for a randomised, double-blinded, placebo controlled 
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trial using LDXGT integrated with antiviral therapy in the management of HZ. The design of 
this study is guided by the findings from the previous systematic review of classical 
literature, clinical, and experimental evidence of Chinese herbal medicine. The trial will not 
be conducted as part of this PhD project. The protocol is made available for researchers who 
wish to conduct such a trial. Researchers would be responsible for obtaining funding and 
ensuring all regulatory requirements are met. 
 
9.2 Aims 
This trial protocol aims to: 
1. To design a rigorous trial protocol for future using LDXGT as an intervention for HZ. 
2. Incorporate data from the previous review to prepare a rigorously designed 
randomised controlled clinical trial (RCT) using LDXGT in the management of HZ. 
 
9.3 Trial compliance 
This protocol complies with the principles of the Declaration of Helsinki and Good Clinical 
Practice guidelines that includes the following:  
1. CPMP/ICH, Note for Guidance on Good Clinical Practice – Annotated with 
Therapeutic Goods Administration (TGA) comments (CPMP/ICH/135/95);  
2. CPMP/ICH, General Considerations for Clinical Trial (CPMP/ICH/291/95);  
3. CPMP/ICH, Statistical Principles for Clinical Trial (CPMP/ICH/363/96);  
4. NHMRC, National Statement on Ethical Conduct in Research Involving Humans;  
5. NHMRC, Guidelines Under Section 95 of the Privacy Act 1988, March 2000.  
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This protocol is developed in line with the Standard Protocol Items: Recommendations for 
Interventional Trials (SPIRIT) 2013 statement: defining standard protocol items for clinical 
trials [365]. 
 
9.4 Trial registration and ethical issues 
The ethical issues of the trial protocol will be required to be assessed and approved by the 
relevant organisation prior to trial implementation (for example, Human Research Ethics 
Committee of RMIT University, Melbourne, Australia). The risks of the trial and the 
strategies proposed to manage the risks will need to be reviewed. The safety, the eligibility of 
target population, and patient informed consent form for the proposed research will need to 
be assessed to protect the participants from harm. Other ethical issues including the storage of 
the research data, dissemination of the research should also require review to protect the 
privacy of the individuals.  
 
Prior to trial implementation, the protocol will also need to be registered with an official 
registry (for example, Australian and New Zealand Clinical Trials Registry, and Therapeutic 
Goods Administration). 
 
9.5 Participants  
This study targets people older than 50 years of age with acute stage HZ, as higher incidence 
rate of HZ is seen with increasing age [3, 34]. Postherpetic neuralgia (PHN) is an intractable 
and common chronic sequelae of HZ also increases with age [3]. As HZ is a self-limiting 
neurocutaneous disease, no specific antiviral therapy needs to be prescribed to young 
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individuals who are at low risk. For the patients beyond the age of 50 years, antiviral therapy 
is recommended in clinical practice guidelines as first line pharmacotherapy to shorten the 
healing process, reduce the incidence, duration and severity of PHN [7, 9].  
 
In order to evaluate the effect of LDXGT plus antiviral therapy, people older than 50 years 
diagnosed with acute stage HZ will be recruited according to the inclusion/exclusion criteria 
listed below. Participants will be randomly assigned into either treatment or placebo groups. 
Informed consent or verbal assent will be obtained prior to trial participation.  
 
9.5.1 Inclusion and exclusion criteria   
Participants recruited for this trial will be required to meet all the following criteria:  
 
1. Diagnosis of HZ: either based on clinical presentation or laboratory confirmed. 
2. Acute stage HZ: acute stage HZ defined as less than 28 days from onset of rash [9]. 
3. Age: ≥50 years. 
4. Immunocompetent patients. 
5. Meet the CM diagnostic criteria for Stagnant heat in the Liver meridian (see Chapter 
2.3 Syndrome differentiation). 
People with any of the following criteria will be excluded for this trial: 
 
1. Diagnosis other than HZ. 
2. Diagnosed as PHN stage. 
3. Age: <50 years. 
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4. Diagnosis of HZ oticus (Ramsay Hunt syndrome), HZ ophthalmicus, HZ encephalitis, 
zoster sine herpete, visceral HZ, or disseminated HZ. 
5. Immunocompromised patients (for example, HIV, cancer, diabetes, pregnant, 
breastfeeding). 
6. Individuals who have taken any Chinese herbal medicine product within the last three 
months. 
7. Diagnosed with a serious illness such as cardiovascular, liver, or renal diseases. 
 
9.5.2 Chinese medicine diagnostic criteria 
According to Chinese medicine (CM) theory, LDXGT is prescribed for the CM syndrome of 
Stagnant heat in the Liver meridian [16, 18, 117]. Participants recruited in this study must be 
diagnosed as having Stagnant heat in the Liver meridian syndrome by a CM practitioner 
registered with the Chinese Medicine Board of Australia. People with syndromes other than 
Stagnant heat in the Liver meridian will not be eligible to participate.  
 
Based on CM textbooks [16, 18, 117], the diagnostic criteria of Stagnant heat in the Liver 
meridian should include the following points: 
1. Lesions: red lesion, tense blister walls, burning heat, and pricking pain. 
2. Accompanying symptoms: irritability, dry throat and bitter taste in mouth, and dry 
stools with yellow urine. 
3. Tongue: red tongue with thin or thick yellow coat. 
4. Pulse: rapid, rolling and string-like pulse. 
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9.6 Procedure of recruitment 
9.6.1 Setting  
Future researchers should consider the setting of this trial. Hospitals and clinics (for example, 
the RMIT Traditional and Complementary Medicine Research Group Clinical Trial Clinic, 
RMIT University, Bundoora West Campus in Melbourne, Australia) can be considered to 
conduct this trial. 
 
9.6.2 Advertising 
Advertising is another issue to be considered by future researchers to recruit participants. For 
the clinical trial conducted in RMIT Traditional and Complementary Medicine Research 
Group Clinical Trial Clinic, the following advertising methods can be considered: 
1. Internet: RMIT website, association websites (such as Australian Traditional 
Medicine Society, and Australian Acupuncture & CM Association)  
2. Poster or flyers: posters or flyers will be placed in RMIT University Bundoora, City 
and Brunswick campuses, local medical centres, clinics of CM practitioners, and community 
libraries of surrounding suburbs in Melbourne. An example study recruitment poster is 
presented in Appendix 9. The poster is required to be approved by RMIT Human Research 
Ethics Committee before being released to the public. 
3. Traditional media: radio and newspaper advertisements. 
4. Referrals from local general practitioners (GPs) in Melbourne. Meetings will be 
organised to explain the study to the GPs and to answer their questions. 
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9.6.3 Screening 
It is anticipated that participants will self-refer to the trial. Expression of interest will be by 
telephone or email. Contact details of interested participants will be recorded on the 
expression of interest form. Participant information and consent forms (PICF) will be sent out 
to potential participants after the telephone interview via email. Potential participants will 
undergo preliminary screening for eligibility over the phone by an investigator, which will 
include a registered CM practitioner. If deemed to be eligible according to the inclusion 
criteria, the first visit will be scheduled. Participant information and consent forms are 
required to be developed in accordance with the relevant ethics committee (for example, 
RMIT Human Research Ethics Committee) guidelines. 
 
9.6.4 Informed consent 
Informed consent will be sought during the initial assessment at the clinic prior to 
randomisation. Written information and verbal explanation concerning the study will be 
provided. Full explanation will be given to any questions that arise prior to the signing of the 
participant information and consent form. Written consent will be required from the 
participants with adequate fluency in English; verbal assent in the presence of a witness will 
be sought from participants who are unable to read and write in English. The witness will be 
someone who is not involved in the clinical trial and whose signature will be required as 
evidence of witnessing the informed consent process. The responsible investigator will record 
the date, time, and location of the provision of informed consent. 
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9.7 Trial design 
9.7.1 Randomisation 
Randomisation will be carried out using computer generated block randomised sequences, 
prepared by an independent researcher. Study numbers will be entered into sealed envelopes 
individually. Each participant will draw an envelope at the time of randomisation. The code 
inside each envelop will correspond with a package number that will contain seven days of 
either LDXGT granules plus valacyclovir, or placebo granules plus valacyclovir. An 
independent researcher who isn’t involved in this trial will keep the study numbers and 
treatment codes in a secure location (either locked filing cabinet or in a password protected 
electronic file). The participant’s treatment allocation can be retrieved in the event of medical 
emergency. 
 
9.7.2 Blinding 
This trial will be conducted in a double blinded design. The randomisation sequence and 
allocation will be unknown to all the researchers, participants, and outcome assessors 
involved in the trial. 
 
9.7.3 Participant withdrawal/drop-outs 
Participants are permitted to withdraw at will at any time during the trial with or without 
reason provided. When serious adverse event occurs, a participant may be withdrawn from 
the study by the researcher. When participants withdraw, they have two options. They can 
withdraw from the study altogether, in which case they should not be contacted further, or 
they can withdraw from treatment but still be contacted for outcome data assessment. For the 
participants who agree to be contacted after withdraw, they will be contacted four weeks 
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following withdrawal, at the follow-up period, to obtain information of visual analogue scale 
(VAS) pain scores. 
 
9.8 Trial intervention 
9.8.1 Long dan xie gan tang 
The ingredients and the dosage of LDXGT are based on the CM textbooks [16-18, 101]:  
 Long dan cao 龙胆草 (Gentiana scabra Bunge.) (6 g). 
 Zhi zi 栀子 (Gardenia jasminoides Ellis.) (9 g). 
 Huang qin 黄芩 (Scutellaria baicalensis Georgi.) (6 g). 
 Tong cao 通草 (Tetrapanax papyrifer (Hook.) K.Koch) (6 g). 
 Ze xie 泽泻 (Alisma orientale (Sam.) Juzep.) (12 g). 
 Che qian zi 车前子 (Plantago asiatica L.) (9 g). 
 Chai hu 柴胡 (Bupleurum chinense DC.) (6 g). 
 Gan cao 甘草 (Glycyrrhiza uralensis Fisch.) (6 g). 
 Dang gui 当归 (Angelica sinensis (Oliv.) Diels.) (3  g). 
 Sheng di 生地 (Rehmannia glutinosa Libosch.) (6 g). 
 
The granules of LDXGT and placebo will be produced by a manufactory that holds a Good 
Manufacturing Practice (GMP) manufacturing practice certificate. Each package will contain 
25 gram concentrated herbal extract granules equivalent to the amount of raw herbs listed 
above. Each package will be labelled with instructions for administration. One package of 
LDXGT granules will be prescribed to the participants in the intervention group once daily 
for seven days. LDXGT administration will be limited to seven days to be consistent with 
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antiviral therapy administration. The granules should be dissolved in 200 ml warm water and 
taken orally after meals.  
 
9.8.2 Placebo 
The placebo granules will consist of starch with no active ingredients. It will be matched as 
closely as possible to the appearance, smell and taste of the LDXGT granules. Each package 
will contain 25 gram placebo granules and will be prescribed to the participants randomised 
to the control group. Granules should be dissolved in 200 ml warm water and taken orally 
after meals once a day for seven days. 
 
9.8.3 Antiviral therapy 
Oral antiviral therapy will be prescribed by a register medical practitioner involved in this 
study to both intervention and control groups using the guideline recommended medication: 
Valacyclovir (Product name: Valtrex ®), 1000 mg, three times daily for seven days [7, 9]. The 
tablet should be swallowed with a glass of water, once in the morning, afternoon and evening. 
The participants will be told to drink plenty of fluids while taking the tablets.  
 
9.9 Trial procedure 
After screening, eligible participants will undergo initial assessments for baseline data 
collection, which includes the VAS pain scores, Medical Outcomes Study Short-Form 36 
(SF-36) assessment, measurement of vital signs (temperature, blood pressure and heart rate), 
and given their daily diary to record medication compliance, usage of any other therapies and 
occurrence of any adverse events. 
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After the initial assessments, participants will be randomly assigned to either the treatment 
(LDXGT and valacyclovir) group or the control (placebo and valacyclovir) group and the 
treatment period will commence immediately. During the first visit, participants will be given 
seven days’ worth of LDXGT or placebo granules, valacyclovir and daily diary. Participants 
will be asked to return their medication packages to enable the counting of left-over 
medication for trial medication adherence monitoring. 
 
Throughout the treatment period, participants will not be permitted to use any complementary 
medicines, such as acupuncture or other herbal medicine. The use of conventional systemic 
therapies, such as analgesic therapy, will not be provided as part of the trial, but patients are 
free to use them. Concomitant medications will be recorded and accounted for in statistical 
analysis. To assist the monitoring of patient compliance and intervention acceptability, 
participants will be required to record their trial medication compliance, usage of any other 
therapies and occurrence of any adverse events in the daily diary. 
 
After the seven day’s treatment period, the participants will be required to have a second visit 
to the clinic. VAS pain scores, and SF-36 assessment will be assessed during the second 
period. 
 
During the follow-up period, VAS pain scores and SF-36 questionnaires will be sent out to 
the participants via post. Participants will be provided with pre-paid envelopes to return trial 
questionnaires. Follow-up assessment will be conducted at weeks four, 12 and 26. The outline 
of trial procedures is illustrated in Figure 9.1. 
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Figure 9.1 Outline of trial procedure 
 
9.9.1 Early termination of the trial 
According to the TGA [366], serious adverse events (SAEs) are defined as “Any untoward 
medical occurrence that at any dose: results in death, is life-threatening, requires inpatient 
hospitalisation or prolongation of existing hospitalisation, results in persistent or significant 
disability/incapacity, is a congenital anomaly/birth defect, or is a medically-important event 
or reaction”. All ingredients of LDXGT are used in daily practice, and within the safe dosage. 
In the event of an SAE that is deemed by the study doctor to be related to the treatment, the 
trial medication will be discontinued. 
 
9.9.2 Procedures for emergency unblinding 
Emergency 24-hour access to the participant identification and treatment codes will be made 
LDXGT + 
antiviral therapy 
Placebo + 
antiviral therapy 
Visit 2/Day 8: 
Outcomes: VAS pain scores, SF-36, daily diary  
Follow-up period (weeks 4, 12, and 26) 
Outcomes: VAS pain scores, SF-36 
Screening 
Visit 1/Day 1:  
Randomisation/treatment start 
Outcomes: VAS pain scores, SF-36 
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available to authorised personnel who has prepared the randomisation and holds the codes at 
the study site. Should the need to unmask the treatment code arise, the authorised personnel 
will have access to the treatment code upon request of the investigator and one of the 
supervisors. The details of adverse events and the unmasking of the treatment code will be 
documented by the investigator with endorsement from one of the supervisors. The code will 
not be revealed to participants or personnel involved in data entry and analysis. 
 
9.10 Assessments and outcome measures 
9.10.1 Primary outcome measurements 
9.10.1.1 Pain severity  
Zoster related pain is one of the characteristic symptom of HZ. In many clinical trials, pain 
severity was the primary outcome in evaluating the efficacy of the intervention [367, 368]. 
One of the most frequently used methods of assessing the pain severity is through VAS pain 
scores, which has a scale 0 to 100 mm (or 0 to 10 cm), with 0 mm being no pain and 100 mm 
(or 10 cm) being the maximum imaginable pain (see Figure 9.2). In this trial, VAS pain 
scores will be assessed at the baseline assessment (before treatment), the time point when 
treatment finished (seventh day of treatment), and at the follow-up period (weeks four, 12, 
and 26) to observe the severity of pain. The change of VAS pain scores from baseline of each 
participant will also be recorded. 
 
 
 
Figure 9.2 Visual analogue scale pain score assessment 
 
     0 
 
              50 
 
                      100 
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9.10.2 Secondary outcome measurements 
9.10.2.1 Quality of life questionnaires 
The pain occurring in the HZ acute phase is always the most significant concern of patients, 
and can remarkably reduce the quality of life [15]. This impacts on four aspects of their life: 
physical health, psychological wellbeing, social functioning and activities of daily living [4-
6]. The SF-36 is a general wellbeing questionnaire, but has also been used in HZ clinical 
trials [15]. The SF-36 covers eight domains, including vitality, physical functioning, bodily 
pain, general health perceptions, physical role functioning, emotional role functioning, social 
role functioning, and mental health. It also provides a summary of physical and mental 
health. In this trial, SF-36 assessment will be performed pre- and post-treatment (first and 
seventh days), and in the follow-up period. 
 
9.10.2.2 Adverse events 
All reactions, including adverse events, will be recorded by participants in the daily diary. 
The record of adverse events aims to evaluate the safety or tolerability of LDXGT in HZ 
patients. Safety will be monitored by a data safety and management board throughout this 
trial. 
 
9.11 Data collection and analysis 
9.11.1 Data identification 
All data will be entered in the Case Report Form (CRF) by authorised personnel of this 
project. Training sessions for data entry will be provided to all personnel prior to the study 
commencement. All data entry will be personally initialled and dated by the responsible 
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personnel. Assessors, data collectors and personnel involved in data entry will be blinded to 
the treatment assignment until the study is completed. Standard operation procedures for data 
entry in the CRF will be developed as a guide to all personnel and will be used as a training 
tool.  
 
9.11.2 Data confidentiality 
Investigators, supervisors and consultants (study doctor and CM practitioner) will have 
access to the source data and outcomes of analysis of the data. Hard copies of the CRF will 
be stored in a locked filing cabinet in a secure location in the site of trial conduct. Electronic 
data will be stored in a password protected file on a secure server. Upon request of regulatory 
authority, the investigator will make available direct access to the source data and other trial-
related records. 
 
9.11.3 Data quality control and quality assurance 
Quality control will be applied to each stage of data handling to ensure reliability and 
accuracy. Any corrections to the data will be documented and the database will be updated 
throughout the study. Double-checking will be performed to ensure accuracy of the data. The 
investigator will be available for agreed visits upon request of the regulatory authority during 
the study for quality assurance. 
 
9.11.4 Data handling and record keeping 
In all CRFs, participants will be identified only by their identification code. All information 
excluding identifiable information of the participants, including the administration of 
interventions, outcome measures, adverse events, and other relevant data will be recorded in 
235 
 
or attached to the CRF, signed and dated by the investigator and stored in a secure place. All 
corrections made to the CRF should be single line through, and correct information as near as 
possible, initialled and dated. All corrections must be personally signed and dated by the 
person responsible.  
 
9.11.5 Sample size 
Before the implementation of the full-scale trial, a pilot trial should be considered. The aim of 
the pilot study is to test the feasibility of the intervention, safety and trial design as opposed 
to gathering data on efficacy. Post-hoc power analysis via effect size estimation of the pilot 
study data should be used to determine sample size for the full-scale trial. There is no 
standard sample size calculation method for pilot trial. A convenience sample size of 30 
participants, with 15 people assigned to the intervention group and 15 people assigned to the 
control group, would be considered appropriate. 
 
9.11.6 Data analysis 
The trial data will be processed and analysed by an independent statistician (for example, 
from the School of Mathematical and Geospatial Sciences at RMIT University), who will be 
blinded to subject allocation. Intention to treat (ITT) analysis will be applied to include all 
randomised participants, which means all patients who were enrolled and randomly allocated 
to treatment are included in the analysis and are analysed in the groups to which they were 
randomised. Last observation carried forward method will be used to account for missing 
data. 
 
Descriptive statistics will be performed on each significant variable to detect unusual or 
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unexpected data. Codes will not be unmasked during descriptive analysis. Treatment codes 
will be broken only when the data validation and editing processes are completed for each 
individual using a code in the database. 
 
Data will be summarised as means and standard deviations and analysed using the SPSS 
software, Windows Version 21.0. Analysis of between and within-groups differences will be 
calculated using t-tests. All P values will be 2-tailed and at α=0.05.  
 
9.12 Dissemination of findings 
No individual identifiable information of participants will be reported or published. Data will 
be published in group form and presented in such a way that no individual will be identified. 
The findings from the results will be published in an international scientific journal, and may 
be presented at national or international conferences 
 
9.13 Financing and insurance 
The researchers who conduct this trial should seek for sufficient funding to ensure its 
completion. The study should be covered by relevant liability insurance (for example, 
Broadform Public and Product Liability Insurance). 
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Chapter 10. General discussion and summary 
10.1 Introduction 
Herpes zoster (HZ) is a characteristic neurocutaneous disease caused by the reactivation of 
the varicella zoster virus (VZV) [7]. The pain induced by the inflammatory response and 
necrosis of the sensory neurons in the acute stage of HZ significantly impacts patient quality 
of life, an aspect that  remains the greatest concern of patients [15, 48]. The effectiveness of 
therapeutic approaches was highlighted as an unmet need for people with HZ according to a 
recent research [15]. 
 
Chinese medicine (CM) which consists of multiple treatment approaches including Chinese 
herbal medicine (CHM), acupuncture therapies may offer alternative and complementary 
treatment methods to conventional medicine. The systematic reviews which evaluated the 
efficacy and safety of CM therapies for HZ identified several gaps, including limited 
databases searched, study inclusion criteria, and statistical analyses. This thesis addressed 
these gaps by conducting more comprehensive search of databases, strict inclusion criteria 
and rigorous review methods guided by Cochrane Handbook for Systematic Reviews and 
Interventions [122]. A rigorous trial protocol evaluating the CM formula Long dan xie gan 
tang (LDXGT) 龙胆泻肝汤 for people with HZ has been designed to generate new clnical 
evidence data and inform future research. 
 
The classical CM literature evidence for HZ had not been reviewed through previous 
databases search. This thesis also systematically evaluated the classical evidence by data 
mining and cluster analysis methods.  
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10.2 Summary of the research 
The classical literature research was conducted in Zhong Hua Yi Dian (ZHYD) 中华医典 
[104], one of the largest collections of CM classical literature in the world. Fifty-four possible 
HZ citations and 44 “most likely” to be HZ citations met the justification criteria based on the 
symptom descriptions in text, and were included for further analysis. The well recognised 
earliest citation of HZ in contemporary CM literature, which is from the Zhu Bing Yuan Hou 
Lun 诸病源候论 [100, 109, 110], was judged to be possible HZ citation due to the 
insufficient information on symptoms. The earliest citation judged to be “most likely” to be 
HZ from this research was from Zheng Zhi Zhun Sheng - Yang Yi 证治准绳·疡医. 
Symptoms described in this citation are consistent with the contemporary clinical and CM 
definition of HZ [7, 17, 18].  
 
Various CM formulas, herbs, acupuncture therapies and other therapies were identified from 
the included citations. Chinese herbal medicine treatments for HZ in the classical literature 
were also consistent with contemporary CM textbooks [16-18]. The most frequently reported 
formula in classical literature, LDXGT, and another commonly reported formula, Chu shi wei 
ling tang 除湿胃苓汤, are both recommended by contemporary textbooks to treat HZ [16-
18]. Likely due to the safety concern, some frequently used herbs and formula (for example, 
xiong huang 雄黄, and Bai ye san 柏叶散 which contains toxic ingredient qing fen 轻粉) are 
not included in contemporary textbooks and guideline. 
 
Another finding of this thesis is the hypothetical symptom structure of HZ through the cluster 
analysis in the classical literature research. The results highlight that the symptoms cluster of 
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heat disease in CM theory is an important symptom classification of HZ. The symptoms 
included in this cluster are also typical manifestations of local signs of inflammation 
according to conventional medicine.  
 
The comprehensive modern literature research was conducted through five English and four 
Chinese databases. Results from the overview of the CHM therapies for HZ showed a slight 
difference when comparing the top ten most frequently used herbs between classical and 
modern literature. Only two herbs ban lan gen 板蓝根 and yan hu suo 延胡索 were not 
identified in the classical citations. This may be caused by the larger number of formulae and 
herbal ingredients that were found in the modern literature compared with the smaller number 
seen in classical literature. Ban lan gen板蓝根 is used for clearing heat and detoxifying and 
is typically used for HZ patients with heat in Liver meridian syndrome, while yan hu suo延
胡索 is for regular qi and managing pain, and is used for treating qi and Blood stasis 
syndrome in contemporary CM practice. Both ban lan gen板蓝根 and yan hu suo延胡索
could be used to resolve HZ symptoms. 
 
A variety of CHM formulae were reported in this overview other than those recommended in 
the contemporary CM textbooks. The key function of the formulae, including “clearing heat, 
and/or detoxifying”, and “activating Blood, and/or dispelling stasis”, echoes the four main 
HZ syndromes seen in CM textbooks. The overview also showed that Long dan xie gan tang 
龙胆泻肝汤 was the most commonly evaluated formula in modern literature. In addition, 
nine of the top ten frequently used herbs are listed ingredients of LDXGT. Evidence from 
both modern and classical literature highlights the importance of LDXGT in the CHM 
management of HZ.  
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This thesis reports on the results of a systematic review which was undertaken to evaluate the 
clinical effectiveness and safety of the LDXGT formula. Modified LDXGT formula was 
found to shorten the time to alleviate pain, reduce the incidence of postherpetic neuralgia 
(PHN) and improve cutaneous outcomes. Modified LDXGT was well tolerated by 
participants with few mild adverse events reported. However, the small number and poor 
quality of the included studies limits the ability to form reliable conclusions about the 
efficacy of LDXGT formula.  
 
Although Izzo et al. reported herbal medicines to be better tolerated by patients than 
conventional medicine, the potential risk of harm to the public health and safety from serious 
adverse events remains a significant point of concern [369]. One ingredient of LDXGT 
formula, Mu tong has been sourced from multiple species. Akebia quinata and A. trifoliata 
(Thunb.) Decne. are considered the official species for Mu tong 木通, while Clematis 
armandii Franch. and C. montana Buch. Ham. are the official species for Chuan mu tong川
木通. However, in the past, Aristolochia species, which contain the toxin aristolochic acid, 
were used as Mu tong 木通 substitutes or adulterants and this led to cases of renal failure 
[116, 117, 370]. In the 1990s, concerns about aristolochic acid containing species led to 
increased pharmacovigilance of CMs and the prohibition of Aristolochia species in CMs 
[371]. This highlights the critical importance of quality assurance of herbal medicine use 
including authentication of species in clinical studies and clinical practice. 
 
This thesis also has reviewed the acupuncture therapies evaluated in modern literature of 
randomised controlled trials. Findings from the general overview showed that the 
acupuncture approaches and the acupuncture points selection in the included studies were 
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consistent with the contemporary acupuncture guideline [12]. Many studies combined two or 
more acupuncture therapies, and/or pharmacotherapies as intervention, which may inform the 
CM practitioner to consider in the management of HZ.  
 
When comparing the modern and classical evidence of acupuncture therapies for HZ, a 
significant development has been seen in the modern literature. For the classical literature, 
only moxibustion and pricking needling therapies were reported to manage HZ, while 
multiple acupuncture approaches has been reported in modern literature and recommended by 
CM textbooks and guidelines [12, 16-18]. Reasons for the improvement may be due to 
developments in technology (that is, electro-acupuncture) and special acupuncture techniques 
(that is, surrounding acupuncture).  
 
Similar to the systematic review of LDXGT, acupuncture and moxibustion showed benefits 
in reducing pain intensity, reducing time to resolution of rash, and reducing the incidence of 
PHN according to meta-analysis. Mild adverse events were reported which related to needles 
puncturing the capillary vessels. Acupuncture and moxibustion were well tolerated by 
participants. However, the clinical evidence was limited by the poor quality of the studies. 
The anti-inflammatory action of acupuncture has been researched in several experimental 
studies, which may contribute to the analgesic effect of acupuncture seen in the clinical 
studies.  
 
The modern literature evidence of this thesis showed CM therapies of both CHM and 
acupuncture were well tolerated by people with HZ and may benefit in hastening pain relief, 
improving cutaneous outcomes, and decreasing the incidence of PHN. As the effectiveness of 
conventional medications are not meeting the needs of people with HZ [15], CM therapies 
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may be complementary or alternative treatments in the management of HZ. More rigorous 
clinical studies are needed to confirm the safety and efficacy of CM therapies. 
 
This thesis provided an overview of the experimental evidence of the most frequently used 
herbs for HZ identified in modern literature research. Much of the evidence has shown anti-
inflammatory actions via inhibition of inflammatory cytokines and pro-inflammatory 
enzymes of the constituents, which may contribute to alleviating acute inflammatory response 
in patients with HZ. This evidence suggests the possible mechanisms of reducing pain 
severity, and improving cutaneous outcomes seen in the clinical evidence of this research. 
 
The modern clinical and experimental literature evidence suggests anti-inflammatory action 
might be the key mechanism of CM therapies (that is, CHM and acupuncture) in managing 
the symptoms of HZ. Not surprisingly, the “whole evidence” of modern and classical 
literature research in this thesis shows “anti-inflammation” is the keyword common 
throughout all components of this thesis. 
 
10.3 Limitations of this thesis 
Classical literature research 
The evidence from the classical literature in this research was sourced from ZHYD. Future 
research using the Chinese materia medica 中华本草全书, which contains more than 6,000 
classical CM books, may help to provide further information and evaluation of CM therapies 
used in ancient times. The results of cluster analysis in data mining of this research might be 
limited by the sample size of the HZ symptoms dataset, similarity measurement and statistical 
tests available for cluster analysis. Future data mining using other statistical software (for 
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example, SAS ® 9.4) may help to validate the cluster analysis results. 
 
Modern literature research 
The modern literature research was conducted in the major Chinese and English databases in 
this thesis. To acquire more comprehensive clinical evidence, future literature search 
conducted in other language databases, particularly the Korean and Japanese databases where 
herbal medicine research is commonly published, would broaden our understanding of the 
clinical benefits of CM for HZ. 
 
The findings from the systematic reviews of CHM and acupuncture were limited by the 
methodological quality of the included studies. In the risk of bias assessment, few studies 
detailed the sequence generation, allocation concealment, blinding of participants, personnel 
and outcome assessors in texts, which may contribute to bias and heterogeneity, and influence 
the reliability of the clinical outcomes. Another limitation of the included studies in these 
systematic reviews was the dosage of the pharmacotherapies in the control groups. Very few 
studies used doses of antivirals which matched those recommended in clinical practice 
guidelines. Other studies used dosages lower than that recommended in guidelines, which 
may exaggerate the efficacy of CM therapies in the clinical research.  
 
Some outcome measurements of the included studies were not validated (for example, 
therapeutic effective rate), and none of the included studies reported on the outcome health-
related quality of life. The clinical evidence of CM therapies in this research should be 
interpreted with caution. Rigorously designed randomised controlled trials are needed to 
provide evidence regarding the efficacy and safety of the CM therapies. To address this gap, 
as part of this thesis a trial protocol using LDXGT integrated with antiviral therapy was 
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developed to inform future research. 
 
This thesis has reviewed the most frequently used herbs in the modern literature search. The 
mechanisms of other less commonly used, but potentially active, CHMs in the management 
of HZ need to be examined further. A comprehensive network medicine research including 
protein-protein interaction and metabolic pathways of the constituents of the herbs may also 
contribute to detail the mechanisms that related to the management of HZ.  
  
10.4 Conclusion 
This thesis applied a systematic approach to summarise classical and modern literature 
evidence of CM therapies in the management of HZ. The whole evidence in this thesis shows 
“anti-inflammation” is the keyword common throughout classical and modern literature 
research of CM for HZ. Data mining results from the classical literature demonstrated that the 
inflammation symptoms cluster was one of components of the HZ symptoms structure. 
Modern literature research showed CM therapies of both CHM and acupuncture were well 
tolerated and may benefit in hastening pain relief, improving cutaneous outcomes, and 
decreasing the incidence of PHN. The clinical evidence of the CM therapies shows that 
Chinese herbal medicine and acupuncture may be alternative and complementary approaches 
in the management of HZ, as there exits unmet satisfaction with the effectiveness of 
conventional medicine. While the clinical evidence was limited by the methodological flaws 
in the included studies of this research, a rigorous trial protocol using LDXGT formula as 
intervention for HZ was designed to inform future research. The anti-inflammatory action of 
the most commonly used herbs and acupuncture from the experimental evidence may be a 
mechanism to explain clinical benefit of CM therapies.  
245 
 
References 
 
1. Sampathkumar, P., L.A. Drage, and D.P. Martin, Herpes Zoster (Shingles) and 
Postherpetic Neuralgia. Mayo Clinic Proceedings, 2009. 84(3): p. 274-280. 
2. Robinson-Papp, J. and D.M. Simpson, Neuromuscular diseases associated with HIV-1 
infection. Muscle Nerve, 2009. 40(6): p. 1043-1053. 
3. Yawn, B.P. and D. Gilden, The global epidemiology of herpes zoster. Neurology, 
2013. 81(10): p. 928-930. 
4. Johnson, R.W., et al., The impact of herpes zoster and post-herpetic neuralgia on 
quality-of-life. BMC Medicine, 2010. 8: p. 37. 
5. Mauskopf, J., et al., The Nottingham Health Profile as a measure of quality of life in 
zoster patients: convergent and discriminant validity. Quality of Life Research, 1994. 
3(6): p. 431-435. 
6. Oster, G., et al., Pain, medication use, and health-related quality of life in older 
persons with postherpetic neuralgia: results from a population-based survey. Journal 
of Pain, 2005. 6(6): p. 356-363. 
7. Gross, G., et al., Herpes zoster guideline of the German Dermatology Society (DDG). 
Journal of Clinical Virology, 2003. 26(3): p. 277-289; discussion 291-3. 
8. Johnson, R.W., Pain following herpes zoster: implications for management. Herpes, 
2004. 11(3): p. 63-65. 
9. Volpi, A., et al., Current management of herpes zoster: the European view. American 
Journal of Clinical Dermatology, 2005. 6(5): p. 317-325. 
10. Gil, A., et al., Epidemiology of severe varicella-zoster virus infection in Spain. 
Vaccine, 2004. 22(29-30): p. 3947-3951. 
11. Adult Vaccine Price List. 2016  [cited 2016 3rd September 2016]; Available from: 
http://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/. 
12. Liu, Z.S., et al., Clinical practice guideline of acupuncture for herpes zoster. Chinese 
Journal of Integrative Medicine, 2013. 19(1): p. 58-67. 
13. Goldman, L. and A.I. Schafer, Goldman's Cecil medicine. 2012, Philadelphia: 
Elsevier Saunders Philadelphia. 
14. Dworkin, R.H., et al., Recommendations for the management of herpes zoster. Clinical 
Infectious Diseases, 2007. 44 Suppl 1: p. S1-26. 
15. Gater, A., et al., Burden of herpes zoster in the UK: findings from the zoster quality of 
life (ZQOL) study. BMC Infectious Diseases, 2014. 14: p. 402. 
16. Li, Y., Chinese External Medicine 2002, Beijing: China Press of Traditional Chinese 
Medicine. 
17. Xuan, G. and D. Chen, Dermatovenereology of Integrative Medicine. 2008, Beijing: 
Science Press. [In Chinese: 禤国维, 陈达灿, 中西医结合皮肤性病学. 2008, 北京: 
科技出版社.]. 
18. Zhao, S., Chinese External Medicine 2002, Beijing: People's Medical Publishing 
House. 
19. Fu, Q., et al., Efficacy of Traditional Chinese Medicine on herpes zoster (Meta-
analysis). Disease Monitor & Control, 2014. 8(03): p. 133-135. 
20. Xu, L., A systematic review of Randomized Controlled Trials: Treating Herpes Zoster 
with Activating Blood and dissolving stasis method. 2009, Chengdu University of 
TCM. 
246 
 
21. Xu, L. and Z.M. Liao, Systematic review of randomized-controlled trials on treatment 
with Danshen pharmaceutics for herpes zoster. Modern Journal of Integrated 
Traditional Chinese and Western Medicine, 2010(25): p. 3150-3153. 
22. Cao, P. and R.D. Yang. A Meta-analysis of Treating Herpes Zoster with Acupuncture. 
in The Ninth Conference of China Association for Acupuncture and Moxibustion. 
2010. Shanghai. 
23. Chen, L.Z., et al., Systematic review of randomized controlled trials of electro－
acupuncture for herpes zoster. Hebei Journal of Traditional Chinese Medicine, 
2013(04): p. 593-596. 
24. Fu, L. and C. Gao, Meta Analysis of Clinical Randomized Controlled Trial about Jiaji 
Points on Herpes Zoster. Chinese Journal of Integrative Medicine, 2009. 8(02): p. 
112-117. 
25. Wang, J.H., H.P. Chen, and J. Chen, A systematic review of Randomized Controlled 
Trials: Treating Herpes Zoster with Fire Needles. Journal of Clinical Acupuncture and 
Moxibustion, 2009. 25(06): p. 16-18. 
26. Yu, X.M., et al., Systematic assessment of acupuncture for treatment of herpes zoster 
in domestic clinical studies. Chinese Acupuncture & Moxibustion, 2007. 27(07): p. 
536-540. 
27. Zhao, T. and Y.H. Wang, Systematic Assessment of Randomized Controlled Trials of 
Acupuncture-moxibustion Treatment of Herpes Zoster. Shanghai Journal of 
Acupuncture and Moxibustion, 2007. 26(06): p. 30-33. 
28. Zheng, C.A. and L. Xu, Moxibustion in the Treatment of Herpes Zoster: Meta 
Analysis of Clinical Randomized Collected Trials. Journal of Clinical Acupuncture 
and Moxibustion, 2011. 27(11): p. 48-50. 
29. Arvin, A., Aging, immunity, and the varicella-zoster virus. The New England Journal 
of Medicine, 2005. 352(22): p. 2266-2267. 
30. Johnson, B., et al., PIN26-Annual Incidence Rates of Herpes Zoster among an 
Immunocompetent Population In The United States. Value in Health, 2015. 18(3): p. 
A232. 
31. Hillebrand, K., et al., Incidence of herpes zoster and its complications in Germany, 
2005-2009. Journal of Infection, 2015. 70(2): p. 178-186. 
32. Nilsson, J., T. Cassel, and L. Lindquist, Burden of herpes zoster and post-herpetic 
neuralgia in Sweden. BMC Infectious Diseases, 2015. 15: p. 215. 
33. Li, Y., et al., Disease Burden Due to Herpes Zoster among Population Aged >/=50 
Years Old in China: A Community Based Retrospective Survey. PLoS One, 2016. 
11(4): p. e0152660. 
34. MacIntyre, R., et al., Increasing trends of herpes zoster in Australia. PLoS One, 2015. 
10(4): p. e0125025. 
35. Araujo, L.Q., C.R. Macintyre, and C. Vujacich, Epidemiology and burden of herpes 
zoster and post-herpetic neuralgia in Australia, Asia and South America. Herpes, 
2007. 14 Suppl 2: p. 40-44. 
36. Gershon, A.A., Epidemiology and management of postherpetic neuralgia. Seminars in 
Dermatology, 1996. 15(2 Suppl 1): p. 8-13. 
37. Wen, S.Y. and W.L. Liu, Epidemiology of pediatric herpes zoster after varicella 
infection: a population-based study. Pediatrics, 2015. 135(3): p. e565-571. 
38. Bricout, H., et al., Herpes zoster-associated mortality in Europe: a systematic review. 
BMC Public Health, 2015. 15: p. 466. 
39. Edmunds, W.J., M. Brisson, and J.D. Rose, The epidemiology of herpes zoster and 
potential cost-effectiveness of vaccination in England and Wales. Vaccine, 2001. 
19(23-24): p. 3076-3090. 
247 
 
40. Brisson, M. and W.J. Edmunds, Epidemiology of Varicella-Zoster Virus in England 
and Wales. Journal of Medical Virology, 2003. 70 Suppl 1: p. S9-14. 
41. Gater, A., et al., The humanistic, economic and societal burden of herpes zoster in 
Europe: a critical review. BMC Public Health, 2015. 15: p. 193. 
42. Tsai, T.F., et al., Herpes zoster-associated severity and duration of pain, health-
related quality of life, and healthcare utilization in Taiwan: a prospective 
observational study. International Journal of Dermatology, 2015. 54(5): p. 529-536. 
43. Hobbelen, P.H., et al., The burden of hospitalisation for varicella and herpes zoster in 
England from 2004 to 2013. Journal of Infection, 2016. 73(3): p. 241-253. 
44. Johnson, B.H., et al., Healthcare resource utilization and costs associated with herpes 
zoster in the US. Journal of Medical Economics, 2016: p. 1-8. 
45. Friesen, K.J., et al., Price of pain: population-based cohort burden of disease analysis 
of medication cost of herpes zoster and postherpetic neuralgia. Journal of Pain 
Research, 2016. 9: p. 543-550. 
46. Conway EL, Lenkic C, and M. CR, Herpes Zoster and Associated Health Care Use in 
General Practice in Australia, in Sydney: Public Health Association of Australia 10th 
National Immunisation Conference. 2006: Sydney, Australia. p. 50. 
47. Stein, A.N., et al., Herpes zoster burden of illness and health care resource utilisation 
in the Australian population aged 50 years and older. Vaccine, 2009. 27(4): p. 520-
529. 
48. Gershon, A.A., et al., Advances in the understanding of the pathogenesis and 
epidemiology of herpes zoster. Journal of Clinical Virology, 2010. 48 Suppl 1: p. S2-
7. 
49. Gershon, A., et al., Varicella-zoster virus. Clinical Virology, 2009: p. 451-473. 
50. Sartori, A.M., A review of the varicella vaccine in immunocompromised individuals. 
International Journal of Infectious Diseases, 2004. 8(5): p. 259-270. 
51. Arvin, A.M., J.F. Moffat, and R. Redman, Varicella-zoster virus: aspects of 
pathogenesis and host response to natural infection and varicella vaccine. Advances 
in Virus Research, 1996. 46: p. 263-309. 
52. Kennedy, P.G., Varicella-zoster virus latency in human ganglia. Reviews in Medical 
Virology, 2002. 12(5): p. 327-234. 
53. Weinberg, J.M., Herpes zoster: epidemiology, natural history, and common 
complications. Journal of the American Academy of Dermatology, 2007. 57(6 Suppl): 
p. S130-135. 
54. Geerlings, S.E. and A.I. Hoepelman, Immune dysfunction in patients with diabetes 
mellitus (DM). FEMS Immunology and Medical Microbiology, 1999. 26(3-4): p. 259-
265. 
55. Heymann, A.D., et al., Diabetes as a risk factor for herpes zoster infection: results of 
a population-based study in Israel. Infection, 2008. 36(3): p. 226-230. 
56. Sato-Takeda, M., et al., The human histocompatibility leukocyte antigen (HLA) 
haplotype is associated with the onset of postherpetic neuralgia after herpes zoster. 
Pain, 2004. 110(1-2): p. 329-336. 
57. Haanpaa, M., T. Nurmikko, and M. Hurme, Polymorphism of the IL-10 gene is 
associated with susceptibility to herpes zoster. Scandinavian Journal of Infectious 
Diseases, 2002. 34(2): p. 112-114. 
58. Hicks, L.D., et al., Family history as a risk factor for herpes zoster: a case-control 
study. Archives Dermatology, 2008. 144(5): p. 603-608. 
59. Thomas, S.L. and A.J. Hall, What does epidemiology tell us about risk factors for 
herpes zoster? The Lancet Infectious Diseases, 2004. 4(1): p. 26-33. 
60. Schmader, K., et al., Are stressful life events risk factors for herpes zoster? Journal of 
248 
 
the American Geriatrics Society, 1990. 38(11): p. 1188-1194. 
61. Harpaz, R., et al., Psychological stress as a trigger for herpes zoster: might the 
conventional wisdom be wrong? Clinical Infectious Diseases, 2015. 60(5): p. 781-
785. 
62. Schmader, K., et al., Racial and psychosocial risk factors for herpes zoster in the 
elderly. The Journal of Infectious Diseases, 1998. 178 Suppl 1: p. S67-70. 
63. Schmader, K., et al., Racial differences in the occurrence of herpes zoster. The Journal 
of Infectious Diseases, 1995. 171(3): p. 701-704. 
64. Johnson, R.W., et al., Postherpetic neuralgia: epidemiology, pathophysiology and 
management. Expert Review of Neurotherapeutics, 2007. 7(11): p. 1581-1595. 
65. Rowbotham, M.C., et al., Cutaneous innervation density in the allodynic form of 
postherpetic neuralgia. Neurobiology Disease, 1996. 3(3): p. 205-214. 
66. Oaklander, A.L., et al., Unilateral postherpetic neuralgia is associated with bilateral 
sensory neuron damage. Annals Neurology, 1998. 44(5): p. 789-795. 
67. Schmader, K.E., Epidemiology and impact on quality of life of postherpetic neuralgia 
and painful diabetic neuropathy. The Clinical Journal of Pain, 2002. 18(6): p. 350-
354. 
68. Meister, W., et al., Demography, symptomatology, and course of disease in 
ambulatory zoster patients. A physician-based survey in Germany. Intervirology, 
1998. 41(6): p. 272-277. 
69. Jung, B.F., et al., Risk factors for postherpetic neuralgia in patients with herpes zoster. 
Neurology, 2004. 62(9): p. 1545-1551. 
70. Scott, F.T., et al., A study of shingles and the development of postherpetic neuralgia in 
East London. Journal of Medical Virology, 2003. 70 Suppl 1: p. S24-30. 
71. Werner, R.N., et al., European consensus-based (S2k) Guideline on the Management 
of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation 
with the European Academy of Dermatology and Venereology (EADV), Part 1: 
Diagnosis. Journal of the European Academy of Dermatology and Venereology, 2017. 
31(1): p. 9-19. 
72. Meister, W., et al., A prognostic score for postherpetic neuralgia in ambulatory 
patients. Infection, 1998. 26(6): p. 359-363. 
73. Johnson, R.W., et al., Herpes zoster and postherpetic neuralgia: optimizing 
management in the elderly patient. Drugs Aging, 2008. 25(12): p. 991-1006. 
74. Johnson, R.W., Zoster-associated pain: what is known, who is at risk and how can it 
be managed? Herpes, 2007. 14 Suppl 2: p. 30-34. 
75. Katz, J. and R. Melzack, Measurement of pain. Surgical Clinics of North America, 
1999. 79(2): p. 231-252. 
76. Dworkin, R.H., et al., Diagnosis and assessment of pain associated with herpes zoster 
and postherpetic neuralgia. Journal of Pain, 2008. 9(1 Suppl 1): p. S37-44. 
77. Zaal, M.J., H.J. Volker-Dieben, and J. D'Amaro, Prognostic value of Hutchinson's 
sign in acute herpes zoster ophthalmicus. Graefe's Archive for Clinical and 
Experimental Ophthalmology, 2003. 241(3): p. 187-191. 
78. Sanjay, S., P. Huang, and R. Lavanya, Herpes zoster ophthalmicus. Current Treatment 
Options in Neurology, 2011. 13(1): p. 79-91. 
79. Wagner, G., H. Klinge, and M.M. Sachse, Ramsay Hunt syndrome. Journal of the 
German Society of Dermatology, 2012. 10(4): p. 238-244. 
80. Esposito, S., et al., A case of meningitis due to varicella zoster virus reactivation in an 
immunocompetent child. Italian Journal of Pediatrics, 2013. 39: p. 72. 
81. Venhovens, J., et al., Ischemic Stroke as a Complication of Varicella Zoster 
Encephalitis: A Case Report with Detailed EEG Discussion. Clinical EEG 
249 
 
Neuroscience, 2013. 
82. Jemsek, J., et al., Herpes zoster-associated encephalitis: clinicopathologic report of 
12 cases and review of the literature. Medicine (Baltimore), 1983. 62(2): p. 81-97. 
83. Gilden, D.H., et al., Zoster sine herpete, a clinical variant. Annals of Neurology, 
1994. 35(5): p. 530-533. 
84. Silverstein, B.E., et al., Disciform keratitis: a case of herpes zoster sine herpete. 
American Journal of Ophthalmology, 1997. 123(2): p. 254-255. 
85. Oxman, M.N., et al., A vaccine to prevent herpes zoster and postherpetic neuralgia in 
older adults. The New England Journal of Medicine, 2005. 352(22): p. 2271-2284. 
86. Werner, R.N., et al., European consensus-based (S2k) Guideline on the Management 
of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation 
with the European Academy of Dermatology and Venereology (EADV), Part 2: 
Treatment. Journal of the European Academy of Dermatology and Venereology, 2017. 
31(1): p. 20-29. 
87. Whitley, R.J., et al., Management of herpes zoster and post-herpetic neuralgia now 
and in the future. Journal of Clinical Virology, 2010. 48 Suppl 1: p. S20-28. 
88. Beutner, K.R., et al., Valaciclovir compared with acyclovir for improved therapy for 
herpes zoster in immunocompetent adults. Antimicrob Agents Chemother, 1995. 
39(7): p. 1546-1553. 
89. Bowsher, D., The effects of pre-emptive treatment of postherpetic neuralgia with 
amitriptyline: a randomized, double-blind, placebo-controlled trial. Journal of Pain 
and Symptom Management, 1997. 13(6): p. 327-331. 
90. Eroglu, Ç., et al., Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin 
receptor responsible for excitatory CNS synaptogenesis. Cell. 139(2): p. 380-392. 
91. van Seventer, R., et al., Efficacy and tolerability of twice-daily pregabalin for treating 
pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized 
trial. Current Medical Research and Opinion, 2006. 22(2): p. 375-384. 
92. Rice, A.S. and S. Maton, Gabapentin in postherpetic neuralgia: a randomised, double 
blind, placebo controlled study. Pain, 2001. 94(2): p. 215-224. 
93. Backonja, M. and R.L. Glanzman, Gabapentin dosing for neuropathic pain: evidence 
from randomized, placebo-controlled clinical trials. Clinical Therapeutics 2003. 
25(1): p. 81-104. 
94. Guan, Y., et al., Efficacy of pregabalin for peripheral neuropathic pain: results of an 
8-week, flexible-dose, double-blind, placebo-controlled study conducted in China. 
Clinical Therapeutics, 2011. 33(2): p. 159-166. 
95. Atkinson, M.J., et al., Validation of a general measure of treatment satisfaction, the 
Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel 
study of chronic disease. Health Qual Life Outcomes, 2004. 2: p. 12. 
96. Joseph, N., L. Gwei-djen, and S. Nathan, Science and civilisation in China. Vol. 5. 
2000, Cambridge: Cambridge University Press. VI: Medicine. 
97. Lozano, F., Basic theories of traditional Chinese medicine, in Acupuncture for Pain 
Management. 2014, Springer. p. 13-43. 
98. Shuai, H. and H. Yin, Fundamentals of traditional Chinese medicine. 1992, Beijing: 
Beijing: Foreign Languages Press. 
99. Xue, C.C., et al., Complementary and alternative medicine use in Australia: a 
national population-based survey. The Journal of Alternative and Complementary 
Medicine, 2007. 13(6): p. 643-650. 
100. Fang, C.Y., Zhu Bing Yuan Hou Lun. 610 AD, Beijing: China Medical Science Press. 
101. Li, J., Formulas. 2006, Beijing: Chinese Press of Tradition Chinese Medicine. 
102. May, B.H., et al., Chinese herbs for memory disorders: a review and systematic 
250 
 
analysis of classical herbal literature. Journal of Acupuncture and Meridian Studies, 
2013. 6(1): p. 2-11. 
103. May, B.H., et al., Systematic assessment of the representativeness of published 
collections of the traditional literature on Chinese medicine. Journal of Alternative 
and Complementary Medicine, 2013. 19(5): p. 403-409. 
104. Zhong Hua Yi Dian, in Encyclopaedia of Traditional Chinese Medicine. 2014, Hunan 
Electronic and Audio-visual Publishing House: Hunan. 
105. May, B.H., C. Lu, and C.C. Xue, Collections of traditional Chinese medical literature 
as resources for systematic searches. Journal of Alternative and Complementary 
Medicine, 2012. 18(12): p. 1101-1107. 
106. Chinese Medicine Board of Australia, Nomenclature list of commonly used Chinese 
herbal medicines. 2015. 
107. Everitt, B.S., et al., Cluster Analysis. 2010: Wiley. 
108. Statistical Package for the Social Sciences (SPSS). 2012, IBM Corporation: San 
Francisco. 
109. Chen, H., Chinese External Medicine 2005, Beijing: China Press of Traditional 
Chinese Medicine. [In Chinese: 陈红风, 中医外科学. 2005, 北京: 中国中医药出版
社.]. 
110. Bao, Y., The research on the history of dermatology in Chinese medicine before Song 
dynasty. 2013. [In Chinese: 鲍燕, 宋以前中医皮肤病史研究. 2013, 山东中医药大
学: 山东.], Shandong University of Chinese medicine: Shandong. 
111. Liang, F.R., Acupuncture. 2005, Beijing: China Press of Chinese Medicine. 
112. Han, J., C. Zhang, and D.X. Fu, The discussioin of the safety of realgar in Chinese 
Pharmacopoeia (2005 edition). China Journal of Chinese Materia Medica, 2008(13). 
113. Commission, C.P., Chinese Pharmacopoeia. 2015, Beijing: China Medical Science 
Press. 
114. Ahmed, H.M., et al., Molecular screening of Chinese medicinal plants for 
progestogenic and anti-progestogenic activity. Journal of Biosciences, 2014. 39(3): p. 
453-461. 
115. Cheung, T.P., et al., Aristolochic acids detected in some raw Chinese medicinal herbs 
and manufactured herbal products--a consequence of inappropriate nomenclature 
and imprecise labelling? Clinical Toxicology, 2006. 44(4): p. 371-378. 
116. Shaw, D., Toxicological risks of Chinese herbs. Planta Medica, 2010. 76(17): p. 2012-
2018. 
117. Zhao, Z., et al., Authentication is fundamental for standardization of Chinese 
medicines. Planta Medica, 2006. 72(10): p. 865-874. 
118. Guidelines for Diagnosis and Treatment of Common Diseases of Dermatology in 
Traditional Chinese Medcine. 2012, Beijing: The Medicine Science and Technology 
Press of China. 
119. Kilburn, S.A., et al., Interventions for cellulitis and erysipelas. Cochrane Database 
Systematic Review, 2010(6): p. CD004299. 
120. Morris, A.D., Cellulitis and erysipelas. BMJ Clinical Evidence, 2008. 
121. NHMRC. NHMRC additional levels of evidence and grades for recommendations for 
developers of guidelines. 2009  [cited 2016 August 13th]; Available from: 
https://www.nhmrc.gov.au/_files_nhmrc/file/guidelines/developers/nhmrc_levels_gra
des_evidence_120423.pdf. 
122. Higgins, J.P.T. and S. Green. Cochrane Handbook for Systematic Reviews of 
Interventions Version 5.1.0. 2011  [cited 2016 August 13th]; Available from: 
http://www.cochrane-handbook.org/. 
251 
 
123. Melzack, R., The McGill Pain Questionnaire: major properties and scoring methods. 
Pain, 1975. 1(3): p. 277-299. 
124. Dubinsky, R.M., et al., Practice parameter: treatment of postherpetic neuralgia: an 
evidence-based report of the Quality Standards Subcommittee of the American 
Academy of Neurology. Neurology, 2004. 63(6): p. 959-965. 
125. Coplan, P.M., et al., Development of a measure of the burden of pain due to herpes 
zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain 
inventory. Journal of Pain, 2004. 5(6): p. 344-356. 
126. Ware, J.E., Jr. and C.D. Sherbourne, The MOS 36-item short-form health survey (SF-
36). I. Conceptual framework and item selection. Medical Care, 1992. 30(6): p. 473-
483. 
127. Rabin, R. and F. de Charro, EQ-5D: a measure of health status from the EuroQol 
Group. Annals of Medicine, 2001. 33(5): p. 337-343. 
128. Schmader, K.E., et al., The impact of acute herpes zoster pain and discomfort on 
functional status and quality of life in older adults. The Clinical Journal of Pain, 2007. 
23(6): p. 490-496. 
129. Cheung, K., et al., EQ-5D User guide. 2009. 
130. Whynes, D.K., Correspondence between EQ-5D health state classifications and EQ 
VAS scores. Health Qual Life Outcomes, 2008. 6: p. 94. 
131. State Administration of Traditional Chinese Medicine, Standard of Diagnosis and 
Therapeutic Effect of TCM Diseases. 1994, Nanjing: Nanjing University Press. 259-
260. 
132. Chen, N., et al., Vaccination for preventing postherpetic neuralgia. Cochrane 
Database Systematic Review, 2011(3): p. CD007795. 
133. Han, Y., et al., Corticosteroids for preventing postherpetic neuralgia. Cochrane 
Database Systematic Review, 2013(3): p. CD005582. 
134. Uscategui, T., et al., Antiviral therapy for Ramsay Hunt syndrome (herpes zoster 
oticus with facial palsy) in adults. Cochrane Database Systematic Review, 2008(4): p. 
CD006851. 
135. Peng, H., Zhong Yi Fang Ji Da Ci Dian. 2005, Beijing: People's Medical Publishing 
House(PMPH). 
136. Review Manager (RevMan). 2014, The Nordic Cochrane Centre: Copenhagen. 
137. Higgins, J.P. and S.G. Thompson, Quantifying heterogeneity in a meta-analysis. 
Statistics in Medicine, 2002. 21(11): p. 1539-1558. 
138. Kongkaew, C. and N. Chaiyakunapruk, Efficacy of Clinacanthus nutans extracts in 
patients with herpes infection: systematic review and meta-analysis of randomised 
clinical trials. Complementary Therapies in Medicine, 2011. 19(1): p. 47-53. 
139. Wang, J., The clinical observation of treating herpes zoster with integrative medicine 
Health must-read magazine, 2012. 11(12): p. 233. [In Chinese: 王俊, 中西医结合治
疗带状疱疹疗效观察. 健康必读（中旬刊）, 2012. 11(12): p. 233.]. 
140. Jiang, Y., 110 cases of treating herpes zoster with Long dan xie gan tang and Chuan 
xiong cha tiao san. Journal of Emergency in Traditional Chinese Medicine, 2010. 
08(19): p. 1431-1432. [In Chinese: 江应政,龙胆泻肝汤合川芎茶调散治疗带状疱疹
110例.中国中医急症, 2010(08): p. 1431-1432.]. 
141. Gao, J. and X. Sun, 92 cases of treating post-herpetic neuralgia in older people with 
tanshinone. China Journal of Leprosy and Skin Diseases, 2007(6): p. 547. [In 
Chinese: 郜家平, 孙学东, 丹参酮胶囊防治老年带状疱疹后遗神经痛 92 例. 中国
麻风皮肤病杂志, 2007(6): p. 547.]. 
142. Gu, J. and B. Dan, 42 cases of treating herpes zoster with integrative medicine 
252 
 
Chinese Modern Medicine, 2004. 2(9): p. 67. [In Chinese: 顾介礼 单宝春, 中西医结
合治疗带状疱疹 42例. 中华当代医学, 2004. 2(9): p. 67.]. 
143. Wang, Y., 49 cases of treating post-herpetic neuralgia with integrative medicine 
Proceeding of Clinical Medicine, 2009. 31: p. 876-877. [In Chinese: 王玉兰, 中西医
结合治疗带状疱疹神经痛 49例临床观察. 临床医药实践, 2009. 31: p. 876-877.]. 
144. Xiao, Y., Q. Wang, and Y. Li, The clinical observation of treating herpes zoster with 
integrative medicine Modern Journal of Integrated Traditional Chinese and Western 
Medicine, 2007(28): p. 4182-4183. [In Chinese: 肖云, 汪黔蜀, 李雁, 中西医结合治
疗带状疱疹疗效观察. 现代中西医结合杂志, 2007(28): p. 4182-4183.]. 
145. Han, X., J. Xu, and F. Wu, 37 cases of treating herpes zoster with Fu qing zhu huo 
dan shen fang. Journal of Sichuan Traditional Chinese Medicine, 2007(4): p. 91-92. 
[In Chinese: 韩晓东, 许静, 吴范武, 傅青主火丹神方治疗带状疱疹 37例临床观察. 
四川中医, 2007(4): p. 91-92.]. 
146. Xu, H., The clinical observation of treating herpes zoster with Jie du huo xue tang 
and Lu huang san. Journal of New Chinese Medicine, 2011(1): p. 48-49. [In Chinese: 
徐鸿雁, 解毒活血汤配合芦黄散治疗带状疱疹疗效观察. 新中医, 2011(1): p. 48-
49.]. 
147. Zhou, H., Y. Shu, and H. Xu, The clinical efficacy of modified Long dan xie gan tang 
in treating herpes zoster Chinese Journal of Dermatovenerology of Integrated 
Traditional and Western Medicine, 2004. 3(2): p. 99-100. [In Chinese: 周海啸, 舒友
廉, 许慧荣,龙胆泻肝汤加味治疗带状疱疹临床疗效分析.中国中西医结合皮肤性
病学杂志,2004(02): p. 99-100.]. 
148. Ye, T., Clinical observation of treating herps zoster with Xiyanping Injection. Modern 
Medicine & Health, 2011(19): p. 2908-2909. [In Chinese: 叶田, 喜炎平注射液治疗
带状疱疹临床疗效观察. 现代医药卫生, 2011(19): p. 2908-2909.]. 
149. Zhang, H. and Q. Qiu, Clinical observation of treating herpes zoster with herb Qi se 
hua. Nursing Practice and Research, 2013(6): p. 63-64. [In Chinese: 张惠芬, 丘秋香, 
草药七色花治疗带状疱疹的疗效观察与护理. 护理实践与研究, 2013(6): p. 63-
64.]. 
150. Zhang, X. and L. Qian, 58 cases of treating herpes zoster with Qing jie hua yu zu 
fang. Henan Traditional Chinese Medicine, 2014(11): p. 2227-2228. [In Chinese: 张
晓军, 钱龙江, 清解化瘀组方治疗带状疱疹 58 例. 河南中医, 2014(11): p. 2227-
2228.]. 
151. Zhu, Y., H. Wang, and L. Ding, 80 cases of treating herpes zoster with topical Chinese 
herbal medicine. Journal of Traditional Chinese Medicine, 2007(07): p. 591. [In 
Chinese: 朱运喜, 王海涛,丁丽君, 中药外敷治疗带状疱疹 80 例. 中医杂志, 
2007(07): p. 591.]. 
152. Gao, Y., Y. Zhao, and J. Luo, The clinical obeservation of topical use of Qin bing san 
in treating herpes zoster. The Chinese Journal of Dermatovenereology, 2010. 10(936): 
p. 123. [In Chinese:  高月平, 赵永辰, 罗金花, 青冰散外敷治疗带状疱疹疗效观察. 
中国皮肤性病学杂志, 2010. 10(936): p. 123.]. 
153. Lang, N., The clinical observation of treating herpes zoster with Du yu bing jie fang, 
in China Academy of China Medical Sciences. 2007. [In Chinese: 郎娜, 毒瘀并解方
治疗带状疱疹毒瘀互结证的临床研究, 中国中医科学院. 2007.]. 
154. Li, Q., The clinical observation of treating herpes zoster with Shu feng jie du 
capsules. Henan Traditional Chinese Medicine, 2014: p. 582-583. [In Chinese: 李奇
俊, 疏风解毒胶囊治疗带状疱疹的临床观察. 河南中医, 2014: p. 582-583.]. 
253 
 
155. Shi, X., 60 cases of treating herpes zoster with Long dan xie gan tang. Journal of 
Practical Traditional Chinese Medicine, 2001. 10(17): p. 18-19. [In Chinese: 施向红, 
龙胆泻肝汤治疗带状疱疹 60例.实用中医药杂志, 2001(10): p. 18-19.]. 
156. Shi, C. and X. Wang, Clinical Research to Treat Herpes Zoster of Early Stage with 
Methods to Cool Blood, Relieve Toxin and Dredge Collaterals. Chinese Journal of 
Experimental Traditional Medical Formulae, 2010(11): p. 197-199. [In Chinese: 史成
和, 王秀娟, 凉血解毒通络中药治疗早期带状疱疹. 中国实验方剂学杂志, 
2010(11): p. 197-199.]. 
157. Wang, D., 32 cases of treating herpes zoster with topical Ba du gao. Journal of North 
Pharmacy, 2013(04): p. 188-189. [In Chinese: 王德霞, 中药拔毒膏外敷治疗带状疱
疹 32例疗效观察与护理干预. 北方药学, 2013(04): p. 188-189.]. 
158. Xu, D. and C. Liu, The clinical observation of treating herpes zoster with oral and 
topical Chinese herbal medicine. Medicine Industry Information, 2006(15): p. 219. 
[In Chinese: 许德坚, 刘春辉, 中草药内外合用治疗蛇串疮的临床疗效观察. 医药
产业资讯, 2006(15): p. 219.]. 
159. Zhong, J., et al., The clinical observation of treating herpes zoster with Xi lan wen shu 
lan and Long xue jie. Guiding Journal of Traditional Chinese Medicine and 
Pharmacology, 2013(05): p. 120-121. [In Chinese: 钟捷, 余艳兰, 涂丽, 刘红娜, 西南
文殊兰联合龙血竭治疗与护理带状疱疹的疗效观察. 中医药导报, 2013(05): p. 
120-121.]. 
160. Gong, L. and J. Zhang, Analgesic Effect of Duyiwei Capsule on Herpes Zoster. 
Journal of Military Surgeon in in Southwest China, 2014(05): p. 515-516. [In 
Chinese: 龚立军, 张娟红., 独一味胶囊对带状疱疹患者的镇痛作用. 西南军医, 
2014(05): p. 515-516.]. 
161. Zhou, W., The clinical observation of treating herpes zoster with principle of 
syndrome differentiations and its effect on incidence of post-herpetic neuralgia, in 
Hubei University of Chinese Medicine. 2011. [In Chinese: 周万伟, 辩证治疗带状疱
疹及对后遗神经痛发生率的影响的观察,湖北中医药大学. 2011.]. 
162. Zhu, Y., 51 cases of treating herpes zoster with topical Ban lan gen liquid. Modern 
Journal of Integrated Traditional Chinese and Western Medicine, 2004(06): p. 732-
733. [In Chinese: 朱永辉, 局部外用板蓝根液治疗带状疱疹 51 例疗效观察. 现代
中西医结合杂志, 2004(06): p. 732-733.]. 
163. Zhuo, K. and Z. Wu, The clinical obeservation of treating herpes zoster in old 
patients with Long dan xie gan tang combined with lotion. Chinese Health care, 
2010(10): p. 122-123. [In Chinese: 卓堪培, 吴兆怀,龙胆泻肝汤配合洗剂治疗老年
性带状疱疹疗效观察. 中国保健, 2010 (10): p.122-123.]. 
164. Wan, G., 45 cases of treating herpes zoster with San ren tang. China Medical Herald, 
2010(16): p. 109-110. [In Chinese: 万桂芹, 三仁汤加减治疗蛇串疮 45例临床观察. 
中国医药导报, 2010(16): p. 109-110.]. 
165. Xu, Y., Cost-effectiveness Analysis of TCM and Western Medicine Schemes in 
Treatment of Herpes Zoster. China Pharmacy, 2005(1): p. 37-38. [In Chinese: 徐运安, 
中西药不同方案治疗带状疱疹的成本-效果分析. 中国药房, 2005(1): p. 37-38.]. 
166. Liu, C., The clinical observation of treating herpes zoster of stagnant heat in Liver 
meridian with Chinese herbal medicine and fire needling, in Heilongjiang University 
of Traditional Chinese Medicine. 2014. [In Chinese: 刘成祥, 中药联合火针治疗肝
经郁热型带状疱疹的临床观察, 黑龙江中医药大学. 2014.]. 
167. Li, Y. and M. Zhao, 50 cases of treating herpes zoster in older people with Chinese 
254 
 
herbal medicine and valacyclovir. Traditional Chinese Medicinal Research, 2012(05): 
p. 24-26. [In Chinese: 李应宏, 赵明芳, 伐昔洛韦联合中药治疗中老年带状疱疹 50
例. 中医研究, 2012(05): p. 24-26.]. 
168. Liang, T., Y. Wu, and Q. Li, 40 cases of treating herpes zoster with Chinese herbal 
medicine steam therapy and acyclovir. Journal of Diagnosis and Therapy on Dermato-
venereology, 2014. 04: p. 308-310. [In Chinese: 梁天山, 吴艳华, 李其林, 中药薰蒸
联合阿昔洛韦静脉滴注治疗带状疱疹 40 例疗效观察. 皮肤性病诊疗学杂志, 
2014. 04: p. 308-310.]. 
169. Wang, M., S. Wang, and L. Zhao, The clinical observation of treating herpes zoster 
with integrative medicine Chinese Journal of Trauma and Disability Medicine, 
2014(11): p. 113-114. [In Chinese: 王明志, 王淑安, 赵莉, 中西医结合治疗带状疱疹
的疗效分析. 中国伤残医学, 2014(11): p. 113-114.]. 
170. Zhao, M., 89 cases of treating herpes zoster with Qing kai ling tablets and 
valacyclovir. Journal of Mathematical Medicine, 2013(01): p. 78-79. [In Chinese: 赵
敏, 清开灵分散片联合伐昔洛韦治疗带状疱疹 89 例疗效观察. 数理医药学杂志, 
2013(01): p. 78-79.]. 
171. Chang, Y., The clinical observation of treating herpes zoster with topical Chinese 
herbal medicine and acyclovir. Chinese Journal of Ethnomedicine and 
Ethnopharmacy, 2009(17): p. 72. [In Chinese: 常玉山, 中药外敷联合阿西洛韦治疗
带状疱疹疗效观察. 中国民族民间医药, 2009(17): p. 72.]. 
172. Cheng, G. and J. Jiang, 30 cases of treating herpes zoster with researchers designed 
Qing zhen zhi tong gao. Guide of China Medicine, 2012(24): p. 575-576. [In Chinese: 
程桂芝, 姜建德, 自拟方清疹止痛膏治疗带状疱疹 30 例临床疗效观察. 中国医药
指南, 2012(24): p. 575-576.]. 
173. Gao, J., The clinical effect of treating herpes zoster with integrated medicine. Journal 
of Qiqihar Medical College, 2010(01): p. 56. [In Chinese: 高建刚, 中西医结合治疗
带状疱疹的疗效观察. 齐齐哈尔医学院学报, 2010(01): p. 56.]. 
174. Hu, B., The clinical observation of treating herpes zoster with topical Chinese herbal 
medicine and acyclovir. Journal of Emergency in Traditional Chinese Medicine, 
2013(07): p. 1244-1245. [In Chinese: 胡冰, 中药湿敷联合阿昔洛韦治疗带状疱疹
临床观察. 中国中医急症, 2013(07): p. 1244-1245.]. 
175. Huang, Z., L. Chen, and L. Sun, 34 cases of treating herpes zoster with integrated 
medicine. Journal of Qilu Nursing, 2014(05): p. 91-92. [In Chinese: 黄志萍, 陈丽, 孙
丽红, 中西医结合治疗带状疱疹 34 例疗效观察及临床护理. 齐鲁护理杂志, 
2014(05): p. 91-92.]. 
176. Li, G. and M. Chen, 46 cases of treating herpes zoster with valacyclovir and 
compound glycyrrhizin. Chinese Journal of Coal Industry Medicine, 2007(05): p. 540-
541. [In Chinese: 李国泉, 陈明春, 盐酸万乃洛韦联合复方甘草酸苷治疗带状疱疹
46例疗效分析. 中国煤炭工业医学杂志, 2007(05): p. 540-541.]. 
177. Liao, X. and X. Zhang, Clinical Observation of Longdan Xiegan Pills Combined with 
Western Medicine for the Treat-ment of 30 Patient with Herpes Zoster. Journal of 
Clinical Research, 2014(4): p. 785-787. [In Chinese: 廖兴隆, 张新强, 龙胆泻肝丸联
合抗病毒药治疗带状疱疹 30例临床观察. 医学临床研究, 2014(4): 785-787.]. 
178. Liu, Y., The clinical observation of treating herpes zoster with integrative medicine 
Chinese Journal of Trauma and Disability Medicine, 2014(03): p. 162-163. [In 
Chinese: 刘屹嵩, 中西医结合治疗带状疱疹的临床疗效观察. 中国伤残医学, 
2014(03): p. 162-163.]. 
255 
 
179. Ma, X., 40 cases of treating herpes zoster in older patients with Jie cao qing yu tang. 
Chinese Journal of Gerontology, 2012(08): p. 1612-1613. [In Chinese: 马学伟, 缬草
清郁汤治疗老年带状疱疹 40例. 中国老年学杂志, 2012(08): p. 1612-1613.]. 
180. Shi, G. and Y. Li, 48 cases of treating herpes zoster with integrative medicine China 
Practical Medical, 2013(03): p. 177-178. [In Chinese: 施桂泉, 李银元, 中西医结合
治疗带状疱疹 48例临床疗效观察. 中国实用医药, 2013(03): p. 177-178.]. 
181. Song, H., L. Chen, and J. Zhao, The clinical observation of treating herpes zoster with 
integrative medicine. Journal of Practical Traditional Chinese Medicine, 2014(04): p. 
297-298. [In Chinese: 宋欢, 陈丽敏, 赵金涛, 中西医结合治疗带状疱疹急性期临床
观察. 实用中医药杂志, 2014(04): p. 297-298.]. 
182. Song, Z., 39 cases of treating herpes zoster with multiple therapies. Contemporary 
Medicine, 2012(09): p. 150-151. [In Chinese: 宋泽恩, 综合法治疗带状疱疹 39例疗
效观察. 当代医学, 2012(09): p. 150-151.]. 
183. Wang, C., The clinical observation of treating herpes zoster with integrative medicine 
Nei Mongol Journal of Traditional Chinese Medicine, 2008(14): p. 16-17. [In 
Chinese: 王翠连, 中西医结合治疗带状疱疹的疗效观察. 内蒙古中医药, 2008(14): 
p. 16-17.]. 
184. Wang, H., Clinical efficacy of Longxuejie joint cobamamide in the treatment of 
elderly patients with herpes zoster. Chinese Journal of Primary Medicine and 
Pharmacy, 2014(19): p. 2963-2964. [In Chinese: 王红,龙血竭联合腺苷钴胺治疗中
老年人带状疱疹疗效观察. 中国基层医药,2014(19): p. 2963-2964.]. 
185. Wang, S., Y. Wu, and H. Zhao, Observation of the Treatment of Dai pao jie du tang、
Famciclovir and Cobamamide for Senile Herpes zoster. Chinese Journal of Health 
Care and Medicine, 2012(05): p. 389-391. [In Chinese: 王素梅, 吴玉敏, 赵浩, 带疱
解毒汤联合泛昔洛韦和腺苷钴胺治疗老年带状疱疹临床观察. 中华保健医学杂
志, 2012(05): p. 389-391.]. 
186. Wang, W., Clinical observation on treating liver and gallbladder damp heat of zoster 
by the Jiawei Longdan Xiegan decoction plus famciclovir. Clinical Journal of Chinese 
Medicine, 2012. 07: p. 32-34. [In Chinese: 王万学, 加味龙胆泻肝汤联合泛昔洛韦
治疗肝胆湿热型带状疱疹的临床疗效观察. 中医临床研究, 2012. 07: p. 32-34.]. 
187. Wang, X., The clinical observation of treating herpes zoster with integrative medicine 
For All Health, 2014(21): p. 39-40. [In Chinese: 王鑫玺, 中西医结合治疗带状疱疹
的疗效观察. 大家健康(学术版), 2014(21): p. 39-40.]. 
188. Xi, J. and D. Chen, 40 cases of treating herpes zoster with integrative medicine 
Chinese Journal of Integrated Traditional and Western Medicine, 2007(01): p. 75. [In 
Chinese: 席建元, 陈达灿, 中西医结合治疗带状疱疹 40 例临床观察. 中国中西医
结合杂志, 2007(01): p. 75.]. 
189. Xu, X., D. Liang, and H. Ma, The cohort study of treating neuralgia of acute herpes 
zoster with Xin huang tablets. Chinese Journal of Pharmacoepidemiology, 2011(08): 
p. 385-387. [In Chinese: 徐翔, 梁东辉, 马红利, 新癀片治疗带状疱疹早期神经痛的
序贯试验. 药物流行病学杂志, 2011(08): p. 385-387.]. 
190. Yang, A., Y. Feng, and D. Xie, 30 Cases of Adjunctive Therapy by Tuire Jieduling 
Granules for Herpes Zoster. Herald of Medicine, 2010(06): p. 725-726. [In Chinese: 
杨爱霞, 冯永芳, 谢岱, 退热解毒灵颗粒辅助治疗带状疱疹 30 例. 医药导报, 
2010(06): p. 725-726.]. 
191. Yang, J., H. Xu, and Y. Liu, The clinical observation of treating herpes zoster with 
integrative medicine Chinese Journal for Clinicians, 2012(12): p. 71-72. [In Chinese: 
256 
 
杨建春, 徐鸿雁, 刘玉兰, 中西医结合治疗带状疱疹临床疗效观察. 亚太传统医药, 
2012(12): p. 71-72.]. 
192. Zhang, Y. and N. shi, The clinical observation of treating herpes zoster with Bai xian 
ta re pian and laser therapy. Chinese Community Doctors, 2012(18): p. 227. [In 
Chinese: 张伊平, 石娜, 百癣夏塔热片联合半导体激光治疗带状疱疹疗效观察. 中
国社区医师(医学专业), 2012(18): p. 227.]. 
193. Zhao, L., J. Zhao, and D. Tan, 39 cases of treating herpes zoster with modified Wu wei 
xiao du yin. Hunan Journal of Traditional Chinese Medicine, 2013. 10: p. 53-54. [In 
Chinese: 赵梁, 赵季友, 谭达全, 五味消毒饮加减治疗带状疱疹 39例总结. 湖南中
医杂志, 2013. 10: p. 53-54.]. 
194. Zheng, G. and D. Wang, 40 cases of treating herpes zoster with San fen cha ji. 
Shaanxi Journal of Traditional Chinese Medicine, 2011(06): p. 710-711. [In Chinese: 
郑改琴, 王迪, 三粉擦剂治疗带状疱疹 40例. 陕西中医, 2011(06): p. 710-711.]. 
195. Zheng, Y., 29 cases of treating herpes zoster in older people with integrative medicine 
Jiangsu Journal of Traditional Chinese Medicine, 2014(05): p. 46-47. [In Chinese: 郑
玉莲, 中西医结合治疗中老年患者带状疱疹急性期 29 例临床观察. 江苏中医药, 
2014(05): p. 46-47.]. 
196. Zhou, G. and W. Xu, 30 cases of treating herpes zoster neuralgia in older people with 
Shang ke jie tu tablets. Chinese Journal of Clinical Rational Drug Use, 2012(22): p. 
101-102. [In Chinese: 周光全, 徐文君, 伤科接骨片辅治中老年人带状疱疹神经痛
30例疗效观察. 临床合理用药杂志, 2012(22): p. 101-102.]. 
197. Zhou, K., S. Song, and C. Lv, 22 cases of treating herpes zoster on head and face 
area with Jia wei xiao chai hu tang. China Health Care & Nutrition, 2013(01): p. 441. 
[In Chinese: 周克伟, 宋顺鹏, 吕成志, 加味小柴胡汤治疗头面部带状疱疹 22例临
床观察. 中国保健营养, 2013(01): p. 441.]. 
198. Zhou, S., The clinical observation of treating herpes zoster with Shang ke ling pen wu 
ji and valacyclovir. Contemporary Medicine, 2012(31): p. 144-145. [In Chinese: 周书
会, 伤科灵喷雾剂联合泛昔洛韦治疗带状疱疹疗效观察. 当代医学, 2012(31): p. 
144-145.]. 
199. Zhuang, H., P. Qu, and R. Chuai, The clinical observation of acyclovir combined with 
Chinese medicine in treating herpes zoster, in The First Academic Meeting of 
Dermatology Congress of Chinese Medicine of Shandong Province. 2005. p. 133-134. 
[In Chinese: 庄洪建, 渠鹏程, 揣瑞梅, 阿昔洛韦联合中频交流电透入中药治疗带
状疱疹疗效分析, 山东中医药学会皮肤病专业委员会成立暨第一次学术会议. 
2005. p. 133-134.]. 
200. Wu, D., The clinical effect of treating herpes zoster in 98 cases. Medical Aesthetics 
and Cosmetology, 2013(4): p. 76. [In Chinese: 吴丹, 中老年带状疱疹 98例临床分
析. 医学美学美容(中旬刊), 2013(4): p. 76.]. 
201. Zhang, C., The clinical observation of treating herpes zoster with syndrome 
differentiations in Chinese medicine. Journal of China Traditional Chinese Medicine 
Information, 2011. 3(16): p. 431. [In Chinese: 张传文, 中医辨证治疗带状疱疹的疗
效观察. 中国中医药咨讯, 2011. 3(16): p. 431.]. 
202. Bi, C., L. Kong, and L. Ma, 60 cases of treating herpes zoster of stagnant heat in 
Liver meridian with Pao zhen ke li. Heilongjiang Journal of Chinese medicine, 
2010(01): p. 13. [In Chinese: 毕春生, 孔连委, 马林, 疱疹颗粒剂治疗肝经郁热型带
状疱疹 60例临床疗效观察. 黑龙江中医药, 2010(01): p. 13.]. 
203. Li, Q., 38 cases of treating herpes zoster with Dan cao jie du tang. China Journal of 
257 
 
Traditional Chinese Medicine and Pharmacy, 2004(05): p. 318. [In Chinese: 李启文, 
胆草解毒汤治疗带状疱疹 38例. 中国医药学报, 2004(05): p. 318.]. 
204. Jiang, C., Treating 68 cases of senile herpes zoster with TCM drugs. Hunan Guiding 
Journal of TCM, 2002(9): p. 553-554. [In Chinese: 蒋成章, 中医药治疗老年带状疱
疹疼痛 68例疗效观察. 湖南中医药导报, 2002(9): p. 553-554.]. 
205. Song, Z. and X. Lv, The clinical observation of treating herpes zoster with syndrome 
differentiations in Chinese medicine. Guide of China Medicine, 2011(24): p. 121-122. 
[In Chinese: 宋振霞, 吕喜东, 中医辨证治疗带状疱疹的临床疗效. 中国医药指南, 
2011(24): p. 121-122.]. 
206. Tang, G., The clinical efficacy of treating herpes zoster with Tong luo liang xue jie du 
tang. Contemporary Medicine Forum, 2014(02): p. 154-155. [In Chinese: 汤国华, 用
通络凉血解毒汤治疗带状疱疹的临床疗效分析. 当代医药论丛, 2014(02): p. 154-
155.]. 
207. Yao, W., 80 cases of treating herpes zoster with Chai hu gong xie tang. Chinese 
Journal of Integrated Traditional and Western Medicine, 2002(10): p. 788. [In 
Chinese: 要武, 柴虎蚣蝎汤治疗带状疱疹 80 例. 中国中西医结合杂志, 2002(10): 
p. 788.]. 
208. Zhong, P., The research on theory and clinical efficacy of treating herpes zoster with 
pinciple of clear heat, in Nanjing University of Traditional Chinese medicine. 2009. 
[In Chinese: 钟萍, 和解清热法治疗带状疱疹热毒互结证的理论与临床研究, 南京
中医药大学. 2009.]. 
209. Zhang, X. and L. Qian, The clinical observation of treating herpes zoster with 
integrative medicine Journal of Chinese Medicine, 2013(28): p. 84-84. [In Chinese: 
张晓军, 钱龙江, 中西医结合治疗带状疱疹疗效观察. 中医学报, 2013(28): p. 84-
84.]. 
210. Cao, Z., 42 cases of treating herpes zoster with integrative medicine Hunan Journal of 
Traditional Chinese Medicine, 2010. 05: p. 83-84. [In Chinese: 曹周军, 中西医结合
治疗带状疱疹 42例. 湖南中医杂志, 2010. 05: p. 83-84.]. 
211. Feng, Y., The clinical observation of treating herpes zoster with Yuan tong he ji and 
valacyclovir. Hubei Journal of Traditional Chinese Medicine, 2010. 03: p. 55. [In 
Chinese: 冯永芳, 元通合剂联合伐昔洛韦治疗带状疱疹疗效观察. 湖北中医杂志, 
2010. 03: p. 55.]. 
212. Huang, D., 42 Cases of treating herpes zoster with integrated medicine. Journal of 
Chinese Medicine, 2014. 29: p. 88-88. [In Chinese: 黄东平, 中西医结合治疗带状疱
疹 42例临床分析. 中医学报, 2014. 29: p. 88-88.]. 
213. Liu, S., G. Xu, and R. Hou, The manufacture and clinical observation of Ba du tu mo 
ji. Journal of Shaanxi College of Traditional Chinese Medicine, 2006. 01: p. 59-60. 
[In Chinese: 刘世贵, 徐桂萍, 侯茹, 拔毒涂膜剂的制备及临床观察. 陕西中医学院
学报, 2006. 01: p. 59-60.]. 
214. Lu, F., The clinical observation of treating herpes zoster with topical Chinese herbal 
medicine and acyclovir. Acta Medicinae Sinica, 2004. 03: p. 402-403. [In Chinese: 陆
富永, 中药外治联合阿昔洛韦治疗带状疱疹. 华夏医学, 2004. 03: p. 402-403.]. 
215. Wang, H. and H. Sun, The clinical observation of treating herpes zoster with Ru yi 
zhen bao wan and valacyclovir. Shanxi Journal of Traditional Chinese Medicine, 
2013. 05: p. 28-29. [In Chinese: 王恒明, 孙浩, 如意珍宝丸联合伐昔洛韦治疗带状
疱疹疗效观察. 山西中医, 2013. 05: p. 28-29.]. 
216. Zhang, Z., The clinical observation of treating herpes zoster with combination of 
258 
 
conventional medicine and Chinese herbal medicine. Guangxi Journal of Traditional 
Chinese Medicine, 2011. 05: p. 14. [In Chinese: 张振汉, 西医常规治疗加中医辨证
治疗带状疱疹疗效观察. 广西中医药, 2011. 05: p. 14.]. 
217. Mai, J., The clinical observation of treating herpes zoster with modified Wei ling tang 
and Chai hu shu gan san. Journal of Liaoning University of Traditional Chinese 
Medicine, 2008. 09: p. 86. [In Chinese: 买建修, 胃苓汤合柴胡疏肝饮加减治疗带状
疱疹临床观察. 辽宁中医药大学学报, 2008. 09: p. 86.]. 
218. He, F., A. Cai, and Y. Liu, 86 cases of treating herpes zoster with Chinese herbal 
medicine. Journal of Emergency in Traditional Chinese Medicine, 2005. 07: p. 638. 
[In Chinese: 贺芳, 蔡爱萍, 刘永胜, 中药治疗带状疱疹 86例. 中国中医急症, 2005. 
07: p. 638.]. 
219. sun, Y., The clinical experience of treating herpes zoster with stagnant heat in liver 
meridian with Long dan xie gan tang. Contemporary Medicine, 2010(18): p. 146-147. 
[In Chinese:  孙毅刚, 龙胆泻肝汤加减治疗肝经郁热型带状疱疹的临床心得. 当代
医学, 2010(18): p. 146-147.]. 
220. Tian, Y., S. Fu, and H. Zhao, 46 cases of treating herpes zoster with Xiao zhen zhi 
tong tang. Henan Traditional Chinese Medicine, 2006. 04: p. 46. [In Chinese: 田瑛瑜, 
付索菊, 赵海燕, 消疹止痛汤加减治疗带状疱疹 46例. 河南中医, 2006. 04: p. 46.]. 
221. Xu, C. and Y. Zhang, 36 cases of treating herpes zoster with Jia wei xiao chai hu 
tang. International Journal of Traditional Chinese Medicine, 2014. 36(7): p. 662-663. 
[In Chinese: 徐春凤, 张艳, 加味小柴胡汤治疗带状疱疹 36例. 国际中医中药杂志, 
2014. 36(7): p. 662-663.]. 
222. Zhang, X., 62cases of treating herpes zoster with oral and topical Chinese herbal 
medicine. Yunnan Journal of Traditional Chinese Medicine and Materia Medica, 2010. 
07: p. 33. [In Chinese: 张学权, 中药内外合治带状疱疹 62例疗效观察. 云南中医
中药杂志, 2010. 07: p. 33.]. 
223. Mai, J., 34 cases of treating herpes zoster with integrative medicine Traditional 
Chinese Medicinal Research, 2009(07): p. 51-52. [In Chinese: 买建修, 中西医结合
治疗带状疱疹 34例. 中医研究, 2009(07): p. 51-52.]. 
224. Zhen, J., The clinical observation of treating herpes zoster with Zi cao xiao zhen tang 
and nerve block therapy. Chinese Journal of Integrated Traditional and Western 
Medicine, 2002. 10: p. 747. [In Chinese: 甄君, 紫草消疹汤联合神经阻滞治疗带状
疱疹的疗效观察. 中国中西医结合杂志, 2002. 10: p. 747.]. 
225. Lu, F., The clinical efficacy of acyclovir combined with Chinese herbal medicine in 
treating herpes zoster. Chinese Journal of Current Clinical Medicine, 2003. 1(3): p. 
244. [In Chinese: 鲁飞, 阿昔洛韦配合中药治疗带状泡疹的疗效分析. 中华现代临
床医学杂志, 2003. 1(3): p. 244.]. 
226. Yin, J. and L. Liang, 40 cases of treating herpes zoster with Liu shen wan and 
acyclovir. Jilin Journal of Traditional Chinese Medicine, 2006. 8: p. 44. [In Chinese: 
尹景霞, 梁连秀, 六神丸加阿昔洛韦治疗带状疱疹 40 例临床观察. 吉林中医药, 
2006. 8: p. 44.]. 
227. Zhang, L. and C. Xu, 46 cases of treating herpes zoster in older people with 
combination of Xing qi qu yu tang and acyclovir. Chinese Journal of Traditional 
Medical Science and Technology, 2013. 04: p. 430-431. [In Chinese: 张利君, 徐传华, 
行气祛瘀汤联合阿昔洛韦治疗老年带状疱疹 46例. 中国中医药科技, 2013. 04: p. 
430-431.]. 
228. Ma, W., The efficacy of treating herpes zoster in older people with Run zao zhi yang 
259 
 
capsules. Modern Traditional Chinese Medicine, 2010. 05: p. 37. [In Chinese: 马文
宇, 润燥止痒胶囊在治疗老年性带状疱疹患者中的应用. 现代中医药, 2010. 05: p. 
37.]. 
229. Du, Y., The clinical observation of treating herpes zoster with integrative medicine 
Journal of Traditional Chinese Medicine, 2008(09): p. 1289. [In Chinese: 杜耀战, 中
西医结合治疗带状疱疹. 光明中医, 2008(09): p. 1289.]. 
230. Lou, X., 47 cases of treating herpes zoster with Pao zhen san and Zhi tong tang. 
Journal of Gansu College of Traditional Chinese Medicine, 2014(02): p. 45-46. [In 
Chinese: 楼小慧, 疱疹散联合止痛汤治疗带状疱疹 47例临床观察. 甘肃中医学院
学报, 2014(02): p. 45-46.]. 
231. Zhuang, Z., Y. Guo, and S. Ding, The clinical observation of treating herpes zoster 
with oral Chinese herbal medicine and nerve block therapy. Chinese Journal of 
Practical Nervous Diseases, 2010. 02: p. 58-59. [In Chinese: 庄志刚, 郭艳严, 丁飒
爽, 神经阻滞加中药内服治疗带状疱疹神经痛疗效观察. 中国实用神经疾病杂志, 
2010. 02: p. 58-59.]. 
232. Jing, Y., The clinical observation of treating herpes zoster with pinciple of clearing 
heat, resolving dampness, activating blood and detoxifying. Information on 
Traditional Chinese Medicine, 2001. 03: p. 46. [In Chinese: 荆玉强, 清热利湿活血解
毒法治疗带状疱疹临床疗效探讨. 中医药信息, 2001. 03: p. 46.]. 
233. Zhou, S. and C. Gao, The clinical observation of treating herpes zoster of damp in 
Spleen meridian type with Yi yi zhu ye san jia wei. Beijing Journal of Traditional 
Chinese Medicine, 2008. 05: p. 369-370. [In Chinese: 周淑桂, 高春秀, 薏苡竹叶散
加味治疗脾经湿盛型蛇串疮疗效观察. 北京中医药, 2008. 05: p. 369-370.]. 
234. Gao, X., Science of Chinese Materia Medica. 2007, Beijing: China Press of 
Traditional Chinese Medicine. 
235. Wang, K., et al., Gentiana scabra Bunge. Formula for Herpes Zoster: Biological 
Actions of Key Herbs and Systematic Review of Efficacy and Safety. Phytotherapy 
Research, 2017. 
236. Fu, Y., The clinical observation of modified Long dan xie gan tang with San huang zhi 
yang cha ji in treating herpes zoster. Journal of Emergency in Traditional Chinese 
Medicine, 2014(12): p. 2346-2347. [In Chinese: 傅燕华, 龙胆泻肝汤加减联合三黄
止痒搽剂治疗带状疱疹的临床观察. 中国中医急症, 2014(12):  p. 2346-2347.]. 
237. Li, N., The clinical observation of modified Long dan xie gan tang with Kang fu xin 
ye in treating herpes zoster. Shanxi Journal of Traditional Chinese Medicine, 2013. 
29(11): p. 18-19. [In Chinese: 李宁波, 龙胆泻肝汤加减联合康复新液外敷治疗带
状疱疹疗效观察. 山西中医, 2013.29(11): p. 18-19]. 
238. Shi, Y., K. Ni, and X. Li, The clinical observation of treating herpes zoster with 
modified Long dan xie gan tang and compound dan shen injection. Yunnan Journal of 
Traditional Chinese Medicine and Materia Medica, 2002. 02(23): p. 322. [In Chinese: 
石云, 倪凯, 李新, 加减龙胆泻肝汤合复方丹参注射液为主治疗带状疱疹的疗效观
察. 云南中医中药杂志, 2002. 02(23): p. 322.]. 
239. Zhou, Y., 40 cases of treating herpes zoster with oral and topical Chinese herbal 
medicine. Medical Information, 2011. 24(9): p. 179-179. [In Chinese: 周运珠, 中药内
服外敷治疗带状疱疹 40例临床疗效观察. 医学信息, 2011. 24(9): p. 179-179.]. 
240. Li, M. and X. Liu, 70 cases of treating herpes zoster with modified long dan xie gan 
tang. Journal of China Traditional Chinese Medicine Information, 2011. 3(2): p. 85-
85. [In Chinese: 李明保, 刘相德, 加减龙胆泻肝汤治疗带状疱疹 70 例. 中国中医
260 
 
药咨讯, 2011. 3(2): p. 85-85.]. 
241. Ding, Y., The clinical efficacy of modified Long dan xie gan tang in treating 26 cases 
of herpes zoster Chinese Community Doctors, 2011(15): p. 166. [In Chinese: 丁有荣,
龙胆泻肝汤加味治疗带状疱疹 26例临床观察. 社区中医药,2011(15): p. 166.]. 
242. Gu, Y., 66 cases of treating herpes zoster with Jia wei long dan xie gan tang. Journal 
of Gansu College of Traditional Chinese Medicine, 2008(01): p. 29-30. [In Chinese: 
顾玉潜, 加味龙胆泻肝汤治疗带状疱疹 66例. 甘肃中医学院学报, 2008(01): p. 29-
30.]. 
243. Li, A., Clinical obeservation of modified Long dan xie gan tang in treating herpes 
zoster. Jian Kang Bi Du, 2012. 03: p. 221. [In Chinese: 李爱菊, 龙胆泻肝汤加减治
疗带状疱疹疗效观察. 健康必读杂志, 2012. 03: p. 221.]. 
244. Li, C. and Y. Li, 60 cases of treating herpes zoster with Jia wei long dan xie gan tang. 
Guangming Journal of Chinese Medicine, 2010(05): p. 800-801. [In Chinese: 李成宾, 
李芸, 加味龙胆泻肝汤治疗带状疱疹 60例. 光明中医 2010(05): p. 800-801.]. 
245. Lin, L., Treating herpes zoster with Long dan xie gan tang. Road To Health, 2014. 12: 
p. 31. [In Chinese: 林龙兴,龙胆泻肝汤治疗带状疱疹.健康之路,2014.12: p. 31.]. 
246. Liu, J., Z. Zhao, and G. Yu, 64 cases of treating herpes zoster with oral and topical 
Chinese herbal medicine. Journal of Practical Traditional Chinese Medicine, 
2012(01): p. 14-15. [In Chinese: 刘建国, 赵智英, 喻国华, 中药内服外敷治疗带状
疱疹 64例观察. 实用中医药杂志, 2012(01): p. 14-15.]. 
247. Liu, X., Clinical Observation on Treatment of Herpes Zoster with Combination of 
Longdan Xiegan Decoction with Ice Silkworm: 60 Cases. Chinese Journal of 
Ethnomedicine and Ethnopharmacy, 2014. 10: p. 38. [In Chinese: 刘西良,龙胆泻肝
汤加减配合冰蚕外用治疗带状疱疹 60 例临床观察.中国民族民间医药, 2014.10: 
p. 38.]. 
248. Liu, Y., Y. Hu, and W. Chao, The clinical observation of treating herpes zoster with 
principle of clearing heat and detoxifying. Today Nurse, 2012(02): p. 122-123. [In 
Chinese: 刘永梅, 胡云仙, 晁卫红, 中药清凉解毒法治疗带状疱疹的疗效观察及护
理. 当代护士 2012(02): p. 122-123.]. 
249. Liu, Z., et al., Clinical obeservation of modified Long dan xie gan tang in treating 
herpes zoster in 81 cases. Journal of Dermatology and Venereology, 2001. 01(23): p. 
74. [In Chinese: 刘子航, 龙胆泻肝汤加减治疗带状疱疹 81例临床观察. 皮肤病与
性病, 2001. 01(23): p. 74.]. 
250. Shi, W., J. Zhao, and M. Yang, 29 cases of treating herpes zoster with Long dan xie 
gan tang. Chinese Medicine Modern Distance Education of China, 2013(18): p. 52. 
[In Chinese: 施伟 龙胆泻肝汤治疗带状疱疹 29 例.中国中医药现代远程教育, 
2013(18): p. 52.]. 
251. Wang, P., The clinical obeservation of modified Long dan xie gan tang in treating 
herpes zoster. Qingdao Medical Journal, 1999(02): p. 146-147. [In Chinese: 王培霞, 
龙胆泻肝汤加减治疗带状疱疹疗效观察. 青岛医药卫生, 1999(02): p. 146-147.]. 
252. Wang, P., Clinical obeservation of modified Long dan xie gan tang in treating herpes 
zoster in 51 cases. Henan Traditional Chinese Medicine, 2008. 09(28): p. 45. [In 
Chinese: 王培东, 龙胆泻肝汤加减治疗带状疱疹 51例临床观察. 河南中医, 2008. 
09(28): p. 45.]. 
253. Wang, X., 64 cases of treating herpes zoster with oral Long dan xie gan tang and 
topical San huang cream. Shaanxi Journal of Traditional Chinese Medicine, 2007(06): 
p. 689-690. [In Chinese: 王孝飞, 内服龙胆泻肝汤外敷三黄软膏治疗带状疱疹 64
261 
 
例. 陕西中医, 2007(06): p. 689-690.]. 
254. Xu, H., The clinical obeservation of Long dan xie gan tang in treating herpes zoster. 
Biotechworld, 2014(05): p. 47. [In Chinese: 许洪滔, 龙胆泻肝汤临床治疗带状疱疹
的效果观察. 生物技术世界, 2014(05): p. 47.]. 
255. Yang, J., The clinical efficacy of Long dan xie gan tang in treating herpes zoster. For 
All Health, 2014. 12: p. 46. [in Chinese: 杨进虎,龙胆泻肝汤治疗带状疱疹的临床效
果观察.大家健康 2014. 12: p. 46.]. 
256. Ye, Z., The clinical observation of treating herpes zoster with oral and topical 
Chinese herbal medicine. Guangxi Journal of Traditional Chinese Medicine, 
2000(04): p. 50. [In Chinese: 叶中峰, 中药内服外涂治疗带状疱疹的疗效观察. 广
西中医药, 2000(04): p. 50.]. 
257. Zheng, J., 32 clinic cases of internal taking Chinese medicine and external 
application for cure zonal herpes of liver-gallbladder wet-heat type. Journal of 
Xinjiang Medical University, 2009(09): p. 1352-1353+1355. [In Chinese: 郑建华, 中
药内服配合外敷治疗肝胆湿热型带状疱疹 32 例临床分析. 新疆医科大学学报, 
2009(09): p. 1352-1353+1355.]. 
258. Zhu, J., 30 cases of treating herpes zoster with Long dan xie gan tang. Journal of 
Zhejiang University of Traditional Chinese Medicine, 2004. 05(28): p. 15. [In 
Chinese: 朱杰, 龙胆泻肝汤治疗带状疱疹 30 例分析. 浙江中医学院学
报,2004.05(28): p. 15.]. 
259. Bensoussan, A., S.P. Myers, and A.L. Carlton, Risks associated with the practice of 
traditional Chinese medicine: an Australian study. Archives of Family Medicine, 
2000. 9(10): p. 1071-1078. 
260. MacPherson, H. and B. Liu, The safety of Chinese herbal medicine: a pilot study for a 
national survey. Journal of Alternative and Complementary Medicine, 2005. 11(4): p. 
617-626. 
261. Yang, Z.B., R.Q. Fan, and B.W. Deng, Chinese Medicine of Dermatology. 2010, 
Beijing: China Press of Traditional Chinese Medicine. 
262. He, Y.M., et al., The anti-inflammatory secoiridoid glycosides from Gentianae 
Scabrae Radix: the root and rhizome of Gentiana scabra. Journal of Natural 
Medicines, 2015. 69(3): p. 303-312. 
263. Li, W., et al., Three new secoiridoid glycosides from the rhizomes and roots of 
Gentiana scabra and their anti-inflammatory activities. Natural Product Research, 
2015: p. 1-8. 
264. Kost, R.G. and S.E. Straus, Postherpetic neuralgia--pathogenesis, treatment, and 
prevention. The New England Journal of Medicine, 1996. 335(1): p. 32-42. 
265. Chen, Q.M., B. Wu, and C.H. Jiang, Comparison of Pain Management of Vitamin B12 
and B1 in Treating Herpes Zoster. Journal of Modern Clinical Medicine, 2006. 32(3): 
p. 195. 
266. Zhang, H. and G.F. Huang, Integrated Traditional Chinese and Western Medicine for 
Herpes Zoster : Progress in the Clinical Research. Journal of Clinical Rehabilitative 
Tissue Engineering Research, 2007. 11(29). 
267. Bian, Z., Clincal Dermatology. 2001, Nanjing: Jiangsu Science & Technology Press. 
268. Chen, C.J. and H.S. Yu, Acupuncture, electrostimulation, and reflex therapy in 
dermatology. Dermatologic Therapy, 2003. 16(2): p. 87-92. 
269. Ursini, T., et al., Acupuncture for the treatment of severe acute pain in herpes zoster: 
results of a nested, open-label, randomized trial in the VZV Pain Study. BMC 
Complementary and Alternative Medicine, 2011. 11: p. 46. 
262 
 
270. Lu, A., The clinical observation of treating herpes zoster with acupuncture, in The 
Ninth Academic Conference of Acupuncture Association of Acupuncture in 
Guangdong. 2004. p. 112. [In Chinese: 卢爱文, 针灸对带状疱疹的临床观察, 广东
省针灸学会第九次学术交流会暨“针灸治疗痛症及特种针法”专题讲座论文汇编. 
2004, 广东省针灸学会: 广东省. p. 3: 112.]. 
271. Yang, R., J. Wang, and C. Li, Therapeutic effect of skin needle stabbing as assistant to 
treat herpes zoster patients. Chinese Nursing Research, 2005. 10: p. 902. [In Chinese: 
杨润莲, 王俊富, 李春娥, 皮肤针叩刺配合治疗带状疱疹的疗效观察. 护理研究, 
2005. 10: p. 902.]. 
272. Luo, S. and J. Zhang, The clinical observation of treating herpes zoster with 
acupuncture combined with acyclovir. Yunnan Journal of Traditional Chinese 
Medicine and Materia Medica, 2008. 06: p. 35. [In Chinese: 罗胜平, 张进城, 针灸配
合阿昔洛韦治疗带状疱疹 40例临床观察. 云南中医中药杂志, 2008. 06: p. 35.]. 
273. Deng, H., Evaluation of the clinical effect of famciclovilr combined with plum 
blossom bin in herpes zoster. Modern Medicine & Health, 2008. 23: p. 3505-3506. [In 
Chinese: 邓宏, 泛昔洛韦联合梅花针治疗带状疱疹临床疗效评价. 现代医药卫生, 
2008. 23: p. 3505-3506.]. 
274. Yue, Z., X. He, and J. Jiang, Clinical study of Flashing-fire moxibustion on zoster. 
Journal of Traditional Chinese Medicine University of Hunan, 2009. 05: p. 70-71+74, 
[In Chinese: 岳增辉, 何新群, 姜京明, 闪火灸法治疗带状疱疹的临床研究. 湖南中
医药大学学报, 2009. 05: p. 70-71+74.]. 
275. Liu, Y., Clinical research on the herpes zoster with different acupuncture and 
moxibustion therapies. 2010. [In Chinese: 刘银妮, 不同针灸方法治疗带状疱疹的临
床研究. 2010, 湖北中医药大学], Hubei University of Chinese medicine. 
276. Jiang, X. and Y. Hu, 50 cases of treating herpes zoster with moxibustion. Shaanxi 
Journal of Traditional Chinese Medicine, 2010. 08: p. 1050-1051. [In Chinese: 姜雪
原, 胡永红, 艾灸治疗带状疱疹 50例. 陕西中医, 2010. 08: p. 1050-1051.]. 
277. Wang, J. and X. Qiu, Therapeutic Observation to Moxa Cone Acupuncture Treating 
Shingles. Journal of Zhejiang University of Traditional Chinese Medicine, 2010. 03: 
p. 402+404. [In Chinese: 王见良, 求晓恩, 艾炷灸治疗带状疱疹临床疗效观察. 浙
江中医药大学学报, 2010. 03: p. 402+404.]. 
278. Lin, L., The research on treatments for herpes zoster. Guide of China Medicine, 2010. 
35: p. 223-224. [In Chinese: 蔺莉莉, 带状疱疹的治疗研究. 中国医药指南, 2010. 
35: p. 223-224.]. 
279. Zhao, M., Y. Wang, and J. Qi, The clinical observation of treating herpes zoster with 
the combination of acupuncture and acyclovir. People's Military Surgeon, 2010. 12: p. 
934-935. [In Chinese: 赵明, 汪月强, 漆军, 针刺联合阿昔洛韦治疗带状疱疹疗效观
察. 人民军医, 2010. 12: p. 934-935.]. 
280. Zheng, X. and L. Li, 40 cases of treating herpes zoster neuralgia with surrounding 
acupuncture and nerve block therapy. Asia-Pacific Traditional Medicine, 2010. 09: p. 
43-44. [In Chinese: 郑新金, 李旅萍, 围针结合神经阻滞治疗带状疱疹神经痛 40例
临床疗效观察. 亚太传统医药, 2010. 09: p. 43-44.]. 
281. Chen, L. and Z. Xu, The clinical observation of treating herpes zoster with 
acupuncture. Aerospace Medicine, 2010. 08: p. 1530. [In Chinese: 陈利远, 徐昭, 针
刺疗法治疗带状疱疹 46例疗效观察. 航空航天医药, 2010. 08: p. 1530.]. 
282. Bao, F., 32 cases of treating herpes zoster with acupuncture. Shandong Journal of 
Traditional Chinese Medicine, 2011. 11: p. 798-799. [In Chinese: 包峰峰, 针灸治疗
263 
 
带状疱疹 32例. 山东中医杂志, 2011. 11: p. 798-799.]. 
283. Li, X., A multi-center randomized controlled trial of acupuncture and moxibustion for 
herpes zoster. 2011. [In Chinese: 李雪薇, 不同针灸方法治疗带状疱疹多中心随机
对照的临床研究. 2011, 成都中医药大学.], Chengdu University of Traditional 
Chinese Medicine. 
284. Wang, M., The observation and nursing experience on herpes zoster with 
comprehensive therapy of acupuncture. Today Nurse, 2011. 09: p. 135-136. [In 
Chinese: 王敏, 针灸综合治疗带状疱疹的疗效观察. 当代护士(专科版), 2011. 09: 
p. 135-136.]. 
285. Zhang, A. and Q. Zhang, The clinical observation of treating herpes zoster with 
electro-acupuncture and Chinese herbal medicine. Journal of Practical Traditional 
Chinese Medicine, 2012. 02: p. 122-123. [In Chinese: 张爱珍, 张强, 电针配合药物
治疗带状疱疹疗效观察. 实用中医药杂志, 2012. 02: p. 122-123.]. 
286. Yang, J., K. Xiang, and Y. Zhang, Treatment of herpes zoster with cotton sheet 
moxibustion: multicentral randomized controlled trial. Chinese Acupuncture & 
Moxibustion, 2012. 05: p. 417-421. [In Chinese: 杨军雄, 向开维, 张玉学, 铺药棉灸
法为主治疗带状疱疹:多中心随机对照研究. 中国针灸, 2012. 05: p. 417-421.]. 
287. Lin, G. and B. Zhao, Acute Herpes Zoster by the Therapy of Surrounding Puncture 
Combined with Suspended Moxibustion. Journal of Clinical Acupuncture and 
Moxibustion, 2012. 06: p. 41-43. [In Chinese: 林广华, 赵斌斌, 围刺为主配合悬灸
治疗急性带状疱疹的疗效观察. 针灸临床杂志, 2012. 06: p. 41-43.]. 
288. Chen, M., Treating herpes zoster with Hao zhen acupuncture technique and 
moxibustion. China Health Care & nutrition, 2012. z2: p. 241. [In Chinese: 陈敏, 毫
针皮下扇形针刺法加艾条治疗带状疱疹. 中国保健营养（中旬刊）, 2012(z2): p. 
241.]. 
289. Zhou, C. and P. Zhang, 90 cases of treating herpes zoster with acupuncture and laser 
therapy. Shaanxi Journal of Traditional Chinese Medicine, 2013. 03: p. 353-354. [In 
Chinese: 周彩霞, 张鹏, 针刺结合半导体激光治疗仪治疗带状疱疹 90 例. 陕西中
医, 2013. 03: p. 353-354.]. 
290. Lei, C., et al., 39 cases of treating herpes zoster with Lei huo moxibustion. Chinese 
Medicine Modern Distance Education of China, 2013. 13: p. 56-57. [In Chinese:  雷
成业, et al., 雷火灸治疗带状疱疹 39 例. 中国中医药现代远程教育, 2013,. 13: p. 
56-57.]. 
291. Zhang, Z. and S. Zhang, Acupuncture Combined with Stab Winding Cutem Cure the 
Herpes Zoster of Clinical Effect. Journal of Zhejiang University of Traditional 
Chinese Medicine, 2014. 12: p. 1425-1427. [In Chinese: 张争艳, 张申, 针灸联合刺
络拔罐治疗带状疱疹的临床疗效观察. 浙江中医药大学学报, 2014. 12: p. 1425-
1427.]. 
292. Zhang, X. and Y. Liu, The clinical observation of treating herpes zoster with 
acupuncture. Journal of Sichuan Traditional Chinese Medicine, 2014. 06: p. 149-150. 
[In Chinese: 张晓妮, 刘跃光, 针灸治疗带状疱疹的临床观察. 四川中医, 2014. 06: 
p. 149-150.]. 
293. Li, M., et al., Clinical Observation on Therapy of Acupuncture with Fine-strip 
Moxibustion on 62 Cases of Herpes Zoster. Journal of Emergency in Traditional 
Chinese Medicine, 2014. 01: p. 98-100. [In Chinese: 李梦, 苟春雁, 唐国良, 王毅刚, 
针刺加细灸条着肤灸治疗带状疱疹临床研究. 中国中医急症, 2014. 01: p. 98-
100.]. 
264 
 
294. Yang, G., 29 cases of treating acute herpes zoster with Hao zhen acupuncture 
technique and moxibustion. Chinese Medicine Modern Distance Education of China, 
2014. 20: p. 76-77. [In Chinese: 杨国辉, 毫针皮下扇形透刺配合艾灸治疗急性期带
状疱疹 29例. 中国中医药现代远程教育, 2014. 20: p. 76-77.]. 
295. Wen, P., Q. Zhan, and M. Chen, The clinical observation of treating herpes zoster 
with moxibustion on Zhi zhu points. Journal of Community Medicine, 2014. 21: p. 
41+46. [In Chinese: 温萍, 詹巧莲, 陈敏, 艾灸蜘蛛穴治疗带状疱疹的临床效果观
察. 社区医学杂志, 2014. 21: p. 41+46.]. 
296. Sun, P., Clinical observation of acupuncture and moxibustion in the treatment of 
herpes zoster. Chinese Community Doctors, 2015. 02: p. 84+86. [In Chinese: 孙鹏颖, 
针灸治疗带状疱疹的临床观察. 中国社区医师(医学专业), 2015. 02: p. 84+86.]. 
297. Chen, Q.M., B. Wu, and C.H. Jiang, Comparison of Pain Management of Vitamin B12 
and B1 in Treating Herpes Zoster. Journal of Modern Clinical Medicine, 2006. 32: p. 
195. 
298. Zhang, H. and G.F. Huang, Integrated Traditional Chinese and Western Medicine for 
Herpes Zoster : Progress in the Clinical Research. Journal of Clinical Rehabilitative 
Tissue Engineering Research, 2007. 11. 
299. Berman, B.M., et al., Acupuncture for chronic low back pain. The New England 
Journal of Medicine, 2010. 363(5): p. 454-461. 
300. Wu, J., H. Lv, and Y. Tang, Study on clinical application of surrounded needling. 
Journal of Clinical Acupuncture and Moxibustion, 2006. 22(10): p. 33-34. [In 
Chinese: 邬继红, 吕海波, 唐玉秀, 浅谈围刺法的临床应用. 针灸临床杂志, 2006. 
22(10): p. 33-34.]. 
301. Chen, D. and R. Fan, Clinical diagnosis and treatment for dermatovenereological 
diseases in Chinese medicine 2013, Beijing: People's Medical Publishing House. [In 
Chinese: 陈达灿, 范瑞强, 皮肤性病科专病中医临床诊治. 2013, 北京: 人民卫生出
版社.]. 
302. Coyle, M.E., et al., Acupuncture plus moxibustion for herpes zoster: A systematic 
review and meta-analysis of randomized controlled trials. Dermatol Ther, 2017. 
303. Lin, G. and B. Zhao, Acute Herpes Zoster by the Therapy of Surrounding Puncture 
Combined with Suspended Moxibustion. Journal of Clinical Acupuncture and 
Moxibustion, 2012. 28(6): p. 41-43. [In Chinese: 林广华, 赵斌斌, 围刺为主配合悬
灸治疗急性带状疱疹的疗效观察. 针灸临床杂志, 2012. 06: p. 41-43.]. 
304. Park, J.E., et al., Adverse events associated with acupuncture: a prospective survey. 
Journal of Alternative and Complementary Medicine, 2010. 16(9): p. 959-963. 
305. White, A., et al., Survey of adverse events following acupuncture (SAFA): a 
prospective study of 32,000 consultations. Acupuncture in Medicine, 2001. 19(2): p. 
84-92. 
306. Witt, C.M., et al., Treatment of the adverse effects from acupuncture and their 
economic impact: a prospective study in 73,406 patients with low back or neck pain. 
European Journal of Pain, 2011. 15(2): p. 193-197. 
307. Ahn, H.J., et al., The Effects of Famciclovir and Epidural Block in the Treatment of 
Herpes Zoster. The Journal of Dermatology, 2001. 28(4): p. 208-216. 
308. Lin, J.G. and W.L. Chen, Acupuncture analgesia: a review of its mechanisms of 
actions. The American Journal of Chinese Medicine, 2008. 36(4): p. 635-645. 
309. Sekido, R., K. Ishimaru, and M. Sakita, Differences of electroacupuncture-induced 
analgesic effect in normal and inflammatory conditions in rats. The American Journal 
of Chinese Medicine, 2003. 31(6): p. 955-965. 
265 
 
310. Du, J.Y., et al., Electroacupuncture attenuates mechanical allodynia by suppressing 
the spinal JNK1/2 pathway in a rat model of inflammatory pain. Brain Research 
Bulletin, 2014. 108: p. 27-36. 
311. Fang, J.Q., et al., Intervention of electroacupuncture on spinal p38 MAPK/ATF-2/VR-
1 pathway in treating inflammatory pain induced by CFA in rats. Molecular Pain, 
2013. 9: p. 13. 
312. Liang, Y., et al., Effect of Electroacupuncture on Activation of p38MAPK in Spinal 
Dorsal Horn in Rats with Complete Freund's Adjuvant-Induced Inflammatory Pain. 
Evidence-Based Complementary and Alternative Medicine, 2012. 2012: p. 568273. 
313. Shen, L.L., H.S. Wu, and X.Y. Wang, The efficacy of long-dan-xie-gan-tang in the 
treatment of herpes zoster: a clinical trial and animal experimental data. Journal of 
Tongji Medical University, 1986. 6(2): p. 109-111. 
314. Bensky, D., S. Clavey, and E. Stoger, Chinese herbal medicine Materia Medica. 3rd 
ed ed. 2004, Seattle: Eastland Press, Inc. 
315. Kakuda, R., et al., Secoiridoid glycosides from Gentiana scabra. Journal of Natural 
Products, 2001. 64(12): p. 1574-155. 
316. Yamada, H., et al., Gentiolactone, a secoiridoid dilactone from Gentiana triflora, 
inhibits TNF-alpha, iNOS and Cox-2 mRNA expression and blocks NF-kappaB 
promoter activity in murine macrophages. PLoS One, 2014. 9(11): p. e113834. 
317. Ozturk, N., et al., Effects of gentiopicroside, sweroside and swertiamarine, 
secoiridoids from gentian (Gentiana lutea ssp. symphyandra), on cultured chicken 
embryonic fibroblasts. Planta Medica, 2006. 72(4): p. 289-294. 
318. Baugh, J.A. and R. Bucala, Mechanisms for modulating TNF alpha in immune and 
inflammatory disease. Current Opinion in Drug Discovery & Development 2001. 
4(5): p. 635-650. 
319. Li, W., et al., Three new secoiridoid glycosides from the rhizomes and roots of 
Gentiana scabra and their anti-inflammatory activities. Natural Product Research, 
2015. 29(20): p. 1920-1927. 
320. Akdis, M., et al., Interleukins, from 1 to 37, and interferon-gamma: receptors, 
functions, and roles in diseases. Journal of Allergy and Clinical Immunology, 2011. 
127(3): p. 701-721.e1-70. 
321. Kobayashi, Y., The regulatory role of nitric oxide in proinflammatory cytokine 
expression during the induction and resolution of inflammation. Journal of Leukocyte 
Biology, 2010. 88(6): p. 1157-1162. 
322. Li, W., et al., Triterpenoids isolated from the rhizomes and roots of Gentiana scabra 
and their inhibition of indoleamine 2,3-dioxygenase. Archives of Pharmacal Research, 
2015. 38(12): p. 2124-2130. 
323. Mellor, A.L. and D.H. Munn, IDO expression by dendritic cells: tolerance and 
tryptophan catabolism. Nature Reviews Immunology, 2004. 4(10): p. 762-774. 
324. Koo, H.J., et al., Anti-inflammatory evaluation of gardenia extract, geniposide and 
genipin. Journal of Ethnopharmacology, 2006. 103(3): p. 496-500. 
325. Koo, H.J., et al., Antiinflammatory effects of genipin, an active principle of gardenia. 
European Journal of Pharmacology, 2004. 495(2-3): p. 201-208. 
326. Chang, W.L., et al., Immunosuppressive iridoids from the fruits of Gardenia 
jasminoides. Journal of Natural Products, 2005. 68(11): p. 1683-1685. 
327. Shi, Q., et al., Geniposide suppresses LPS-induced nitric oxide, PGE2 and 
inflammatory cytokine by downregulating NF-kappaB, MAPK and AP-1 signaling 
pathways in macrophages. International Immunopharmacology, 2014. 20(2): p. 298-
306. 
328. Suk, K., et al., Flavonoid baicalein attenuates activation-induced cell death of brain 
266 
 
microglia. Journal of Pharmacology and Experimental Therapeutics, 2003. 305(2): p. 
638-645. 
329. Yang, J., X. Yang, and M. Li, Baicalin, a natural compound, promotes regulatory T 
cell differentiation. BMC Complementary and Alternative Medicine, 2012. 12: p. 64. 
330. Lappas, C.M. and N.T. Lappas, D-Limonene modulates T lymphocyte activity and 
viability. Cellular Immunology, 2012. 279(1): p. 30-41. 
331. Yoon, W.J., N.H. Lee, and C.G. Hyun, Limonene suppresses lipopolysaccharide-
induced production of nitric oxide, prostaglandin E2, and pro-inflammatory cytokines 
in RAW 264.7 macrophages. Journal of Oleo Science, 2010. 59(8): p. 415-421. 
332. Schulz, S., et al., Perillic acid inhibits Ras/MAP kinase-driven IL-2 production in 
human T lymphocytes. Biochemical and Biophysical Research Communications, 
1997. 241(3): p. 720-725. 
333. Pearson, G., et al., Mitogen-activated protein (MAP) kinase pathways: regulation and 
physiological functions. Endocrine Reviews, 2001. 22(2): p. 153-183. 
334. Raphael, T.J. and G. Kuttan, Immunomodulatory activity of naturally occurring 
monoterpenes carvone, limonene, and perillic acid. Immunopharmacol 
Immunotoxicol, 2003. 25(2): p. 285-294. 
335. Huang, Y., et al., Immunoenhancement effect of rehmannia glutinosa polysaccharide 
on lymphocyte proliferation and dendritic cell. Carbohydrate Polymers, 2013. 96(2): 
p. 516-521. 
336. Baek, G.-H., et al., Rehmannia glutinosa Suppresses Inflammatory Responses Elicited 
by Advanced Glycation End Products. Inflammation, 2012. 35(4): p. 1232-1241. 
337. Chen, Y., et al., Assessment and comparison of immunoregulatory activity of four 
hydrosoluble fractions of Angelica sinensisin vitro on the peritoneal macrophages in 
ICR mice. International Immunopharmacology, 2010. 10(4): p. 422-430. 
338. Qin, T., et al., Selenylation modification can enhance immune-enhancing activity of 
Chinese angelica polysaccharide. Carbohydrate Polymers, 2013. 95(1): p. 183-187. 
339. Yang, T., et al., Immunomodulatory activity of polysaccharide isolated from Angelica 
sinensis. International Journal of Biological Macromolecules, 2006. 39(4-5): p. 179-
184. 
340. Yang, X., et al., Macrophage activation by an acidic polysaccharide isolated from 
Angelica sinensis (Oliv.) Diels. International Journal of Biochemistry and Molecular 
Biology, 2007. 40(5): p. 636-643. 
341. Fu, R.H., et al., Lipopolysaccharide-stimulated activation of murine DC2.4 cells is 
attenuated by n-butylidenephthalide through suppression of the NF-kappaB pathway. 
Biotechnology Letters, 2011. 33(5): p. 903-910. 
342. Su, Y.W., et al., Ligustilide prevents LPS-induced iNOS expression in RAW 264.7 
macrophages by preventing ROS production and down-regulating the MAPK, NF-
kappaB and AP-1 signaling pathways. International Immunopharmacology, 2011. 
11(9): p. 1166-1172. 
343. Kim, N.Y., et al., In vitro inducible nitric oxide synthesis inhibitors from Alismatis 
Rhizoma. Biological and Pharmaceutical Bulletin, 1999. 22(10): p. 1147-1149. 
344. Matsuda, H., et al., Effects of sesquiterpenes and triterpenes from the rhizome of 
Alisma orientale on nitric oxide production in lipopolysaccharide-activated 
macrophages: absolute stereostructures of alismaketones-B 23-acetate and -C 23-
acetate. Bioorganic & Medicinal Chemistry Letters, 1999. 9(21): p. 3081-3086. 
345. Chen, H.W., et al., Effect of alisol B acetate, a plant triterpene, on apoptosis in 
vascular smooth muscle cells and lymphocytes. European Journal of Pharmacology, 
2001. 419(2-3): p. 127-38. 
346. He, L.W., et al., Total synthesis and anti-viral activities of an extract of Radix isatidis. 
267 
 
Molecules, 2014. 19(12): p. 20906-20912. 
347. Yang, L., et al., Indole alkaloids from the roots of Isatis indigotica and their inhibitory 
effects on nitric oxide production. Fitoterapia, 2014. 95: p. 175-181. 
348. Shin, E.K., et al., The anti-inflammatory effects of a methanolic extract from Radix 
Isatidis in murine macrophages and mice. Inflammation, 2010. 33(2): p. 110-118. 
349. Xiao, P., et al., In vitro antioxidant and anti-inflammatory activities of Radix Isatidis 
extract and bioaccessibility of six bioactive compounds after simulated gastro-
intestinal digestion. Journal of Ethnopharmacology, 2014. 157: p. 55-61. 
350. Wang, L., et al., The Antinociceptive Properties of the Corydalis yanhusuo Extract. 
PLoS One, 2016. 11(9): p. e0162875. 
351. Zhang, Y., et al., A novel analgesic isolated from a traditional Chinese medicine. 
Current Biology, 2014. 24(2): p. 117-123. 
352. Liao, Z.G., et al., Correlation between synergistic action of Radix Angelica dahurica 
extracts on analgesic effects of Corydalis alkaloid and plasma concentration of dl-
THP. Journal of Ethnopharmacology, 2010. 129(1): p. 115-120. 
353. Ishiguro, K., et al., Dehydrocorydaline inhibits elevated mitochondrial membrane 
potential in lipopolysaccharide-stimulated macrophages. International 
Immunopharmacology, 2011. 11(9): p. 1362-1367. 
354. Oh, Y.C., et al., Tetrahydropalmatine inhibits pro-inflammatory mediators in 
lipopolysaccharide-stimulated THP-1 cells. Journal of Medicinal Food 2010. 13(5): p. 
1125-1132. 
355. Kim, T.S., et al., Induction of interleukin-12 production in mouse macrophages by 
berberine, a benzodioxoloquinolizine alkaloid, deviates CD4+ T cells from a Th2 to a 
Th1 response. Immunology, 2003. 109(3): p. 407-414. 
356. Chiang, L.C., et al., In vitro cytotoxic, antiviral and immunomodulatory effects of 
Plantago major and Plantago asiatica. The American Journal of Chinese Medicine, 
2003. 31(2): p. 225-234. 
357. Huang, D.F., et al., Immunomodulatory activity of the seeds of Plantago asiatica L. 
Journal of Ethnopharmacology, 2009. 124(3): p. 493-498. 
358. Yamada, H., et al., Plantagoside, a novel alpha-mannosidase inhibitor isolated from 
the seeds of Plantago asiatica, suppresses immune response. Biochemical and 
Biophysical Research Communications, 1989. 165(3): p. 1292-1298. 
359. Aikawa, Y., T. Yoshiike, and H. Ogawa, Effect of glycyrrhizin on pain and HLA-DR 
antigen expression on CD8-positive cells in peripheral blood of herpes zoster patients 
in comparison with other antiviral agents. Skin Pharmacology, 1990. 3(4): p. 268-
271. 
360. Steain, M., et al., Analysis of T cell responses during active varicella-zoster virus 
reactivation in human ganglia. Journal of Virology, 2014. 88(5): p. 2704-2716. 
361. Baba, M. and S. Shigeta, Antiviral activity of glycyrrhizin against varicella-zoster 
virus in vitro. Antiviral Res, 1987. 7(2): p. 99-107. 
362. Shebl, R.I., et al., Antiviral activity of liquorice powder extract against varicella 
zoster virus isolated from Egyptian patients. Chang Gung Medical Journal, 2012. 
35(3): p. 231-239. 
363. Oh, C., et al., Induction of T lymphocyte apoptosis by treatment with glycyrrhizin. The 
American Journal of Chinese Medicine, 1999. 27(2): p. 217-226. 
364. Akasaka, Y., et al., Suppressive effects of glycyrrhetinic acid derivatives on tachykinin 
receptor activation and hyperalgesia. Journal of Pharmacological Sciences, 2011. 
117(3): p. 180-188. 
365. Chan, A.W., et al., SPIRIT 2013 statement: defining standard protocol items for 
clinical trials. Annals of Internal Medicine, 2013. 158(3): p. 200-207. 
268 
 
366. Australian Government: Department of Health and Aging, T.G.A. The Australian 
Clinical Trial Handbook. 2006  [cited 2016 27th Dec ]; Available from: 
http://www.tga.gov.au/sites/default/files/clinical-trials-handbook.pdf. 
367. Arora, A., et al., Double-blind study comparing 2 dosages of valacyclovir 
hydrochloride for the treatment of uncomplicated herpes zoster in 
immunocompromised patients 18 years of age and older. The Journal of Infectious 
Diseases, 2008. 197(9): p. 1289-1295. 
368. Fleckenstein, J., et al., Acupuncture in acute herpes zoster pain therapy (ACUZoster) - 
design and protocol of a randomised controlled trial. BMC Complementary and 
Alternative Medicine, 2009. 9: p. 31. 
369. Izzo, A.A., et al., A Critical Approach to Evaluating Clinical Efficacy, Adverse Events 
and Drug Interactions of Herbal Remedies. Phytotherapy Research, 2016. 30(5): p. 
691-700. 
370. Cheung, T.P., et al., Aristolochic acids detected in some raw Chinese medicinal herbs 
and manufactured herbal products--a consequence of inappropriate nomenclature 
and imprecise labelling? Clin Toxicol (Phila), 2006. 44(4): p. 371-8. 
371. Zhang, L., et al., Pharmacovigilance practice and risk control of Traditional Chinese 
Medicine drugs in China: current status and future perspective. Journal of 
Ethnopharmacology, 2012. 140(3): p. 519-525. 
372. Shi, X., 60 cases of treating herpes zoster with Long dan xie gan tang. Journal of 
Practical Traditional Chinese Medicine, 2001(10): p. 18-19. [In Chinese: 施向红, 龙
胆泻肝汤治疗带状疱疹 60例.实用中医药杂志, 2001(10): p. 18-19.]. 
373. Zhou, H., Y. Shu, and H. Xu, The clinical efficacy of modified Long dan xie gan tang 
in treating herpes zoster Chinese Journal of Dermatovenerology of Integrated 
Traditional and Western Medicine, 2004(02): p. 99-100. [In Chinese: 周海啸, 舒友廉, 
许慧荣,龙胆泻肝汤加味治疗带状疱疹临床疗效分析.中国中西医结合皮肤性病学
杂志,2004(02): p. 99-100.]. 
374. Jiang, Y., 110 cases of treating herpes zoster with Long dan xie gan tang and Chuan 
xiong cha tiao san. Journal of Emergency in Traditional Chinese Medicine, 2010(08): 
p. 1431-1432. Hubei University of Chinese medicine. [In Chinese: 江应政,龙胆泻肝
汤合川芎茶调散治疗带状疱疹 110例.中国中医急症, 2010(08): p. 1431-1432.]. 
  
269 
 
Appendix 1: Search terms for Zhong Hua Yi Dian 
Pinyin Chinese 
Characters 
English Translation (direct 
translation) 
English Translation 
(translation from the 
meaning of Chinese 
characters) 
Bai she chan 
yao 
白蛇缠腰 A white snake encircling 
waist 
Snake (or belt) shape rashes 
encircling waist  
Chan yao 缠腰 Encircling waist Encircling waist 
Chan yao 
chuang 
缠腰疮 Rashes encircling waist Rashes encircling waist 
Chan yao dan 缠腰丹 Pellets encircling waist Rashes encircling waist 
Chan yao huo 
dan 
缠腰火丹 Fire pellets encircling waist Red rashes encircling waist 
Chan yao huo 
long 
缠腰火龙 Fire dragon encircling waist Red rashes encircling waist 
Chan yao long 缠腰龙 Dragon encircling waist Rashes encircling waist 
Chuan yao 
long 
串腰龙 Dragon encircling waist Rashes encircling waist 
Feng chi 
chuang qi 
风赤疮痍 Red rashes and wind Red rashes and wind 
Fu xing zhen 匍行疹 Rashes creeping forward Rashes extending 
Huo dai 
chuang 
火带疮 Fire rashes shape like a belt Belt shape red rashes 
Huo dan 火丹 Fire pellets Red rashes 
Huo dan 
chuang 
火丹疮 Fire pellets Red rashes 
Huo liao 
chuang 
火燎疮 Fire rashes Red rashes 
Huo yao dai 火腰带 Fire encircling waist Rashes encircling waist 
Huo yao dai 
du 
火腰带毒 Fire and toxin encircling 
waist 
Rashes encircling waist 
Pao zhen 疱疹 Blisters and papules Blisters and papules 
She chan 
chuang 
蛇缠疮 Rashes shape like a snake 
twining 
Snake (or belt) shape rashes 
twining 
She chan dan 蛇缠丹 Pellets shape like a snake 
twining 
Snake (or belt) shape rashes 
twining 
She chan hu 
dai 
蛇缠虎带 Snake and tiger stripe 
twining like a belt 
Snake (or belt) shape rashes 
twining 
She chuan 
chuang 
蛇串疮 Rashes shape like a snake or 
necklace 
Rashes shape like a snake 
She dan 蛇丹 Snake pellets Snake (or belt) shape rashes 
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Pinyin Chinese 
Characters 
English Translation (direct 
translation) 
English Translation 
(translation from the 
meaning of Chinese 
characters) 
She dan yu 
hou tong 
蛇丹愈后痛 Pain after snake pellets 
healed 
Pain after resolution of 
rashes 
She ke chuang 蛇窠疮 Rashes shape like a snake Rashes shape like a snake 
She pan 
chuang 
蛇盘疮 Rashes shape like a snake 
encircling 
Rashes shape like a snake 
She xing dan 1 蛇型丹 Rashes shape like a snake Rashes shape like a snake 
She xing dan 2 蛇形丹 Rashes shape like a snake Rashes shape like a snake 
Sheng she 生蛇 Onset of snake shape rashes Onset of snake shape rashes 
Zeng dai 
chuang 
甑带疮 Rashes like a belt  Rashes like a belt 
Zhi zhu 
chuang 
蜘蛛疮 Rashes like spiders Rashes like spiders 
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Appendix 2: Hits of search terms in Zhong Hua Yi Dian 
Pinyin Chinese 
Characters 
Title/Heading 
Hits 
Full Text Hits 
Bai she chan yao 白蛇缠腰 0 5 
Chan yao 缠腰 16 106 
Chan yao chuang 缠腰疮 0 2 
Chan yao dan 缠腰丹 0 12 
Chan yao huo dan 缠腰火丹 9 30 
Chan yao huo long 缠腰火龙 0 0 
Chan yao long 缠腰龙 2 0 
Chuan yao long 串腰龙 0 0 
Feng chi chuang qi 风赤疮痍 4 8 
Fu xing zhen 匍行疹 0 5 
Huo dai chuang 火带疮 1 15 
Huo dan 火丹 145 1047 
Huo dan chuang 火丹疮 2 13 
Huo liao chuang 火燎疮 0 1 
Huo yao dai 火腰带 0 2 
Huo yao dai du 火腰带毒 0 1 
Pao zhen 疱疹 0 34 
She chan chuang 蛇缠疮 3 14 
She chan dan 蛇缠丹 4 12 
She chan hu dai 蛇缠虎带 0 1 
She chuan chuang 蛇串疮 1 10 
She dan 蛇丹 4 29 
She dan yu hou tong 蛇丹愈后痛 0 0 
She ke chuang 蛇窠疮 3 10 
She pan chuang 蛇盘疮 0 1 
She xing dan 1 蛇型丹 0 0 
She xing dan 2 蛇形丹 0 0 
Sheng she 生蛇 5 71 
Zeng dai chuang 甑带疮 1 1 
Zhi zhu chuang 蜘蛛疮 8 25 
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Appendix 3: Possibly herpes zoster citations 
Citation 
Number 
Full Texts 
4 又有腰间红肿一道名缠腰丹亦名缠蛇疮 
缠腰丹遍身起泡如蛇缠有赤白缠  
182 雄黄（八两） 朱砂（一两） 蜗牛（二两） 冰片（一钱） 麝香（五分） 
共为细末，蟾酥为锭，银朱为衣。 
盖谓痈疽者皆因气血凝滞，阴阳相搏而成也，今诚修合此药，能治一切痈疽发背，无名肿毒，对口疔疮，诸般恶疮，疼痛
肿硬及一切蝎螫蛇咬，夏月毒虫蜈蚣咬伤，湿气疼痛，蛇带火丹等疼痛不止者，俱用凉水磨化，重者用陈醋磨化，涂搽患
处，立见奇效。  
197 其疱色白，或赤如火丹，疮头瘭浆白脓者轻，若紫色作根，隐隐在肌肉者甚重。 
218 （蟾酥锭 雄黄 240克 朱砂 30克 麝香 1.5克 冰片 3克 蜗牛 60克 共研细末，蟾酥为锭，银朱为衣。）盖谓痈疽者皆因气血
凝滞，阴阳相搏而成也，今诚修合此药，能治一切痈疽发背，无名肿毒，对口疔疮，诸般恶疮，疼痛肿硬及一切蝎螫蛇
咬，夏月毒虫蜈蚣咬伤，湿气疼痛，蛇带火丹等疼痛不止者，俱用凉水磨化，重者用陈醋磨化，涂搽患处，立见奇效。 
227 医宗金鉴治缠腰火丹加连翘，便秘加生大黄。 
232 （案 14）缠腰火丹已经泡溃，延漫未止，加之忍痛，气滞脉络不舒，清蕴兼理气。 
233 香白芷 西赤芍 淡黄芩 杜藿香 金银花 建连翘 左秦艽 六一散 土贝母 地丁草 
案 112）暑风入肺，始由腰间发泡，形如火丹，继则四肢遍满，痛痒并作，即丹毒之重候也。 
516 龙胆泻肝汤见腰部缠腰火 
517 龙胆泻肝汤见腰部缠腰火(丹) 
518 龙胆泻肝汤见腰部缠腰火(丹) 
519 龙胆泻肝汤见腰部缠腰火(丹) 
521 龙胆泻肝汤见腰部缠腰火(丹) 
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Number 
Full Texts 
522 柏叶散见腰部缠腰火(丹) 
530 火丹者，心火妄动，三焦风热乘之，故发于肌肤之表，有干湿不同，红白之异。 
化斑解毒汤 
化斑解毒汤石膏 玄参知母共连翘 
黄连升麻蒡子等 甘草人中黄更高 
治三焦风热上攻，致生火丹，延及遍身痒痛者。 
 
除湿胃苓汤 
除湿胃苓汤草朴 陈皮二术泽猪苓 
防风滑石山栀等 木通薄桂赤苓名 
治脾、肺二经湿热壅遏，致生火丹作烂疼痛者。 
 
柏叶散 
柏叶散中蚯蚓粪 赤豆大黄君莫混 
加上黄柏轻粉霜 水调敷上何须问 
治三焦火甚致生火丹，作痒或作痛，延及遍身。 
 
缠腰火丹，方用宝钞一张，烧化存性，研为细末，用米醋调稀，鸡翎蘸涂患上，一日三次即愈。 
 
如意金黄散见肿疡门 
 
治火丹不论新久痒痛，用新汲水调敷，靛汁亦好。 
578 {方歌}除湿胃苓火丹疮，脾肺湿热疱白黄，胃苓汤用通栀子，滑石防风共作汤。 
582 白鳝泥（敷火带疮。） 剪春罗（敷火带疮。 
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583 （《纲目》） 
{主治}火带疮，水洗取泥炒研，香油调敷（时珍）。 
585 带状匐行疹 汉名火带疮。其名火带疮。 
586 《多能鄙事》 
火带疮，绕腰生者。 
587 火带疮。 
591 （《理例》） 
窦汉卿曰：火腰带毒，乃心肝二经热毒，流滞于膀胱不行，壅于皮肤，此风毒也。（《全书》） 
薛立斋曰：火腰带生系带之处，初起如桃，渐渐红肿，宜用断毒截腰法敷之。 
592 甑带疮者，绕腰生。 
699 生腰下，长一二寸，或碎如饭，或红腰坚硬。以： 
雄黄 
研末，醋调敷，极效。  
701 此丹毒也。生腰下，长一二寸，或碎如粟、或红肿坚硬、有灯火向两头烧五次，并用雄黄外敷内服，极效。 
又方：陈石灰，麻油调敷即愈。 
又方：旧粪桶箍篾烧灰，麻油调敷，其效尤速。或照游风丹毒各方治之。  
710 抑诸处出齐匀朗红润，而腰间稠密灰滞作痛者，名缠腰，此毒滞千阴，不能成浆，九日危，迟则不过十一日也。 
711 治缠腰丹 急救方：用旧伞纸烧存性为末，香油调敷。 
720 蛇丹验方 治小儿大人缠腰丹，其色红赤，形如蛇有头有尾。 
729 痘科之流传久矣，自昔遵用鼻苗，由肺传肝及脾肾，相攻相伐，逆传命门，攻出先天伏毒，毒因逆攻而出，发无定处，设
遇蒙头、锁项、缠腰，以致变症丛生，调治不善，在在惊其险巇。 
731 又有腰间红肿一道，名缠腰丹，又名缠蛇疮（方见痈毒诸方门），又有鸡冠丹、茱萸丹两种。 
740 又有腰间红肿一圈，名缠腰，甚毒火甚更，是心包及内肾有毒热感风邪而成，其发甚速，顷刻伤生，无法救治也。 
744 若连珠环绕，名曰缠腰，此毒伏于肾也。缠 
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755 （《启玄》）白蛇缠腰，乃腰里起一红泡圈子，若不早治，被其缠到者不救。缠腰者如袴腰样也。 
756 腰胁生之，肝火妄动，又名缠腰丹，柴胡清肝汤主之。）缠腰丹腰生一红蕾，两边生红筋，缠至脐必死，（金墨磨浓和雄
黄末涂之。 
767 （目上下胞属脾、脾有风湿、则虫生弦烂、又新瓦炙为末、少加雄黄、麻油调敷、治蛇串疮、有人食乌梢蛇、浑身变黑、
渐生鳞甲、见者惊缩、郑奠一令日服晚蚕砂五钱、尽一二斗、久之乃退。 
771 一方柿油搽之，并搽蛇串疮。 
779 （遍身搔痒 身上无故一孔出血 半身不遂 两胁痛 腰疼 两腋狐臭 汗斑 黄肿嗜茶 自汗盗汗 雀斑酒刺白屑风皮等症 串蛇丹 点痣 
背心寒 治瘤 贴骨瘤极痛人身救急便方，诸汗 诸汗涂脐法 坐板疮） 
 
遍身搔痒 
苍耳子，煎水洗之。 
 
串蛇丹二方 
先于七寸处，灯火三灸。 
780 （《秘方摘要》） 
蜘蛛疮 （生颈上） 蛇丹疮（生腰上，多生于夏秋之间） 雄黄末调熟猪油，多敷疮上，以愈为度。 
792 又串蛇丹 先于七寸处灯火三灸，用苋菜根烧灰，存性，麻油调搽。 
795 治缠蛇丹 灶心土干研，青油调涂。 
801 治缠蛇丹，灶心土干研，清油调涂。 
807 蛇窠疮，生于身体脐腹之上下左右，本无定处，其形象宛如蛇也。治蛇窠疮，兼治蛇咬伤成疮，俱神。（蜈蚣十条，为
末，不可经火，白芷三钱，为末，白者佳，雄黄三钱，为末，生甘草末，三钱，香油二两，将三味（注：此处言三味，上
文只说以雄黄、白芷佐治，故恐无甘草也。原注说“三”应为“四”。）浸之三日，或随浸调搽，皆能建功也。） 
808 解蛇油 治蛇窠疮，生于皮毛作痛，并治诸恶疮。 
811 糯米粉合盐嚼涂之。或龙胆草研末，柿漆调搽。  
812 糯米粉和盐嚼涂之。  
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813 蛇缠丹毒 糯米粉和盐嚼涂之。 
814 杂甘草擂醋搽蛇缠丹毒。 
815 又 蛇缠丹毒，糯米粉合盐嚼涂，或龙胆草研末，柿漆调涂。 
816 治蛇缠丹妙方 旧破草席，人睡过有汗的更好，烧灰，香油调敷。 
817 治蛇缠丹，用旧破草席人睡过后有汗者，烧灰，香油调敷。 
818 蛇缠丹毒 
糯米粉合盐嚼涂之。 
819 王师禁土鬼丹及蛇缠丹 
霹雳 
一气念二十一遍，吹在病处，自立东南方上，令病人在西北，以大指掐中指本节文，以第二指掐大指中节，两手皆然，吹
时即放手，持咒四十九日，于五更初向北受持可用。 
820 治蛇缠丹、匝腰则死。 
822 王师禁土鬼丹及蛇缠丹 
霹雳 
一气念二十一遍，吹在病处，自立东南方上，令病人在西北，以大指掐中指本节文，以第二指掐大指中节，两手皆然，吹
时即放手，持咒四十九日，于五更初向北受持可用。 
823 治蛇缠丹、匝腰则死。 
824 治蛇缠丹，旧破草席人睡过有汗者，烧灰香油调敷。 
827 嘉庆癸亥，予寓西溪吴氏家，次子年十五，忽腹背患起红瘰，蔓延及腰如带，或云蛇缠疮，或云丹毒，乃风火所结，血凝
滞而成。 
828 蛇缠疮，用雄黄为末，醋调涂。 
830 蛇缠疮出危氏方） 
以雄黄为末。 
833 （案 109）蛇缠疮化势非定，红晕开大，势将腐烂。 
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836 白蛇缠疮，有头尾，俨似蛇形。 
840 治蛇缠疮 
上用雄黄研为末，以醋调涂，仍用酒调服。 
862 蜘蛛疮生于皮肤之上，如水窠仿佛，其色淡红，微痛，三三两两，或群攒聚，宛似蜘蛛，故以蜘蛛名之。 
解蛛丹 治蜘蛛疮。 
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Appendix 4: “Most likely” to be herpes zoster citations 
Citation 
Number 
Full Texts 
35 生腰肋间，累累如珠形，有干湿不同，红黄之异。干者色红赤，形如云片，上起风粟，作痒发热，属肝胆风热，宜服
龙胆泻肝汤。湿者色黄，或起白水泡，大小不等，作热，烂流水，较干者更疼，属肝脾湿热，宜服胃苓汤加山栀、防
风、石膏，其小泡用线针穿破。外俱用粪桶箱，炭火烧存性研末，香油调敷。或用蛇蜕（煅、）毛厕蹲板上泥，等
分，麻油调敷俱效。此证不速治，缠腰已遍，毒气入脐，令人膨胀闷呕者危险，须急治之。 
胃苓汤 
苍术 陈皮 泽泻 厚朴 猪苓 生甘草 
上水煎，温服。 
除湿逐丹汤治蛇串白泡。 
防风（五钱） 苍术（三钱） 赤苓（五钱） 陈皮（一钱） 厚朴（一钱） 山栀（三钱） 甘草（三分） 白术（三钱） 薄
桂（三钱） 
水煎服，连服数剂，丹退而愈。 
龙胆泻肝汤通用九。 
250 又 缠腰火丹，凡腰间起红泡一圈，若不早治，缠转者，不救。 
263 又，缠腰火丹，如带围住发红，用龙胆草研末，柿漆调敷。 
342 缠腰火丹者，即火带疮，由心肾不交，肝火内炽，流入膀胱，缠于带脉，故腰间生疮，累累如珠，如束带者然，急宜
服药以解之（宜仙方活命饮），壮实者下之（宜内疏黄连汤），外用清热解毒药敷之，不早治，毒由脐入，亦膨胀死
也。 
514 龙胆泻肝汤见腰部缠腰火丹 
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524 缠腰火丹蛇串名，干湿红黄似珠形，肝心脾肺风热湿，缠腰已遍不能生。 
缠腰火丹图 
龙胆泻肝汤 
龙胆草 连翘（去心） 生地 泽泻（各一钱） 车前子 木通 黄芩 黄连 当归 栀子（生研） 甘草（生，各五分） 生军（便
秘加之，二钱） 
水二盅，煎八分，食前服。 
{方歌}龙胆泻肝火丹生，形如云片粟多红，芩连栀胆车归尾，生地军翘泻木通。 
{方歌}除湿胃苓火丹疮，脾肺湿热疱白黄，胃苓汤用通栀子，滑石防风共作汤。 
{方歌}柏叶散搽火丹方，大黄赤豆柏雄黄，柏叶轻粉蚯蚓粪，研末香油调更良。 
527 缠腰火丹方 挑瞎蛇头上眼。 
531 于腰为肾俞发，为蛇串、缠腰火丹。为疮鼓，为天火丹毒，为瘴疽，为痛风，为痒风，为毒气攻心，为疮口误入毒
水，为诸疮生蝇蛆，为暑令疡毒小疖，为体气，为黑子痣。 
555 缠腰火丹蛇串名，红黄干湿各分形。 
556 柏叶散 见缠腰火丹。 
557 解毒泻心汤 松叶散 见缠腰火丹。 
579 即缠腰火丹。见该条。  
696 此疮生于腰间系带之处，初起红肿，痛如火烧而不可忍，约三日间破皮出水，但不成脓，乃急症也。治法内服中九丸
解毒，外用青黛敷于患处，以止其痛，看其所敷之物干了又换；至红肿消退而不作热时，再以麻凉膏敷之（加倍子末
一两于膏内），如恐其干燥，可滴入少许清油以调剂之，水干即愈。  
697 此症，绕腰生疮，累累如珠。由心肾不交，肝火内炽，流入膀胱，环于带脉，形如束带，俗呼蛇蛋疮。须急用化斑解
毒汤，迟则毒由脐入，膨胀不食。 
化斑解毒汤 
治三焦风热，致生火丹，遍身痒痛。兼治漆疮。元参 知母 石膏 人中黄 黄连 升麻 连翘 牛子（各一钱） 甘草（五分） 
淡竹叶（廿片 水煎服。 
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704 （《曹氏验方》） 
白蛇缠腰 腰起红泡一圈，若不早治，被其缠到，不救。 
722 若腰胁生之，乃肝火妄动，名曰缠腰丹，用柴胡清肝散，以慈婴散敷之。 
724 〔蛇窠疮〕 即缠腰火丹。千百缠腰如蛇形。 
725 又 缠腰火丹，凡腰间起红泡一圈，若不早治，缠转者，不救。 
727 缠腰疮 腰生红瘤，两边生红筋，围至脐即死。 
728 又，缠腰火丹，如带围住发红，用龙胆草研末，柿漆调敷。 
746 缠腰火丹 
俗名蛇串疮，有干湿不同，红黄之异，皆如累累珠形。若单生腰肋，系肝火妄动，宜服柴胡清肝汤（元），其丹上小
疱，用线针穿破，外用柏叶散（李）敷之，若不急治，缠腰已遍，毒气入脐，令人膨闷，毒气入心令人呕哕，急服清
心散、护心丸（为）救之。 
748 缠腰火丹 一名火带疮。 
则缠腰已遍。 
749 缠腰火丹蛇串名，干湿红黄似珠形，肝心脾肺风热湿，缠腰已遍不能生。若腰肋生之，系肝火妄动，宜用柴胡清肝汤
治之，其间小疱，用线针穿破，外用柏叶散敷之；若不速治，缠腰已遍，毒气入脐，令人膨胀、闷呕者逆。 
龙胆泻肝汤 
龙胆草 连翘（去心） 生地 泽泻（各一钱） 车前子 木通 黄芩 黄连 当归 栀子（生研） 甘草（生，各五分） 生军（便
秘加之，二钱） 
水二盅，煎八分，食前服。 
750 腰胁生之，肝火妄动，名曰缠腰丹，柴胡清肝汤。 
缠腰火丹，方用宝钞一张，烧化存性，研为细末，用米醋调稀，鸡翎蘸涂患上，一日三次即愈。 
752 缠腰火丹 
俗名蛇串疮，有干湿红黄之别。湿者色黄，串起水泡大小不等，溃流黄水，较前多疼，此属脾肺湿热，治宜除湿胃苓
汤（见五卷往字号）；若单缠腰肋系肝火妄动，宜服柴胡清肝汤（见五卷元字号）。 
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758 或问：绕腰生疮，累累如珠何如？曰：是名火带疮，亦名缠腰火丹。此证若不早治，缠腰已遍，则毒由脐入，膨胀不
食而死。 
764 缠腰火丹，方用宝钞一张，烧化存性，研为细末，用米醋调稀，鸡翎蘸涂患上，一日三次即愈。 
765 又，缠腰疮，腰生红瘤，两边生红筋，围至脐不救。 
766 即缠腰火丹。见该条。  
768 又新瓦炙，为末，少加雄黄，麻油调敷，治蛇串疮。 
769 又，缠腰火丹，如带围住发红，用龙胆草研末，柿漆调敷。 
770 俗名蛇串疮，有干、温不同，红、黄之异，如累累珠形；干者，色红形如云片上起风粟，作痒发热，此心肝二经风
火，治宜龙胆泻肝汤，外敷如意金黄散（见二十四卷）；湿者，色黄白，串起小泡，大小不等，溃流黄水，较干者多
疼，此脾肺二经湿热，治宜除湿胃苓汤。 
772 俗名蛇串疮。 
838 蛇缠疮亦往往生腰间，如蛇盘之状（宜醋调雄黄末涂之，仍酒调服）。 
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Appendix 5: Cluster analysis of likely erysipelas citations  
 
 
Figure appendix 5.1 Single linkage dendrogram: Jaccard coefficient 
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Figure appendix 5.2 Complete linkage dendrogram: Jaccard coefficient 
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Figure appendix 5.3 Average linkage (between groups) dendrogram: Jaccard coefficient 
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Figure appendix 5.4 Average linkage (within groups) dendrogram: Jaccard coefficient 
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Figure appendix 5.5 Single linkage dendrogram: Sneath and Sokal measurement 
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Figure appendix 5.6 Complete linkage dendrogram: Sneath and Sokal Measurement 
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Figure appendix 5.7 Average linkage (between groups) dendrogram: Sneath and Sokal 
measurement 
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Figure appendix 5.8 Average linkage (within groups) dendrogram: Sneath and Sokal 
measurement 
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Appendix 6: Search terms for Chinese language databases: 
Interventions:  
Chinese Herbal Medicine: 中医 OR 中西医 OR 中医疗法 OR 辨病论治 OR 辨证 OR 辨证
论治 OR 辨症施治 OR 汉方 OR 祖国医学 OR 传统医学 OR 传统治疗 OR 替代医学 OR 
替代治疗 OR 中国传统医学 OR 民族医药 OR 草药 OR 中草药 OR 中药 OR 中药疗法 
OR 中西药 OR 传统医药 OR 中成药 OR 植物药 OR 中医治法 OR 熏洗 OR 药浴 OR 沐
足 OR 足浴 OR 灌肠 OR 熨法 OR 药熨 OR 熨药 OR 热熨 OR 热敷 OR 敷脐 OR 药枕 
OR 药烘 
Acupuncture: 针刺 OR 灸 OR 针法 OR 刺法 OR 体针 OR 腹 OR 温针 OR 火针 OR 电针 
OR 电磁针 OR 梅花针 OR 水针 穴位注射 OR 经络注射 OR 穴位按压 OR 穴位按摩 OR 
指压穴位 耳压 OR 耳针 OR 耳穴 OR 耳豆 OR 埋藏疗法 OR 埋线 
Other Chinese Medicine Therapies: 外治 OR 推拿 OR 按摩 OR 拔罐 OR 药罐 OR 推罐 OR 
闪罐 OR 电罐 OR 火罐 OR 砭石 OR 砭术 OR 砭法 OR 刮痧 OR 刮搓 OR 挑治 OR 割治 
OR 发泡 OR 导引 OR 吐纳 OR 气功 OR 太极 OR 八段锦 OR 刺经 OR 刺血 OR 放血 OR 
三棱针 
Study designs: 系统评价 OR meta OR 荟萃分析 OR 系统分析 OR 综述 OR 进展 OR 概
况 OR 现状 OR 近况 OR 临床观察 OR 临床评估 OR 临床试验 OR 临床效果 OR 临床研
究 OR 疗效 OR 评价研究 OR 前瞻性 OR 随访 OR 对比研究 OR 多中心 OR 随机 OR 对
照 OR 病例报告 OR 病例研究 OR 病例分析 OR 病例报道 
Search Terms for English language databases: 
Interventions:  
Chinese Herbal Medicine: Traditional Chinese Medicine OR Chinese Traditional Medicine 
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OR Chinese Herbal Drugs OR Chinese Drugs, Plant OR Medicine, Traditional OR 
Ethnopharmacology OR Ethnomedicine OR Ethnobotany OR Medicine, Kampo OR Kanpo 
OR TCM OR T.C.M. OR Medicine, Ayurvedic OR Phytotherapy OR Herbology OR Plants, 
Medicinal OR Plant Preparations OR Plant Extracts OR Plants, Medicine OR Materia 
Medica OR Single Prescription OR Herbs OR Chinese Medicine Herb OR Herbal Medicine 
Acupuncture: Acupuncture OR Meridians OR Electroacupuncture OR Moxibustion OR 
Auriculotherapy OR plum blossom OR acupressure OR ear acupuncture OR ear acupressure 
OR acupuncture, ear OR acupuncture therapy OR moxa OR laser acupuncture OR seven star 
needle OR acupuncture analgesia OR acupuncture points OR electro-acupuncture OR electro 
acupuncture OR TENS OR transcutaneous nerve stimulation OR transcutaneous electric 
nerve stimulation OR transcutaneous electrical nerve stimulation OR electro-stimulation OR 
electro stimulation OR pharmacopuncture OR point injection OR catgut embedding 
Other Chinese Medicine Therapies: Tai Ji OR Tai chi OR Breathing exercises OR Qi gong OR 
Qigong OR Chi Kung OR Tuina OR anmo Tuina OR Chinese massage OR cupping OR 
guasha OR blood letting OR bloodletting OR diet therapy OR therapy, diet OR therapies, diet 
OR phlebotomy 
Study designs: 
Randomized Controlled Trial: randomized controlled trial OR controlled clinical trial OR 
randomized OR placebo OR drug therapy OR randomly OR trial OR groups 
Reviews articles: Systematic 
Other Studies: cohort studies OR case-control studies OR comparative study OR risk factors 
OR cohort OR compared OR groups OR case control OR multivariate OR case series 
 
292 
 
Appendix 7: Summary of ingredients Chinese herbal medicine used in included randomized controlled trials 
Formula Name (Pinyin or 
translation, Chinese) 
Herbs Ingredients (Pinyin, Chinese) Number of Studies 
Formulae for clearing heat and detoxifying (38 formulae) 
Long dan xie gan tang龙胆
泻肝汤 
Variant 1: Long dan cao 龙胆草, huang qin 黄芩, lian qiao 连翘, zhi zi 栀
子, jin yin hua 金银花, mian yin chen 绵茵陈, ze xie 泽泻, che qian zi 车前
子, ban lan gen 板蓝根, tong cao 通草, sheng di 生地, chai hu 柴胡, gan cao 
甘草 
25 studies [139, 144, 161, 163, 
166, 177, 178, 180, 182, 186, 
200, 201, 205, 210, 212, 216, 
218, 219, 223, 229, 231, 232, 
372-374] 
Variant 2: Ban lan gen 板蓝根, da qing ye 大青叶, zi cao 紫草, ze xie 泽泻, 
yan hu suo 延胡索, jin yin hua 金银花, ju hua 菊花, ling xiao hua 凌霄花, 
yi yi ren 薏苡仁, chi shao 赤芍  
Variant 3: Long dan cao 龙胆草, chai hu 柴胡, mu tong 木通, zhi zi 栀子, 
ban lan gen 板蓝根, ze xie 泽泻, fu ling 茯苓, huang qin 黄芩, sheng di 生
地, gan cao 甘草 
Variant 4: Long dan cao 龙胆草, huang qin 黄芩, zhi zi 栀子, ze xie 泽泻, 
mu tong 木通, che qian zi 车前子, dang gui 当归, sheng di 生地, chai hu 柴
胡, gan cao 甘草 
Variant 5: Long dan cao 龙胆草, huang qin 黄芩, sheng di 生地, ze xie 泽
泻, mu dan pi 牡丹皮, chi shao 赤芍, che qian zi 车前子, dang gui 当归, zhi 
zi 栀子, zi cao 紫草, ban lan gen 板蓝根, gan cao 甘草 
Variant 6: Long dan cao 龙胆草, huang qin 黄芩, mu tong 木通, zhi zi 栀子, 
dang gui 当归, chuan lian zi 川楝子, chai hu 柴胡, ze xie 泽泻, mo yao 没
药, ru xiang 乳香, sheng di 生地, che qian zi 车前子, yan hu suo 延胡索, 
zhi ke 枳壳 
Variant 7: Long dan cao 龙胆草, chai hu 柴胡, zhi zi 栀子, ze xie 泽泻, ku 
shen 苦参, da qing ye 大青叶, huang qin 黄芩, dang gui 当归 
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Variant 8: Long dan cao 龙胆草, zhi zi 栀子, huang qin 黄芩, chai hu 柴胡, 
che qian cao 车前草, ze xie 泽泻, mu tong 木通, sheng di 生地, dang gui 当
归, chuan xiong 川芎, jing jie 荆芥, fang feng 防风, qiang huo 羌活, bai zhi 
白芷, xi xin 细辛, bo he 薄荷, gan cao 甘草 
Variant 9: Long dan cao 龙胆草, ze xie 泽泻, che qian zi 车前子, dang gui 
当归, zhi zi 栀子, huang qin 黄芩, chai hu 柴胡, sheng di 生地, tong cao 通
草, gan cao 甘草 
Variant 10: Long dan cao 龙胆草, mu tong 木通, huang qin 黄芩, sheng di 
生地, dang gui 当归, zhi zi 栀子, chai hu 柴胡, chuan lian zi 川楝子, che 
qian zi 车前子, ze xie 泽泻, zhi ke 枳壳, yan hu suo 延胡索, ru xiang 乳香, 
mo yao 没药 
Variant 11: Long dan cao龙胆草, huang qin 黄芩, zhi zi 栀子, ze xie 泽泻, 
mu tong 木通, che qian zi 车前子, dang gui 当归, sheng di 生地, chai hu 柴
胡, gan cao 甘草 
Variant 12: Long dan cao 龙胆草, huang qin 黄芩, zhi zi 栀子, ze xie 泽泻, 
mu tong 木通, dang gui 当归, sheng di 生地, chai hu 柴胡, huang lian 黄连, 
huang qi 黄芪, gan cao 甘草 
Variant 13: Long dan cao 龙胆草, chai hu 柴胡, ze xie 泽泻, che qian zi 车
前子, mu tong 木通, sheng di 生地, dang gui 当归, zhi zi 栀子, huang qin 
黄芩, gan cao 甘草, ban lan gen 板蓝根, guan zhong 贯众, zi cao 紫草, fu 
ling 茯苓, bai zhu白术 
Variant 14: Long dan cao 龙胆草, huang qin 黄芩, zhi zi 栀子, ze xie 泽泻, 
dang gui 当归, chai hu 柴胡, gan cao 甘草, che qian zi 车前子 
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Variant 15: Long dan cao 龙胆草, lian qiao 连翘, sheng di 生地, ze xie 泽
泻, che qian zi 车前子, huang qin 黄芩, zhi zi 栀子, mu dan pi 牡丹皮, zao 
xiu 蚤休, ban lan gen 板蓝根, da qing ye 大青叶, tian hua fen 天花粉, gan 
cao 甘草 
Variant 16: Long dan cao 龙胆草, zhi zi 栀子, huang qin 黄芩, ban lan gen 
板蓝根, da qing ye 大青叶, che qian zi 车前子, sheng di 生地, chuan lian zi 
川楝子, dang gui 当归, chai hu 柴胡, mu dan pi 牡丹皮, ye ju hua 野菊花, 
yan hu suo 延胡索, gan cao 甘草 
Variant 17: Long dan cao 龙胆草, zhi zi 栀子, huang qin 黄芩, chai hu 柴胡, 
dang gui 当归, sheng di 生地, ze xie 泽泻, che qian cao 车前草, mu tong 木
通, gan cao 甘草, ban lan gen 板蓝根, fu ling 茯苓, cang zhu 苍术 
Variant 18: Long dan cao 龙胆草, che qian zi 车前子, sheng di 生地, ze xie 
泽泻, huang qin 黄芩, zhi zi 栀子, chai hu 柴胡, dang gui 当归, mu tong 木
通, gan cao 甘草,  
Variant 19: Long dan cao 龙胆草, huang qin 黄芩, zhi zi 栀子, mu dan pi 牡
丹皮, mu tong 木通, gan cao 甘草, lian qiao 连翘, sheng di 生地, ze xie 泽
泻, che qian zi 车前子, dan shen 丹参, dang gui 当归, chi shao 赤芍, ru 
xiang 乳香, mo yao 没药 
Variant 20: Chai hu 柴胡, bai shao 白芍, chi shao 赤芍, zhi zi 栀子, huang 
qin 黄芩, sheng di 生地, che qian zi 车前子, ze xie 泽泻, chuan xiong 川芎, 
dang gui 当归, chen pi 陈皮, zhi ke 枳壳, fu ling 茯苓, xiang fu 香附, yu jin 
郁金, yan hu suo 延胡索, gan cao 甘草 
Variant 21: Long dan cao 龙胆草, zhi zi 栀子, huang qin 黄芩, chai hu 柴胡, 
ze xie 泽泻, sheng di 生地, ban lan gen 板蓝根, da qing ye 大青叶, mian 
yin chen 绵茵陈, yu jin 郁金, che qian zi 车前子, gan cao 甘草 
Variant 22: NS 
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Huang lian jie du tang 
combined with long dan xie 
gan tang 黄连解毒汤合龙胆
泻肝汤 
Long dan cao 龙胆草, huang lian 黄连, huang qin 黄芩, huang bo 黄柏, zhi 
zi 栀子, che qian zi 车前子, ze xie 泽泻, sheng di 生地, dang gui 当归, chai 
hu 柴胡 
1 study [169] 
Yin guan he ji 银贯合剂 Jin yin hua 金银花, lian qiao 连翘, guan zhong 贯众, chi shao 赤芍, long 
dan cao 龙胆草, huang qin 黄芩, jiang can 僵蚕 
1 study [225] 
Tui re jie du ling ke li 
(granule) 退热解毒灵颗粒 
NS 1 study [190] 
Ku shen jie du tang 苦参解
毒汤 
Ku shen 苦参, jin yin hua 金银花, lian qiao 连翘, da qing ye 大青叶, bai 
xian pi 白鲜皮, huang qin 黄芩, huang lian 黄连, huang bo 黄柏, long dan 
cao 龙胆草, mu dan pi 牡丹皮, sheng di 生地, chi shao 赤芍, zi cao 紫草, 
fang feng 防风, gan cao 甘草 
1 study [167] 
Dan cao jie du tang胆草解
毒汤 
Long dan cao 龙胆草, huang qin 黄芩, sheng di 生地, mu dan pi 牡丹皮, 
lian qiao 连翘, ban lan gen 板蓝根, ze xie 泽泻, tu fu ling 土茯苓, quan xie 
全蝎, gan cao 甘草 
1 study [203] 
Zi cao xiao zhen tang紫草消
疹汤 
Zi cao 紫草, chai hu 柴胡, long dan cao 龙胆草, ban lan gen 板蓝根, huang 
qin 黄芩, chi shao 赤芍, dan shen 丹参, yan hu suo 延胡索, che qian zi 车
前子, zao xiu 蚤休, si gua luo 丝瓜络 
1 study [224] 
Bai xuan xia ta re pian 
(tablet) 百癣夏塔热片 
NS 1 study [192] 
Shu feng jie du jiao nang 
(capsule) 疏风解毒胶囊 
NS 1 study [154] 
Huo dan fen (powder) 火丹
粉 
Da huang 大黄, huang bo 黄柏, qing dai 青黛, hua shi 滑石, gan cao 甘草, 
bing pian 冰片 
1 study [222] 
Qing jie hua yu zu fang 清解
化瘀组方 
Ku shen 苦参, jing jie 荆芥, she chuang zi 蛇床子, long dan cao 龙胆草, zhi 
zi 栀子, chi shao 赤芍, dang gui 当归, wu gong 蜈蚣, ji li 蒺藜, sheng di 生
地, ban lan gen 板蓝根  
1 study [209] 
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Qing kai ling fen san pian 
(tablet) 清开灵分散片 
NS 1 study [170] 
Xiao zhen zhi tong tang消疹
止痛汤 
Chai hu 柴胡, jin yin hua 金银花, ban lan gen 板蓝根, long dan cao 龙胆草, 
huang qin 黄芩, zhi zi 栀子, zi cao 紫草, mu dan pi 牡丹皮, yi yi ren 薏苡
仁, che qian zi 车前子, yan hu suo 延胡索, chuan xiong 川芎, bai zhi 白芷, 
xi xin 细辛, gan cao 甘草 
1 study [220] 
Chai hu gong xie tang柴虎
蚣蝎汤 
Chai hu 柴胡, shan ci gu 山慈菇, ban lan gen 板蓝根, hu zhang 虎杖, fu 
ling 土茯苓, ling xiao hua 凌霄花, chi shao 赤芍, dang gui 当归, bai shao 
白芍, lu feng fang 露蜂房, wu gong 蜈蚣, quan xie 全蝎 
1 study [207] 
Xin huang pian (tablet) 新癀
片 
Variant 1: NS 2 studies [146, 188] 
Variant 2: Jiu jie cha 九节茶, tian qi 田七, niu huang 牛黄, shui niu jiao 水
牛角, zhen zhu ceng fen 珍珠层粉 
Dai pao jie du tang带疱解毒
汤 
Jin yin hua 金银花, lian qiao 连翘, niu bang zi 牛蒡子, huang qin 黄芩, fu 
ling 茯苓, ze xie 泽泻, che qian zi 车前子, sheng di 生地, dan shen 丹参, 
gua lou 瓜蒌, hong hua 红花, gan cao 甘草 
1 study [185] 
Ru yi zhen bao wan (pill) 如
意珍宝丸 
Zhen zhu 珍珠, niu huang 牛黄, shui niu jiao 水牛角, jin meng shi 金礞石, 
he zi 诃子, jue ming zi 决明子, pang xie 螃蟹, hong hua 红花, cao guo 草
果, tian zhu huang 天竺黄, mu xiang 木香, chen xiang 沉香 
1 study [215] 
Li shi jie du tang利湿解毒
汤 
Jin yin hua 金银花, ban lan gen 板蓝根, tu fu ling 土茯苓, sheng di 生地, 
hua shi 滑石, huang bo 黄柏, chen pi 陈皮, zhi ke 枳壳, zi cao 紫草, bai hua 
she she cao 白花蛇舌草, chi shao 赤芍, gan cao 甘草 
1 study [231] 
Chuang yu ye (topical 
solution) 创愈液 
Hu zhang 虎杖, di yu 地榆, ren dong teng 忍冬藤, bai ji 白及, da huang 大
黄, bing pian 冰片 
1 study [181] 
Yuan tong he ji (oral 
solution) 元痛合剂 
Long dan cao 龙胆草, chai hu 柴胡, huang qin 黄芩, zhi zi 栀子, ze xie 泽
泻, che qian zi 车前子, mu tong 木通, ban lan gen 板蓝根, yan hu suo 延胡
索, dang gui 当归, sheng di 生地 
1 study [211] 
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Fu qing zhu huo dan shen 
fang傅青主火丹神方 
Si gua zi 丝瓜子, xuan shen 玄参, dang gui 当归, sheng ma 升麻, chai hu 柴
胡 
1 study [145] 
Wu wei xiao du yin 五味消
毒饮 
Variant 1:Jin yin hua 金银花, lian qiao 连翘, niu bang zi 牛蒡子, dan zhu ye 
淡竹叶, chan tui 蝉蜕, shan dou gen 山豆根, jiang can 僵蚕, xue jie 血竭, 
pu gong ying 蒲公英, zi hua di ding 紫花地丁, ku shen 苦参, huang qi 黄
芪, gan cao 甘草, fu ling 茯苓, wu gong 蜈蚣 
2 studies [165, 193] 
Variant 2: NS 
San huang fen (powder) 三黄
粉 
Da huang 大黄, huang bo 黄柏, huang lian 黄连, ru xiang 乳香, mo yao 没
药 
1 study [182] 
San huang san (powder) 三黄
散 
Da huang 大黄, huang lian 黄连, huang bo 黄柏, fu pen ye 覆盆叶 1 study [173] 
Qing dan hu (cataplasm) 清
丹糊 
Huang bo 黄柏, huang lian 黄连, qing dai 青黛, cang shu 苍术, bing pian 冰
片 
1 study [205] 
She xian tang蛇苋汤 Nan she le 南蛇簕, ma chi xian 马齿苋 1 study [158] 
Ji de sheng she yao pian 
(tablet)季德胜蛇药片 
NS 1 study [165] 
Self-designed formula 1  Ku shen 苦参, long dan cao 龙胆草, huang qin 黄芩, zhi zi 栀子, jie xue 
teng 鸡血藤, ren dong teng 忍冬藤, zi cao 紫草, yan hu suo 延胡索, chai hu 
柴胡, mu tong 木通, bing pian 冰片 
1 study [168] 
Self-designed formula 2 Chai hu 柴胡, huang qin 黄芩, che qian zi 车前子, ze xie 泽泻, mu tong 木
通, zhi zi 栀子, long dan cao 龙胆草, di long 地龙, yan hu suo 延胡索, 
sheng di 生地, dang gui 当归, pu gong ying 蒲公英, zi hua di ding 紫花地
丁, tu fu ling 土茯苓, zi cao 紫草, bai xian pi 白鲜皮, da qing ye 大青叶, 
ban lan gen 板蓝根, gan cao 甘草 
1 study [187] 
Self-designed formula 3 Da huang 大黄, huang bo 黄柏, huang lian 黄连, ma chi xian 马齿苋 1 study [174] 
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Self-designed formula 4 Chai hu 柴胡, long dan cao 龙胆草, chuan lian zi 川楝子, bai zhi 白芷, 
huang qin 黄芩, ban lan gen 板蓝根, xi xin 细辛, xia gu cao 夏枯草, xuan 
shen 玄参, pu gong ying 蒲公英, mu dan pi 牡丹皮, quan xie 全蝎, bai hua 
she she cao 白花蛇舌草, gan cao 甘草, bai xian pi 白鲜皮, dang gui 当归, 
chi shao 赤芍, chuan xiong 川芎 
1 study [191] 
Self-designed formula 5 Long dan cao 龙胆草, huang qin 黄芩, zhi zi 栀子, che qian zi 车前子, dang 
gui 当归, sheng di 生地, ban lan gen 板蓝根, tian hua fen 天花粉, hu zhang 
虎杖, yan hu suo 延胡索, gan cao 甘草 
1 study [222] 
Self-designed formula 6 Bai jiang cao 败酱草, ma chi xian 马齿苋, ban lan gen 板蓝根, zi cao 紫草, 
jin yin hua 金银花, lian qiao 连翘, huang qin 黄芩, zhi zi 栀子, yan hu suo 
延胡索, chuan lian zi 川楝子, sheng di 生地, dang gui 当归, chi shao 赤芍, 
da huang 大黄 
1 study [143] 
Self-designed formula 7 Da huang 大黄, huang bo 黄柏, huang lian 黄连, qing dai 青黛, wu bei zi 五
倍子, mang xiao 芒硝, ru xiang 乳香, mo yao 没药, bing pian 冰片 
1 study [151] 
Self-designed formula 8 Jin yin hua 金银花, pu gong ying 蒲公英, zi hua di ding 紫花地丁, yi yi ren 
薏苡仁, ban lan gen 板蓝根, xiang fu 香附, hong hua 红花, huang lian 黄
连, huang bo 黄柏, huang qin 黄芩, lian qiao 连翘 
1 study [199] 
Self-designed formula 9 Huang lian 黄连, huang qin 黄芩, ren zhong huang 人中黄, jin yin hua 金银
花, lian qiao 连翘, zi cao 紫草, da qing ye 大青叶, mu dan pi 牡丹皮, yan 
hu suo 延胡索 
1 study [142] 
Self-designed formula 10 Ban lan gen 板蓝根 1 study [162] 
Formulae for clearing heat, detoxifying and resolving dampness (2 formulae) 
Modified Yi yi zhu ye san薏
苡竹叶散加味 
Yi yi ren 薏苡仁, dan zhu ye 淡竹叶, hua shi 滑石, bai kou ren 白蔻仁, fu 
ling 茯苓, lian qiao 连翘, tong cao 通草 
1 study [233] 
Yi ren chi dou tang薏仁赤豆
汤 
Yi yi ren 薏苡仁, chi xiao dou 赤小豆, che qian zi 车前子, cang shu 苍术, 
chen pi 陈皮, bai zhu 白术 
1 study [216] 
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Formulae for clearing heat, detoxifying and activating Blood and dispelling stasis (4 formulae) 
Jie du huo xue tang解毒活
血汤 
Long dan cao 龙胆草, chi shao 赤芍, huang qin 黄芩, da qing ye 大青叶, 
bai shao 白芍, chai hu 柴胡, gan cao 甘草, zhi zi 栀子, huang bo 黄柏, ku 
shen 苦参, sheng di 生地, dang gui 当归, chuan xiong 川芎, chuan lian zi 川
楝子, ban lan gen 板蓝根, fu ling 茯苓 
1 study [146] 
Pao zhen ke li ji (granule) 疱
疹颗粒剂 
Chai hu 柴胡, long dan cao 龙胆草, yan hu suo 延胡索, chuan lian zi 川楝
子, yu jin 郁金, ban lan gen 板蓝根, jiang huang 姜黄, jin yin hua 金银花, 
quan xie 全蝎, di long 地龙, wu gong 蜈蚣, gan cao 甘草 
1 study [202] 
Du yu bing jie fang毒瘀并
解方 
Huang qin 黄芩, zhi zi 栀子, er zhu 莪术, yan hu suo 延胡索, zhu ling猪苓 1 study [153] 
Self-designed formula 11 Jin yin hua 金银花, lian qiao 连翘, ye ju hua 野菊花, dan shen 丹参, hong 
hua 红花, mo yao 没药, ru xiang 乳香, yan hu suo 延胡索, ren dong teng 忍
冬藤, chi shao 赤芍, chai hu 柴胡, yu jin 郁金, shui zhi 水蛭, gan cao 甘草 
1 study [156] 
Formulae for resolving dampness (3 formulae) 
San ren tang 三仁汤 Yi yi ren 薏苡仁, bai kou ren 白蔻仁, xing ren 杏仁, dan zhu ye 淡竹叶, 
hua shi滑石, tong cao 通草, hou po 厚朴, fu ling 茯苓, pu gong ying 蒲公
英, lian qiao 连翘 
1 study [164] 
Chu shi wei ling tang除湿胃
苓汤 
Variant 1: Cang shu 苍术, hou po 厚朴, chen pi 陈皮, zhu ling 猪苓, ze xie 
泽泻, fu ling 茯苓, bai zhu 白术, hua shi 滑石, fang feng 防风, zhi zi 栀子, 
mu tong 木通, rou gui 肉桂, gan cao 甘草 
4 studies [139, 161, 201, 218] 
Variant 2: Bai zhu 白术, cang shu 苍术, hou po 厚朴, chen pi 陈皮, yan hu 
suo 延胡索, fu ling 茯苓, che qian zi 车前子, ze xie 泽泻, ban lan gen 板蓝
根, yi yi ren 薏苡仁, gan cao 甘草 
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Variant 3: Cang shu 苍术, chen pi 陈皮, hou po 厚朴, zhu ling 猪苓, ze xie 
泽泻, bai zhu 白术, hua shi 滑石, yi yi ren 薏苡仁, ban lan gen 板蓝根, da 
qing ye 大青叶, yan hu suo 延胡索, lian qiao 连翘, zi cao 紫草, gan cao 甘
草 
Variant 4: NS 
Shen ling bai zhu san参苓白
术散 
NS 1 study [175] 
Formulae for activating Blood and dispelling stasis (16 formulae and 1 single herb) 
Qing jie hua yu zu fang 清解
化瘀组方 
Ku shen 苦参, jing jie 荆芥, she chuang zi 蛇床子, long dan cao 龙胆草, zhi 
zi 栀子, chi shao 赤芍, dang gui 当归, wu gong蜈蚣, ji li蒺藜, sheng di 生
地, ban lan gen 板蓝根,  
1 study [150] 
Du yi wei jiao nang (capsule) 
独一味胶囊 
NS 1 study [160] 
Zhi tong tang止痛汤 Huang qi黄芪, dan shen 丹参, bai shao 白芍, chuan shan jia 穿山甲, bai zhi 
白芷, ge gen 葛根, gan cao 甘草 
1 study [230] 
Long xie jie chang rong pian 
(tablet) 龙血竭肠溶片 
NS 1 study [184] 
Huo xue hua yu tang活血化
瘀汤 
NS 1 study [175] 
Tong luo liang xue jie du 
tang通络凉血解毒汤 
Sheng di 生地, dang gui 当归, chuan xiong 川芎, mu dan pi 牡丹皮, chi 
shao 赤芍, tian qi 田七, dan shen 丹参, yu jin郁金 
1 study [206] 
Xing qi qu yu tang (self-
designed formula) 行气祛瘀
汤 
Huang qi 黄芪, yan hu suo 延胡索, chuan lian zi 川楝子, chai hu 柴胡, 
dang gui 当归, chi shao 赤芍, ru xiang 乳香, mo yao 没药, mu dan pi 牡丹
皮, ban lan gen 板蓝根, qing dai青黛, zi cao 紫草 
1 study [227] 
Long xue jie jiao nang 
(capsule)龙血竭胶囊 
NS 1 study [159] 
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Xie cao qing yu tang缬草清
郁汤 
Xie cao 缬草, hong teng 红藤, luo shi teng 络石藤, ren dong teng 忍冬藤, li 
zhi he 荔枝核, sheng di 生地, chuan xiong 川芎, ze xie 泽泻, mu dan pi 牡
丹皮, zhi ke 枳壳, yan hu suo 延胡索, fu shen 茯神, huang qi 黄芪 
1 study [179] 
Shang ke jie gu pian (tablet) 
伤科接骨片 
NS 1 study [196] 
Shang ke ling pen wu ji 
(spray) 伤科灵喷雾剂 
NS 1 study [198] 
Tao hong si wu tang桃红四
物汤 
Variant 1: Shu di 熟地, dang gui 当归, bai shao 白芍, chuan xiong 川芎, tao 
ren 桃仁, hong hua 红花 
2 studies [161, 218] 
Variant 2: Tao ren 桃仁, hong hua 红花, dang gui 当归, chuan xiong 川芎, 
chi shao 赤芍, zhi ke 枳壳, zi cao 紫草, ban lan gen 板蓝根, dan shen 丹参, 
ru xiang 乳香, mo yao 没药, mu dan pi 牡丹皮, xuan shen 玄参, gan cao 甘
草 
Huo xue san yu tang 活血散
瘀汤 
Tao ren 桃仁, hong hua 红花, ji xue teng 鸡血藤, yan hu suo 延胡索, xiang 
fu 香附, chen pi 陈皮, chai hu 柴胡, yu jin 郁金, sheng di 生地, bai shao 白
芍, mu dan pi 牡丹皮, gan cao 甘草 
1 study [231] 
Shi run shao shang gao 
(ointment) 湿润烧伤膏 
NS 1 study [229] 
Yun nan bai yao (powder) 云
南白药 
NS 1 study [220] 
Single herb Xi nan wen shu lan 西南文殊兰 1 study [159] 
Formulae for cooling Blood and detoxifying (1 formula) 
Self-designed formula 11 Di yu 地榆, bing pian 冰片 1 study [171] 
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Formulae for treating abscess, ulcer and detoxifying (11 formulae) 
Ba du gao (ointment) 拔毒膏 Xiong huang 雄黄, ming fan明矾, bing pian 冰片 1 study [157] 
Qing zhen zhi tong gao 
(ointment) 清疹止痛膏 
Xiong huang 雄黄, bai fan 白矾, ru xiang 乳香, mo yao 没药, bing pian 冰
片 
1 study [172] 
San fen ca ji (liniment) 三粉
擦剂 
Xiong huang 雄黄, ming fan 明矾, hu po 琥珀 1 study [194] 
Liu shen wan (pill) 六神丸 Niu huang 牛黄, zhen zhu珍珠, xiong huang 雄黄, chan su 蟾酥, she xiang 
麝香, bing pian 冰片 
1 study [226] 
Ba du tu mo ji (film coating 
agent) 拔毒涂膜剂 
Xiong huang 雄黄, bai fan白矾 1 study [213] 
Ba du san (powder) 拔毒散 Xiong huang 雄黄, bai fan白矾 1 study [213] 
Pao zhen san (powder) 疱疹
散 
Xiong huang 雄黄, bing pian 冰片, qing dai 青黛, shi gao 石膏, bai zhi 白
芷, guan zhong 贯众, ma chi xian 马齿苋, gan cao 甘草 
1 study [230] 
Lu huang san (powder) 芦黄
散 
Xiong huang 雄黄, wu gong 蜈蚣, bai zhi 白芷, bing pian 冰片, lu hui 芦荟 
1 study [146] 
Pao zhen gao (ointment) 疱
疹膏 
Da huang 大黄, huang bo 黄柏, bai zhi 白芷, xiong huang 雄黄, dan nan 
xing 胆南星, zhang nao 樟脑, bing pian 冰片 
1 study [222] 
Liu shen wan (pill) 六神丸 NS 1 study [229] 
Zi jin ding (pill) 紫金锭 Zi jin ding 紫金锭, qing dai 青黛  1 study [204] 
Formulae for clearing heat, activating Blood and regulating qi (5 formulae) 
Modified Xiao chai hu tang
加味小柴胡汤/小柴胡汤化
裁 
Variant 1: Chai hu 柴胡, huang qin 黄芩, zhi zi 栀子, fa ban xia 法半夏, jin 
yin hua 金银花, zi hua di ding紫花地丁, chuan xiong 川芎, bai shao 白芍, 
chen pi 陈皮, yan hu suo 延胡索, gan cao 甘草 
3 studies [197, 208, 221] 
Variant 2: Chai hu 柴胡, ban xia 半夏, gan cao 甘草, huang qin 黄芩, zhi zi 
栀子, lian qiao 连翘, fang feng 防风, jing jie 荆芥, chuan xiong 川芎, bai 
shao 白芍, chen pi 陈皮  
303 
 
Formula Name (Pinyin or 
translation, Chinese) 
Herbs Ingredients (Pinyin, Chinese) Number of Studies 
Variant 3: Chai hu 柴胡, huang qin 黄芩, zhi zi 栀子, yu jin 郁金, chuan lian 
zi 川楝子, ban lan gen 板蓝根, gan cao 甘草  
Chai hu shu gan san 柴胡疏
肝散 
Variant 1: Chai hu 柴胡, bai shao白芍, chi shao 赤芍, chuan xiong 川芎, 
dang gui 当归, chen pi 陈皮, zhi ke 枳壳, xiang fu 香附, yu jin 郁金, long 
dan cao 龙胆草, ye ju hua 野菊花, jin qian cao 金钱草, gan cao 甘草 
2 study [183, 201] 
Variant 2: Chai hu 柴胡, sheng di 生地, dang gui 当归, bai shao 白芍, chi 
shao 赤芍, zhi ge 枳壳, xiang fu 香附, chuan lian zi 川楝子, hong hua 红花, 
chen pi 陈皮, chuan xiong 川芎, yan hu suo 延胡索, yu jin 郁金, san leng 
三棱, er zhu 莪术, gan cao 甘草 
Fu yuan huo xue tang 
combined with Chai hu shu 
gan san 复元活血汤合柴胡
疏肝散 
Chai hu 柴胡, xiang fu 香附, chi shao 赤芍, hong hua 红花, tao ren 桃仁, 
ren dong teng 忍冬藤, si gua luo 丝瓜络, dang gui 当归, chuan xiong 川芎, 
zhi ke 枳壳, ru xiang 乳香, mo yao 没药 
1 study [216] 
Xiao yao san逍遥散 NS 1 study [139] 
Self-designed formula 12 Jin yin hua 金银花, da qing ye 大青叶, pu gong ying 蒲公英, ma chi xian 
马齿苋, huang qin 黄芩, zhi zi 栀子, long dan cao 龙胆草, yi yi ren 薏苡仁, 
ze xie 泽泻, che qian cao 车前草, dan shen 丹参, chai hu 柴胡, yan hu suo 
延胡索, gan cao 甘草 
1 study [175] 
Formulae for clearing heat and tonifying qi (2 formulae) 
Yi qing qu pao tang  
益清祛疱汤 
Huang qi 黄芪, wu wei zi 五味子, dang gui 当归身, mai dong 麦冬, da qing 
ye 大青叶, long dan cao 龙胆草, jie geng桔梗, bo he 薄荷, hong hua 红花, 
yan hu suo 延胡索, mu dan pi 牡丹皮, gan cao甘草 
1 study [195] 
Qi shen tang芪参汤 Huang qi 黄芪, xuan shen 玄参, dan shen 丹参, jin yin hua 金银花, dang gui 
当归, tu fu ling 土茯苓, gan cao 甘草 
1 study [158] 
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Formula Name (Pinyin or 
translation, Chinese) 
Herbs Ingredients (Pinyin, Chinese) Number of Studies 
Formulae for resolving dampness and regulating qi (1 formula) 
Wei ling tang combined with 
Chai hu shu gan san 胃苓汤
合柴胡疏肝散 
Zhu ling猪苓, ze xie 泽泻, fu ling 茯苓, gui zhi桂枝, hou po厚朴, cang 
zhu 苍术, chai hu 柴胡, chuan xiong 川芎, zhi ke 枳壳, bai shao 白芍, long 
dan cao 龙胆草, huang qin 黄芩, huang qi 黄芪, gan cao 甘草 
1 study [217] 
Formulae for moistening dryness and resolving itch (1 formula) 
Run zao zhi yang jiao nang 
(capsule) 润燥止痒胶囊 
Sheng di 生地, he shou wu 何首乌, ku shen 苦参, sang ye 桑叶, hong huo 
ma 红活麻 
1 study [228] 
Chemical compounds extracted from the herbs (2 chemical compounds from single herbs) 
Compound Glycyrrhizin 
tablet 复方甘草酸苷片 
Gan cao 甘草 1 studies [176] 
Dan shen tong jiao nang 
(capsule) 丹参酮胶囊 
Dan shen 丹参 1 study [141] 
Not Specified formula (1 formula) 
She bu guo zhi (topical 
solution) 
NS 1 study [165] 
Single herb treatment (1 single herb)  
Single herb Qi she hua 七色花 1 study [149] 
NS, not specified 
Note: Ingredient chuan shan jia 穿山甲 is on the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES) 
list in Australia (Appendix II). The trading of chuan shan jia 穿山甲 is strictly restricted in Australia  
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Appendix 8: Search terms for experimental evidence 
Herb Name (Pinyin, Chinese) Scientific Name Key Chemical Compounds 
Long dan cao龙胆草 1. Gentiana manshurica Kitage. 
2. Gentiana scabra Bge.  
3. Gentiana triflora Pall.  
4. Gentiana rigescens Franch. 
Secoiridoids: gentiopicroside (gentiopicrin), swertiamarin, 
sweroside, trifloroside, scabroside, rindoside, amarogentin, 
gentiopicroside tetraacetate 
Alkaloids: gentiofavine, gentianine 
Other constituents: lognic acid gentianose 
Zhi zi栀子 1. Gardenia jasminoides Ellis  Iridoid and flavonoid gylcosides: gardenoside, geniposide, 
genipin-1-gentiobioside, shanzhiside, gardoside, jasminoidin 
Huang qin黄芩 1. Scutellaria baicalensis Georgi  Flavonoids: baicalein, wogonin, norwogonin 
Gan cao甘草 1. Glycyrrhiza uralensis Fisch. 
2. Glycyrrhiza inflata Bat. 
3. Glycyrrhiza glabra L. 
Tripterpenes: glycyrrhizic acid, glycyrrhizin, glucoronic 
acid 
Flavonoids, flavonoid glycosides: licoflavone 
Alkaloids, coumarin derivatives 
Chai hu柴胡 1. Bupleurum chinense DC. 
2. Bupleurum scorzonerifolium Willd. 
Triterpene saponines: saikosaponine 
Volatile oil: limonene, myrcene, carvacrone, carveol, 
pulegone, myrtenol, -terpineol 
Dang gui当归 1. Angelica sinensis (Oliv.) Diels Volatile oil: humulene, guaiacol, ethylresorcinol, 
isoeugenol, vanillin; ligustilide, butylidenephthalide, 
angelicide 
Other constituents: angelicin 
Di huang 地黄 1. Rehmannia glutinosa Libosch. Iridoids and iridoid glycosides: leonuride, rehmannioside 
rehmaglutin, acteoside, glutinoside, geniposide, ajugoside, 
jionoside  
Sugars, organic acids, amino acids 
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Herb Name (Pinyin, Chinese) Scientific Name Key Chemical Compounds 
Ban lan gen板蓝根 1. Isatis indigotica Fort. Alkaloids: indgotin (indigo), indirubin 
Amino acids, glycosides 
Other constituents: epigoitrin, tryptanthrine 
Ze xie泽泻 1. Alisma orientalis (Sam.) Juzep. Tetracyclic triterpenes: alisol 
Sesquiterpenes: alismol, alismoxide 
Amino acids, fatty acids 
Yan hu suo延胡索 1. Corydalis yanhusuo W.T. Wang Alkaloids: dehydrocorydaline, tetrahydropalmatine, 
berberine 
Other constituents: mucilage, volatile oil 
Che qian zi车前子 1. Plantago asiatica L. 
2. Plantago depressa Willd. 
Iridoid gylcosides: aucubin,  
Phenylpropane glycosides: plantainoside, plantamajoside, 
Organic acids 
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Appendix 9: Study recruitment poster example  
 
 
